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ABSTRACT
A fully stereocontrolled asymmetric synthesis of the Southern Hemisphere intermediate 426 for the 
bryostatin family of antitumour agents is described in this thesis. It details how the strategy evolved from 
(E)-1,4-hexadiene 450 including a Roush-Masamune coupling between 462 and 507, cyclisation to glycal 
505, selective epoxidation and in-situ Fischer glycosidation to 503 and an aldol / dehydration sequence to 
establish the (E)-exocyclic olefin. We also document a rare example of slow bond rotation in the C(18)- 
C(19)-bond of 426 and provide an explanation of this phenomenon.
In addition, the synthesis of two truncated bryostatin analogs 525 and 526 is described, and the 
interaction of 525 with the CRD2 of human PKC-a discussed.
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Scheme 1 The bryostatin family of antitumour macrolides.
The bryostatins (Scheme 1) are a structurally novel family of marine macrolides whose prototype, 
bryostatin 1, was first isolated in 1968 from the bryozoan invertebrate Bugula neritina Linnaeus by Pettit and
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coworkers, in their search for new anti-cancer drugs 1. Several years later a number of other family 
members were isolated from Amathia convulata. Both marine animals are colonial filter feeders, known for 
their ability to attach to ships hulls. So far 18 members of the bryostatin family have been isolated from 
collections of both organisms. These bryazoans are found in the Gulfs of Mexico, California and Sagami off 
Japan.
It was not until 1982, that the structure of bryostatin 1 was eventually deduced by detailed 
spectroscopic and X-ray crystallographic analysis. This revealed some interesting functionality embedded in 
the bryostatin array. All of the bryostatins possess a 20-membered macrolactone containing three pyran 
rings and an (E)-disubstituted olefin. Two of the pyrans also contain hemiketals in the A and C rings, and 
always, the A and B pyrans are bridged by a methylene unit. Geminal dimethyl groups at C(8) and C(18) 
are always present, as is the C(24)-C(27) side chain. B- and C-ring exocyclic methyl enoates are also 
present in all but bryostatin 3, which has an extra stereocentre at C(22) which ties up the enoate as a 
butanolide. Most of the differences between the various bryostatin family members lie in the remote ester 
functionality at the C(7) and C(20) positions. Further structural differences can be found in bryostatins 16 
and 17 which have a glycal at C(19)-C(20). Also bryostatins 17 and 18 have opposite methyl enoate 
geometry in the C-ring.
1.1 Biosynthesis of bryostatin 1
Through radiolabelling experiments, Kerr and coworkers 2 have shown that acetate, glycerol and 
S-adenosylmethionine (SAM) are all key building blocks in the biosynthesis of bryostatin 1; Propionate, n- 
butyrate, isobutyrate and succinate are not required for its biosynthesis. The geminal dimethyl groups are 
thought to originate from series of a SAM methylations on the corresponding acetate units, as was 
observed for the biosynthesis of lankacidin and aplasmomycin. The exocyclic olefin units possibly arise 
from the addition of acetate to a polyketide chain, followed by dehydration. The exact sites where the radi 
labelled precursors are being incorporated are presently under investigation by Kerr, and further are eagerly 
awaited.
2
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1.2 Bryostatin biology3> 4
1.2.1 The antitumour profile of bryostatin 1
Bryostatin 1 shows remarkable in vitro and in vivo antitumour effects against a range of mouse 
cancer cell lines that include P388 lymphocytic leukaemia, ovarian sarcoma 5, B16 melanoma 6’ 7, and 
M5076 reticulum cell sarcoma. Moreover when bryostatin 1 was administered alongside auristatin PE and 
dolastatin 10, a successful cure of 7/10 SCID mice, with chronic human lymphocytic leukaemia xenographs 
was achieved 8.
Bryostatin 1 has recently completed a large number of anticancer trials in man 01 10. Its most 
noteworthy anticancer effects were seen against ovarian cancer and relapsed non-Hodgkin’s lymphoma. Its 
total cure of a 41 year old woman with stage 4 follicular small-cell-cleaved non-Hodgkin’s lymphoma was of 
particular interest. This patients disease had recurred at multiple sites five years after originally having been 
brought into remission with alkylator drug therapy. The treatment regime that elicited this cure consisted of 
eight fortnightly cycles of bryostatin 1 by 72 h intravenous infusion at a dose of 120 pg m'2. Although this 
represents the only cure to date, bryostatin 1 has brought about many partial remissions The main side- 
effect of bryostatin 1 treatment is myalgia 11.
1.2.2 Mechanisms of antitumour action
The antitumour effects of bryostatin 1 have been linked to its ability to selectively modulate the 
functioning of protein kinase C (PKC) isozymes within cells 12. PKC’s are serine and threonine kinases that 
play a pivotal role in the O-phosphorylation of proteins involved in the signal transduction pathways 13,14 
that control cell growth and proliferation. Their over- or under- expression is linked with the transition of 
some tissues into malignancy. This observation was first made by Mushinski and coworkers, when they 
noticed that over-expression of n-PKC-e in NIH 3T3 cells made them highly neoplastic and tumourigenic 
towards mice 15. The elevation of n-PKC-e levels in rat fibroblasts 16 also renders them malignant and 
tumourogenic, while over-expression of PKC-p makes them highly susceptible to transformation with the 
Ha-ras oncongene. Both Ha-ras and c-myc oncogenes serve to increase PKC-piI levels in the 
cotransfection of human small-cell lung carcinoma, and this has been correlated to their conversion to a
3
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much more malignant large-cell phenotype. It has also been reported that in human A549 lung cancer cells, 
cPKC-a levels are higher than in healthy neighbouring tissue 17, suggesting that up-regulation of PKC might 
be contributing to onset of this particular cancer. PKC activity is also significantly raised in human breast 
cancer tissue when compared to nearby normal tissue. Collectively, these results strongly suggest that the 
up-regulation of PKC signalling could be contributing to the onset of a range of tumours.
Because bryostatin 1’s ability to inhibit human A549 lung and MCF-7 breast cancer cells correlates 
closely with its down-regulation of PKC-a, an extrapolation to the PKC isozymes of many other cell types 
seemed logical for explaining its mechanism of action. However, that this extrapolation cannot be made can 
be seen from bryostatin 1’s protection of some PKC-8s from down-regulation; this leading to tumour growth 
inhibition. PKC-8 levels appear to play a decisive role in determining whether cells become cancerous; their 
degree of expression frequently deciding whether a cell undergoes growth-arrest and proliferation. This is 
evident from the over-expression of PKC-S in mouse keratinocytes which result in apoptosis 18, and in its 
overexpression in NIH 3T3 cells which halts their proliferation 19. Here PKC-8 is believed to function as an 
efficient tumour suppresser. PKC-8 can also nullify the effects of an over-expressed c-src-proto-oncongene 
in 3Y1 fibroblasts, preventing them from undergoing transformation 20. By way of contrast, PKC-8 under­
expression in some cells has been correlated with a greatly enhanced rate of growth 21. The fact that 
bryostatin can prevent PKC-8 from undergoing down-regulation in mouse keratinocytes and human 
fibroblasts 22 suggests that bryostatin might be inhibiting the growth of some tumours via a PKC- protective, 
or stabilising mechanism23.
Thus it would appear that bryostatin acts upon the individual PKC isozymes in a highly tissue- 
specific manner and this therefore complicates our ability to rationalise many of its observed antitumour 
effects by a single, all-encompassing, and general mechanism.
Bryostatin 1 competitively binds to the phorbol ester-diacylglycerol binding sites of PKC isozymes 
at two highly conserved regions known as the cysteine-rich domains 1 and 2 (CRD’s 1 and 2). The three- 
dimensional structures of several CRD’s have now been elucidated. There is an NMR solution structure for 
a murine PKC-a CRD2 construct 24, and a 2.2 A resolution X-ray crystal structure of phorbol-13-acetate 
complexed PKC-8 CRD2 25. The crystallographic data have confirmed that the tumour promoting phorbol 
ester sits in a polar groove that exists between two opened (3-strands at one tip of the CRD, and that this 
complexation does not produce significant conformational changes in the PKC activator domain. It appears
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that once the phorbol ester is bound to the protein, it creates a long continuous hydrophobic surface that 
covers approximately one third of the protein. The enhanced hydrophobicity of the phosphorylated PKC-8- 
phorbol ester complex has led to the proposal that this promotes its translocation from the cytoplasm 
plasma and nuclear membranes to mediate specific signals within the cell that include tumour propagation. 
Similar increases in lipophilicity are also thought to occur when bryostatin 1 becomes bound to the CRDs of 
PKCs, although in this case it is likely that different conformational changes are elicited in the target in the 
PKCs compared with the phorbol esters. It is thought that when bryostatin 1 binds to PKC-8s, it induces a 
“stabilising” conformational change in the enzymes that prevents them being degraded by the ubiquitin 
proteasome. However, when bound to phosphorylated PKCs that are down-regulated by bryostatin, the 
complexation is thought to induce a conformational change that favours the insertion of the protein into the 
cell, and subsequent ubiquitinilation.
In this regard, the way in which bryostatin down-modulates PKC-a in renal epithelial cells, and 
PKC-a and PKC-e in human fibroblasts, has been elucidated by Bingham Smith and coworkers 26f elegant 
32P-labelling studies. They have shown that for these two cell lines, PKC down-modulation proceeds 
through the ubiquitin-proteasome pathway (Scheme 2). Soon after bryostatin 1 complexes to PKC, 
autophosphorylation occurs, resulting in the translocation of the drug-protein complex from the cytosol into 
the plasma membrane. Once embedded, the complex is apparently rendered susceptible to 
dephosphorylation by the membrane bound alkaline phosphatases, yielding a catalytically inactive form of 
the PKC protein. The inactive membrane-bound PKC is then degraded by the ubiquitin-proteasome causing 
PKC down-regulation.
The ability of bryostatin 1 to bind selectively to different PKC isoforms and therefore to render 
them susceptible or non-susceptible to undergoing down-regulation within cells is probably central to many 
of its observed antitumour effects. For some cancers, the down-regulatory ability of bryostatin 1 to arrest a 
particular up-regulated PKC pathway might be the critical requirement; for others, a bryostatin-mediated 
PKC-up-regulation might be all that is needed to correct the tumourigenic state.
It has been recently demonstrated that PKC-p isozyme levels can greatly affect whether some 
cells rest or proliferate. This is significant because bryostatin 1 is capable of selectively targeting PKC-pIIs 
in both human erythroleukaemia (K562) and promyelocytic (HL60) cells. After complexation, bryostatin- 
PKC-p complexes selectively insert into the nuclear membrane and phosphorylate lamin B at the Ser-395
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and Ser-405 residues 27. This phosphorylation is associated with the disassembly and increased 
solubilisation of the nuclear lamina network during mitosis. It causes a breakdown of the nuclear envelope, 
and enhances proliferation of these cells. Thus, in some cell types bryostatin might prove to be 
tumourogenic.
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Scheme 2 Mechanism by which bryostatin downregulates PKC-a and PKC-e in human fibroblasts.
The majority of the biological research on bryostatin 1 has attributed its antitumour effects to its 
interactions with various PKC isozymes, although there is gathering evidence which suggests that
bryostatin 1 is able to function as a powerful immunostimulant. Indeed, it has been suggested that this
28might be the primary means by which bryostatin 1 exerts its antitumour properties in some patients . 
Bryostatin 1 readily activates resting human T-cells and neutrophils 29 both in vitro and in vivo 30, and in a 
number of patients, it has also been shown to raise the levels of tumour-necrosis factor (TNF); a powerful 
tumouricide produced by the body in response to immunostimulation. Bryostatin 1 can also induce the rapid 
release of TNF from MONO-MAC-6 cells 31. It can also significantly increase TNF mRNA expression and 
production in the murine macrophage ANA-1 cell line. This enabled bryostatin 1 to synergise with INF in the
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production of [N02]' and in the expression of the nitric oxide synthase (/-NOS) gene, which catalyses the in 
vivo production of NO from L-arginine. In turn, this confers powerful tumouricidal effects upon murine 
macrophages. The production of NO is known to induce apoptosis in tumour cells 32. These results very 
clearly support the idea that bryostatin 1 could be exerting some of its antitumour effects via an 
immunostimulatory mechanism.
While C(20)- oxygenated bryostatins 1, 3, 8 and 9 are all capable of activating neutrophil 
chemiluminesence and the cytotoxic killing of K562 cells, no such data exists for a member of the C(20)- 
deoxy class. Bryostatin 13, which is reported to be amongst the most potent antitumour agents in the 
bryostatin family, is incapable of mimicking their ability to stimulate colony formation from bone marrow 
progenitor cells 33. This suggests that while an immunostimulatory antitumour mechanism might be 
significant for the C(20)-O-acyl bryostatins, a similar mode of action is unlikely for the C(20)-deoxygenated 
bryostatins.
The many divergent actions of the bryostatins on the numerous PKCs, along with the ability of 
certain family members to function as immunostimulants, mean that a singular, overall mechanism of 
antitumour action is unlikely to ever be proposed. The data gathered from the numerous human trials has 
suggested that the efficacy of bryostatin 1 varies from patient to patient, it depending both on the cancer cell 
type and on the PKC content of the patients cell.
This overall somewhat contradictory behaviour of bryostatin towards PKCs can be exploited in a 
clinical programme that would involve initial in vitro screening of the patients before therapy is commenced. 
This could establish whether bryostatin 1 would have a realistic chance of success.
There is an urgent need for significant quantities of the bryostatins, due to the scarcity of a natural supply, 
and this has attracted significant interest in their chemical synthesis. To date only three members of the 
bryostatin class have succumbed to total synthesis, although in the myriad of chemical transformations 
carried out in the name of bryostatin research, much headway has been made in the probing of the 
bryostatin mode of action.
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1.3 Bryostatin total synthesis34
1.3.1 Masamune’s enantioselective total synthesis of bryostatin 7 (1990)35
1.3.1.1 Masamune’s retrosynthetic strategy for bryostatin 7
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Scheme 3 Masamune’s retrosynthetic planning for bryostatin 7.
There were a number of key elements in the tactical planning employed by Masamune and 
coworkers for their proposed approach to bryostatin 7 (Scheme 3). Their strategy was predicted upon the 
regioselective macrolactonisation of seco-acid 1 for 20-membered macrolide ring assembly. It also called 
for installation of the C(3)-hydroxyl via the use of a reagent-controlled acetate aldol reaction, which would 
also serve to introduce the C(1) and C(2) carbons of the polyketide framework. Connection of the three 
pyran segments and construction of the sterically inhibited C(16)-C(17)-frans-alkene would be 
accomplished by Julia olefination 36. Assembly of the B-ring would rely upon a chemoselective oxy- 
mercuration of the less hindered olefin 37 in diene 5, and a borolane-mediated asymmetric aldol reaction 
was envisioned for uniting the A- and B-ring sections. Sulfone 4 looked accessible from the open chain 
ketone 8 by addition of a vinylmetallic to the chiral a-alkoxy aldehyde 10. Central to this plan, of course,
8
Chapter 1: Introduction
was addition proceeding under chelation control, which would favour the desired stereochemistry emerging 
at C (20)38.
1.3.1.2 Synthesis of the C(3)-C(16) segment
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Scheme 4 Masamune’s synthesis of the C(3)-C(16)AB fragment 24.
For the preparation of methyl ketone 6 (Scheme 4), an expedient pathway for constructing the 
1,3,5- hydroxy array was the primary concern. Previously, during their work on the antifungal agent 
amphotericin B 39, Masamune and Sharpless had devised a powerful solution for this general synthetic 
problem. Their protocol generated an appropriate chiral 2,3,4,5-6/s-epoxy alcohol via the AE, and thereafter 
implemented a regioselective ring-opening at the C(2) and C(4) positions with REDAL 40. The desired
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epoxide 14, required for assembly of the A-ring was prepared in nine steps from 2,2-dimethylpropane-1,3- 
diol 11 (Scheme 4). Diol 11 was converted to the aldehyde 12 by selective O-benzylation and oxidation. A 
Wadsworth-Homer-Emmons (WHE) olefination, DIBAL ester reduction and Sharpless AE delivered the 2,3- 
epoxy alcohol 13 in 92% ee. Swern oxidation of 13, chain extension via a Wittig olefination, and borohydride 
reduction delivered the desired allyiic alcohol substrate. A second AE was performed, which enhanced the 
de of the bis-epoxide 14 to 99%. As expected, treatment with REDAL promoted a regiospecific alkoxide- 
directed ring-opening to deliver 15 as a single reaction product. Primary O-silylation and acetonide 
formation completed triol protection to yield 16. A Birch O-benzyl reduction followed by Swern oxidation, 
methyllithium addition, and a second Swern oxidation concluded the sequence to methyl ketone 6.
The chiral boron enolate 19 was produced by treatment of ketone 6 with the (R.R)-borolane triflate 
18 and Hunigs base. It combined readily with the dienyl aldehyde 7 to furnish the desired p-hydroxy ketone 
20 with 8:1 selectivity. Fischer glycosidation of 20 with MeOH, PPTS and trimethylorthoformate 
isopropylidene cleavage and instigated pyran formation to deliver the a-methyl glycoside 5. An 
intramolecular oxymercuration, C(7) O-acetylation, and free radical oxidative demercuration aided B-ring 
cyclisation. Unfortunately this resulted in a 1:1 mixture of alcohols 23, epimeric at C(15). This adverse 
stereochemical outcome could, however, be redressed by Swern oxidation to aldehyde epimers 24, and 
equilibration with alumina, which thus provided 3 as the major component of a 9:1 mixture at C(15).
"OTh p  (')n-BuLi, 
HC H O .TH F
(89%)
25
OTHP (ii) RedAI-H. THF, then l2
(90%)
HO
26
OTHP
(iii)TBDPSCI, im, 
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Cul, Et20  (77%)
-IP
r u n
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28
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(vi) (py)2Cr0 3 .
CH^ fe 
(92%, 2 steps)
OTBDPS 
7
Scheme 5 Masamune’s synthesis of the C(11 )-C(16) B-ring fragment 7.
The route to aldehyde 7 (Scheme 5) began with addition of 25 to formaldehyde, which 
subsequently allowed a Corey trisubstituted olefin synthesis 41 to be applied to obtain the (Z)-iodo allyiic 
alcohol 27. After O-silylation, copper catalysed allyl Grignard addition formulated the requisite C(11)-C(16) 
segment 28. Cleavage of the THP protecting group, followed by a Collins oxidation, yielded 7.
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1.3.1.3 Synthesis of the C(17)-C(27) segment 4
h o 2cV^OH
n h 2
29
(i) N aN 02, I
h 2s o 4, h 2o  h o 2c n ^ A
OH
30
OH
(ii) MeOH, AcCI I
(iii) (MeO)2CMe2, p-TsOH MeQ2C ^ A
(64%, 3 steps)
31
(iv) DIBAL-H
(v) Ph3P=CH2 o
32
(vi) Sia2BH,
h 2o 2 HO (vii) PCC 
0   ► OHC
33
(54%, 4 steps)
(viii) Allenyl-ZnBr 
(53%)
34
(ix) NaH. PMBCI
PMBO O
(x) f-BuLi, C IC 02Me
M e 0 2C PMBO O - 
37
PMBO,,,
(xi) /7-Bu3SnCu.LiBrMe2S, _ | | \ /
"0(64%, 3 steps)
Bu3Sn
38
C 0 2Me
(xii) DIBAL-H
(xiii) TBDPSCI, 
Imidazole
PMBO,,
QPMB
Bu3Sn
PMBO,,
(52%, 4 steps)
OTBDPS OTBDPS
39
(xvi) TESOTf, 2,6-lutidine p^g  
(xvii) DDQ (1 eq.)
(xviii) Me2SO, Ac20 ,  Et3N 
(70%, 3 steps)
OPMB
TESO
OTBDPS
or BF3.Et20 , MeOH  
(40%, 3 steps)
(xv) n-BuLi,
then 10
40  OTBDPS
P h 0 2S .
(xix) M0O 5.HMPA. H20  ^  | (J)Me |-|
’" ' V '  (xx) DDQ, Si0 2
(xxi) TMSOTf, TM SOMe T E S O ' N r ^  / " " O
OTBDPS
Scheme 6 Masamune’s route to the bryostatin 7 “Southern Hemisphere”.
The coupling strategy proposed for 4 utilised fragments 9 and 10 as important intermediates 
(Schemes 6 and 7). Firstly the vinyl iodide 9 was assembled from L-threonine 29. The desired C(25)-C(26) 
hydroxy stereocentres were set after amine diazotisation; this was followed by O-esterification and O- 
isopropylidination to acquire methyl ester 31 42. DIBAL reduction to the aldehyde next facilitated a carbon 
homologation via Wittig olefination with methylenetriphenylphosphorane. Conversion of alkene 32 into 
alcohol 33 was achieved by hydroboration and oxidative work-up; this was then further oxidised to aldehyde 
34. A chelation-controlled coupling with allenylzinc bromide elaborated the necessary acetylenic unit 
required for manipulation to the exocyclic olefin, and also set the C(23) stereocentre with 8:1 selectivity. The 
influence of coordination to the C(26) alkoxy group in order to achieve high levels of selectivity is of note, as 
p-alkoxy aldehydes are not normally considered good substrates for the chelation-controlled nucleophilic 
additions of organometallic reagents.
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Protection of the hydroxyl in 35 as a PMB ether allowed the alkyne to be homologated with f-BuLi 
and methyl chloroformate to produce the alkynyl ester 37. The (E)-vinyl-stannane was prepared by 
stereoselective stannylcupration 43. Ester reduction of 38 with DIBAL and protection provided 39, which then 
underwent a halogen-metal exchange with iodine to yield vinyl iodide 9. Treatment of 9 with n-BuLi afforded 
a vinyllithium species that added readily to aldehyde 10 providing a 6:1 mixture of alcohols at C(20), 
enhanced in the desired chelation-controlled product 40. An O-triethylsilylation, followed by selective 
removal of the DMP group and oxidation yielded the ketone 41. MoOPH oxidation of the thioether 
introduced the sulfone unit under conditions which left the double bond intact. Removal of the PMB group 
released the 8-hydroxy ketone and cyclisation to the hemiketal was achieved via mild acid treatment. Final 
conversion to the methyl glycoside 4 was accomplished by exposing the hemiketal mixture to Me3SiOMe 
and Me3SiO Tf44. The pathway used to aldehyde 10 is described in Scheme 7. A Sharpless AE and a 
phenylurethane mediated intramolecular epoxide ring-opening featured as key steps. Subsequent 
protecting group interchange and thiophenyl installation completed the sequence to 10.
(vi) PhNCO, Et3N
BnO OH
42
(92% ee)
BnO
(vii) BF3.Et20 ,  
10% aq. H2S 0 4
OCONHPh
(81%, 2  steps)
43
(viii) K2COS, MeOH
(ix) (MeO)2CMe2, PPTS
(x) NaH, 2,4-dimethoxy-
benzyi chloride 
(79%, 3 steps)
BnO
(xi) Raney Ni, H2 
(xii) MsCI, Et3N, PhSNa
(xiii) HCI, MeOH
(xiv) N a l04, pH7 
(76%, 4  steps)
PhS
u .C H O
10
Scheme 7 Synthetic pathway to aldehyde 10.
1.3.1.4 The Masamune bryostatin 7 endgame
The AB- and C-rings 3 and 4 were connected together via a Julia olefination (Scheme 8). This also 
set the C(16)-C(17) disubstituted olefin stereochemistry with good stereocontrol (E:Z 6.2:1). An O- 
desilylation / resilylation tactic allowed selective O-acetylation of the C(20)- and C(7)- hydroxyls. Further O- 
desilylation with TBAF secured triol 46 and this was then oxidised with Mn02 in THF. The procedure
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employed by Corey for oxidising enals to methyl enoates 45 was then used to obtain the b/s-methyl enoate 
which underwent a Swern oxidation of the primary alcohol to give aldehyde 47.
(xxiv) PhU, THF, -78°C
MeQ
P h 02S
then add
TBDPSO
TBDPSO
TESO
OTBDPS
MeO )Ac
HO
OH
'Me H
46
AcO
•OH
.OTBDPS  
then BzCI, DMAP, -78°C to RT
(xxv) Na-Hg, MeOH/EtOAc, NaHP04l -20°C  
(60%, 2  steps)
(xxx) MnQ2 THF, then 
MeOH, NaCN and AcOH
(61%)
(xxxi) (COCI)?, M62SO, 
CH2CI2, -78°C; EtaN,
then 0°C
OTBDPS
OTBDPS
(xxvi) TBAF, THF 
Q /  (xxvii) TBSCI, DMF, Im
O ' (xxviii) Ac20 , py, DMAP 
(xxix) TBAF. THF 
(100%, 4 steps)
MeO >Ac
CHO
AcO'"'
B - 0 48
^-SCEt3
f-Pr2NEt, Et20 , -100°C to -78°C  
(83%, 2 steps) (3R:3S - 3 :1 )
(xxxiii) CSA, MeOH (40%)
(xxxiv) TESOTf, CH2CI2, 
2,6-lutidine, 0°C
M e 0 2C MdOoC
(xxxv) NaHP0 4 , 
'COSC(Et)a H g(02CCF3h, THF 
OTES
(xxxvi) HF.py, 
THF, -20°C  
(64%, 3 steps)
C 0 2Me C 0 2Me
M e 0 2CM e 0 2C
(xxxix) TBSCI, (xxxx) Ac20 ,
Et3N, DMAP
M e 0 2C
(xxxvi I) DCC, 
PPTS. py, 
CI2CH2CH2CI2, A
(xxxviii) K2C 0 3, 
MeOH; then 5% 
aq. HCI workup 
(28%, 2  steps)
M e 0 2C
„  (xxxxi) HF, 
0  MeCN
O (40%, 2 steps) 
OTES
CO^e C 0 2Me
C 0 2Me
B r y o u a i r w
C 0 2Me
Scheme 8 Masamune’s synthetic route to bryostatin 7.
Installation of the C(1)-C(2) unit was accomplished by aldol addition with enolate 48. The required 
alcohol was obtained with 3:1 selectivity. Treatment of the product with CSA-MeOH released the C(25)- 
C(26) diol array, and a global O-silylation subsequently procured 49. Deprotection apparently aided the 
hydrolysis of the C(1)-thioester. Global O-desilylation subsequently released the seco-acid 1 which 
underwent a highly regioselective macrolactonisation at the OH(25)-hydroxy group mediated by DCC and 
PPTS in pyridine/dichloroethane at reflux 46. These conditions also caused a selective glycoside hydrolysis
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at C(9). However the C(19)-glycoside remained intact, presumably because of the electron withdrawing 
C(20) O-acetate which makes the anomeric OMe less basic and susceptible to protonation. Such a 
grouping would further disfavour hydrolysis.
This proved to be an inconvenience as double glycoside hydrolysis had been called for in the 
original synthetic plan. A great deal of work was carried out to effect C(19)- glycoside hydrolysis, under 
conditions which did not also cause destruction of the remainder of the molecule.
The solution to this problem was to cleave both the C(20) and C(7)-0-acetates with catalytic 
KOMe, which increased the acid lability of the C(19)-OMe, and resulted in the formation of the labile 
hemiketal 50. This strategy was adventurous so far on in the synthesis as these acetates were required in 
the target compound, and the lactones could have undergone transesterification; that it survived was of 
particular note. Distinguishing the remaining hydroxyls was now called for. Transient blocking of the C(26)- 
OH as its O-triethylsilyl ether 51 allowed the re-positioning of the 0(7) and 0(20) acetates in 52. Completion 
of this landmark total synthesis was accomplished by O-desilylation with aqueous HF, to yield bryostatin 7. 
This was the first bryostatin family member ever to be synthesised.
1.3.2 The Evans enantioselective total synthesis of bryostatin 2 (1999)47
1.3.2.1 Model work by Evans (1990)48
pEt
P -O E t
,OMEM.OMEM
°  MeCN (1mM) 
(80%) OMeO OMe
'OPMBOPMB
HO V •OAc
OH
'0  0O 2Me 
Bryostatin 1Me
Scheme 9 The tethered phosphonoacetate strategy for exocyclic olefin construction in the bryostatins.
Evans’ first synthetic endeavours in the bryostatin field led to him evaluating the potential of 
tethered phosphonoacetates for stereoselective control of the remote enoate geometry via the 
intramolecular WHE macro-olefination process 49. Models suggested that a six-carbon tether could be ideal 
for controlling olefin geometry in the bryostatin B-ring, and molecular mechanics calculations further 
indicated a difference of more than 10 kcal mol'1 between the two possible (E)- and (Z)-alkene 14-
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membered macrocycles that could potentially be produced with the desired (E)- form being favoured. Under 
high dilution conditions, Evans and Carreira found that treatment of the tethered phosphonoacetate 54 with 
a large excess of lithium chloride and triethylamine in acetonitrile produced only the desired (E) olefin 53 in 
a modest 60% yield (Scheme 9). Previous model studies had indicated that these diester dilactone tethers 
could be successfully cleaved via a transesterification without competing olefin isomerisation. However, 
such a cleavage was not actually reported for 53 itself. This strategy, although not used in the final 
bryostatin synthesis, still remains an important method for future assembly of related olefinic arrays.
1.3.2.2 Evans’ retrosynthetic analysis of bryostatin 2 (1999)
HQ
.OH
OH
OH
-^O  C02Me 
Bryostatin 2Me
MeO
TES< .OPMB
•Mo H OTES,
OPMB
60
MeO V .OPMB
IMe H OTES.
H O '' OH
55
MeO V .OPMB
•Me H OTES,
OPMB
Olefination via 
Fuji's Chiral
MeO .OPMB
'Me H OTES,
OPMB
CBS reduction 56
Phosphonoacetate
MeO .OPMB
•M? y  OTES,
OPMB
Aldol /  Dehydration To
Install Exocyclic Olefin 
at C(21)
TESi
Sul fon t Anion
OPMB OPMB PhSO*,, / * ^ « O P M B
CONHPh
H OTES o .V J IteJ otbs
OPMB OPMB
OPMB
CONHPh
M acrolactonlsatlon Glycal E poxidation/
Glycosldatlon
TBS'° V ^ Y ^ 1OTs
v°65 I +
CHO
Julia Olefination
PhS0 2^ * ^ 0 \ l > v ^ 0 TBS
6 8  ^  "" 'O PM B
Scheme 10 Evans’ retrosynthetic analysis of bryostatin 2.
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Having tackled the bryostatin problem over a number of years and learnt much about the 
idiosyncrasies that lay within its boundaries, Evans’ final overall strategy for bryostatin 2 (Scheme 10) relied 
upon delaying the introduction of the exocyclic olefins until late-on in the projected synthesis. Installation of 
the C(13)-C(34) B-ring enoate would be accomplished via an asymmetric WHE involving Fuji’s chiral 
phosphonate 59 50 and the advanced macrocyclic diketone 58. The C(21)-C(35) olefin positioned would be 
positioned via an aldol-dehydration sequence on 57. The latter would be accessible from the addition of 
methyl glyoxalate to an appropriate C(20)-ketone intermediate.
A stereoselective reduction of this keto-enoate addition product would then be required to furnish 
the desired C(20)- stereochemistry for 55. The requisite diketone 58 would be available from the tris-pyran 
seco-acid 61, itself derived from glycal 62. Implicit in the bryostatin planning was the ability to distinguish 
the more electron-rich C(19)-C(20) enol ether double bond in 62 in a regioselective epoxidation reaction 
which would subsequently allow methyl glycosidation at 0(19) on route to 61, with the positioning of the 
requisite C(20) hydroxyl. Finally, a C(1) anilide to acid conversion would have to be grappled with prior to 
macrolactonisation. The pyran linking sequence would involve a Beau-Sinay alkylative C-glycosidation 51 
between sulfone 63 and triflate 64 as a key step, and the BC-fragment would be assembled via a Julia 
olefination between 65 and 66, in a notably more convergent synthesis than Masamune.
1.3.2.3 Asymmetric synthesis of the C(1)-C(9) glycosulfone 63
The synthesis of A-ring 63 began with the conversion of methallyl chloride 67 to aldehyde 72 in 
five straightforward steps, one of which included the acid-induced cyclopropylmethanol rearrangement of 71 
(Scheme 1 1 )52. Aldehyde 72 underwent an Evans asymmetric aldol reaction 53 with oxazolidinone 73 to 
produce the syn-aldol adduct 74 after dehalogenation. This sequence set the C(7)-hydroxyl stereocentre 
with 9:1 (S:R) selectivity to favour the desired diol intermediate 76 after reductive removal of the auxiliary. 
For differentiating between the two hydroxyls, an O-p-methoxy-benzylidenation and a regioselective 
reductive acetal opening 54 was used to position a PMB group on 0(7). The primary alcohol that remained 
was thereafter oxidised under Swern conditions to aldehyde 77, and an acetoacetate aldol reaction 
performed with the disilyl enol ether 78 to effect the homologation to 79.
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67
(i) Phenol
(76%) i Ph 
68
(ii) KOBu-f, Me2SO
100°C, 20 min OPh 
69
(iii) N2CH2C 0 2Et, 
Cu bronze
E t0 2C.
HO, fh
(iv) PhU P
OPh
70
O O
(vo A  x
o1
(v) NaHS04, 
Me2CO,
H20 ,  A. 5.5 h 
OPh (80%, 5 steps) 
71
PtK P^h
Ph2C" y r  'H  
f
72
Bn 73
Bu2OTf, /-Pr2NEt, 
C H ^ f r  then 72 
-78°C, 20 h
(vii) Zn, 2:1 PhY Phn H 0  O (viii) LiBH4, MeOH,
THF/AcOH
diastereoselection 9:1
n u  (ix) PMPCHfOMefe, ^  , ... j i 7a
Ph 10 mol% PPTS, OPMB (xil) A A n U a
(x) DIBAL-H, CH2CI2, 0°C
(94%, 2 steps)
(xi) (COCI)2, DMSO, NEt3, 
CH2CI2, -78°C (96%)
TMS9 9TMS 
O M e.
THF, 0°C
(67%, 3 steps)
75 B"
PMB
TiCI2(OPr-/)2, PhCH3, 
-78°C, (83%) 
(94:6 ds)
(xiii) Me4NHB(OAc)3
AcOH/MeCN, -35°C, 
OMe (92%)
79 O
OPMB
80 OH O
(xiv) PPTS, C6H6,80°C
(xv) TBSOTf, 2,6-lutidine, 
OMe CH2CI2,-1 0 oC
(64%, 2 steps)
Ph
.OPMBIPMB (xvi) MesAI, HCI.H2NPh, Ph' 
CH2Cl2 , -10°C (75%)
Ph'
82 TBSOOTBS
(xvii) 0 3, 10:1 O^Cfe/M eO H, 
-78°C, then Me2S, (72%)
(xviii) AC2 0 , py, 48  h
AcO OPMB
NHPh
™*V.>OoPMB
(97:3 u p )
(xx) roCPBA, 
NaHC03, EtOAc, 
(76%, 3 steps)
,NHPh  
TBSO O  63
Scheme 11 Evans’ synthesis of the A-ring glycosyl phenylsulfone 63.
The diastereocontrol achieved in this Lewis acid mediated aldol condensation 55 greatly depended 
upon the reaction solvent employed, with dichloromethane delivering a modest 6:1 selectivity in favour of 
79, which increased to 94:1 when upon the reaction was carried out in toluene. Hydroxy-directed reduction 
of the p-keto ester 79 56 was accomplished with 91:9 selectivity under Saksena-Evans conditions and set 
the final C(3) stereocentre present in synthon 80. A mild acid catalysed lactonisation was next effected in 
order to temporarily block the C(5) hydroxyl. O-Silylation and lactone opening aniline hydrochloride and 
trimethylaluminium furnished 82. Ozonolytic cleavage of 82 produced a 3:2 mixture of the (p/a)-lactols and 
the C(9)-epoxide. The undesired epoxide by-product arose from an end-on approach of ozone to the 
sterically-demanding alkene 57. The desired hemiacetals were readily O-acetylated, and a Hanessian- 
Guindon thioglycosidation reaction58 was applied on 83 to access the thioether. Exhaustive oxidation of the 
thioether unit with buffered m-CPBA completed the synthesis of phenylsulfone 63.
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1.3.2.4 Evans’ asymmetric route to C(1 )-C(16)-B-ring fragment 65
(i) f h  2+
<°Vw °>V'-N'—Cu— 86
A  OB„ »TMS!  I™5 (Smd») >» ? 1  ?H . .  ffiSXESfSPfc ff 9H JH
CH2CI2, -90 C (84% ) (94 -6 ds)
84  8 8  (85%) (99% ee) #7  88
(vii) TBSCI, Im,
DMAP, CH2CI2
(li)F3CC02H.CH2Cl2 T E S C L ^ O  HCV ' T ^ 0H ^"a^Oh! E K ? ^ '  ^ TBS(XV ^ f ^ O T B S
T °  (vi) BF3 .Et20 , Et3SiH, V 0  (ix) (COCI)2, M ejS , C ^ C fe , V 0
, o? i I  CH2Cl2 , -20°C 1 -78°C; Et3N then 0°C
(77%, 2 steps) ^ 0Bn (84 %, 2 steps) OBn (66%, 3 steps)
(94:6 ds) 85
89 90 03
Scheme 12 Evans’ B-ring synthesis.
The catalytic asymmetric acetoacetate aldol reaction of Evans, Murry and Koslowski59 constitutes 
a powerful method for the construction of 1,3-diol subunits when combined with the stereoselective 
reduction of (3-hydroxy ketones. Together these technologies look tailor-made for use in the bryostatin field, 
and they were employed by Evans for his assembly of the B-ring synthon 65. The critical aldol process was 
effected with aldehyde 84 and disilyl enol ether 85 (Scheme 12), and delivered the p-hydroxy ketone 87 in 
99% ee when the C2-symmetric copper(ll) complex ([Cu(R, R)-Ph-pybox])(SbF6) 86 was used as the chiral 
catalyst. A subsequent Saksena-Evans reduction 56 ceded the diol 88 as a 94:6 (anthsyn) mixture enriched 
in the desired isomer. A two-step lactonisation and protection strategy next delivered the 8-lactone that 
underwent a one-carbon homologation with p-methoxybenzyllithium 60 proceeded by ionic reduction of the 
resulting a-lactols 61, to finalise the desired carbon framework of 90. The positioning of the final 
stereocentre at C(11) was completed in a favourable 94:6 ds, and the resulting diol underwent O-silylation, 
benzyl removal and Swern oxidation to conclude this expedient route to 65.
1.3.2.5 Synthesis of the C-ring sector and elaboration into the BC-segment 64
In his route to the C-ring glycal 66, Evans began prepared sulfone 95 in a four-step procedure 
involving diol 11 (Scheme 13). Aldehyde 95 was then chain elongated with pentylmagnesium bromide to
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deliver 97 after Swern oxidation. A two-step dihydroxylation and oxidative cleavage thereafter converted 97 
to aldehyde 99.
HO OH 
11
ft) TsCI (0.2 eq.). py, 
CH2CI2, 0°C to RT
(ii) NaH, PhSH, 
DMF, 80cC
PhS OH 
94
(iii) m-CPBA, CH2CI2, 
0°C to RT
(iv) (COCI)2. M62SO. 
CH2CI2 , -78°C; E^N, 
then 0°C
PhS02
CHO
95
96
(V )
1:1 Et20 /C H 2Cl2, 
0 °C  to RT
(vi) (COCI)2, Me2SO. 
CH2CI2. -78°C; 
Et3N, then 0°C
PhS02
97
(vii) 2  mol% 
K20 S 0 4(0H2)2. pns° 2  
2  mol% quinuclidine,
Ke3Fe(CN)6, K2C 0 3,
1:1 t-BuOH/H20
(x) 20 mol% Sml2l 
p -N 0 2-C6H4CH 0, 
THF. 0°C
(76%)
PhS02
PhS02
(viii) N a l04> NaHCOs,
f-BuOH/H20/TH F (2:2:1) 
(78%, 2 steps)
PhS02
0? ™ Z.OH
23 25
OPMB
(xlv) />-BuLi( 
THF, -78°C; 
then
(«) y
M e ^ Y M 8  P h S 02 
9 3  OPMB
(-)-DIPCI, Et3N, CH2CI2, 
-78°C; then 99, -70°C  
(87%) OPMB
(xi) TBSOTf, 2,6-Lutidine, p h s o 2 
CH2CI2 , -15°C
(xii) LiOH, THF/MeOH/H20  
(2:2:1) (86%) OPMB
(xiii) 5 mo)% CSA 
CeHe.A
102
OTBS
O Hcr o  
warm to -50°C
66
Me "'OPMB AC2O, DMAP, CH2CI2 
(xvi) Mg, 20 mol% HgCfc 
(64%, 4 steps)
OTBS
OTBS
103 v  Me "'OPMB
(E:Z= 95:5)
OTBS
(xvii)TB A F,TH F,-15°C
(xviii) Tf2 0 ,2,6-Lutidine,
Me "OPMB
CH2CI2 , -10°C  
(71%, 2 steps)
Scheme 13 Evans’ synthesis of the bryostatin 2 BC-ring synthon 64.
A Brown-Patterson DIP-CI-mediated asymmetric aldol reaction 62 with the pre-prepared ketone 93 
produced the desired p-hydroxy-ketone 100 with 93:7 ds in favour of the desired adduct. Scheme 14 details 
the route taken to ketone 93, which involved a Sharpless kinetic resolution 40, a protection and an 
ozonolysis.
Ph
TBSO
Me
91
OH
(i) 15 mol% L-(+)-DIPT, 
10 mol% Ti(OPr-/)4
t-Bu0 2 H (0.7 eq.) 
CH2CI2 , -20°C
Ph
TBSO
92
Me
(ii) NaH, PMBBr, cat. BiuNI,
THF. 0°C  to RT
(iii) 0 3, CH2Cl2/MeOH. -78°C, 
then M62S, warm to RT
(25-35%, 3 steps)
TBSO
93
Scheme 14 Asymmetric synthesis of methyl ketone 93.
Fortuitously, the samarium-catalysed Tischenko reduction 63 of 100 not only installed the requisite 
stereochemistry for the C(25)-hydroxy, it also positioned a p-nitrobenzoate group on 0(23) in 101 (Scheme 
13). Subsequent silylation and set the stage for dehydration to the phenylsulfone glycal 66. A Julia
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olefination 36 between 65 and 66 forged the C(16)-C(17) double bond with high geometric control (E:Z = 
95:5) procuring 63 in a reasonable 64% yield. Selective O-desilylation of the primary silyl protecting group 
and exposure to triflic anhydride and 2,6-lutidine subsequently delivered the triflate ester 64.
1.3.2.6 Completion of the bryostatin 2 synthetic venture
The cornerstone of Evans’ the synthetic strategy for bryostatin 2 was his linking of the 
aforementioned A- and BC- segments via a Beau-Sinay glycosulfone C-alkylation reaction 51 (Scheme 15). 
The coupling of the anion derived from 63 with 64 initially produced a glycosyl sulfone mixture 104 which 
underwent ready hydrolysis to the hemiketals 62, which existed as alongside a small amount (15-20%) of 
the open-chain hydroxy ketone isomer. The high-yield of this alkylation was indeed impressive given the 
severe steric hindrance around the C(9) anionic site, and the electronically deactivating B-ring pyran oxygen 
that was present in the triflate component. The next step of the synthesis was ring-opening of the hemiketal 
in 62 with TESCI, and conversion of the anilide to a benzyl ester.
The anilide protecting group cleavage was best performed by protecting the anilide nitrogen, with a 
Boc prior to treatment with LiOBn. The protected ester 106 then underwent a selective epoxidation of the 
more electron-rich glycal double bond at C(19)-C(20) and an acid-catalysed epoxide ring-opening with 
methanol acquired the methyl glycoside 107. Dess-Martin oxidation 64 at C(20), and a global O-desilylation 
with HF-MeOH also brought about a Fischer glycosidation, which delivered the triol 109 in good yield.
A selective O-triethylsilylation was now performed at hydroxyls -3 and -13, followed by 
hydrogenative cleavage of the benzyl group using a Pd/C catalyst in cyclohexa-1,4-diene 65. The seco-acid 
61, then underwent macrolactonisation under the conditions developed by Yamaguchi 66. Ketone 60 was 
then selectively O-desilylated at 0(13) and oxidised to the diketone 58. Positioning of the required (E)-olefin 
at C(13)-C(34) was accomplished with Fuji’s chiral phosphonoacetate 59 50 and delivered an isomeric mix 
of 5.5:1 in favour of the correct geometry to yield 57. Interestingly, steric hindrance in the vicinity of C(19) 
resulted in no olefination occurring at the adjacent C(20) position. The second exocyclic olefin was installed 
in a slightly better 12:1 (E:Z) isomeric mix, via an aldol/dehydration sequence with methylglyoxalate to 
obtain 56. Here, a CBS-reduction completed the installation of the final stereocentre at C(20). The isolation 
of 111 was aided by the trapping of the unstable alcohol as an O-methoxyacetate.
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Scheme 15 Unification of the A-and BC-ring systems and the final stages of Evans’ bryostatin 2 synthesis.
Selective hydrolysis of the C(9) methyl glycoside and desilylation at 0(3) was achieved with PPTS 
in aqueous THF. As had previously been pointed out by Masamune 35 in his synthesis of bryostatin 7, 
hydrolysis of the C(19)-methyl glycoside under mildly acidic conditions was hampered by the presence of a
2 1
Chapter 1: Introduction
C(20)-O-acyl protecting group. The Masamune O-deacylation tactic overcame this problem allowing the 
glycoside to be hydrolysed with p-TsOH in aqueous MeCN, without any product decomposition. To 
complete of this elegant synthesis of bryostatin 2, the C(20) acid side-chain was installed via a selective 
esterification with octadienoic acid and the PMB at C(7) was deprotected with DDQ 38.
1.3.3 The Nishiyama-Yamamura total synthesis of bryostatin 3 (2000)67
1.3.3.1 The retrosynthetic planning for bryostatin 3
Bryostatin 3 is unique amongst all the bryostatin family members, by virtue of its C(22)- 
stereocentre being involved in an a-p-unsatu rated y-lactone system. This extra feature clearly adds to the 
synthetic challenge of these molecules. Nishiyama’s initial plan for this molecule called for a 
macrolactonisation of the seco-acid 113 under Yamaguchi conditions to establish its 20-membered 
macrolide ring (Scheme 16).
MeQMeOMeQ .OTBS•OAcHQ V leQMeQ .OTBS.OAc Mel -OTBSMel
:hq CO2AII BnO 116 117
114 OTBSOH
Julia Olefination
‘O /"'O H ‘O I 'OTES ph0zS
BOMI•Me H
113 CHO OMe Me
Bryostatin 3 TESO""Yamaguchi 
Macrolactonisation and 
Fuji Asymmetric 
Olefination
OTES HO"" 119
115 OTBDPS
118 OTBDPS
Scheme 16 The Nishiyama-Yamamura retrosynthetic analysis of bryostatin 3.
Final introduction of the B-ring exocyclic olefin would be accomplished with Fuji’s chiral 
phosphonoacetate 50, although the greater complexity of the ketone on which this would be attempted 
offered considerably greater uncertainty for acquiring the desired (£)-geometry. Disconnection across the 
C(16)-C(17) trans olefin next led to AB-ring segment 114 and the C-ring segment 115 which would be 
conjoined via a Julia olefination 36. For the “Northern Hemisphere” 114, a dithiane coupling between 117 
and iodide 116 was envisioned while for the “Southern Hemisphere”, a chelation-controlled addition 
between vinyliodide 118 and aldehyde 119 would set the C(22) stereocentre.
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1.3.3.2 Preparation of the enantiopure B-ring iodide 116 from D-mannitol
,,.OH
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(ii) N a l04, CH2CI2, 
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OH vacuum dist 
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(vi) 0 3, then Me2S 
(vii) K2C 0 3
OSiMe3
ZnCI2, CeHe, RT 
(72%)
121
CHO
125 MeO OMe
(vii) NaBH4
(viii) NaH, DMF, BnBr 
(61%, 4 steps)
(ix) IR-120 H+, MeOH
(xi) N a l04, aq. NaHC03, MeOH 
(xii) NaBH« (76%, 3 steps)
123
(iv)<^ MgBr 
Cul, Me2SiCI
DMPU, THF
(92%)
OH OBn
MeO OMe 
126
(xiii) TsCI, py (89%)
(xiv) Nal, Me2CO
124 O
MeQ
Me
BnO
O
116
Scheme 17 The Nishiyama-Yamamura synthesis of the B-ring synthon 116.
At the outset of their synthetic venture, Nishiyama and Yamamura’s plan was to utilise materials 
emanating from the chiral pool, with construction of the requisite B-ring iodide 116 commencing with the 
known conversion of D-mannitol into protected aldehyde 121 68. This then underwent a zinc-mediated 
hetero-Diels-Alder (HDA) reaction 69 with Danishefski’s diene 122 to produce the enone 123 as the single 
(S)-isomer.
The stereospecific addition of a vinyl anion at the glycosidic position was carried out via a copper- 
mediated Grignard coupling to yield 124, allowing protection of the keto unit as its O-dimethyl acetal, under 
conditions that preserved the existing O-isopropylidene acetal. This opened the gateway to ozonolytic 
cleavage of the terminal olefin to produce the axial aldehyde. However this undesired stereochemical 
situation could quickly be rectified by a base-induced epimerisation to the more stable, desired equatorial 
aldehyde 125. A borohydride reduction of this aldehyde then allowed O-benzylation, acetonide removal, 
and manipulation of the diol into alcohol 126. A primary tosylation / halide displacement sequence furnished 
the B-ring synthon 116.
1.3.3.3 Preparation of the AB-ring intermediate 114
In the synthesis of the dithiane coupling partner 117 with iodide 116, the Keio group employed 
some of the chemistry described by Masamune in his work for the AB-ring sector (see Scheme 4). Epoxide 
13 readily underwent regioselective reductive ring opening, O-silylation and O-debenzylation to yield 127. A
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Swem oxidation to the aldehyde then allowed dithiane installation to give 117 with no loss of the acid-labile 
silyl ethers.
The 2-lithio-anion of 117 underwent addition to the iodide 116 to set the C(5)-C(16) carbon chain, 
and a selective O-desilylation and oxidation yielded the aldehyde 129. The aldol addition of the C(1)-C(4) 
spiroacetal protected synthon 130 delivered the C(5) stereocentre in 131, when the acetai unit was cleaved 
to reveal the p-hydroxy ketone allowing a hydroxyl-directed reduction 56 and completing the final chiral 
centre array in 132 at C(3).
HO OH 
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Scheme 18 Nishiyama-Yamamura synthetic strategy for the AB-aldehyde synthon 114.
After removal of the dithiane moiety with mercuric-chloride, Fischer glycosidation and O-silylation 
afforded the methyl glycoside 133. Hydrogenolytic cleavage of the benzyl ether and protecting group 
interchange next yielded the allyl ester 134, and TPAP oxidation of the C(16) alcohol completed the 
synthesis of the AB-ring synthon 114.
24
Chapter 1: Introduction
1.3.3.4 Synthesis of the C-ring sulfone 115
135
(i) TsCI (1.5 eq.), py
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60°C (65%)
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(vi) UAIH4, 
Et20 ,  A. 12 h 
(99%)
CHO O  
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Scheme 19 Synthesis of the C(22)-C(27) aldehyde segment 119.
The chiral building block selected for the synthesis of the C(22)-C(27) aldehyde 119 was the 
carbohydrate derivative diacetone D-galactose, as this precursor possessed two of the required 
stereocentres. It is available from diacetone D-glucose 135 by O-tosylation at OH(3), base-catalysed 
elimination with KOH, and face-selective hydrogenation of 136 70. After conversion to 137 a two-step 
deoxygenation of the hydroxyl via tosylation and LiAIH4 reduction delivered the b/s-acetonide 138.
The furanose ring was then opened with 1,3-propanedithiol, and a re-protection of the 1,2-diol 
formed alcohol 139 in excellent yields. The aldehyde precursor 119 was completed by a BOM etherification 
and thioketal hydrolysis.
The synthesis of vinyl iodide 118 (Scheme 20), again began from diol 11. After conversion to the 
thiophenyl aldehyde 142, Wittig olefination and Sharpless asymmetric dihydroxylation 71 collectively 
permitted installation of the C(20)-stereocentre. Acetal protection of the diol array in 142 gave 143, and set 
the stage for ester reduction and subsequent dibromo olefination under Corey-Fuchs conditions 72 to furnish 
144. Conversion to the lithium acetylide with n-BuLi and exposure to paraformaldehyde next resulted in the 
expected propargylic alcohol. Hydroxyl directed hydroalumination of the alkene, and in-situ trapping with 
iodine delivered the required vinylic iodide, and acid cleavage of the acetonide yielded the triol 145.
Selective O-silylation and diol differentiation led to 118, to complete the synthesis of the desired 
coupling target. The crucial union of 118 and 119 was accomplished by halogen-metal exchange with a 
mixture of methyl- and f-butyl lithium, and proceeded with 3:1 selectivity in favour of the desired alcohol. O- 
Silylation subsequently procured 147. Thioether oxidation to the corresponding sulfone, DDQ mediated 
cleavage of the PMB group and C(19) oxidation 64 delivered the ketone 148 in excellent yield. The BOM
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ether was then cleaved by hydrogenation without damage to the alkene functionality. A novel Fischer 
glycosidation 44 was then carried out to yield the methyl glycoside 149. Silyl group interchange then 
delivered the phenyl sulfone 115.
(i) MsCI, py, 
CH2CI2
(iii) PhSNa, OMF, 
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Scheme 20 The Nishiyama-Yamamura synthetic pathway to the bryostatin 3 C-ring synthon 15.
1.3.3.5 Union of the AB- and C-ring intermediates and synthesis of bryostatin 3
As had been described by Masamune with a similar related C-ring intermediate, a successful Julia 
olefination 36 could be effected between the lithiated sulfone 114 and the aldehyde 115. In-situ benzoylation 
yielded the expected benzoyl sulfone mixture 150, which then underwent Na/Hg elimination to yield the 
desired (E)-olefin 151 (Scheme 21).
The different labilities of the various silyl ethers was exploited first by a selective cleavage of the 
allylic and C(22)-OTES ethers to give diol 152. Selective oxidation of the allylic primary OH then followed; it 
was accomplished by hemi-acetal formation and further oxidation to the butanolide unit. Selective removal 
of the C(20)-OTES subsequently afforded 154.
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Scheme 21 The union of the AB- and C-ring intermediates 114 and 115 in the synthesis of bryostatin 3.
The octadienyl ester side-chain was appended to 154 under the Yamaguchi esterification 
conditions 66. Compound 155 then underwent acetonide cleavage to the diol 156. The C(3) and C(26)- 
hydroxyls were then selectively silylated, for steric reasons, and the seco-acid 113 unveiled by cleavage of 
the ally) ester with tetrakis palladium (0).
A Yamaguchi macrolactonisation was then performed on 113, under conditions of high dilution. A 
global O-desilylation in aqueous HF not only cleaved the silyl groups, it also brought about hydrolysis of the 
C(9) glycoside and C(13) ketal to yield 157. Olefination at C(13) was then effected using Fuji’s chiral
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phosphonoacetate 95 50. Although this reaction was potentially problematic and very high risk, it resulted in 
a favourable 9:1 (E:Z) ratio of the product, in good yield. This system gave much better E/Z selectivity than 
Evans’ much simpler system (58 in scheme 15). As had been reported in the previous total syntheses, the 
lability of the C(19) glycoside was problematic with the C(20) ester flanking functionality present, however 
by using aqueous TFA at room temperature, it was found that desired C(19) hydrolysis could be 
accomplished without the need for ester cleavage.
The final hydroxyl elaboration to position an acetal at C(7) was accomplished by a transient 
protection of the C(26) hydroxyl as its silyl ether 158, and installation upon exposure to acetic anhydride. 
Interestingly, the C(3), hydroxyl was left untouched in this manipulation, and this was assumed from a 
hydrogen-bond network involving the C(9) and C(19)- hemiketals to render this position locked inside the 
macrolide ring. The final step in the synthesis was the removal of the silyl ether at C(26) to secure 
bryostatin 3 in a remarkable synthesis, and the synthetic efforts in this area opens the potential for future 
commercial applications.
1.4 Synthetic studies on the bryostatins
In conjunction with the three total syntheses reported to date, there has been significant work in 
bryostatin synthetic programmes from a number of groups. This considerable effort has led to the 
publication of a number of individual pyran ring sections capable of further manipulation.
1.4.1 Thomas’s synthetic route to bryostatin 11 73
1.4.1.1 Thomas’s retrosynthetic strategy for bryostatin 11
In his synthetic efforts towards members of the C(20)-deoxy class of bryostatins, Thomas has 
described an approach to the of a B-ring synthon 159, and the C-ring phenylsulfone 160 (Scheme 22).
Thomas’ plan for procuring the C(10)-C(16) B-ring intermediate 159 would exploit a vinyl radical 
cyclisation to establish the pyran ring-system and simultaneously set the exocyclic enoate and C(11) 
stereocentre. They postulated that the (Z)- vinyl radical 162 would lie in the equilibrium with its (E)-
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counterpart, and that the (Z)- radical would cyclise more rapidly, due to its transition state for addition being 
less hindered than that for the (E)-isomer.
ho >PMB
OH
H-atom abstraction on 
Lass Hindered Underside
«^C 02Me
6 -Endo-T rig Captodatlve 
Radical cyclisation
M e 0 2C ^ 5>ix ^ Y ^ OH M e0 2C ^ V ^ Nf '  Me0 2C
/
T °
159  OTBS
x °161 OTBS
QMe
162
t
OTBS
OH 
(S)-glycidol
P h 02S
bryostatin 11
160
C 0 2Me
PhS.
OPMB
164
163
Mlglta Pd(0) Catalysed
Cross-Coupling
Scheme 22 Thomas’s retrosynthetic plan for the bryostatin 11 B- and C- ring intermediates.
A sterically favourable hydrogen abstraction from BuaSnH from the a-face of the ring in 161 would 
thereafter place the carboxymethyl substituent equatorial. Further retrosynthetic analysis of 162 led to (S)- 
glycidol being selected as an appropriate starting material as it exhibited a stereochemical match with the 
C(15) stereocentre of 159. For construction of the C-ring synthon 163, the cross-coupling of vinyl bromide 
165 with enol stannane 164 was envisaged; further underlining the range of strategies that can potentially 
be employed in the bryostatin field.
1.4.1.2 Thomas’s racemic free-radical routes to the bryostatin B-ring (1989 and 2000)
To validate his proposed synthetic route, Thomas initially employed racemic glycidol (Scheme 23) 
in his synthesis of the B-ring synthon 159. The route commenced with the O-silylation of ±glycidol to obtain 
166, and a ring opening with the lithiated methyl propiolate to access alcohol 167. A rhodium catalysed 
carbene insertion of 168 into the hydroxyl of 167 thereafter led to the alkoxymalonate 169 74, and 
subsequent alkylation 75 yielded the aminomalonate 170. The latter underwent quaternisation and 
decarboxylative elimination upon exposure to methyl iodide in acetonitrile at reflux, to furnish the enol ether 
171 in 70% yield.
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To access the desired precursor 172 for the proposed radical cyclisation, a tributyltin hydride free 
radical mediated addition to the acetylene of 171 was effected under carefully monitored conditions. The 
vinyl stannane 172 was then subjected to a halogen-metal exchange to obtain the vinyl iodide 173.
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Scheme 23 Thomas’s free radical cyclisation to control the B-ring olefin geometry.
It was found that by heating 173 with tributyltin hydride and AIBN in refluxing benzene, the desired 
cyclisation proceeded to give a mixture of the B-ring enoates 175 and 174 in a 4:1 ratio in favour of the 
desired (£)-exocyclic enoate. The enhanced electrophilicity of the C(10) ester was then exploited for a 
selective borohydride reduction to deliver the final B-ring synthon 159 in a creditable 9 steps. In an attempt 
to improve the observed selectivity in the cyclisation process, the synthetic route was repeated with a PMB 
ether positioned at OH(16) (Scheme 24).
1# C 0 2Me 1#
5  0 ) NaH. n  M eO ,C / S ? /l  (v/iii) Bu3SnH, ^C O jM e W ^ ^ C 0 2Me ^ ^ ^ ^ ^ C O z M en-Bu4Nlv  < Y   ™ 2 I cat AIBN M e 0 2C ^  Y  T  M e 0 2C y
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Scheme 24 Alternative protecting group strategy in the bryostatin B-ring synthesis.
Initial etherification of the racemic epoxide to 177 followed by conversion to the vinyl iodide 178 as 
before allowed this ring cyclisation to be studied. Although the 6-endo addition to the (E)-enoate was carried
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out in a comparable 4:1 ratio, the stereochemical integrity at C(10) of the products was diminished 
considerably. It was suggested that this unfavourable outcome was the result of intramolecular hydrogen 
abstraction from the benzylic position of the protecting group rather than from the stannane.
1.4.1.3 Thomas’s asymmetric synthesis of the C-ring sulfone 163 (2000)
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Scheme 25 Thomas’s palladium (0) catalysed coupling strategy for the bryostatin 11 C-ring.
The route to vinylic bromide 186 set off from the a-p-unsaturated ester 182 and featured a 
reduction to the allylic alcohol 183 and an O-silylation as the first two steps in the synthesis. A Sharpless 
asymmetric dihydroxylation on olefin 184 positioned the C(25) and C(26) stereocentres in 185 which were 
then O-isopropylidenated; subsequently desilylation yielded the Masamune intermediate 33. An oxidation 
and conversion to the vinyl stannane 39 was accomplished under the conditions previously reported by 
Masamune35/ (see Scheme 6).
The final halogen-metal exchange with A/-bromosuccinimide delivered the required C(21)-C(27) 
synthon 186. Its cross- coupling with the enol acetate 190 was readily implemented with palladium (0 )76 to 
establish the C(17)-C(27) carbon backbone. A thioether to sulfone oxidation with m-CPBA completed the C- 
ring synthon 163. The coupling partner 190 was readily acquired from the ketone 187 in four steps (see 
Scheme 25).
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1.4.2 Vandewalle’s synthetic studies on bryostatin 11 (1990’s ) 77
1.4.2.1 Attempted construction of the C(1)-C(9) backbone via a dithiane coupling strategy
OH
191
(i) UAIH4, THF, 
0°C, then 
reflux, 5h
(ii) 3-Pentanone, 
p-TsOH, THF, A. 5 h
(81%, 2  steps)
(vo r ^ iS^S
HO !>c
192
PMBO
194
n-BuLi, THF, 
-10°C, 3 h 
(100%)
PMBC
195
OPMB
199
OH OTBDPS 
(4%)
PMBO
+
198
(iii) f-BuOK, THF,
PMBO, RT, 12 h
(94%)
(iv) 10% H C im iF , PMBO
RT, 5 h 
(92%)
(vii) f-BuOK, THF, 
BnBr, RT, 0.5 h,
,O H
OH
(84%)
OBn PMBO
(ix )H g (d 0 4)2,
C aC 03,
THF/H20 ,  
RT, 2 h 
OH OTBDPS (100%) 200
193
(v) NaH, THF/DMF, 
RT, 4 h; then
tosylimidazole, 2  h 
(92%)
(viii) n-BuU, TMEDA, 
then DMPU
PMBO
OTBDPS
OBn PMBO
(x) NaBH4,
M eO H ,R T HO
10 min 
(52%)
OH OTBDPS OH OTBDPS
(13%)
Scheme 26 Vandewalle’s attempted dithiane strategy for assembly of the C(1)-C(9)-sector.
Vandewalle’s strategy for the A-ring employed a dithiane / epoxide coupling strategy to assemble 
the requisite C(1)-C(9) carbon framework. This entailed the epoxide precursors 194 and 197 with the 
appropriate dithiane partners. The former epoxide was secured from (R)-pantalactone 191 in five steps by a 
pathway developed by Lavallee 78. Commencing with the reduction of 191, the placement of an acetal on 
the 1,2-diol function allowed the primary hydroxyls to be differentiated. After a PMB etherification, removal 
of the acetal, diol 193 was obtained and connected to the terminal epoxide 194 via base-induced 
elimination.
Oxirane 197 was readily prepared in three steps from (Z-)-malic acid 79. The first of the proposed 
couplings, with the lithio-anion of 1,3-dithiane provided 195 quantitatively. Although 195 underwent O- 
benzylation at C(7) fairly readily, the resulting dithiane 196 performed poorly in the second coupling with 
epoxide 197, with only a disappointingly low yield of the desired alkylated product 198 being isolated along 
with a small amount of the p-eliminated side-product 199. This first generation synthesis was completed by 
a mercury-induced cleavage of the dithiane unit, and reduction of the resulting ketone 200 to 201. However 
due to the significant impasse encountered in the aforementioned late coupling step, this synthetic strategy 
was later abandoned in favour of the one shown below.
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1.4.2.2 Synthesis of the C(1 )-C(9)-segment of the bryostatins (1991)
(Vi)
m ;
CuCNLi2
2
PMBO
194
Et20 ,0 ° C  
(84%)
PMBC
(vii) t-BuOK, 
OH THF, then 
BnBr, R T ,1 2 h
(x)
PMBO
,OBn
'C H O
206
r i r ^ i 207
O OTBDPS 
LDA, THF, -78°C;
then add 206 
(77%)
(96%)
PMB(
OBn (v iii)0s04, 
NMO,
h 2o / t h f ,
RT, 5 h
PMBO
204 C(5) = R
205 C(5) = S
fix) Pb(OAc)4, 
PhMe, py, RT, 
10  min
(90%, 2 steps)
,OBn (»i) M ^C tO M eh , 
Amberlyst-15, 
CH2CI2i RT, 0.5 h
PMBO. -OBn (xi) Lil, Et20 , PMBO. 
LiAIH(OBu-f)3,
-78°C *
(94%)(90%)
209208
OTBDPS OH OTBDPS
(>97% ds)
.OBn
PMBO
TBDPSO.
1
(95% ds) 210
Scheme 27 Vandewalle’s stereocontrolled route to the C(1 )-C(9) segment of the bryostatins.
An alteration of the synthesis led to the opening of epoxide 194 with the Lipschutz vinylcuprate 80 
to access the allylic alcohol 202 which was then O-benzylated and oxidatively cleaved to the aldehyde 206. 
An aldol addition between ketone 207 and 206 served to not only set the required C(5) stereocentre in 
excellent control, but also the C(1)-C(4) sector to be introduced in one fell swoop. The presence of the p- 
hydroxyketo unit in 208 lent itself to a hydroxyl-directed reduction, and literature precedent suggested good 
1,3-anti-selectivity would be achieved with the Evans reagent Me4NBH(OAc)3 56. However, this turned out 
not to be the case. After numerous reagents were evaluated, Li(f-BuO)3AIH in the presence of L il81 effected 
the desired antf-reduction, positioning the C(3)OH stereocentre in 209 with 95% ds. Subsequent protection 
as an acetonide produced the target synthon 210. Further elaboration of this late-stage intermediate will be 
needed in order to deliver a synthon capable of being further advanced towards the bryostatins. However, 
as yet, no additional results in this area have been published.
1.4.2.3 Model studies on the bryostatin B-ring (1991)
Vandewalle and coworkers have also reported a model study for obtaining the bryostatin B-ring 
system. The crux of Vandewalle’s B-ring strategy lies in a sterically-controlled, Wittig-Horner-Emmons 
olefination tandem intramolecular Michael sequence being applied on an appropriate hemiketal precursor to 
setup the pyran ring and C(11) centre. The C(15) centre emanates from (L)-erythrulose as shown in 
Scheme 28. After various manipulations, this chiral triol was converted to protected aldehyde 212, and then
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reduced, tosylated and alkylated with 2-TMS-1,3-dithiane 214. C-Desilylation, chain homologation, and 
treatment with mild acid led to the a-lactols 217 which then engaged in the proposed Michael addition to 
deliver the pyran 220.
HO J L oH
OH
L-Erythrulose
ZnCl2 ,Na2S0 4  HO 
(81%)
O « , £ £ “  ?T S . W h S S "  T t-T M S’x /  — , MeOH 1 I
O (Hi)Nal04. 0 A  (v )T s a .E t3N I K  (vii) / ~ [\  T
211  THF/H20  212 (76%, 4 steosl O  < >— TMS |
MeO^ ^.OMe
(viii) TBAF, THF, RT, 2 h ,
(ix) n-BuLi,
BrCH2CH(OMe)2 - g .
THF/HMPA -60°C ' ° ^ /
216
to -20°C, 36 h 
(78%, 2 steps)
(90%)
(xi) O O
(x) HCI (3%), C  ! 3 K ^ Y " 0 H  M e0~F
THF, RT, 2 h S k ^ O  Me°
n-BuLi, DME, 
OH 85°C, 12 h, (75%)
217
213 S 214  
n-BuLi, THF, -60°C  
to RT, (82%)
219 220
Scheme 28 Vandewalle’s synthesis of a C(9)-C(16) B-ring synthon 220.
Although Vandewalle’s group have reported no further work in this direction, Jadav’s group later 
used this type of approach in their route to a bryostatin AB fragment (see section 1.4.9).
1.4.2.4 Vandewalle’s strategy for the C-ring in bryostatins 1 and 11 (1994)
f-BuO..
(i) MO MCI, /-Pr2NEt, 
CH2CI2 (92%) .OH (iii) (COCI)2, M e ^ O ,  Et3N, CH2CI2, -78°C
Y Y
(vii) AliylSnBu3,
(v) f-BuOK, THF, C H ^fe , MgBr2 .Et20 ,
OH PMBCI (69%) o H C ^ Y ° PMB -78°C to O^C
/  ' c m  00 LiAIH4, THF, >  (iv) AllylSnBu3. CH2CI2,
Na2S 0 4 .10H2O OMOM MgBr2 .Et20 ,  -78°C to 0 C '
221 (83%) 222 (78%, 2 steps) 223 (>97% ds)
H O ,,^ O P M B OMBO. -  .OPMB * 8 0 ,.
(vi) Os0 4, 
»"OMOM N a l04, THF/H20  
(81%)
4,iOMOM
(97%)
DMBBr (79%) | | CH2CI2, H20
'"O M O M  (v i)O s04, N a l04, H O ' ^ y  ^ "" O M O M  (92%) 
Me2CO (81 %) OH
225 226
xi Q
)PMB DMBO„,
OHC
227
(xi) n-BuLi, THF, DMBO,,, 
C IC 02Me
(95%)
M e 0 2C
OPMB (xii) Bu3SnCu.Me2S.LiBr, 
THF, -78°C,
' "OMOM then MeOH (1.7 eq.)
"OMOM t-BuOK, THF, 
-78°C to -20°C  
(100%)
(xiii) /-Bu2AIH, Et20 ,
-78°C to 0°C  (95%)
OPMB
"OMOM
229
230
(xv) l2, CH2CI2 
(100%)
DMBO,(/ OPMB (xiv) t-BuLi (2 eq.), THF,
-78°C, then add 234 (50%)
0 M 0 M  (xiv) f-BuU (2 eq.), E t jO *
OTBDPS 0.5 h, then 236,
2 3 3  2-thienylCuCNLi, THF, (29%)
(xvii) S 0 3-py, Me2SO, Et3N, 235 R 1 = -OH, R2 = (R)-OTBS
CH2CI2 (100%) 237 R! = H, R2 = (O)
DMBO OPMB
OMOM
(xiv) TBDPSCI, DMAP, 
C H ^fe , (95%), 31 C 0 2Me
QDMB
OPMB
"OMOM  
OTBDPS
OPMBDMBO.
Bu3S n _ J  X 0 M 0 M  
^OTBDPS
232
PhS^  PhS
“T^-OTBS + "/
234
CHO 236
Scheme 29 The bryostatin C-ring synthesis of Vandewalle and coworkers
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Vandewalle’s group have also reported a convergent strategy to the C-ring intermediates 235 and 
237. Vandewalle’s routes to these compounds relied upon the addition of a common vinyl iodide 233 to 
either the aldehyde 234 or the epoxide 236 respectively. The synthesis of 233 began with the protection 
and reduction of D-isobutyl lactate 221 to obtain 222 (Scheme 29). After Swern oxidation, the C(26) 
stereocentre in the product aldehyde was used to direct stereochemical outcome of a Keck allylation 82 with 
allyllstannane which delivered 223 in high stereocontrol.
A p-methoxybenzyl etherification of the resulting hydroxyl allowed an oxidative cleavage of the 
terminal olefin to give an aldehyde 224, which then underwent a second Keck allylation to install the C(23)- 
hydroxy stereochemistry, again, with high stereocontrol. Subsequent protection of alcohol 225 as its O- 
dimethoxybenzyl ether permitted a two-step oxidative degradation to yield aldehyde 227 which was 
alkynylated with the Seyferth-Gilbert diazo-phosphonate 228 83. The lithio-anion of the resulting alkyne 229 
was then trapped with methylchloroformate, and the resulting alkynyl ester 230 subjected to a Piers 
conjugate addition. Vinyl stannane 231 was now reduced and O-silylated, and 232 converted to the vinyl 
iodide 233 by halogen-metal exchange. The coupling of aldehyde 234 with the vinyllithium obtained from 
233 delivered the C(20) hydroxylated intermediate 235 as a mixture of epimers. The coupling of the 
corresponding vinylcuprate with epoxide 236 also produced the C(20) non-hydroxylated intermediate 237, 
after Swern oxidation. The latter stages of the synthesis to 235 mirrored those carried out by Masamune 35 
(Scheme 6). However, the selectivity in the crucial vinyliodide addition step was eroded significantly when 
compared to that achieved by Masamune.
HO (iii) TsCI, py. DMAP Ph« 
(100%) (v) MeOH, ph<i H2S 0 4
(vi) NaH, Ph? 
TsCI, THF
192
Civ) f-BuOK, PhSH, 
0  Me2SO, 80°C
(97%) 239
,0 / V _  (76%) (68%)
236
:o
(vii) FBuPh(MeO)SiBr 
Et3N, DMF (80%)
Ph« i«  (x)TPAP, NMO, PhR
‘v ^ O T B S  CH2CI2
“ CHO (90%)
PhS PhS
(ix) HF.py, 
.OTBS MeCN
(viii) TBSOTf, 
.OTBS 2,6-lutidine, .OH
234 243 OH
(100%) I  CH2a 2
2 4 2  OTBP(OMe)S (100%) OTBP(OMe)S
Scheme 30 Vandewalle’s route to the aldehyde 234 and epoxide 236.
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The routes developed to the addition precursors 234 and 236 are shown in scheme 30, and 
proceed from the common intermediate 240 (Scheme 30).
1.4.2.5 Vandewalle’s use of (ft)-carvone for a the synthesis of Masamune’s C(27)-C(34)-alkyne 
fragment (1994)
244
(i) H20 2 . NaOH, 
MeOH, -10°C, 3 h
(92%)
(vi) LiBH4, THF,
RT, 6h; HO,
0
A  _________.
^  \  / .....  then Amberlyst-15,
MeOH, THF, 1 h 
(91%)OTBS
(ii) Ph2Se2. NaBK*. 
EIOH, AcOH
0°C, 15 min 
(63%)
245
(iii) TBDPSOTf. 
CH2CI2, 2 ,6 -lutidine, 
v "  0°C, 20 min, (89%)
„ (iv )O s04, K I04,fc
Uf1 THF:H20  (1:1), 12 h
246 (63%)
'O TB S
(v) m-CPBA (20 eq.), 
CH2CI2 . RT. 6  d;
then Me2S 
(70%)
247
(vii) (Me0 j2CMe2 , THF,
PPTS, RT. 2 h 
OH (viii) MeOH. PPTS, RT, 2 h
(73%, 2 steps) PMBC
248 249
(ix) TBDPSCI, py, DMAP, 
CH2CI2, 0°C, 16 h 
(x) PMBOC(NH)CCI3, 
TfOH, RT, 1 h
OTBDPS
(xi) n-Bu4NF, THF 
(72%, 3 steps)
(xu) S 0 3.py, CH2CI2, DMSO, 
Et3N, -10°C, 4 h (91%)
(xiii) (M e0 )2P(0)CHN2, 
t-BuOK, THF, -78°C to -30°C  
(95%)
PMBO,
36
250
Scheme 31 Vandewalle’s alternative route to the Masamune C-ring synthon 36 from (R)-carvone
A novel approach has been adopted by Vandewalle for construction of Masamune’s C(27)-C(34) 
alkyne intermediate 36 which utilises (R)-carvone as the chiral starting material. An initial face-selective 
epoxidation with basic hydrogen peroxide 84 afforded 245 which was then regioselectively opened in an 
organoselenium-mediated reduction 85 to produce 246 along with its C(2) epimer in an easily separable 4:1 
ratio.
An O-silylation on the remaining hydroxyl, and oxidative cleavage of the terminal olefin 
subsequently yielded diketone 247. A double Bayer-Villiger oxidation was next performed using an excess 
of m-CPBA; this installed the C(26) hydroxyl in masked form, and its identity was revealed after conversion 
the tetraol 249. A series of protecting group manipulations yielded the differentially protected C(21)-C(27) 
subsection 250, and the protected terminal alcohol to alkyne employed a Seyferth-Gilbert chain extension to 
deliver the desired Masamune intermediate 36. The increased number of operations required in this route 
compared with Masamune’s pathway detract from the worth of this sequence. Vandewalle has also 
reported an alternative synthetic pathway, that leads to 253; it is shown in Scheme 32.
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o
A
A c O * * \  / "
248 OTBS
(vi) PLE (EC 3.1.1.1), 
pH7 buffer, Me2CO,
35°C (78%)
(vii) MEMCI, APr2NEt, 
CH2CI2, RT, 16 h
(92%)
O
X
MEMCr \  ) .....
(viii) #-Bu2AIH, 
CH2CI2, -78°C, 1 h
(75%) M E M O " \  / "
251 OTBS 252
OTBS
(ix) (OMefcPfOJCHNj, MEMO, 
f-BuOK, THF,
-78°C to -30°C  
(45%)
OTBS
253
Scheme 32 Vandewalle’s synthesis of the alkyne intermediate 253 from (R)-carvone
1.4.3 R. W. Hoffmann’s racemic route to the C(1)-C(9) segment 267(1995) 86
(') f  ^ 2 5 5
v (iii)SO2CI2, \  (iv)Br2CH2Li,
CHO SnCI; X , O H  Et3N -90°C q  p  -806C (89-97%)
^O A c (ii) KOH ^  T (6 8%) " ^ n 'S'o  (v) TBSOTf,"
(69%, 2 steps) OH 0  °  2 6-lutidine Br-
254 256 257 (97%)
.O TB S (vi) n-BuLi 
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K ^ O T B S  f|x) Me4NBH(OAc)3 
I (95%, ds = 9:1)
1" r~~ (x) Me2C(OMe)2
H+ (88%)
267 T  266
'C02Bu-f
OTBS
(viii) Me3N O ' 
,.OH 6  d
0  (35% from 258)
C02Bu-f
OTBS 0 U0 264
OBu-f
OTBS
B
Br 262 o p h
263
C02Bu-f
Bs Trapp solvent 
O O -110°C. add 
aq. NH4CI
<OTBS
260 Br
|-110°C
^^^OTBS
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Scheme 33 R. W. Hoffmann’s pathway to a racemic C(1)-C(9) bryostatin fragment.
For his synthesis of an advanced bryostatin A-ring synthon 267, R. W. Hoffmann demonstrated the 
utility of the Matteson haloboronate displacement technology 87 for the efficient construction of the carbon 
framework (Scheme 33). Tin(ll)-mediated addition of prenyl chloride 255 to aldehyde 254 and subsequent 
hydrolysis led to the racemic diol 256 which could be converted to the cyclic sulfate 257. After nucleophilic 
displacement of 257 with the lithium anion of methylenedibromide, TBS- protection of the liberated alcohol 
yielded the intermediate dibromide 258.
When treated with base, 258 gave rise to two carbenoid intermediates 259 and 260 with 3:1 
selectivity. Whilst 260 underwent spontaneous ring closure to the [3.5]bicyclo- system 261, it proved 
possible to selectively trap the desired organolithium 259 with the cyclic boronate 262, and react the 
product of this union, 263, with the di-enolate 264 to assemble the C(1)-C(9) chain in 265. Oxidative 
removal of the boronic ester was achieved by extended exposure to trimethylamine-A/-oxide and revealed 
the (3-hydroxy ketone 266. After a Saksena-Evans anti-reduction 56, the 1,3-diol array was protected as an 
isopropylidene acetal to yield the desired precursor 267.
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1.4.4 The Kalesse enantioselective route to the C(1)-C(9)-segment 257 (1996) 88
Q 269
P I  cO,Et ^ ™ S (ii) BnOC(NH)CCl3, Bn0 (iv) Bakers Yeast,
2 H O ^ ^  CH2c J ,(7 7 % ) Bn0 V ^  H20 , sucrose, 72 hH ----------------- ^
TMS THF, NaH (1 eq.). 0°C, Ft (iii) KF, 18-crown-6, C 0 2Et (38%)
268 then LDA (1 eq.),-78°C  IT 2 DMF, H20  (99%) [ I
(83%) O 270 271
ii (vii) BH3, THF (41%) \ /
Bnrv ^  (v) Lindlar Catalyst, H2, EtOH BnO*. s  (viii) Dess-Martin periodinane
Y  <7o%> \  <«»> b k Y
^ " ^ C Q j E t  (vi)LiAIH4 ,E t20  L ^ \ .  (ix) \ , j ^ / T M S
272 6 H (67%) 2 73  OH OH J  2?4  2 7 5  Y ^ l
ee = 84% T iC U .C H ^ fe  ° H ° H
(6:1 selectivity at C7)
Scheme 34 Kalesse’s chemoenzymatic approach to C(1 )-C(9) assembly for the bryostatins.
In his efforts towards the bryostatins, Kalesse has reported an A-ring synthon for the C(1)-C(9) 
framework that employed a biotransformation to induce the chirality present in the target (Scheme 34).
An acetoacetate aldol reaction between the propargylic aldehyde 268 and ethyl acetoacetate 269 
formed the p-hydroxyketone 270. O-Benzylation and O-desilylation delivered p-keto ester 271 possessing 
the required array for kinetic resolution by stereoselective reduction with Baker’s yeast; a process that 
furnished alcohol 272 in 82% de and 84% ee. Manipulation of the terminal moieties by alkyne 
hydrogenation with Lindlar catalyst, and ester reduction procured 273, which then underwent a 
hydroboration and Dess-Martin oxidation. A chelation-controlled Sakurai reaction, under Lewis acid 
conditions thereafter resulted in an inseparable 6:1 mixture of alcohols enriched in 275.
1.4.5 The Kiyooka reagent-controlled asymmetric route to the C(1)-C(9)-segment (1997) 89
(i) °V °'I ,B _ H
x-s  ^ 1TM SO ^ ,OEt CHO Ts 278
276
S S
TBSO OBn
C 0 2Et
OBn C ^ C fe , -78°C, 8  h 
277
(vi) Ni2B, H2, EtOH, RT, 
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DMF, RT, 16 h
(iv) <-Bu2AIH, CH2C12i 
-78°C, 2 h (71%, 2 steps)
-S
279
(ii) Ni2B, H2, EtOH, RT, 
16 h (64%, 2 steps) 
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(iv) /-Bu2AIH, CH2CI2i TBSO OBn 
OH OBn -78°C, 2 h
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(v) °y \
T l
B -H
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CHO
TBSO^^^
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283
<V> \ V h
Y t
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OTMS 
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OEt
CH2CI2, -78°C, 8  h
H
C V T S .
^ •S  OEt 
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Scheme 35 Kiyooka’s asymmetric aldol approach to C(1 )-C(9) segment of the bryostatins.
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The presence of a partially masked 1,3,5 anti-anti hydroxyl array in the C(1 )-C(9) section of the 
bryostatins led Kiyooka to investigate a catalytic asymmetric aldol approach to the synthon 285, using the 
valine derived boranes 278 and 281 as chiral Lewis acids (Scheme 35). By employing the mixed silylketene 
thioacetal 276 for a series of boron-mediated aldol reactions with aldehydes 277 and 280, the required 
acetate aldol products were isolated after desulfurisation with nickel-boride.
The desired A-ring synthon 285 was produced as the sole product of a final aldol addition between 
283 and 284. The excellent levels of stereocontrol evident in this synthesis, coupled with the expedience of 
the route is testament to the utility of this strategy.
1.4.6 Roy’s synthetic studies on bryostatin 1 (1989,1990)90
1.4.6.1 The synthetic path to the C(1 )-C(9) fragment of bryostatin 1
co2mc (i) NaBH4, MeOH C 0 2Me (iii) a-chymotrypsin CO2H
CC»2Me («) H2C(OMe)2. P20 5 
(87%, 2 steps)
CO2MO (91%)
(iv) EtOCOCI, Et3N H 0
286
CHO
C 0 2Me 
OMOM
290
287
OMOM 288
C O ^ e  (v) NeBH4, THF 
OMOM (81%, 2 steps)
>94% ee
289
(ii) PDC, 
CH2CI2
C 0 2Me (84%) 
OMOM
(vii)
t-BuS
TMS
BF3.Et20 , CH2CI2, 
-7 8 C  (81%) 
(292:293 = 1.9:1)
281  (-BuS(O)C 
 >  HO
°  (viii) Me4NBH(OAc)3 <-BuS(0)C' ° H (ix) Hg(CF3C0 2)2 
HO.
(84%)
C 0 2Me 
OMOM
292 C(5) = (R)-OH
293 C(5) = (S)-OH
+ 294
C 0 2Me 
OMOM
296
C02Me
OMOM
294 C(5) = (R)-OH
295 C(5) = (S)-OH (-BuS(O)C
(ix) Me2C(OMe)2, 
CeHe, p-TsOH
(81%)
C 0 2Me 
OMOM
297 C(5) = (R)-OH
298 C(5) = (S)-OH
Scheme 36 Roy’s chemoenzymatic route to the bryostatin A-ring.
Roy’s synthesis of two potential bryostatin A-ring synthons has also exploited an enzyme mediated 
transformation for asymmetric induction. After a non-selective reduction of dimethyl 3-ketoglutarate 286 and 
subsequent MOM etherification of the resulting racemate 287 (Scheme 36), the key enzyme-catalysed step 
was the enantioselective hydrolysis of the pro-S ester, performed with a-chymotrypsin to yield the monoacid 
288 in 94% e e 91.
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A borohydride reduction of the mixed anhydride derived from 288, and partial re-oxidation led to 
the aldehyde 290, which readily participated in a Mukaiyama aldol condensation 92 with the silyl enolether 
291. Considerable effort was expended before BF3.Et20  was found to deliver the desired anf/-product 293 
as the predominant isomer of an inseparable 1.9:1 mixture of anti'.syn C(5) epimers. The two p-hydroxy 
ketones 292 and 293 were next subjected to a hydroxyl-directed reduction under Saksena-Evans conditions 
to yield the diols 294 and 295, which could be separated after lactonisation as only one isomer lactonised. It 
was possible to isopropylidenate and then separate out the desired C(1)-C(9) fragment 297.
1.4.6.2 Roy’s enantiospecific route to a C(21)-C(27) synthon 307
(ii) H2. 5% Pd-C, 
Et3 N, EtOAc
(i) HBr, AcOH, AcQ 
Ac20
AcQ (iii) UBH4 , THF, 
0°C to RT
(iv) Me2 C(OMe)2 . 
p-TsOH, C 6 H6
(87%)
(v) MeOH, p-TsOH i d S ? 2 ? f f lU % l’ 12 h RT -10 C to RT (84% ) ^
* 0  '  o r1 % l2 in HO / " O  (vii) K2 C0 3 , MeOH
304
MeOH
(77%) 305
(83%)
300
.OAc
(viii)
v ' O . /  S ^ S
"O '  n-BuLi, THF,
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Scheme 37 Roy’s synthesis of a C(21)-C(27)-dithiane intermediate for the bryostatins.
Roy’s analysis of the C(21)-C(27) section of bryostatin 1 indicated that there was matching of the 
C(23), C(25) and C(26) hydroxyl stereochemistry of D-galactose. Conceptually a selective deoxygenation of 
the C(3) and C(6) positions of D-galactose is required followed by chain extension at C(11). With this in 
mind, Roy selected the chiral building block D-galactono-1,4-lactone 299 as the starting material for the 
synthesis of 307.
After bromination and acetylation to yield the fris-acetate 300, elimination and stereospecific 
hydrogenolysis were employed for the deoxygenation of C(3). This was followed by in-situ dehalogenation 
to deliver the acetoxy-lactone 302, which underwent exhaustive reduction with lithium borohydride to reveal 
the bare tetraol 303. A series of acetonide manipulations 93 then afforded diol 305. Selective tosylation of 
305 was followed by formation of the epoxide 306. Completion of 307 involved selective opening of 306 with 
the lithio-anion of 1,3-dithiane. No further work on the elaboration of 307 has been reported.
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1.4.7 The H.M.R. Hoffmann route to the C(1)-C(16) AB-segment of bryostatin (2000)94
1.4.7.1 H.M.R. Hoffmann’s retrosynthetic analysis of the AB-ring 308
.OAc
>Tf
>TBS-OTBS
TPSO +TPSO.0
HO'-O TIPSO 309 310308 OTPSOTPS
" OH
314
ORTiO
Me Bryostatin 1 P4.
O
313
■OBn
312
316311 ,0
R°-f? T o o
315
324
314
^ / = \ 3 2 3  l-FO x
319 C02Me
OMe
y P
3 18  OBu-f
Scheme 38 H. M. R. Hoffmann’s retrosynthetic plan for the bryostatin northern hemisphere 308.
Hoffmann’s retrosynthetic strategy for the top-half of bryostatin 1 is shown in Scheme 38. He 
envisioned generating the AB system 308 from the union of the B-ring triflate 309 with the A-ring dithiane 
310. The triflate 309 was thought derivable from the enoate 311 via a WHE exocyclic olefination 49 on 
ketone 312. It was speculated that the steric hindrance from the bulky C(11)-trityl protecting group might 
shield one side of the pyran, and lead to production of the thermodynamically favoured (E)-olefin 311. 
Potentially this could be derived from the alkene 313 via ozonolysis and enzymatic desymmetrisation. 
Ketone 313 itself could be potentially be prepared from an iron-mediated furan [4+3] cycloaddition to the 
tetrabromide 315; a technology that had originally been devised by Hoffmann’s and Noyori’s groups 95,96.
The furan addition tactic was also thought applicable to the construction of the A-ring dithiane 
subsection; on this occasion the addition would be between enol 323 and furan 314 to deliver the racemic 
pyranones 321 and 322. The important alkene to lactone transmutation was thought possible via ketone 
reduction, alcohol protection and a Brown asymmetric hydroboration 97, the latter step proceeding 
selectively on the more electron-rich double bond. A subsequent Bayer-Villager oxidation would then yield
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320. Reduction of 320 to the hemiketal 319, and dithiane installation would then provide the linear-chain 
317. A chain homologation, and selective reduction would complete the desired C(1)-C(9)-synthon 310. 
With this as background, we will now discuss the Hoffmann route to 308 in more detail.
1.4.7.2 H.M.R. Hoffmann’s asymmetric synthesis of the C(19)-C(9)-dithiane 310
324 Cl
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Scheme 39 H. M. R. Hoffmann’s asymmetric synthesis of the A-ring dithiane synthon 310.
In a modification of Hoffmann’s original [4+3]- cycloaddition process, Fohlisch 96/// has shown that 
by reacting the a-chloromethylketone 324 with furan and lithium perchlorate, the racemic ketones 321 and 
322 are produced in 66% yield (Scheme 38). Hoffmann utilised this method in his outset to 310 (Scheme 
39). He subjected the addition products 321 and 322 to a stereoselective reduction with L-Selectride and an 
O-benzylation to obtain the alkenes 325 and 326. Asymmetric hydroboration was then carried out with (-)- 
IPC2 BH, but was not regioselective. However this impasse could be overcome by a PCC and Bayer-Villager 
oxidation which allowed the lactones 320 and 327 to be easily separated by chromatography.
Transesterification of 320 provided a mixture of the hemiacetals 319 which were ring-opened with 
BF3.Et20  and propane dithiol. Dithiane 317 then underwent a Claisen condensation with the enolate derived 
from 318 to yield the (3-hydroxy ketone 316.
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An Evans hydroxyl-directed reduction of the p-hydroxy ketone introduced the final stereocentre 
needed for the A-ring synthon, and the 1,3-anti diol array in 328 was protected as an acetonide, and the 
ester reduced to obtain alcohol 329. Removal of the benzyl ether is of particular note due to the labile 
dithiane moiety98, followed by selective positioning of a triphenylsilyl ether at OH(1) led to 331, and a final 
O-silylation resulted in the orthogonally protected C(1)-C(9) A-ring synthon 310.
1.4.7.3 H.M.R. Hoffmann’s construction of the AB-system 308 via the B-ring triflate 310
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Scheme 40 H. M. R. Hoffmann’s B-ring synthesis and formation of a bryostatin “Northern Hemisphere”.
The synthesis of the meso-ketone 313 had been previously reported by Noyori and coworkers 96 
from tetrabromo-acetone and furan in the presence of diiron nonacarbonyl catalyst. Initially this [4+3]- 
cycloaddition affords the dibromo adducts 332 and 333 (Scheme 40). A zinc-mediated reduction of the 
pyranones then produces the desired intermediate 313 quantitatively. Hoffmann protected ketone 313 as 
the acetal 324, thereby avoiding potential problems in the reduction of the b/s-aldehyde formed from the 
ozonolytic cleavage of the alkene.
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Acetylation of 334 yielded the meso-diacetate intermediate 335 required for enzymatic 
differentiation of the two enantiotopic acetoxymethyl groups, which was best accomplished with lipase PS at 
neutral pH; the desired alcohol 336 was obtained with excellent stereoselectivity. Removal of the cyclic 
acetal was accomplished with catalytic palladium(n) and protection of the C(10) hydroxyl followed. 
Trityloxymethyl ether 337 then underwent acetal deprotection to give 338. The planned olefination was next 
investigated, and as expected, the trityl ether had a most beneficial effect on directing the stereochemical 
outcome of this reaction. It was found that by exposing 338 to isopropyl phosphonoacetate for extended 
periods, the exocyclic olefin 339 was formed in superb (98%) ee. An O-silylation at OH(16) and ester 
reduction furnished 340, which was then further silylated, this time, with triphenylsilyl chloride. Selective 
removal of the trityl ether from 341 was accomplished with zinc-bromide, and did not cause concomitant 
loss of the potentially labile allylic protecting group. Alcohol 342 was then converted to triflate 309, the 
requisite intermediate needed for dithiane coupling.
This union was best achieved by adding the triflate 309 to a solution of the lithio-anion of dithiane 
310 in THF/HMPA. This produced the desired C(1)-C(16) carbon framework in reasonable yields. Hoffmann 
had also shown that by altering the protecting group at C(16), dramatic effects can ensue on the coupling 
yield. In completion of the synthetic route, a protecting group interchange was carried out to free the C(16)- 
hydroxyl in preparation for the coupling to a suitable bryostatin C-ring synthon. The expediency of this 
pathway is most noteworthy.
1.4.8 Janda’s polymer-supported synthesis of the bryostatin 1 C(21)-C(27)-sector (2000)99
In a novel solid phase synthesis of a bryostatin C-ring synthon 356, Janda has explored the use of 
a polymer support 344 (synthesised in four steps from dihydroquinone). This was attached to nitro-propanol 
345 at the dihydropyran position (Scheme 41), and an intermolecular nitrile oxide cycloaddition reaction 
effected with methyl vinylketone 347, yielded the racemic isoxazolines 348. Keto reduction with L-selectride 
thereafter produced the diastereomeric alcohols 349 and 350. In order to facilitate the separation these 
intermediates, treatment with Novozyme-435 and vinyl acetate as an acyl donor, delivered the requisite 
protected 351 and unreacted 349 in excellent selectivity, although in diminished yields.
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Scheme 41 Janda’s soluble-supported polymer pathway to a bryostatin C-ring synthon 419.
Cleavage of the polymer was completed by exposure to aqueous HF; the alcohols 352 and 353 
were readily separated by conventional methods. O-Silylation of 352 yielded 354 which was then reduced to 
the p-hydroxy ketone with Ra-Ni. A Saksena-Evans reduction and selective protection of the more 
nucleophilic C(23)-hydroxyl completed the route 356, which could potentially be used in a convergent 
strategy similar to those previously reported.
1.4.9 Yadav’s synthesis of the bryostatin “Northern Hemisphere” (2001)
M e 0 2C ^
OMOMOMOM
C 0 2Me 
Bryostatin 1
OMOM
Scheme 42 Yadav’s retrosynthetic planning for the bryostatin “Northern Hemisphere" 357.
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In their synthetic efforts towards the bryostatins, Yadav and coworkers have described the 
synthesis of an AB-ring segment 357 (Scheme 42) that has considerable for being further developed using 
the exocyclic olefination tactic employed by Nishiyama in their bryostatin 3 synthesis.
Their plan for the closure of the B-ring relied upon the Vandewalle intramolecular Michael addition 
tactic being applied to the enone 358. The latter would be available through a WHE olefination. A Fischer 
glycosidation would be employed to close the A-ring. The precursors for the requisite WHE coupling were 
the phosphonate 359 and the aldehyde 360.
1.4.9.1 Yadav’s asymmetric synthesis of the ketophosphonate 359
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Scheme 43 Yadav’s synthesis of the C(1)-C(10)-ketophosphonate 359.
An initial kinetic resolution of the homochiral epoxide 361 using Jacobsen’s procedure 101 reliably 
produced a mixture of 362 and 363 that were separated (Scheme 43). Epoxide 363 was ring-opened under 
BF3-catalysis with the lithio anion of a propargyl synthon. An O-benzylation and THP deprotection then 
ensued to procure the known alcohol 364, which underwent reduction to the allylic alcohol with LAH. A 
Sharpless AE helped position the C(5)-stereocentre with good levels of control. However, the surplus O- 
functionality in 365 needed to be removed.
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For this, the epoxyalcohol 365 needed to be iodinated, and the iodohydrin reduced with Zn dust. 
Protection of the remaining hydroxyl as a TIPS ether then delivered the terminal olefin 366. Hydroboration 
and Swern oxidation reaction subsequently yielded the aldehyde 367 which was condensed with the anion 
derived from methyl isobutyrate.
A 2:3 mixture of alcohols emerged from this addition in favour of the desired 369. O-Desilylation 
and O-isopropylidination now protected the OH(5)-OH(7) array. The phosphonate unit was elaborated by 
condensation of 369 with the lithio-anion of dimethyl methylphosphonate which gave 359 in 74% yield.
1.4.9.2 Completion of the AB-intermediate 357
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Scheme 44 Yadav’s synthetic route to the bryostatin 1 “Northern Hemisphere”.
For aldehyde 357, the diester 370 served as the starting material. Ketone protection, ester 
reduction and mono-benzylation were the first steps implemented to obtain 371 (Scheme 44). A Wittig / 
Sharpless AE sequence next ensued, and halogenation/elimination and O-silylation subsequently led to 
alkene 374. A three-step procedure oxidatively degraded the extra carbon atom to yield the primary alcohol 
375. Protecting group rearrangement released the C(10)-hydroxy for the final Swern oxidation needed to 
obtain the required aldehyde 360. The critical WHE olefination between 360 and 359 produced the desired
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(E)-enone 358 in moderate yields, and desilylation at C(15) induced the in-situ pyran formation to place the 
C(9)-side-chain in 377 in an equatorial configuration. Fischer glycosidation finally removed the acetonide 
and closed the A-ring thereby completing the bryostatin C(1)-C(16)-synthon 357.
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1.5 Synthesis of bryostatin analogues
1.5.1 Wender’s analogue work (1998,2000)3> 102
The early difficulties associated with isolating large quantities of bryostatin from natural sources
have led to a number of synthetic groups embarking on the synthesis of simplified bryostatin analogues that
will function as antitumour agents by an identical PKC-modulating mechanism. Many of these groups have 
also hoped to identify more potent analogues that could be administered orally. So far, only Wender’s group 
has made any in-roads into the development of analogues.
The early analogue studies of Pettit and Wender had shown that alterations could be made to the 
northern hemisphere that did not interfere with the PKC binding activity, whereas slight structural changes 
to the southern hemisphere resulted in substantial loss of PKC modulatory and anticancer activity. 
Therefore Wender’s later strategy for analogue design was to dispense with as much of the AB-ring 
segment as possible. To aid in the design of the analogues, molecular modelling was used in an effort to 
identify compounds that appeared capable of mimicking the hydrogen-bonding present in the natural 
bryostatins (Figure 1).
OAc
O-
h — o
O - H
‘OHO M e
RO
O M e
Figure 1 The bryostatin intramolecular hydrogen-bond network
These internal H-bonds are formed by interactions between the C(3)-OH and the 0(5) and 0(11) 
pyran oxygens, and also with the OH(19) hemiketal. This analogue search led to a number of candidates 
being proposed for synthesis, that had undergone sweeping changes to the C(3)-C(15) motif of the 
bryostatin framework. Indeed some of these targets possessed a relatively bare carbon chain but retained 
the crucial C(5) and C(15) pyran ring oxygens needed for maintaining the internal hydrogen bonding 
network. Significantly some of the compounds prepared have exhibited potent in vitro activity against a
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range of human cancer cell lines (Scheme 45), and similar PKC binding activities to bryostatin 1 have been 
found.
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Scheme 45 Some examples of Wender’s bryostatin analogues and their antitumour activities.
Wender’s analogue work to date has suggested the need for certain structural features in all such 
analogues to ensure potency in their binding to PKC. These features include the presence of a 20- 
membered macrolactone containing the free C(3)- and C(26)-hydroxy groups of (R)- configuration. 
Significantly the B-ring enoate and A-ring pyran can be totally deleted3' 116.
The central intermediate used in the assembly of Wender’s bryostatin analogues was the C-ring 
aldehyde 402, referred to as the recognition domain; which was prepared in 25 steps from methyl (R)- 
lactate 381 (Scheme 46). Its deployment in the synthesis of one representative analogue 379 will now be 
illustrated. After an initial Ag(i)-mediated benzylation, partial reduction of ester 382 to the aldehyde 383 
permitted a Sakurai reaction to be effected with allyl trimethylsilane and tin(iv) chloride. Following protection 
of the newly generated hydroxyl as a PMB ether, the olefin in 384 was ozonolytically cleaved to give the 
aldehyde 385. A non-stereoselective aldol condensation with the diketone 389, and acid-catalysed ring 
cyclisation / dehydration, thereafter yielded the glycal pyranones 390 as a 1:1 mixture of epimers. The two 
pyranones were separated, and the desired pyranone subjected to a Luche reduction 110 to set the C(21) 
equatorial hydroxyl.
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Resin, CH2CI2,4 A  
MS, RT, 46 h
0  (xxx) H2, Pd(OH)2, 
EtOAc, RT. 3 h
(88%, 2  steps)
OBn
C 7H15' ^ 0  ^ C 0 2Me 405 C7Hi5 C 0 2Me 379
Scheme 46 Wender’s asymmetric synthesis of the simplified bryostatin analogue 442.
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This served to direct the stereochemical outcome of the following epoxidation with m-CPBA in 
CH2CI2 and MeOH; the acidity of the reaction mixture was sufficient to bring about methanolysis to yield the 
methyl glycoside 391. A careful differentiation of the ring hydroxyls was accomplished by an equatorial 
benzoate protection, and an axial oxidation, to yield the ketone 392.
This allowed deoxygenation to be effected at C(21) with samarium diiodide, and an aldol addition 
to be performed with methyl glyoxalate. A two step mesylation / dehydration procedure was required to set 
up the desired ketoenoate 394 as a single isomer, in good yields. A second Luche reduction now followed; 
it very efficiently set the C(20)-stereochemistry of 395. Due to the ready availability of caprylic acid, and its 
potential for mimicking the bryostatin 1 C(20) side-chain, an esterification was performed with this acid 
under Yamaguchi conditions 66 to yield 396. All that now remained was development of the C(17) alkene 
moiety. For this, an O-desilylation and subsequent oxidation to the aldehyde 397 was implemented. An 
allylboration and acetylation next procured 398, whose olefin moiety was oxidatively cleaved and subjected 
to p-elimination to reveal the a-p-unsaturated aldehyde 400. Removal of the PMB ether at OH(25) now 
furnished 401, and it was considered prudent at this stage, to cleave the C(19) glycoside, as a later stage 
removal could have been problematic.
The desired glycoside hydrolysis could be accomplished with aqueous HF despite the flanking 
ester functionality, in an improvement over previous attempts at hydrolysis. The alcohol in 402 was then 
esterified with the AB-ring synthon 403 by the Yamaguchi protocol. After tethering of the AB-ring section 
had been accomplished, a desilylation and treatment with mild acid closed the 20-membered macrolactone 
to form the cyclic acetal 405. The final step in the synthesis of 379 involved O-debenzylation by 
hydrogenation over Pearlmans’ catalyst. Amazingly, notwithstanding the presence of the olefin and enoate 
motifs, this selective deprotection succeeded, to yield one of the most biologically potent analogues so far 
synthesised by Wender.
The synthesis of the AB-ring synthon 403 is shown in Scheme 47. In this, the spiro-acetal 406 was 
oxidised to the aldehyde 407 and a hetero-diels-alder (HDA) reaction was performed with Danishefski’s 
diene to produce the a-p-unsaturated 8-pyranone 408 in excellent yields. Luche reduction next introduced 
the equatorial hydroxyl of 409, and this was then protected with ethyl vinylether. In the presence of n- 
nonane, a Claisen rearrangement could then be effected by heating at 145°C to obtain 410.
52
Chapter 1: Introduction
nn (i) Dess-Martin
D - ^ 0  OH periodinane.
CH2CI2, 0.5 h 
(90%)
406
(iv) Hg(TFA)2,
^^ OEt ,
5°C, 20 h
(v) Nonane, 
145°C, 3 h 
(71%)
r^V^CHO (ii)
I o _ o  ™so OMe
407
(+)-Eu(hfc)3, 
CH2CI2, RT, 20 h; 
then TFA w. up 
(100%)
CHO
(vi) H2i Pd/C, EtOAc, 0.5 h 
(vii) (-)-lpc2BOMe, allylMgBr,
Et20 , RT, -78°C, 2 h 
(viii) TBSOTf, /-Pr2NEt, 
CH2CI2 (60%, 3 steps)
c r t y  ceci3'7Hi'?'
MeOH, RT, 
40 min 
(82%)
408
(ix) KMn04, N a l04, 
/-BuOH/H20
410 411
TBSO
OXr“
409
(x) HF/py, THF, RT, 18 h
(xi) TESCI, CH2CI2, Et3N I V
(53%, 3 steps)
403
c o 2h
TESO
Scheme 47 Wender’s asymmetric synthesis of the “Spacer Domain” of analogue 403.
Hydrogenation of the alkene was followed by a second allylboration, and a subsequent O-silylation 
to yield the protected olefin 411. The remainder of the synthesis consisted of an oxidative cleavage of the 
alkene to the seco-acid, and a silyl ether exchange delivered the acid 403.
Wender’s route to the analogue 379 was completed in a total of 43 steps, and had a longest linear 
sequence of 31 steps. Although this represents a significant reduction in steps when compared to the three 
bryostatin total syntheses, its great length and lack of stereocontrol in some places may prevent future 
commercial exploration. It does however serve to demonstrate that it is possible to greatly simplify the 
bryostatin framework without destroying the biological activity, allowing potential for further removal of 
functionality in related intermediates.
1.5.2 Wender’s refinement of the simplified bryostatin analogues (2002)103
In his quest to improve potency and still further reduce structural complexity, Wender identified a 
related analogue that replaced the C(27) methyl group with a H-atom (Scheme 48). A very economic 
strategy has been devised to 423 starting from neopentyl glycol 11. It was selectively monosilylated and 
oxidised to the aldehyde 412, and a chain homologation effected with b/s(chloromagnesium)butoxide; a 
double oxidation was then executed to obtain the b/'s-carbonyl 413. Introduction of the C(23)-hydroxy 
stereocentre was completed via a Keck allylation in the presence of trimethoxyboron in 92% ee. Closure of 
the 8-hydroxy ketone 414 to the pyran was next accomplished by treatment with mild acid. The resulting 
glycal was then epoxidised and ring opened to position the methyl glycoside. The 4:1 mixture of isomers at 
C(20) was then oxidised to the ketone 415 using catalytic TPAP.
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HO OH 
11
(i) NaH, TBSCI, 
THF, RT
(ii) S 0 3.py, Et3N, 
Me2SO, CH2CI2. RT
TBSO.
(iii)MgCI
OH
THF, -78°C
TBSO.
CHO (COCQ2, Me2SO,
CH2CI2. -78 C; then Et3N 
4 1 2  (54%, 4 steps) 413
(v) ^ ^ ^ \^ S n B u 3
R-BINOL (10 mol%),
HO Ti(0/-Pr)4 (5 mol%), 
B(OMefe, CH2CI2, RT 
(77%)
TBSO.
414
(vi) cat p-TsOH, PhMe, RT
(vii) MMPP, N aH C 03, TBSO  
CH2CI2/MeOH (2:1), 0°C (4:1 dr)
(viii) TPAP (10 mol%), NMO, 
CH2CI2/MeCN (6:1), 0°C to RT 
(52%, 3 steps)
(ix) K2C 0 3, MeOH, 
0 H C C 0 2Me, RT
(72%)
TBSO.
415
(x) NaBKU, MeOH, 
CeCI3.7H20 ,  -30°C
TBSO
C 0 2Me
(xi) C7H15C 0 2H, DIG,
DMAP, CH2CI2, RT o"
(93%, 2  steps) I
CrHis^O C 0 2Me
OHC
417
(xii) HF, EfcN, THF, RT 
(xiii) Dess-Martin 
periodinane,
NaHCOs, CH2CI2, 
0°C to RT 
(87%, 2 steps)
OHC
C 0 2Me
(»v) Br'w 0E t  
t-BuLi, Me2Zn,
Et20 , -78°C; 
then 1M HCI, RT 
(90%)
OHC
C 0 2Me
(xv) AD-Mix-p,
/-BuOH/H20  (1:1), 0°C
(xvi)p-TsOH, MeCN, H20  
(xvii) TBSCI. Im. CH2CI2, RT O'
(33%, 3 steps) / LC7H15 O
420
C(25)(R:S = 2.5:1)
OTBS
C 0 2Me
'C 0 2H
OTBS
2,4,6-trichloro-benzoyt chloride, 
DMAP, PhMe, RT, 1 h 
(87%)
(xxvii) HF.py, THF, RTOTB! OH
OHC' (82%)
OHOTBS
C7Hi5 O CC^Me 422
Scheme 48 Wender’s synthesis of the modified analogue 423.
The condensation with methyl glyoxalate was carried out in relatively mild conditions, and the 
resulting enone 416 was stereospecifically reduced under Luche conditions. Addition of the caprylic acid 
side-unit furnished the protected olefin 417. An O-desilylation followed by oxidation gave the aldehyde 418 
which was readily converted to the enal 419 by a coupling with the organozinc reagent derived from 
bromoethoxy-ethane. A Sharpless AD was then performed on the alkene, yielding a 2.5:1 mixture in favour 
of the desired diol. Its terminal hydroxyl was then selectively protected as a TBS ether, to produce the Co­
ring synthon 420, and it was at his juncture that the isomers were separated.
The AB-ring segment 421 was coupled to alcohol 420 under the Yamaguchi esterification 
procedure to afford 422. A global protecting group removal served to release the C(3)- and C(26)-hydroxyls, 
and close the lactone to deliver 423 in a remarkably efficient synthesis. The significance of removing the 
C(27) methyl unit served to increase the potency dramatically, when compared to the previously 
synthesised analogue 379, and indeed showed over a 100-fold increase in potency over bryostatin 1.
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1.6 Mendola’s aquaculture solution to the bryostatin 1 supply problem (2000)104
Before departing fully from our introductory discussion, a truly significant contribution has come 
from Dominic Mendola’s laboratory with regard to bryostatin aquaculture. In an attempt to cultivate 
meaningful quantities of Bugula neritina, Mendola has developed a marine aquaculture method in which 
colonies of bryozoan larvae are established, and cultivated at sea over a number of months. Gratifyingly, it 
is found that upon harvesting, the isolated yields of the bryostatins match those typically acquired from 
natural sources, meaning a large-scale production could possibly deliver the large amounts needed of 
between 100-200 g per annum for ca. $800,000. The aquaculture method of obtaining bryostatin 1 has the 
added advantage of being able to deliver the natural product at much lower cost than synthetic routes, 
although the limiting factor is still the relatively arduous task of isolation.
In an effort to impart an even greater degree of control over the colony production, Mendola 
investigated the possibility of using sea-water tanks. Unfortunately, this relied on the availability of large 
amounts of cultured plankton as food-stock, and since this was difficult to obtain, only limited quantities of 
the bryostatins were isolated. Other artificial sources of food were also investigated, however these were 
poorly received, and this route was therefore abandoned.
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1.7 Hale’s synthetic work on the bryostatins (1995,2000)105
1.7.1 Hale’s retrosynthetic planning for bryostatin 1
.OPMBTBDPSO.Me02C'^i
O CO2M0
Me Me \
424 I
Bryostatin 1 426 OTB DPS
Scheme 48 The Hale retrosynthetic analysis of bryostatin 1.
A total synthesis programme towards the bryostatins has been undertaken by our group, which 
has so far culminated in the development of some advanced intermediates and some novel PKC-a binding 
analogues. Our most recent retrosynthetic analysis of the bryostatin 1 array (shown in Scheme 48) has a 
chemoselective macrolactonisation on 424 delivering the final target. Further disconnection across the trans 
olefin suggested a Julia coupling 36 between the phenyl sulfone 426 and aldehyde 425 as a major fragment- 
joining step. Given the past precedents set by Masamune 35, Evans 47 and Nishiyama 67 in their respective 
endeavours, we anticipated that this would successfully install the desired (E)-geometry.
Aldehyde 425 appeared accessible from the union of the B- ring aldehyde 427 with the glycosyl 
sulfone 427a, in a modified Julia olefination (Scheme 49). One could easily imagine that this would afford 
an exocyclic glycal capable of undergoing conversion to the methyl glycoside under mild conditions 
(PPTS/MeOH). Subsequent selective PMB benzyl ether removal and oxidation would then yield 425.
Our original retrosynthetic proposal for the B- ring aldehyde 427 (Scheme 50) called for the acid- 
mediated Williamson intramolecular ring closure 106 of 429. Epoxy alcohol 429 itself looked accessible from
.OPMB.CHO P h S 02<„,TBDPSO.TBDPSO. .OPMB
OPMB
OTBS OTBS
Scheme 49 Our retrosynthetic plan for the “northern hemisphere” of bryostatin 1.
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the methyl enoate 430 via a series of hydroxy-differentiating steps. Retrosynthetic cleavage across the 
olefin, in turn, revealed the C2-symmetric ketone 432. Installation of the enoate either through a Wittig, 
WHE, or Peterson olefination would potentially allow complete control of the alkene geometry due to the C2- 
symmetry of the substrate. This key intermediate could itself potentially be formed via a Smith-Tietze bis- 
alkylation reaction 107 between TBS-dithiane 433 and the protected epoxide 434.
Me° 2C^  431
M e0 2C,
TBSO
TBDPSO'
PMBO OPMB PMBO OPMB
PMBO OH PMBO 430 432 p K .
428 429 1
4 3 4  OPMB
Scheme 50 Our tactics for complete control of the B-ring olefin geometry.
Retrosynthetic analysis of the C- ring phenyl sulfone 426 suggested that it could be prepared from 
the bicyclic lactone 435 (Scheme 51). An acid-catalysed bis-ring closure was proposed for the construction 
of this array on p-keto ester 436. It, in turn, could potentially be derived from a Claisen condensation 
between methyl isobutyrate 437 and ester 438. A series of Sharpless catalytic AD reactions were planned 
for introducing the requisite C(23)- C(25)- and C(26)- hydroxy stereocentres.
Ph S 02
M0 O2Cy437
OMe M
'"OTBS
MgOjC
QPMB 9TBS + OPMB OTBS
TESO"
4 2 6  OTBDPS
Scheme 51 Retrosynthetic tactics for the C-ring of bryostatin 1.
1.7.2 Hale’s C2-symmetry breaking olefination tactic for the construction of the B-ring 105/
The synthesis of the bryostatin B-ring synthon 428 commenced with the proposed Smith-Tietze 
b/s-alkylation (Scheme 52) between 2-lithio-2-TBS-dithiane 433 and the protected epoxide 434 108 (obtained 
in one step from (S)-glycidol). The inclusion of HMPA was critical to ensure clean TBS C- to O- migration, to 
generate the new monoalkylated 1,3-dithianyl anion capable of reacting with a second equivalent of epoxide
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434. Trapping of the resulting alkoxide as its TBS ether led to the formation of the desired dithiane 439 in 
good yield.
ns s
TBS
433
(i) t-BuLi, HMPA, THF, 
-78°C, 0.5 h
-78°C to 0°C, 1.5 h; 
-78°C add TBSCI 
warm to RT (87%)
A  (ii)C a C 0 3.
TBSO S^s OTBS Hg(CI0 4)2.xH2 0 I 
• ■ THF:HzO (4:1),
OPMB OPMB
439
0°C, 0.3 h 
(86%)
TBSO OTBS
(iii) .jjsJ'Xx-MflBr
(1 M), THF, 0°C, 0.3 h
OPMB OPMB (80%)
432
(iv) OsO, CHO
TBSO /  OH OTBS N a l04, aq. THF TBSO (  OH OTBS DMAP, CH2CI2,
76%
OPMB OPMB
440
OPMB
(v) (CF3C0 )2 0 , Et3N, OHC. 
TBSQ | OTBS
OPMB OPMB
4 5 °C ,16 h 
(80%)
441
OPMB
(viii) M n02,
CHCI3, RT, 24 h 
(80%)
(ix) CF3C 0 2H,
OPMB CH2CI2, anisole, HO 
4 4 3  -25 C, 8  h
(90%)
(xii) NaBH4, 
CeCI3.7H20 ,
MeOH. 0°C, 
1.5 h (87%)
446
OPMB
(vi) /-Bu2AIH, 
CH2CI2i -78°C
(vii) n-Bu4NF (1 M), 
OPMB OPMB THF, RT 8  h
442 (81%, 2 steps)
(xi)(x) Cyclohexanone, 
OH EtOAc, p-TsOH, 6  h
447
(xiii) f-BuPh2SiCI, 
imidazole, DMF,
0°C, 1 h 
(95%)
445
OTBDPS
OPMB
NHX
PMBO CCI3
PPTS, CH2CI2, 
RT, 8 h 
(88%)
(xiv)
HS SH 
BF3 .Et20 , CH2CI2,
-78°C to -10°C, 1 h 
(81%)
448
OTBDPS
OPMB
449
(xv) MsCI, collidine, 
CH2CI2, 0°C, 4.5 h
(81%)
(xvi) NaH, imidazole, 
THF, 0°C,0.4 h
(80%)
TBDPSO'
r'TJH
PMBO
429
(xvii) CSA (10 
mol%), CH2CI2, 
RT, 0.8 h
(87%)
TBDPSO
OPMB
428
Scheme 52 Hale’s fully stereocontrolled asymmetric synthesis of the B-ring 428.
The most favourable conditions for the removal of this thioketal involved treating 439 with mercuric 
perchlorate in aqueous THF. Frustratingly, however all our subsequent efforts to implement olefination via 
Wittig, WHE or Peterson methods on 432 were unsuccessful. However, an alternative less direct method for 
olefination employing allyl magnesiumbromide proved more fruitful. This addition led to alcohol 440 which 
then underwent facile oxidative cleavage to give 441. After trifluoroacetic anhydride- induced p-elimination 
to yield the enal 442, 1,2-aldehyde reduction with DIBAL and O-desilylation revealed triol 443. Due to the 
similarities of the hydroxyls present in 443 there was little room for manoeuvre in their differentiation.
However, allylic oxidation with Mn02 proved most versatile for this purpose, it allowing the 8- 
lactone to be generated. Cleavage of the terminal O-PMB ethers with trifluoroacetic acid and anisole 109 
thereafter formed 444. Selective protection of the 1,2-diol as its cyclohexylidene acetal 445 enabled the 
remaining OH to be protected as a PMB ether, the lactone to subsequently be reduced under Luche
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conditions 110 to afford the diol 447. A selective O-silylation of the primary OH with TBDPSCI then provided 
448 which underwent a Lewis-acid catalysed chemoselective removal of the acetal with propane-1,3-dithiol 
111 to triol 449. The mesyl chloride-collidine system of Burke and O’Donnell 112 was next employed for 
regioselective O-mesylation, and the resulting hydroxy mesylate treated with two equivalents of NaH. It was 
thought that epoxide formation might be followed by an in-situ ring-opening to yield the target. However only 
8-hydroxy epoxide 429 was ever isolated from this reaction. The desired pyran was obtained after 429 was 
exposed to mild acid 106. This totally stereocontrolled route to the requisite B-ring synthon was achieved in 
6.3% overall yield from epoxide 434, and is amenable to the production of 428 on multigram scale.
1.7.3 Hale’s early studies on the synthesis of the “Southern Hemisphere” of bryostatin 1.
r tu  o h  ii) NBuM 82SiCI,
i)AD-Mix-p, : : imidazole, QTBS
<-Bu0H:H20 (1 :1 ),  ^ D M F ,85°C ,4h
N 0°C, 72h “  HO + HO ° H + ° H ”  ^ TBS
450 451 452  453 4 5 4
trace trace (58%)
iii) cat. 0 s 0 4> N a l04, OTBS iv) Ph3P=CHC 02Et. v) /-Bu2AIH, CH2CI2, .O TB S
THF:H20 ,0 °C -R T , 3.5h ^  CH2CI2 ,33h , RT ^ ^ O T B S  -60°C, 3.5h
S ‘U'i h o n(70% ) o  6 TBS (97%) EtO20  ^ " " O T B S  (93% ) 0TB S
455 456 457
vi) (-)-DET, 
Ti(OPR-/)4, f-Bu02H,
CH2CI2l 4A MS. 
-40 to RT 
(96%)
- TB_ vii) REDAL, THF. 
,O TB S .2 0oc  14h
""OTBS (90%)
458 459
viii)An(OMe)2 ,
PPTS. DMF, PMPv
28mmHg,
50°C, 1.5 h 
(92%) 460
ix) ABu2A]H,
CH2CI2, -78°C PMBO  
to 0°C. 4.5h
xx) Me2SO,
(89%)
PM BO , / \ ^ O T B S  (COCI)2. CH2CI2, PM BO ,<^ \ . O T B S  xxi) Ph3P =C H C 02Et, 
f  Y  -78°C to -55°C; J  \  CH2CI2. RT. 15 h
. . .  OTBS E W 0 - C  0 H °  0T B S  (8 9 % ,2 .» P S )461
OTBSPMBO,,
"'OTBSE t0 2C
463
Scheme 53 Hale’s synthetic studies on the C-ring of bryostatin 1.
Our plan for creating the C-ring synthon 426 was based on a series of Sharpless asymmetric 
oxidation reactions 113 (Scheme 53) which began with the asymmetric dihydroxylation (AD) of (E)-1,4- 
hexadiene 450 at its more electron-rich double bond. This installed the required C(25) and C(26)-hydroxy 
stereocentres with high stereocontrol (94% ee). By employing 0.6 equivalents of AD-mix-p, only a slight 
amount of the undesired diol 451 and the over-oxidised tetraol 452 were ever produced; the predominant 
product was always 453. O-Silylation of the resulting diol gave 454 which then underwent oxidative
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degradation with Nal04 and catalytic 0 s 0 4 to give aldehyde 455, which readily participated in a Wittig 
olefination and a DIBAL reduction to secure the allylic alcohol 457.
A Sharpless asymmetric epoxidation was now performed with (-)-diethyl tartrate to set the C(23)
Positioning of a PMB ether protecting group at OH(23) was accomplished by p-methoxybenzylidination and 
selective reduction to alcohol 461. Oxidation at C(25) followed by a second Wittig olefination delivered the 
chain-elongated a-p-unsaturated ester 463. A second AD was then performed on 463 with AD-mix-p to 
introduce the C(20) hydroxy stereocentre (Scheme 54), and an acetal protection of the diol motif was 
completed with 2,2-dimethoxypropane. Implementation of a Claisen condensation with the anion from 
methyl isobutyrate delivered the p-keto ester 436, and the b/s-ring formation now looked within reach.
This desired ring closure would have to be carried out under acidic conditions; conditions that 
would almost certainly cause O-desilylation. Therefore it was reasoned that by converting these silyl ethers 
into more acid-stable pivaloyl esters, ring closure could be achieved cleanly. Dipivaloate 466 was easily 
accessed; it underwent cleavage of the PMB ether with DDQ to form the requisite 5-hydroxy ketone 467. 
Treatment of 467 with methanolic HCI then led to cleavage of the acetonide and effected an in-situ 
butyrolactonisation upon the C(20)-hydroxyl, yielding the methyl glycoside 435. This cyclisation nicely 
differentiated between OH-(20) and OH-(21)114.
oxygen stereocentre. The epoxy alcohol 458 was then regioselectively opened with REDAL 39 to yield 459.
.OTBSPMBO,, f-BuOH:H20 ,
'"OTBS
xii) AD-Mix-p, 
M eS 0 2NH2, OPMB
xiii) PPTS, 
Me2CO, 
Me2C(OMe)2l
.OTBS
"'OTBS
OPMB
463 (93%) OH 464
40°C, 16h 
(91%)
xiv) MeO,CCH(Me)2. 
LDA, -78 C to -55 C 
then -20°C, 1h
MeO
(89%)
OPMBOPMB xv) HF-Pyridine, 
^O TB S  C H jC I,. -40°C to 
-5 C, 30h
OTBS /ooo/\
,OH xvi) Me3CCOCI, Py, 
CH2CI2,0 °C  to RT
(96%)
xviii) AcCI, 
MeOH, 0°C  
then 40°C, 28h
OPMB
OPv xvii) DDQ, CH2CI2, |^eo . 
'  H20 , RT, 3h
"OPv iq 6%\
xx) PPh3=C H 0O 2Bu-f, 
CH2CI2, RT
(60%)
(E:Z selectivity = 3:1) C 0 2Bu-f
Me OMe H
xix) RuCI3 .H20 ,  N a l0 4, 
MeCN:CCI4:H20  (2:2:3), RT, 3 h
(92%)
468
Scheme 54 Continuation of Hale’s synthesis of the bryostatin 1 C-ring.
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Oxidation of the resulting hydroxyl 115 delivered ketone 468 which was then reacted with the 
phosphonate Ph3P=CHC02Me. Unfortunately, this led only to a 1:1 mixture of exocyclic olefins, with similar 
results being obtained under WHE conditions. The butyrolactone unit was clearly not exhibiting enough of a 
steric influence to favour the desired (E)-enoate, so an increase in the steric bulk of the ylid component from 
OMe to Of-Bu was examined. This led to a 3:1 mixture enriched in the desired olefin and completed the 
synthesis of the late-stage synthon 469.
It was at this point that I began my involvement in the project; my aim was to complete the synthesis of the 
desired C-ring synthon 426 via manipulation of 435.
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2 . 0  D is c u s s io n
2.1 Continuation of the first generation synthesis
Given the poor selectively encountered in the olefinations of 468, we decided to now position a 
more sterically demanding group on the C(20) hydroxyl; something that would clearly be much bigger and 
bulkier than the y-lactone. Our hope was to induce a much greater level selectivity in the Wittig olefination 
than was previously encountered. A triethylsilyl ether was deemed suitable in this capacity, and one could 
readily envision such a system reacting in the desired way (Scheme 55). We envisioned that the cardinal
intermediate in our new plan would be 471 and that it could readily be derived from 435.
Sulfone Installation  
\  Lactone
openingPhSO;
ProtectionOxIdation/oleflnatJon
Scheme 55 Overall retrosynthetic planning for completing the Bryostatin C(17)-C(27) C-ring.
Our strategy was first to position a suitable protecting group on the free hydroxyl at C(21), and 
then to exchange the pivaloyl esters at OH(25)/OH(26) for an acetonide. The likely ease with which a p- 
methoxybenzyl ether could be differentiated from the other functionality present in 435 led to its selection for 
blocking the C(21)-OH.
Treatment of 435 with excess PMB-trichloroacetimidate 116 in CH2CI2 and a catalytic amount of 
pyridinium-p-toluene sulfonate (Scheme 56) led to 473 in 70% yield, but extended reaction times were 
required. The slow rate of benzylation was presumably due to the unfavourable 1,3-diaxial interaction 
encountered with the anomeric OMe, and the steric bulk of the imidate. Saying this, any starting material 
that remained in this reaction could always be recovered.
Purification of the PMB ether 473 was usually hampered by the fact that an excess of the imidate 
had to be used, and it degraded to by-products possessing very similar Rf values to the product. Successful 
etherification was confirmed by the appearance of aromatic AX doublets at 5 7.20 and 6.82 ppm which
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exhibited a J coupling of 8 . 6  Hz in the 500 MHz 1H NMR spectrum in CDCI3i with accompanying loss of the 
broad OH doublet at 8  2.34 ppm.
Ether 473 was then subjected to hydrolysis using a large excess of a freshly made 1M sodium 
methoxide solution in MeOH at room temperature for 3 days. This served only to remove the remote 
pivaloate ester functionalities, leaving the lactone unit intact, possibly due to shielding from the adjacent 
geminal dimethyl entity, or to a Thorpe-lngold effect favouring butyrolactonisation after initial ring-opening.
19) PMBTCA (5eq.), 
PPTS (0.5eq.), CH2CI2 
(0.13M), RT, 48-96 hrs
20) NaO M e(1M ), 
MeOH (0.11M), 
RT, 72 hrs
OPMBOPMB
21) 2,2-DMP (0.13M), 
Me2CO (0.13M), PPTS 
40.25eq.), +4Q°C, 20 mine
22) Superhydride / UBH4 / 
L1AJH4, THF, -78°C to 0°C
OPMB OPMB
475 476
Scheme 56 Protecting group manipulation followed by attempts at lactone opening.
Amberlite IR-120 H+ neutralisation and work-up allowed the isolation of diol 474 in 73% yield. The 
loss of the two O-pivaloates was confirmed by the disappearance of the two t-Bu singlets at 8  1.17 and 1.15 
ppm in the 500 MHz 1H NMR spectrum in CDCI3. The ester carbonyl peaks which resonated at 8  177.5 and
177.3 ppm in the 125 MHz 13C NMR spectrum of 473 in CDCI3  were also absent. A broad OH stretching 
absorption appeared at 3446 cm' 1 in the IR spectrum of 474, and its HRMS confirmed our structural 
assignment, it showing an [M+Na]+ ion at m/e 447.1995 suggesting an empirical formula of C2 2 H3 2 0 8.
Gentle heating of the c/s 1,2-diol in a 1:1 mixture of acetone and 2 ,2 -dimethoxypropane containing 
a catalytic amount of PPTS caused rapid acetonide formation to give 475 typically in quantitative yield. The 
presence of two methyl singlets at 8  1.35 and 1.32 ppm in the 500 MHz 1H NMR of 475 in CDCI3, together 
with the loss of the broad OH resonance in the IR spectrum confirmed that protection had been successful. 
This now meant that the critical butanolide ring-opening could be attempted.
In our efforts to achieve this goal, a number of differing reducing agents were examined, including 
an excess of Superhydride® [LiB(Et)3 H)j or sodium borohydride in THF at -78°C. To our dismay, these 
served only to generate a large number of products according to TLC analysis. However, encouragement
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came when a 1M solution of lithium aluminium hydride (LAH) in Et20  at room temperature was employed 
for the reduction. It generated a mixture of the desired intermediate lactols, and although relatively small 
yields of product were seen, the reaction did occur cleanly and was associated with no other decomposition 
by-products. We reasoned therefore that if some protecting group changes were made, then the pivotal 
lactone opening could be achieved in higher yield under similar conditions.
We now judged benzyl ethers to be acceptable protecting group alternatives at this juncture, and 
therefore adopted a comprehensive benzylation stratagem. With this intention, the pivaloyl esters in 435 
were again hydrolysed with an excess of 1M sodium methoxide, yielding triol 477 in quantitative yield 
(Scheme 57). HRMS again provided the evidence for product formation, it showing an [M+Na]+ ion at m/e 
327.1420 suggesting an empirical formula of C 1 4 H2 4 O7 . O-Benzylation was now effected by treatment with 
an excess of sodium hydride (60% dispersion in mineral oil) in DMF at 0°C for 40 mins, followed by addition 
of excess benzyl bromide and warming to room temperature. The f/vs-O-benzyl ether 478 was isolated in 
76% yield after Si0 2  chromatography. The appearance of a large 15 proton multiplet at 6  7.21 ppm in the 
500 MHz 1H NMR spectrum (CDCI3) confirmed the presence of the 3 phenyl rings. The 6  benzylic proton 
doublets at 8  4.62 - 4.41 ppm were also readily discerned. Together with the disappearance of the broad 
OH signal at 3394 cm' 1 in the IR spectrum, the available evidence suggested that protection had gone to 
plan.
19) NaOMe (1M), 
MeOH (0.12M), 
RT, 48 hrs
then BnBr(10eq.), 
0°C to RT, 1.5 hrs 
76%
22) PivCI, py, CH2CI2 
OR
TB SC I/TB S O Tf, DMF
479 480
Scheme 57 Protecting group reorganisation allowing a successful lactone opening.
Although this route circumvented the cumbersome PMB etherification, and its associated 
purification problems, it did now necessitate a later-stage deprotection / reprotection strategy. To our 
satisfaction, treatment of 478 with 5 equivalents of a 1M solution of LAH in Et20  at 0°C in THF, and slow 
warming to ambient temperature over 3.5 hours led to the starting lactone and intermediate lactol being
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consumed according to TLC analysis. On re-cooling to 0°C and quenching with MeOH, the crude product 
was vigorously stirred with a 10% aqueous solution of Rochelle salt prior to extraction. This helped remove 
all the aluminium salts. The subsequent purification of the unstable diol 479 was best achieved by rapid 
Si02 flash chromatography; it provided 479 as a viscous oil in a pleasing 88% yield. The appearance of a 
new AB quartet at 8 3.53 ppm in the 500 MHz 1H NMR spectra in CDCI3 for the C17 protons confirmed the 
CH2OH group was present.
Due to the greater nucleophilicity and reactivity of the primary alcohol over the secondary, we were 
confident in our rationale that we could selectively protect the newly formed C(17)- and C(20)- hydroxyls in 
479. Disappointingly, problems were encountered when selective primary silyl etherification or pivaloyl 
esterification methods were employed, due to competing elimination reactions both at the glycosidic 
position. Difficulties were also met when we tried to effect a selective thioetherification of the primary 
alcohol in 479 using diphenyl disulfide as the phenylthiolate anion source (Scheme 58). Although a clean 
reaction took place according to TLC, purification of the resulting product showed no thiophenyl signals, and 
mass spectral analysis confirmed that a tetrahydrofuran had formed, possibly again due to a favourable 
Thorpe-lngold effect from the geminal dimethyl groups which would clearly favour intramolecular 
displacement of the phosphonium ion intermediate.
22) (PhS)2.
Scheme 58 Attempted selective thioetherification of intermediate diol 479.
Gratifyingly, we later found that by subjecting the unstable diol 479 to rapid treatment with 10 
equivalents of benzoyl chloride at 0°C in a 0.04M solution of 1:1 CH2CI2 and pyridine, only the primary 
benzoate 483 was formed (69% yield) (Scheme 59). Confirmation of this result came from the appearance 
of the carbonyl resonance at 8 172.3 ppm in the 125 MHz 13C NMR spectrum, and the HRMS which 
showed an [M+Na]+ ion at m/e 705.3403 suggesting an empirical formula of C4 2H50O8.
The major source of instability of these intermediates was always found to be the great ease of 
which the anomeric methoxy group underwent elimination to either the glycal or the hemiketal, principally 
when the C20 hydroxyl was left unprotected.
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23) TBSCI or BzO. 
? Bn TB S O Tf/TM S O M e
-Scheme 59 Attempted si!yl etherification at C(20).
This elimination meant that all our endeavours at trying to position a silyl ether protecting group at 
OH(20) on 483 were unsuccessful, even when a methoxide source was added to the reaction mixture, 
which we thought would alleviate this misfortune 117.
In view of these unforeseen setbacks, and also due to the large and ever increasing number of 
steps required to complete the synthesis of the target, we elected to abandon this strategy in favour of a 
potentially more facile route, that involved fewer transformations. However, we did not want to abandon the 
chemistry developed by Lennon entirely, and so a suitable intermediate was sought on his route that would 
allow us to deviate and access our target 426 more economically. Again, our original postulate of 
positioning a bulky protecting group at OH(20) was the conceptual driving-force behind our new approach.
2.2 Modified retrosynthetic analysis of the bryostatin C-ring
P h S 02
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\
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Scheme 60 Modified retrosynthetic analysis employing a linear backbone strategy.
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The intermediate diol 464 was now singled out as a potentially useful starting point for the new 
approach, as it already contained the requisite C(26)/C(25)/C(23) and C(20) stereocentres, and so our 
modified retrosynthetic analysis began from this point (Scheme 60). By inducing a PMB migration, a 
subsequent O-silylation and partial ester reduction could allow a prenylation reaction to be performed on 
aldehyde 489 to yield the protected benzoate 488. Olefin degradation towards the primary alcohol 487 
would then allow the sulfone unit to be anchored. Debenzoylation and hydroxyl oxidation would then lead us 
to intermediate 486 that could undergo Fischer glycosidation to give 485. Oxidation and olefination could 
then yield 426.
It was found that by subjecting the diol 464 to 1.2 equivalents of DDQ in CH2CI2 in the presence of 
flame activated 4A molecular sieves, a clean C- to O- benzylic migration could be accomplished to give 490 
in 76% yield (Scheme 61). Sometimes lower yields (65%) were encountered and attributed to the fact that 
DDQ could act as a PMB ether cleavage reagent when traces of H20  were present. The disappearance of 
the benzylic AB quartet and the appearance of a high-field singlet at 8 5.44 ppm in the 500 MHz 1H NMR 
spectrum of 490 in CDCI3 indicated that the desired migration had occurred. As expected, HRMS showed 
the loss of two hydrogens, thus being an [M+Na]+ ion at m/e 635.3411 indicative of an empirical formula of
C3iHs608Si2.
14) 'BuMe2SiCI (2.5eq.),
13) DDQ (1.2eq.), E t O ^ O
OPMB CH2CI2 (0.08M),
E t O ^ O  L ^ ^ O T B S  4A MS, 0°C, 2h ,
""OTBS
76%
464
im (3.5eq.), DMF 
O TBS (0.25M), RT, 4.5 hrs
O TBS
99%
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EtO . ^O
O TBS
1 5 )excess 
DIBAL-H, 
CH2CI2, -78°C
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15) DIBAL-H (1.0eq.), 
CH2CI2 (0.15M), -78°C, 
60mins
93%
Scheme 61 Formation of the aldehyde 489 via a PMB migration tactic.
Although in our initial retrosynthetic analysis we had envisioned positioning a triethylsilyl ether at 
OH(20) (426 in scheme 48), further reasoning concluded that a TBS ether could be subjected to a greater 
array of intermediate transformations due to its increased stability. To this end, O-silylation of the C(20) 
hydroxyl in 490 was achieved by treatment with 2.5 equivalents of ferf-butyldimethylsilyl chloride and 3.5 
equivalents of imidazole in DMF for 4.5 hours, in typically quantitative yields. Final confirmation of product
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synthesis came from the HRMS which showed the addition of a C6H15Si unit, with an [M+Na]+ ion at m/e 
749.4276, indicative of an empirical formula of C37H7o08Si3.
Our next objective was the ester to aldehyde conversion, and our initial planning had involved a 
two-step procedure involving exhaustive reduction of the ester followed by partial alcohol oxidation. Work 
was investigated along these lines, however poor yields of the product were often encountered, as well as a 
disproportionate amount of degradation material. A one-step partial ester reduction looked a viable 
alternative, and indeed, treatment of the ester 491 with a equimolar quantity of Superhydride© in THF 
effected this transformation.
This method was superseded, however, by treating 491 with an equimolar amount of a 1.5M 
solution of diisobutylaluminiumhydride in toluene at low temperature. After 1 hour the reaction mixture was 
quenched with MeOH and on warming to 0°C the crude product was vigorously stirred with a 10% aqueous 
solution of Rochelle salt. Isolation of the desired aldehyde 489 was completed in a credible 93% yield with 
only trace amounts of the over-reduced alcohol being formed. This advantageous result could be explained 
by the internal chelation of the alkoxyaluminium species preventing its ready breakdown, thereby limiting 
the amount of the desired aldehyde present in our mixture, until aqueous work-up was completed.
The observation of an aldehyde proton resonance at 8 9.73 ppm in the 1H NMR spectrum of 489 in 
CDCI3, and of the aldehyde carbon at 8 202.9 ppm in the 125 MHz 13C NMR spectrum confirmed we had 
been successful. Moreover the HRMS of 489 showed that the OEt unit had been lost with the [M+Na]+ ion 
at m/e 683.4195 which was suggestive of a correct product analysis.
Attention now turned towards the important prenylation reaction that would introduce the C(18)- 
C(17) segment of our linear chain. To probe the possible selectivity issues that might be raised in this 
addition, we carried out some crude studies using Grignard tactics, and found that methyl- / allyl- / and 
prenyl- magnesium bromide additions occurred in reasonably high yields, albeit in diminished selectivities. 
Even though a selective stereochemical outcome for these transformations was not called for in our target 
analysis, loss of stereointegrity would hamper our overall strategy, and make the subsequent olefin 
manipulation problematical. Indeed from these findings, an undesirable oxidation at the newly formed C(19) 
hydroxyl looked the only option open at this point, and so alternative methods were sought to alleviate this 
problem.
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Our interest turned to some work carried out by Paquette et al using crotyl and allyl indiums as 
reagents for C-C bond formation 118. They had shown that allylic indium bromides readily add to numerous 
aldehydes in a 1:1 mixture of H20  and THF, in a predictive asymmetric manner.
The added advantage of utilising their chemistry meant that the reactions could be carried out at 
ambient temperatures, and in aqueous media. Following the protocol developed by Paquette, aldehyde 489 
was dissolved in a 0.2 M solution of 1:1 H20:THF and stirred with 2 equivalents of indium powder. Upon 
addition of prenyl bromide, a rapid addition of the allylic unit was observed and upon purification, a single 
isomer 493 was isolated, in 59% yield. The observation of a single product agreed with the findings 
reported, where a bulky OTBS was positioned a to the aldehyde. Such groups were suggested to exist in 
the more stable equatorial position in the transition state analysis (Figure 2), with the bulky R group residing 
in the more stable equatorial position
Me
M e
M e
favoured disfavoured
conformation conformation
Figure 2 Analysis of the transition state indium prenylation of 489.
The TBS protected alkoxy group is suggested not to partake in any secondary coordination to the 
indium centre. Confirmation of the terminal olefination was provided by the 500 MHz 1H NMR spectrum of 
493 in CDCI3, which contained a two hydrogen multiplet at 5 4.99 ppm and a single hydrogen double 
doublet at 5 5.83 ppm, with c/s- and trans- J couplings of 10.4, 18.0 Hz with the C(17) proton across the 
other side of the double bond.
It was felt prudent as this stage to protect the hydroxyl and carry out the olefin installation later 
(Scheme 62). Initial attempts at O-pivaloylation were found to be slow and so an alternative acid chloride 
was sought. It was found that by reacting the alcohol 493 with an excess of benzoyl chloride in a CH2CI2 / 
py mix, with one equivalent of DMAP and heating at 80°C, the secondary benzoate 487 was formed in 86% 
yield after 72 hours. The extended reaction times were needed due to the severe steric crowding around
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the C(19)-0H exerted by the geminal dimethyl group and the a-TBS ether. The product identity was 
confirmed by the appearance of an ester carbonyl peak at 8 166.0 ppm in the 125 MHz 13C NMR spectrum 
of 487, and its LRMS which showed that the a C7H40  unit had been added ([M]+ ion at m/e 857).
To position a CH2OH at C(17), the olefin would now need to be oxidatively degraded. 
Dihydroxylation via 0 s 0 4 and in-situ cleavage with Nal04 looked a viable procedure. This method was, 
however, found to be unsatisfactory, and although the consumption of starting alkene 487 was seen, only a 
number of undesired degradation by-products were formed. It was then postulated that by performing the 
initial dihydroxylation, and isolating the product at this point, that we might get better results in the vicinal 
glycol cleavage using Pb(OAc)4.
17) BzCI (10eq.), py (0.6M), 
CH2CI2 (0.7M). DMAP 
,OTB S (1eq.1), 80°C, 72 hrs
'"'OTBS THF:H20 (1 :1 ) (5 m l/  
mmol of RCHO), RT, 
10  mins
59%
18) 0 s 0 4 (0.05eq.)t 
acetone:H20  (1:1) (0.33M), 
NMO (1.5eq.), RT, 96 hrs
19) Pb(OAc)4 
(2eq.), THF (0.1 M), 
,OTBS O C . 15 mins TBSO''TBSO"
Scheme 62 Chain elongation via an indium catalysed addition.
The desired diol intermediate 494 was obtained in a reliable way by dissolving 487 in a 1:1 mixture 
of acetone:H20  and exposing it to 10 mol% of a 0.04 M solution of Os04. To aid the solubility of the olefin, a 
small amount of fe/f-butanol was added. 1.5 Equivalents of methyl morpholine-/V-oxide (NMO) was also 
added as a co-oxidant. Prolonged reaction times were necessary in order to maximise the product yield, 
and addition of a large excess of Na2 S0 3  was needed for the osmate ester reduction; a 1:1 mixture of diols 
was isolated. The appearance of a large broad OH stretching vibration at 3424 cm’1 in the IR spectrum of 
494 confirmed that dihydroxylation had indeed taken place. To our great delight, exposure of diol 494 to two 
equivalents of Pb(OAc)4 in THF caused a clean and rapid conversion to the aldehyde 495 in 94% yield.
The desired olefin to alcohol conversion was completed by reducing the aldehyde 495 with five 
equivalents of sodium borohydride in methanol, and typically proceeded in quantitative yield (Scheme 63).
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Scheme 63 Installation of the sulfone unit at C(17).
With alcohol 495 now in hand, the ensuing thioetherification became the next synthetic hurdle to 
traverse. After much experimentation, it was eventually found that by heating 495 with 10 equivalents of 
diphenyl disulfide and tri-n-butyl phosphine in DMF for 14 hours, the required thioether 496 was obtained in 
91% yield. Loss of the broad OH resonance at 3472 cm'1 in the IR spectrum of 496, and the appearance of 
5 phenyl protons between 5 7.30 - 7.10 ppm in the 500 MHz 1H NMR spectrum of 496 in CDCI3 indicated 
that thio-etherification had been a success.
Thioether oxidation was carried out by treating 497 with 6 equivalents of sodium bicarbonate and
2.5 equivalents of mefa-chloroperbenzoic acid in expeditious fashion, and reasonable yield. Due to the 
enhanced acidity generated at the a-sulfone position, the C(17) protons exhibited a shift of 8 0.27 ppm in 
the 500 MHz 1H NMR spectrum of 498.
Removal of the benzoate ester protecting group from 498 was accomplished by the low 
temperature addition of 2.2 equivalents of a 1.5 M solution of diisobutylaluminium hydride in toluene and dry 
dichloromethane. After 10 minutes, the mixture was quenched with methanol and stirred with saturated 
aqueous Rochelle salt to aid the extractive work-up; the secondary alcohol 499 was isolated in quantitative 
yield. The absence of any acetal opening was attributed to the enhanced electrophilicity of the ester 
functionality and the slow conversion rate of the undesired benzylic C-0 cleavage. The absence of all 
benzoate protons in the 500 MHz 1H NMR spectrum, and the disappearance of the carbonyl ester 
resonance at 8 165.7 ppm in the 125 MHz 13C NMR spectrum in CDCI3, indicated complete ester reduction. 
Finally the HRMS revealed an [M+Na]+ ion at m/e 903.4729 suggesting the empirical formula C45H8o09Si3S.
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A Swern oxidation to deliver the requisite C(19) ketone 485 looked a feasible operation, and work 
along these lines using trifluoroacetic anhydride (TFAA) as the electrophilic component was investigated 
(Scheme 64). The oxidation of the p-hydroxy sulfone 499 produced the ketone 486 in excellent yields, as 
shown by the appearance of a carbonyl resonance at 8 209.7 ppm in the 13C NMR spectrum, and by a large 
C=0 stretching vibration at 1717 cm*1 in the IR spectrum, with concomitant loss of the broad OH resonance 
at 3509 cm*1. HRMS also confirmed the loss of two protons with an [M+Na]+ ion at m/e 901.4572 suggesting 
the empirical formula C4 5 H7 8 0 9 Si3 S.
^O TBS  
""OTBS
Scheme 64 Attempted ring cyclisation to the Fischer glycoside 485.
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Now that the linear framework was in place, all that remained was for us to remove the PMP acetal 
and perform a Fischer glycosidation to install the anomeric methoxy and access the crucial pyran 485. Our 
first attempts at Fischer glycosidation used mild acids in methanol (PPTS, 10 mol%, MeOH; TsOH, 10 
mol%, MeOH) and resulted only in complex reaction mixtures, which we attribute to the acid sensitive silyl 
ether moieties undergoing non-selective cleavage. We now attempted a catalytic hydrogenation protocol 
involving Pearlmans’ catalyst to remove the PMP acetal, and although this delivered what we presumed 
was the hemiketal 500 it was formed only in low yields, making purification difficult to achieve. A 
chemoselective oxidation was therefore attempted on the axial C(21) hydroxyl with ruthenium based 
oxidants (Scheme 65) but due to the significant amount of the open chain form that existed in solution, the 
production of ketone 501 was hampered.
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Scheme 65 Attempted oxidation at OH-(21) to ketone 501.
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Another avenue open to us was the catalytic DDQ removal of the PMP acetal in an aqueous 
acetonitrile mix, but again our efforts were thwarted; the reaction producing many products according to 
TLC. Not to be rebuffed easily, we hydrogenated 486 with a large excess of Pd(OH)2 in EtOH; consumption 
of the acetal occurred with little evidence of degradation. After filtration of the catalyst, and removal of the 
solvent, the cyclisation was attempted with methanol and catalytic PPTS, but unfortunately this served only 
to produce hemiketal 500, albeit in slightly improved yields.
Continuation along this synthetic course seemed futile at this juncture, but we had significantly 
added to our knowledge of how the late-stage intermediates needed to be handled. We now though it 
necessary to rethink our overall strategy for accessing target 426.
2.3 An alternative approach to the bryostatin C-ring 119
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Scheme 66 Modified retrosynthetic analysis via a late-stage aldol condensation tactic.
In our remodelled retrosynthetic analysis (Scheme 66), we envisioned uniting the aldehyde 462 
with the phosphonate 507, to form the C(17)/C(27) backbone intermediate 506. The phosphonate itself 
would potentially be accessible from 2,2-dimethyl-propane-1,3-diol 11. Dehydrative ring-closure of 506 
should furnish the glycal 505 which could potentially be converted to 503 by glycal epoxidation, 
methanolysis, and oxidation. Ketone 503 could then be used in an aldol / dehydration sequence involving
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504. Selective enone reduction and O-silylation should then furnish the target 426. The advantage of this 
new strategy was its potential for leading to a considerably abridged pathway to 426, if successful. It also 
used the first 10 steps of the original Lennon route 105"'.
Our new synthetic pathway to 507 began with the thioetherification of 2,2-dimethylpropane-1,3-diol 
11 with 1.1 equivalents of diphenyldisulfide and 1.2 equivalents of tri-n-butyl phosphine in DMF 120 at room 
temperature, for an extended period (Scheme 67). It was subsequently found that the reaction time could 
be reduced considerably by heating the reactants at 70°C for 12 h 121. After aqueous work-up, the room 
temperature protocol delivered the mono thioether 509 in 63% yield. None of the b/s-thioether was seen, 
presumably because of the unfavourable steric influence exerted by the thiophenyl constituent.
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Scheme 67 Synthesis of the C(17)-C(20) sulfone phosphonate 507.
Oxidation to the sulfone 510 was accomplished with m-CPBA and sodium bicarbonate in CH2CI2 at 
0°C, for extended reaction times in 90% yield. The very long time required for this transformation could be 
significantly shortened by using 2.8 equivalents of Oxone™ in a mixture of MeOH/THF/H20  at room 
temperature; the oxone protocol only required 2 h at room temperature to reach completion, and delivered 
alcohol 510. Alcohol to acid oxidation was accomplished with ruthenium trichloride and sodium-mete- 
periodate in MeCN/CCl4/H20  (2:2:3) for 12 h; this led to the acid 508 in 85% yield.
Methylation of the acid 508 was achieved by exposure to a large excess of methyl iodide and 
potassium carbonate in DMF 122 over a period of 12 hours, with the resulting methyl ester 511 being 
isolated in 95% yield. Treatment of 511 with an excess of the lithio anion derived from methyl 
dimethylphosphonate (2.5 equivalents) 123 allowed a clean condensation to occur, and resulted in the 
C(17)/C(20) subsection 507 being formed in 5 steps and 38% overall yield from diol 11. The p-keto
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phosphonate exhibited an absorption at 1709 cm'1 in its IR spectrum attributable to the keto C =0 group. 
HRMS also confirmed product formation with an [M+H]+ ion at m/e 349.0875, which indicated an empirical 
formula Ci4H2 i 0 6SP.
Crucial to the continuation of our route was the union of aldehyde 462 with phosphonate 507, and 
the WHE conditions developed by Masamune / Roush 124 looked applicable to the situation at hand. We 
found that by treating a slight excess of phosphonate 507 with the crude aldehyde 462, in the presence of 
flame-activated lithium chloride and dry diisopropylethylamine in acetonitrile, a single (E)-enone 506 could 
be obtained in 82% yield from alcohol 461 (Scheme 68). The newly formed olefinic proton at C(20) 
resonated at 8 6.55 ppm as a doublet with a J3 coupling of 15.3 Hz, confirming the trans relationship with 
H(21). The strongly deshielded C(21) olefin proton resonated at 8 7.00 ppm as a doublet of triplets with J3 
couplings of 7.4 and 15.3 Hz. The increased down-field is presumably because this proton sits inside the 
deshielding cone of the ketone carbonyl.
The IR spectrum of 506 showed the expected C=0 and C=C resonances at 1693 and 1621 cm'1 
respectively, again consistent with the conjugated system present. The addition was also confirmed by 
HRMS with an [M+ Na]+ ion at m/e 755.3809, which confirmed an empirical formula of C39H6407Si2S. The 
saturated 8-hydroxy ketone 513 was our next synthetic target. It looked as though it could be prepared by 
the exhaustive hydrogenation of the olefin and PMB ether moieties in 506. However, our initial efforts along 
these lines using 10% palladium on carbon in ethyl acetate proved fruitless. Typically a large number of 
products were formed according to TLC analysis. To circumvent this problem, a successive olefin saturation 
and PMB deprotection protocol was investigated.
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512 513
Scheme 68 Installation of the C(17)-C(27) carbon framework via a Roush / Masamune coupling.
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It was found that by hydrogenating enone 506 in EtOAc with 20% palladium hydroxide for 1.5 h at 
1 atmosphere, the ketone 512 was isolated in 94% yield very cleanly. The loss of the olefin resonances in 
the 500 MHz 1H NMR spectrum of 512, and the down-field shift of the C =0 resonance by 12 ppm in the 13C 
NMR spectrum in CDCI3, confirmed enone reduction. In the IR spectrum of 512, the C =0 absorption was at 
a frequency 16 cm"1 higher than for 506, consistent with the C=C bond now no longer being in conjugation.
We had previously proved the validity of utilising a DDQ-mediated PMB cleavage in the synthesis 
of the precursor to the bis-pyran lactone 435, and similar conditions were again employed here 125. By 
dissolving 512 in an 18:1 CH2CI2:H20  solvent mix and adding 1.5 equivalents of DDQ, rapid generation of 
the expected 8-hydroxy ketone 513 resulted in near quantitative yield. The p-methoxy singlet at 8 3.77 ppm 
and the arene AX system at 8 7.25 and 6.83 ppm in the 500 MHz 1H NMR spectrum of 512 in CDCI3 had 
now disappeared from the corresponding spectrum of 513. The appearance of a broad OH resonance at 
3538 cm"1 in the IR spectrum further confirmed our assignment. The loss of a p-MeOC6H4CH unit in the 
HRMS confirmed that the desired overall transformation had been successful.
Of note at this point was the 1H and 13C NMR spectrum for 513. When recorded in CDCI3, what 
initially appeared to be an impurity was evident, however these minor resonances were unobserved when 
the spectrum were recorded in C6D6. Further analysis showed the deuterated chloroform to be of acidic 
enough in nature to effect a small amount of the hemiketal form, whereas the more neutral solvent C6D6 
had this equlibria firmly in the open chain form. This could again be seen with the small hemiketal C(19) 
peak resonating at ~94ppm in the 13C NMR for CDCI3.
Later work showed that the fundamental reason why the advantageous one-step PMB cleavage 
and olefin hydrogenation was unsuccessful most likely lay in our method for oxidising the requisite aldehyde 
462. The Swern residues apparent in this procedure were invariably carried through, and even though they 
were present in very small quantities, they were sufficient to poison the catalyst thereby halting the PMB 
ether removal and favouring O-desilylation. We then discovered an alternative oxidation that used catalytic 
amounts of tetrapropylammonium perruthenate (TPAP) to produce the aldehyde 462. Again, coupling of 
this crude material with the phosphonate 507 produced the single (E)-isomer 506 but in slightly reduced 
yields (Scheme 69). On hydrogenation with 20% Pd(OH)2 in MeOH the 8-hydroxyketone 513 was now 
isolated successfully in 81% yield.
76
Chapter 2 :  Discussion
PMBCX, 
HO.
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-JO ^O TBS
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Scheme 69 Modified one-step hydrogenation procedure to produce the 6-hydroxy ketone 513.
The lower yields of 513 from the modified one-step synthesis from 506, when compared to the 
higher yields achieved by the two-step methodology, meant that although it added an extra element to our 
synthetic route, the latter protocol was the more desirable.
Having arrived at the 8-hydroxyketone 513, ring closure to the glycal was our next aim. In this work 
on the southern hemisphere of bryostatin 2 47,/, Evans had shown the efficiency of forming a glycal 
precursor with camphorsulfonic acid (CSA) in C6H6 at reflux (66 in scheme 13). By applying similar 
conditions to 513, a rapid ring closure to 514 ensued, followed by dehydration; the desired glycal 505 was 
isolated in a creditable 90% yield (Scheme 70). The successful outcome of this reaction was confirmed by 
the appearance of the newly-formed vinylic C(20) proton which resonated as a double doublet at 8 4.43 
ppm in the 500 MHz 1H NMR spectrum in C6D6, which showed J3 couplings with the H(22)eq and H(22)ax of
2.5 and 4.7 Hz also consistent with the imposed rigid ring system. In the 125 MHz 13C NMR spectrum in 
C6D6, the ketone resonance at 8 211.7 ppm had now disappeared and the anomeric C(19) carbon now 
resonated at 8 94.2 ppm. The IR spectrum of 505 conferred a strong the C=C stretching vibration for the 
glycal at 1670 cm'1. HRMS data gave final confirmation for pyran formation, there being an [M+Na]+ ion at 
m/e 619.3285, consistent with an empirical formula of C3iH5605Si2S. Our planning now called for the 
implementation of a three-step sequence to secure the ketone 503, with glycal epoxidation with DMDO at 
its heart.
Ph S 02
513
14) CSA (0.05eq.), PhH 
OTBS (0.03M), 85°C, 45 mins
'"OTBS
90%
PhS02
OH H
"OTBS
P h S 02
-H20 OTBS
'"OTBS
514 505
Scheme 70 Ring closure and dehydration sequence to the glycal 505.
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In the formation of oligosaccharides, Danishefsky had shown the potential of using 
dimethyldioxirane (DMDO) over conventional methods to epoxidise glycosidic C=C double bonds 126f due to 
its high electrophilicity, its generation of acetone as the only by-product, and its neutrality. We reasoned that 
if we could epoxidise glycal 505 then the problematic methyl glycoside might be installed by opening 
selectively at the anomeric position with added methanol.
127Generation of the DMDO was carried out according to the procedure described by Adam et al 
which is useful for producing large quantities of an approximately 0.07 M solution in acetone. The 
determination of molarity is carried out by its slow addition to trans stilbene. Our initial foray in this area 
started by employing a two-step procedure, first isolating the epoxide 515 and then subjecting it to trans- 
diaxial ring-opening with PPTS in MeOH (Scheme 71). It was found that treatment of the glycal 505 in dry 
CH2CI2 with a 0.07 M solution in acetone of redistilled DMDO in the presence of flame activated 4A 
molecular sieves, gave rise to a very clean and almost totally stereospecific epoxidation on the a-face of the 
alkene, after only 10 mins.
then PPTS (0.5eq.), P h S 02. 
MeOH (0.01 M), RT, „  
10  mins
15) DMDO P h S 02.
(0.07M /Me2CO),
(2 .2eq.) '
PhSO;
""OTBS ^ "" O T B S
516 R *  Me
517 R * H
P h S 02.PhSO-
Scheme 71 Epoxidation sequence of glycal 505.
TLC analysis at this stage reveals that all the starting material is consumed; however, several 
products are observed to be formed on the TLC plate due to the high lability of 515 on Si02. Concentration 
of the mixture after 10 minutes, followed by dilution with methanol and addition of a catalytic amount of 
PPTS unfortunately delivered a number of undesired side-products along with the required methyl glycoside 
516. This was attributed to the trace amounts of water that were always present in our redistilled DMDO / 
acetone solutions, which, during the concentration process, inevitability caused a significant amount of 
epoxide hydrolysis to form the unstable hemiketal mixture 517.
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While ordinarily, this side-reaction is not problematical with less-reactive aldose-type glycals, it 
was seriously detrimental here where a more reactive ketose-type glycal was being epoxidised. Reasoning 
that a limiting amount of desired material was still being produced, we believed that an in-situ epoxide 
opening might circumvent this complication, and allow an efficient one-pot procedure. To our delight, it was 
found that by treating a solution of the glycal 505 in MeOH with a 0.07 M solution of DMDO in acetone in 
the presence of 4A molecular sieves at 0°C, a rapid stereospecific epoxidation occurred on the a-face of 
the double bond. When the consumption of glycal had occurred, a catalytic amount of PPTS was added and 
the mixture allowed to warm to room temperature. As the reaction mixture warmed, in-situ trans-diaxial ring 
opening occurred with the large excess of methanol that was present, which was present in substantially 
higher amount than any H20  present in the original DMDO solution. This sequence yielded only the desired 
product 516 in a predictable and less cumbersome fashion.
As our earlier experiences had shown, substrates possessing the methyl glycoside and an 
unprotected C(20) hydroxyl were extremely labile. However the unstable intermediate 516 could be purified 
if it was rapidly subjected to conventional Si02 flash chromatography. It was obtained as a crystalline solid, 
even if in slightly diminished yield. Confirmation that 516 had been formed was provided by its 1H NMR 
spectrum in C6D6. The C(20) olefinic proton now resonated at 5 3.55 ppm, and methoxy protons resonated 
as a singlet at 5 3.32 ppm. In the 125 MHz 13C NMR spectrum, C(19) now appeared at 100.7 ppm, as 
expected for a pyranoside; C(20) peak that appeared at 94.2 ppm in 505 was also now absent. The IR 
spectra showed the appearance of a broad peak at 3492 cm'1 associated with the newly formed OH. 
Clearly our new modification of the Danishefsky-Murray epoxidation method offers distinct advantages for 
the preparation of “simple” ketose-type glycosides from reactive trisubstituted glycals.
Once the epoxidation / opening sequence had been successfully negotiated, the alcohol at C(20) 
was oxidised. Exposure to 2 equivalents of pyridinium dichromate (PDC) in dry DMF at room temperature 
was the method of choice (Scheme 72). The oxidation could also be performed on the crude 516, avoiding 
the potentially risky purification step. This two-step procedure to ketone 503 could be achieved in good 
overall yield from the glycal; typically 60-85% yield. The resonance at 6 207.4 ppm in the 13C NMR 
spectrum of 503 in C6D6 confirmed the presence of the C=0. The very strong absorption at 1724 cm'1 in the 
IR spectrum of 503 confirmed this assignment. Final verification of the identity of 503 was provided by the 
HRMS, which showed an [M+Na]+ ion at m/e 665.3340, indicative of the empirical formula C32H5807Si2S.
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P h S 02 15) DMDO (0.07M in PhS02 
n T B .  Me2CO) (1.3eq.), MeOH 
U lb b  (0.02M), 0°C, 10 mins
'OTBS
505
then PPTS (0.2eq.), 
RT, 15 mins 
92%
OMe M ‘ O OTBS
OTBS
16) PDC (2eq.), P h S 0 2 
DMF (0.1 M),
RT, 14 h
64% '"OTBS
516 503
Scheme 72 In-situ epoxidation of glycal and oxidation to ketone 252.
We now set about introducing the desired exocyclic olefin via an aldol / dehydration sequence. 
Initial model studies were investigated along these lines with a non-nucleophilic base. Treatment of ketone 
503 with 1.5 equivalents of a 0.5 M solution of potassium hexamethyl disilazide (KHMDS) in THF at -78°C 
for 30 minutes and subsequent exposure to either acetaldehyde or isobutylaldehyde produced a single 
isomeric product in good overall yields, with no addition taking place a- to the sulfone (Scheme 73). 
Preliminary investigations into the geometry of the methyl or isopropyl side unit suggested that it had the 
(£)- stereochemistry.
PhS02 P h S 02>
O M e n  17) KHMDS (1.5M), 30 _  DMe h,OU \^^ OTBS mjns ^  RCH0
OTBS
503
OTBS
'"OTBS
517 R ■ Me
518 R -  'Pr
Scheme 73 Investigative studies of aldehyde addition to ketone 503.
This led us to conclude that the desired exocyclic olefin geometry could also be achieved Marshall’s’ 
aldehyde 504 if could be employed. Marshall’s’ aldehyde 128 504 is available in two steps from ethylene 
glycol 519 via a mono silylation and Swern oxidation. Product yields are typically 85% over the two steps 
(Scheme 74).
HO'
519
1) NaH (1.15eq.), THF (0.1 M), 
0°C to RT, 45 mins
then TBDPSCI 
(1.15eq.), 2  h
HO
x \^ O T B D P S
2) (COCIJa (1.1eq.), DMSO  
(2.2eq.), CH2CI2 (0.3M), 
-78°C, 5 mins.then 272
520
in CH2CI2 (1.6M), 15 mins 
then Et3N (4.9eq.)
82% (2  steps)
X ^ O T B D P S
504
Scheme 74 Formation of Marshall’s aldehyde 273.
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After screening a range of experimental conditions for effecting the desired aldol conversion of 503 
to 521, we eventually found that the best results in terms of yield and cleanliness of reaction utilised the 
lithium enolate obtained from treating 503 with n-BuLi in hexanes and THF for 5 mins at -78°C. This was 
then transferred to a pre-cooled -78°C solution of the aldehyde 504 in THF, whereupon a rapid addition 
occurred. The elimination took place in-situ after the reactants were warmed to room temperature (Scheme 
75); the resulting enone was typically isolated in a pleasing 77% yield.
P h S 02
OMe h  O
17) "BuLi (2.5M in hex. 1.5eq.) 
0TB S THF (0.02M), -78°C, 5 mins
OTBS then O 504
^X^OTBDPS
H
(5eq.) in THF  
(0.06M), 5 mins
PhS02
OMe h
'"OTBS
OTBDPS
PhSO
then warm to 
RT, 25 mins
-H20
77%
OMe h
"OTBS
Scheme 75 Aldol addition and in situ dehydration to enone 502.
To confirm that the correct (E)-stereochemistry had been achieved, detailed 2-D NMR studies 
were undertaken with 502. Of special relevance was the 500 MHz 1H NMR 2D nOe spectrum in C6 D6  which 
showed cross-peaks between the C(22) ring protons and the C(35) methylenic protons. The C(19) OMe 
also showed a strong correlation with the C(23) axial ring proton, indicating that they had a cis relationship 
to one another. The carbonyl resonance shifted by 12 ppm to 8  195.4 ppm in the 125 MHz 13C NMR 
spectrum in C6 D6  which was consistent with enone conjugation. The new olefinic carbons appeared at 8
140.7 and 135.9 ppm. We now had all the required heteoroatoms in place and past precedent in Wenders’ 
and Evans’ work 1 0 2 , 4 7  suggested that good selectivity could be attained in a stereospecific reduction of the 
enone 502 using a multitude of reducing agents. However the Luche 1 1 0  conditions looked the easiest and 
most convenient to effect.
It was found that vigorous stirring of the 502 with 10 equivalents of cerium trichloride heptahydrate 
in methanol at room temperature over 45 minutes ensured coordination of the metal. On cooling to -78°C, 1 
equivalent of sodium borohydride was added every 5 minutes for 25 minutes to avoid a large excess of the 
reducing agent being present in the mixture. The reaction was then warmed to 0°C. This unstable 
intermediate was isolated as a single isomer in 80% yield after rapid purification by S i0 2  flash 
chromatography. The 125 MHz 13C NMR spectrum of 522 showed a shift of the C(20) carbon resonance
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from 8  195.4 ppm to 8  72.6 ppm. The C=0 stretch at 1698 cm' 1 in the IR spectrum of 522 was now replaced 
by a broad OH peak at 3478 cm' 1 (Scheme 76).
Protection of the newly formed hydroxyl as its triethylsilyl ether was accomplished with TES-triflate 
in dichloromethane (Scheme 76). The addition of an excess of 2,6-lutidine was required to buffer the triflic 
acid that was generated which would destroy the sensitive product 426.
Small amounts of a side product, tentatively assigned as the elimination product 523, were also 
formed, making the total purification of 426 difficult to achieve. It was thought that this by-product was 
induced by the anomeric oxygen displacing the labile trifiate from the silyl moiety with the resulting triflate 
stripping the H(20) causing elimination across C(19)/C(20) (Scheme 77). A transient oxonium ion species 
could also contribute to this elimination mechanism, and this by-product would also be stabilised by the 
double bond conjugation; unfortunately 523 was inseparable from 426 by conventional Si0 2  flash or prep, 
thin layer chromatography.
PhSO-
^  '"OTBS 
.OTBDPS
502
18)CeCI3.7H2O (10eq.), 
NaBH4 (5eq.). MeOH  
(0.05M), -78°C to RT, 1 h
80% PhSC2
OTBDPS
PhSO; PhSO-19) Et3SiOTf (3eq.), 
2,6-Lutidine (10eq.), 
CH2CI2 (0.03M), .OTBS .OTBS
0°C to RT, 40 mins 
82%
^  '"OTBS 
.OTBDPS
'"OTBS
•OTBDPS
^ '" O T B S
•OTBDPS
522 426 523
Scheme 76 Completion of the C(17)/C(27) bryostatin C-ring “Southern Hemisphere” 426.
PhS02.PhSO-
""OTBS
OTBDPS OTBDPSOTBDPS
426 523
Scheme 77 Proposed mechanism for the formation of the eliminated by-product 523.
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To ascertain if the correct stereochemistry had been installed at C(20) in 426, a series of 1-D and
2-D NMR experiments were performed. It was found that the 1D 500 MHz spectra of 426 in C6D6 and 
toluene-d8 were temperature dependent, suggesting that the rate of internal rotation for the sterically 
congested C(18)-C(19) bond was slow on the NMR time scale (Figure 3).
%  /-SV'M eX —
T
Ph O  M e  > < \
OMe
Me
■ Si
Figure 3 Slow bond rotational forms about the C(18)-C(19) bond for 426.
There were seen many broadened resonances in benzene-d6 and toluene-d8 at room temperature. 
At elevated temperatures (70°C for benzene-c/6 and 90°C for toluene-d8) these spectra sharpened quite 
dramatically as a result of the increased rate of C(18)-C(19) bond rotation, which now became fast on the 
NMR time scale. Under these conditions the rotationally averaged spectrum of 426 was observed.
PhS02
OMe h
.OTBS
TESO"" ^ " O T B S  
OTBDPS4 2 6
H(20)H(34)
Figure 4 1H NMR spectra in C8D6 at 0°C for 426.
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Figure 5 1H NMR spectra in C6D6 at 70°C for 426.
A 2-D nOe NMR experiment, in toluene-d8 at 90°C, revealed cross-peaks between the H(20) 
singlet at 5 4.38 ppm and the C(18) geminal dimethyl singlets at 6 1.64 and 1.58 ppm - as was expected, 
and also with the C(19)-0Me resonating at 8 3.27 ppm confirming their cis- relationship (Figure 6). H(20) 
also gave rise to an nOe cross-peak with the C(34) exocyclic triplet at 5 5.68 ppm, while the allylic C(35) 
methylenes at 8 4.26 and 4.23 ppm showed nOe’s with the equatorial H(22) which appeared as a multiplet 
at 8 2.10 ppm. The combination of these results enabled us to confidently assign the C(20)-alkoxy and 
olefin stereochemistry.
OTBSM§. OMe
Me,
’OTBS
PhS02-
OTBDPS
Figure 6 Rotationally averaged conformation at 70°C in C6D6, with relevant nOe data for 426.
The desired C-ring target 426 was produced in 4.02% overall yield from diene 450 for the 19 step 
longest linear sequence, and 3.45% for the 18 step longest linear synthesis, in an overall 25 / 26 step
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sequence. Confirmation of the identity of 426 came from the HRMS showing an [M+Cs]+ ion at m/e 
1171.4801 suggesting an empirical formula of C5 6 H9 4 0 8 Si4 S. This is the shortest route so far to a fully- 
elaborated, appropriately protected, bryostatin 1 “Southern Hemisphere”.
2.4 Synthesis of bryostatin analogues 1 2 9
Although a significant amount of our synthetic effort in the bryostatin area has been concerned 
with bryostatin total synthesis, a significant amount of work has also been concerned with the design and 
synthesis of simplified analogues for evaluation as antitumour agents and probes of PKC enzyme activity. 
Given the availability of the CRD2-phorbol ester X-ray crystal structure, we removed the phorbol ester from 
the crystal structure and attempted the computer assisted docking of some potential C-ring analogue 
structures within the phorbol-ester / bryostatin 1 binding site of the CRD2 domain. We identified three key 
analogues from these studies, two of which were based solely on the C-ring (524 and 525), and a third 
more elaborate analogue structure 526 based on the bryostatin B/C-ring array (Figure 7).
These analogue structures contained many of the key criteria lay down by Wender 3  in his 
postulates for potency in the PKC-binding of simplified bryostatin molecules 102. Whilst the phenylsulfone 
intermediate 524 possessed the desired exocyclic enoate, the C(20)-acyloxy substituent, the C(19) 
hemiketal and the C(26)-hydroxyi of bryostatin 1, it lacked the 30-membered macrolactone bearing the 
(3R)-OH.
Analogue 525 looked as though it would benefit from significant H-bonding between the allylic OH 
and the C(25)-OH, which would restrict rotation of the side-chain. Modelling within the CRD2 suggested that 
it would form 4-H-bonds within the PKC-d bryostatin binding site and so bind potently. Our initial decision to 
model these phenylsulfone analogues 524 and 525 stemmed from the notion that they might themselves 
serve as useful precursors to more elaborate analogues, in particular 526. We reasoned that if these 
simplified designs were unable to bind to the CRD2, the potential for further elaboration to analogues 
possessing a greater congruence with the bryostatin structure would give us a greater chance of observing 
potent binding to the CRD2, without the macrolactone.
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""OH
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524 525 526
Figure 7 Modelled target intermediates with potential for PKC binding.
Analogue 525 was readily prepared from 522 in 2 steps, by acetylation and treatment with aq. HF, 
which not only caused O-desilylation but also glycoside hydrolysis. The acetylation of 522 was best effected 
with 5 equivalents of acetic anhydride and pyridine in 0.05 M CH2 CI2, and a catalytic amount of 
DMAP(Scheme 78). The OAc group gave rise to a singlet at 8  1.69 ppm in the 500 MHz 1H NMR spectrum 
of 527 in C6 D6. The ester carbonyl resonated at 5 169 ppm in the 125 MHz 13C NMR spectrum in C6 D6, and 
527 also gave rise to an [M+Na]+ ion at m/e 989.4885 confirming the empirical formula of C5 2 H8 2 0 9 Si3 S.
Of special note at this point was the appearance of a sharp clearly defined 500 MHz 1H NMR 
spectrum for 527 toluene-d8> which indicated that the slow room temperature C(18)-C(19) bond rotation in 
426 was a direct consequence of steric crowding exerted by the bulky OTES group at C(20).
In their efforts towards bryostatin 3, Nishiyama and Yamamura had effected a key desilylation and 
ketal hydrolysis step utilising HF in aqueous acetonitrile. In an attempt to mimic this transformation, the 
acetate 527 was diluted with a 0.05 M solution of 1:1 THF:MeCN, with subsequent addition of 4 equivalents 
of a 40% aqueous HF solution. After two hours, basic work-up allowed the highly polar tetraol 525 to be 
purified via conventional flash chromatography in a gratifying 85% yield as a crystalline solid.
The 500 MHz 1H NMR spectrum for 525 in methanol-c/ 4  indicated that it existed as an approximate 
3.6:1 mixture of ring-closed:open forms (Scheme 79); the same was true in benzene-d6. In methanol-c/4 , the
PhSO-
.OTBS
^  '"OTBS 
•OTBDPS
19) Ac20  (5eq.), py (5eq.), P h s 0 ‘  
DMAP (0.5eq.), CH2CI2 
(0.05M), 0bC to RT. 10 mins
^ " " O T B S
•OTBDPS
20) aq. HF (40%), P h S 0 ‘  
THF:MeCN 1:1 
(0.05M), RT, 2 h .OH
62% 85% ""OH
522 527 525
Scheme 78 Formation of the truncated bryostatin 1 C-ring analogue 525.
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H(20) resonated at 8  5.14 ppm in the closed form 525a and at 8  6.03 ppm in the open form 525b due to the 
increased ketone electronegativity. The ketone carbonyl peak at 8  ~208 ppm was also evident in the 125 
MHz 13C NMR spectrum for 525b. Final confirmation of the structure of 525 came from the HRMS which 
showed an [M+Na]+ ion at m/e 509.1821 suggesting an empirical formula of C2 3 H3 4 O9 S.
OHOH OH
PhSO-P h S 02
OHOH
Ac O'"; AcO'"]
.OH-OH
525a "Closed Form" 3 : 1 "Open Form" 525b
Scheme 79 Equilibrium structures for the C-ring analogue 525.
The interaction of 525 was studied with the human PKC-a CRD2 by 600 MHz 1H NMR 
spectroscopy. The CRD2 construct of human PKC-a that we had used had been very kindly been prepared 
by Dr Peter Parker of the CRUK Laboratories at Lincoln’s Inn Fields. Its sequence and folding were verified 
by comparing its 1D 1H spectrum in 2 H20  with the previously published resonance assignments of Ichikawa 
and Hommel 13°. To our great dismay, upon the addition of phorbol-12,13-acetate (PA) or phorbol-12,13- 
butyrate (PB) to our CRD2 in 2 H2 0 , our ligand-protein complexes immediately precipitated. Following a 
suggestion in the literature 131, 25% C2 H3CN was added to the complexes, and this was found to markedly 
improve their solubility. A careful examination of the 1D and 2D spectra of the CRD2 in this solvent system 
confirmed that the structure of the protein had not been significantly affected by the addition of the organic 
solvent, which suggests that this mixed NMR solvent system will be generally useful for studying the binding 
of very hydrophobic ligands to this protein.
Residues that appeared to be most affected by the binding of PA and PB corresponded to those 
observed in the binding pocket of the PA-PKC- 8  CRD2 X-ray crystal structure. Bryostatin 1 was also found 
to affect several of these residues but clearly interacted much more tightly than PA or PB. Our observations 
conclusively prove for the first time ever that the binding site for bryostatin 1 does indeed overlap with that 
of PA and PB.
The binding of our simplified analogue 525 also affected some, but not all, of the residues bound 
to PA, suggesting that 525 occupies a part of the same binding pocket. Chemical shift changes in the amide 
region were apparent for 525 and for the PA and PB over similar concentration ranges, showing that their
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binding constants must indeed be very similar under these conditions. Our combined data proves that it is 
possible to design bryostatin C-ring analogues that bind specifically to the human PKC-a CRD2, in a novel 
manner, and with an affinity of the same order of magnitude as those of the phorbol esters. An evaluation of 
the antitumour properties is therefore awaited with great interest.
This is elegantly shown in figure 8 132 where the docking of 525 was modelled in the cavity of the 
CRD2 of PKC-5. The space filled diagrams show that the allylic alcohol sits in the bottom of the cavity, and 
the phenyl and dimethyl units create a hydrophobic outer surface that extends across the surface of the 
protein.
a. b.
Figure 8  Undocked (a) and docked (b) analogue 525 to the CRD2 of PKC-5.
Given these extremely encouraging NMR binding studies with 525, we embarked on the much more 
formidable task of acquiring the BC target 526. Retrosynthetic analysis had suggested a late-stage global 
desilylation / glycoside hydrolysis for accessing 528 (Scheme 80), similar to that executed for 525. 
Disconnection across the C(16)-C(17) trans olefin led to the selection of a Julia olefination between the C- 
ring sulfone 426 and the B-ring aldehyde 529 for creating 526.
Due to the significant number of transformations needed to acquire both these B- and C- ring 
intermediates, we reasoned that the critical Julia olefination sequence could be explored using less valued 
material. The glycal 505 was identified as a suitable starting point from where to commence such model 
studies, and cyclohexanecarboxaldehyde suggested itself as a useful B-ring mimetic. It was found that 
deprotonation a- to the sulfone could be readily achieved with n-butyl lithium, and cyclohexanecarbox­
aldehyde readily combined with the resulting anion.
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Scheme 80 Retrosynthetic analysis for the formation of the B/C analogue 282.
The diastereomeric p-hydroxy sulfone mixture that was produced could be isolated as a white solid 
by conventional flash chromatography. However, to our disappointment, all attempts at acetylating or 
benzoylating the resulting alcohols were unsuccessful. We therefore decided on an in-situ esterification, 
and subsequently found that by treating the intermediary alkoxides with an excess of benzoyl chloride and 
triethylamine, and an equimolar amount of DMAP, the desired a-benzoyl sulfone 530 could be obtained 
after stirring for 50 minutes at RT (Scheme 81).
PhSOz^
. 1 H
i T j
505
Scheme 81 Initial attempts for the Julia olefination of the glycal 505.
1) nBuLi (2.5M, 1.15eq.), THF  
OTBS (°  ° 15M >- -78°c * 2 2  mins BzO'
OTBS then rv—' "V 2 eq.), 2  mins CHO
then BzCI (5eq.), Et3N (6eq.), 
DMAP (1eq.), RT, 50 mins
0 2SPh
2) Mg (5eq.), 
HgCI2 (0.25eq.), 
EtOH (0.01 M), 
0°C to RT, 12 h
OTBS
OTBS
80%
530
J3 -1 5 .8  Hz
OTBS
"OTBS
531 one Isomer
Due to the large number of diasteroisomers now present, NMR data was of minimal value, 
although it did serve to confirm the loss of the C(17) AB quartet. Compelling evidence for the formation of 
530 came from the HRMS which showed an [M+H]+ ion at m/e 813.4616 suggesting an empirical formula of 
C45H7207Si2S. It was thought that a magnesium / mercuric chloride mix 133, forming an in situ magnesium 
amalgam similar to that described by Evans 47", could effect the key benzoyloxysulfone elimination step, 
and a number of solvent systems were investigated. It turned out that by subjecting 530 to an excess of 
mercury (II) chloride and a catalytic amount of magnesium powder (~50 mesh) in dry ethanol at 0°C and 
allowing to warm slowly to room temperature, produced a single product.
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NMR analysis confirmed the loss of all aromatic signals, and to our satisfaction showed the newly- 
formed C(16)-C(17) double bond protons were mutually coupled, possessing a J3  coupling of 15.8 Hz in the 
500 MHz 1H NMR, indicating that the desired trans stereochemistry had been achieved. Further 
confirmation of the structure of 531 came from its HRMS which showed an [M+H]+ ion at m/e 551.4316 
suggesting the loss of the 0 2SPh and OBz groups, and an empirical formula of C3 2 H6 2 0 3 Si2 .
With a reasonable amount of information to hand regarding the Julia olefination, our attention now 
focussed on the all-important union of the B- and C-ring intermediates 529 and 426. Since the B-ring 
intermediate 428 needed to be further elaborated to reach the requisite aldehyde 529, we set off from this 
point. Firstly, O-triethylsilylation was completed by treating the primary alcohol 428 with a slight excess of 
triethylsilyl triflate in dichloromethane and 2 ,6 -lutidine; this caused a clean and rapid protection in essentially 
quantitative yield (Scheme 82). 500 MHz 1H NMR analysis of 532 in CDCI3  now revealed a triplet at 6  0.95 
ppm which integrated to nine hydrogens, and a six hydrogen quartet at 8  0.60 ppm that was coupled, to the 
former signal, indicating that installation of the triethylsilyl group had been achieved.
18) TESOTf (1 ,5eq), CH2CI2 19) DDQ (1.5eq.),
' OH (0.08M). 2,6-lutidine (5eq.), r ^ ^ r ^ N ^ O T E S  CH2CI2:H20  (18:1)
TBDPSO I 6  -20°C ,5m ins  TBDPSO T  X  (0.08M). OoC. 1.5 h
97% | 81%
532 ' 0P M B
OTES 20) TPAP (0.1eq.), r ^ s r ^ Y ^ ' O T E S
TBDPSO k . O  NMO (2eq.), 4A MS. T B D P S 0
MeCN (0.05M), RT. '  HQ
5 33  'O H  25 mins 52g
Scheme 82 Further manipulation of the B-ring alcohol 428 to facilitate the Julia coupling.
Utilising our previous protocol for DDQ-mediated PMB ether removal, 532 was subjected to 1.5 
equivalents of DDQ in an 18:1 dichloromethane:water solvent mix, which procured the C(16) primary 
alcohol 533 in reasonable yields. The loss of the multiplet signals at 8  7.21, 6.85 and the OMe resonance at 
8  3.78 ppm in the 500 MHz 1H NMR spectrum in CDCI3  confirmed the desired PMB ether protecting group 
cleavage. The released hydroxyl also showed a broad resonance at 3395.2 cnf1 in the IR spectrum of 533.
All that remained to complete this sequence was oxidation of the primary alcohol in 533 to the 
aldehyde. Initial efforts using Swern methodology proved disappointingly fruitless, with a number of 
products being produced as seen by TLC. This hurdle was overcome, however, by employing a catalytic
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amount of TPAP and an excess of NMO for oxidation in dry acetonitrile - aided by the addition of flame 
activated molecular sieves. This lead to complete consumption of starting alcohol. The newly formed crude 
aldehyde 529 was generally used immediately to avoid any partial degradation occurring.
Following the reports of Masamune 3 5  and Nishiyama 67, we had anticipated that deprotonation at 
the C(17) a-sulfone position of 426 might be a formidable obstacle. However given the past success of 
Masamune and Nishiyama, we elected to use the deprotonation methodology developed by these workers 
to effect the union of 426 with 529 (Scheme 83). In developing this methodology towards the key bryostatin 
B/C- ring coupling, Masamune had investigated a number a different bases to effect the desired 
deprotonation. It was found that the use of weak bases such as 'Pr2NLi and Et2NLi resulted in insufficient 
deprotonation, and that stronger bases such as *BuLi and nBuLi formed aryl anion species, possibly from 
the greater ease with which the aryl protons could be accessed. To circumvent this problem, phenyllithium 
was investigated and found to effect the desired deprotonation.
It was with all this information in mind that we embarked on the crucial pyran coupling. Initial 
attempts at this addition proved remarkably unsuccessful when undertaken at -78°C with bases such as 
*BuLi and nBuLi, resulting in complete recovery of the sulfone 426 and concomitant loss of all aldehyde 529 
traces. This led us to believe that the required sulfone deprotonation was not occurring, and that the 
resulting base remaining in the solutions was itself adding to the aldehyde.
When the deprotonation was initiated at -78°C with 1.5 equivalents of a 1. 8  M solution of phenyllithium in 
THF, and the reactants allowed to warm slowly to -50°C over 20 minutes, the familiar sulfone yellow / green 
anion colour was finally seen for the first time (Scheme 83) .  After a period of 20 mins, the resulting sulfone 
anion was re-cooled to -78°C and a solution of aldehyde 529 in THF added. A number of spots were 
apparent by TLC along with a significant amount of starting sulfone. The reaction mixture was then allowed 
to warm to ambient temperature, although little change was seen by TLC. This was presumably due to 
insufficient deprotonation occurring and the quenching of any base still present by the aldehyde. Fortunately 
any unreacted sulfone could be recovered, but again all aldehyde residues were destroyed.
Due to the inconclusive information we received from TLC, we thought it prudent to isolate the a- 
hydroxysulfone 534 in a measured, stepwise procedure. The sulfone mixture 534 was isolated as a viscous 
oil, and as in our earlier efforts towards 530, it was difficult to obtain relevant NMR data.
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21) PhLi (1.8M in hex, 
1.25eq.), THF (0.1 M), -78°C to 
-50oC, 40 mins, then
TBDPSO L ^ O
I 529
CHO
(0.85eq.) in THF (0.18M),
35 mins then warm to RT, 2 h 
26% (63% based on recovered 426)
TBDPSO
TESO""
534
OTBS
O2SP1I 
OMe H
OTBDPS
Scheme 83 Julia coupling of sulfone 426 and aldehyde 529.
The yield of this two step procedure was 26% based on the aldehyde. As much of the unreacted 
sulfone could be recovered, a 63% yield could also be calculated based on the amount of sulfone 426 
recovered.
In some earlier model work on the union of benzaldehyde with sulfone 426, the desulfurisation / 
elimination of the a-hydroxy sulfone could be achieved directly with 6 % sodium-mercury amalgam. This 
protocol was therefore used for the elimination of the a-hydroxysulfones 534. The best conditions used an 
excess of 6 % sodium-mercury amalgam in a 2 : 1  methanol:ethyl acetate solvent mix at reduced 
temperatures (Scheme 84), in the presence of disodium hydrogen orthophosphate to buffer the basic nature 
of the reactants. To our great delight, these conditions produced a single alkene product spot as judged by 
TLC.
After filtration of the metallic residues, purification of the resulting product 535 was carried out by 
Si0 2  flash chromatography. The yield of 535 was somewhat disappointing, however. Fortunately though, 
the correct (E)- olefination had been achieved, with proof coming from the 500 MHz 1H NMR spectrum of 
535 in C6 D6. The H(17) resonance appeared as a doublet at 8  6.40 ppm, whilst H(16) resonated as a 
double-doublet at 8  5.58 ppm, with the large J3 coupling value of 15.9 Hz between them confirming their 
trans relationship.
22) Na2H P 04 (25g/mmol of 291), 6 %  
Na/Hg (50g/mmol of 291), MeOH 
(0.025M), -20°C, 4.5 h then 0°C, 2 h
OTES
TBDPSO
OTBS
TESO""
OTBDPS
534
32%
OH
TBDPSO
OTBSOMe H
OTBS
TESO""
.OTBDPS
535
Scheme 84 Desulfurisation / elimination to deliver the trans C(16)/C(17) olefin.
92
Chapter 2 :  Discussion
In an extremely fortuitous event, the 1H NMR spectrum also showed that the C(10) primary triethyl 
silyl group had been selectively cleaved, whilst all other silyl protecting groups had been left intact. This 
could be explained by the greater acid lability of the TES group over both the TBS and TBDPS groups, and 
also from the enhanced lability of the C(10) primary over C(20) secondary position due to the steric 
crowding around C(20). Confirmation that is was indeed the primary TES group that had undergone 
cleavage came from the 2-D NMR NOESY spectrum, with the H(20) singlet showing cross-peaks with the 3 
x CH2  ethyl quartets (Figure 9).
.OTBS
H ^ ° HnOe O M e
O TB S  
,OTB DPS
'K J
nOe
M e MeTB D P S O '
nOenOe
535
Figure 9 Relevant nOe data for the B/C coupled trans olefin 535.
The NOESY spectrum also served to solidify our postulate of the correct olefination, with H(16) 
showing a cross peak with the geminal dimethyl unit, and also with H(14)ax. The HRMS also confirmed the 
unification of the two pyran rings with the additional loss of the single TES group, there being an [M+Naf 
ion at m/e 1327.7676 in the spectrum, suggesting an empirical formula of C/sH^oOgSis.
The primary hydroxyl in 535 was now exposed to a large excess of benzoyl chloride at low 
temperatures to introduce the requisite OBz group. This produced the desired benzoate 536 in expedient 
fashion and reasonable yields (Scheme 85).
TBDPSO.
TBDPSO
23) BzCI (10eq.), 
DMAP (1eq.), 
.OTBS CH2CI2 (0.01M)
24) aq. HF (40%). 
THF:MeCN  
.OTBS (1.5:1), (0.02M)
py (0.23M), 
■50°C, 15 mins
^  '"OTBS 
-OTBDPS
Scheme 85 Completion of the C(10)/C(27) B/C-ring analogue 526.
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The ester carbonyl now resonated at 8  167.5 ppm in the 125 MHz 13C NMR spectrum of 536 in 
C6 D6  and 500 MHz 1H NMR spectrum in the same solvent also showed a new phenyl ring system 
resonating between 5 8.07 and 7.05 ppm. The disappearance of the OH stretch at 3481 cm-1 in the IR 
spectrum and the HRMS furtherc confirmed the addition of a C6 H5 C =0 benzoyl unit.
All that remained was the global desilylation / hemiketalisation, and similar conditions to that 
employed in our synthesis of the C-ring analogue 525 again proved advantageous. The benzoate 536 was 
stirred in a 3:2 mix of THF:acetonitrile, followed by the addition of 6  equivalents of a 40% aqueous solution 
of hydrogen fluoride. The cooled solution was allowed to warm to 0°C and stirred for a further 12 hours, 
whereafter mildly basic work-up revealed the hexanol 526 in a pleasing 89% yield as a white crystalline 
solid.
The 500 MHz 1H NMR spectrum in methanol-d4  confirmed the total loss of all silyl residues and the 
anomeric methoxide singlet at 8  3.37 ppm. Interestingly, 526 exhibited only the “closed form” for the C-ring 
hemiketal. The HRMS also served to confirm product formation had been successful, although due the high 
stability of the tertiary oxonium ion formed from the loss of H20  at one of the hemiketals an [M+Na-H2 0 ]+ 
ion was now observed at m/e 581.2727 suggesting the empirical formula C3 1 H4 4 O10. Unfortunately due to a 
lack of time, analogue 526 has not yet had its interaction with the PKC CRD2 investigated by NMR.
The synthesis of 526 has a longest linear sequence of 24 steps and proceeds in 0.62% overall 
yield, with 43 synthetic operations being required overall. Although we had had some successes in this 
area, limiting time factors, as well as the limiting amount of material available did not allow us to optimise 
the synthetic transformations en route to 526.
In the synthesis of both bryostatin 7 and bryostatin 3, Masamune and Nishiyama were far more 
successful than us in their Julia olefination steps; 60% and 52% respectively for their two step procedures, 
compared with our modest 26% (see schemes 8  and 23). Crude molecular modelling studies showed that 
by changing the C(25)/C(26) di-silyl ether to its acetonide altered the way in which the C-ring positioned 
itself, and it became apparent that the acetonide protected synthon 4 caused a greater degree of planarity 
of the ring compared to 426, presumably from the decrease in steric repulsion. At first sight this might not 
serve to radically alter the reactivity of the molecule, however this slight modification was thought to 
possibly allow an easier access to the sulfone methylene protons thereby increasing the degree of 
deprotonation available.
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2.5 Synthetic studies on bryostatin 7 1 34
In light of these observations on the Julia reactions with phenylsulfone 426, our attention now 
focussed on the use of compound 4 for our total synthesis work, as this previously had given good results in 
Julia couplings in the bryostatin field. It will be recalled that this intermediate had previously been employed 
by Masamune3 5  in his total synthesis of bryostatin 7. However, his synthesis of 4 required 34 steps. We felt 
that this could be shortened considerably by adapting our previous synthesis of 426.
Kochienski olefination I  
glycal methanolysis
MeOHO .OPMBTBDPSlTBDPSI .OAc.OAcMe02C '^ i
CHO -OTBDPS OPMB427 537
OTBDPS
PhSO- Acetate aldol 
at C(3)Jufia °  I 
olefination .
AcO
OMe h
""OH
TESO'"
macrolactonisation
Bryostatin 7
OTBDPS
Scheme 86 Modified retrosynthetic analysis of bryostatin 7.
Our first attempts towards 4 were initiated from the enone 502 (Scheme 87) where we considered 
a tris-silyl deprotection followed by an allylic hydroxyl re-protection and an O-isopropylidination might yield 
the requisite enone 541. Subsequent Luche reduction and O-triethyl silylation would complete the target 4.
It was found that by treating the enone 502 with HF/py complex (3.5 ml per mmol of 502) in dry THF at - 
40°C and warming to 0°C for 13 hours, compound 538 was formed in 57% yield. All traces of the silyl 
resonances in the 1H NMR spectrum were removed, and the IR spectrum now showed a large broad OH 
stretch at 3388 cm’1. The HRMS showed an [M+Na]+ ion at m/e 479.1716 suggesting an empirical formula 
of CjsHazOsS where no silyl protecting groups were present.
We had good reason to believe that a selective TBDPS protection could now be accomplished on 
the allylic alcohol, but to our disappointment we found that this always resulted in either degradation of the 
starting material or no reaction at all. An alternative whereby the c/s-1,2 diol of 538 was isopropylidinated at 
the outset was then investigated.
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Of 251), THF (0.02M), 
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19) TBDPSCI 
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57% ""OH
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\ /  19) 2,2-DMP, 
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PhSO- PhSO-
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540 541
Scheme 87 Attempted desilylation and protecting group manipulation tactics of 502.
However, it was discovered that Me2 C(OMe) 2  reacted with all the free hydroxyl sites, when treated 
under our standard acetonide formation conditions. Slight modifications did nothing to solve this 
impediment, so we realised this was an unsuitable approach.
Retreating somewhat in our efforts to acquire 4, we sought to complete the DMDO epoxidation / 
aldol sequence with the acetonide already installed, and the glycal 505 presented itself as a credible 
foundation. By effecting an Osilyl to acetonide interchange, the chemistry developed for the synthesis of 
our initial target 426 might then be applied to the new route.
Therefore at the outset, the silyl ethers of 505 were removed in almost quantitative yields by 
treatment with tetrabutylammonium fluoride (TBAF) at ambient temperature (Scheme 8 8 ). The IR spectrum 
clearly showed the formation of a large OH resonance at 3489 cm'1; NMR analysis showed loss of both silyl 
residues, and HRMS confirmed the loss of the two TBS groups with the presence of an [M+Naf ion at m/e 
369.1736 which confirmed the empirical formula Ci9 H2 8 0 5 S.
PhSO- -------------- --------  DhC^ -  — ----------------------    D h cr>-
Immediate reprotection using the same procedure as for 475 meant mild heating with acetone and
2,2-dimethoxypropane along with 25 mol% of PPTS. This caused a rapid, and again high yielding reaction.
THF) (Z.8 eq.), 
THF (0.17M)
""OTBS 0°C to RT 12 h
505 95% 542 97% 543
Scheme 88 Silyl to acetonide protecting group change to 543.
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The methyl units of the acetonide now resonated at 8  1.30 and 8  1.23 ppm in the 500 MHz 1H NMR 
spectrum of 543 in C6 D6 , and the IR showed the loss of the OH resonance.
In our first attempts at effecting the DMDO / opening sequence, we found that consumption of the 
glycal occurred readily. However, upon addition of PPTS under our original conditions, and warming to 
room temperature, we discovered that the acetonide was being cleaved. We reasoned this problem was not 
insurmountable, and sought to alleviate the undesired acid mediated transketalisation by introducing an 
isopropylidene source so that if cleavage still occurred, there would be an equal chance of re-introducing 
the same group.
Thankfully this turned out to be the case, for it was subsequently found that after dissolving the 
glycal 505 in a cooled 1:1 solution of methanol and 2,2-dimethoxypropane, (containing flame activated 
molecular sieves), the addition of our freshly distilled DMDO solution caused its rapid consumption 
(Scheme 89). After addition of a stock solution of PPTS in methanol -  which allowed the addition of only 1 
mol % of acid, and warming to room temperature, the formation of the product 544 was seen. From our 
earlier work on this procedure, we had shown that the alcohol could undergo crude oxidation to the much 
more stable ketone, so 544 was dissolved in dry DMF and stirred with an excess of PDC at room 
temperature.
PhSO:
543
17) DMDO (0.07M in PhS02
Me2CO, 2.5eq.), MeOH  
(0.04M). 2.2-DMP (0.04M),
0°C, 12 mins, then 
PPTS (1 mol%),
RT, 10 mins
OMe h- o
544
18) PDC (4eq.), P h S 02 
DMF (0.1 M). O M e n
RT. 20 h ^ J ^ O .
58% (2 steps)
545
Scheme 89 Modified glycal epoxidation sequence to ketone 545.
We had noticed the formation of two closely separated major products for the epoxide opening 
step. However, after oxidation a single product was obtained. This could be explained by epoxidation step 
being less stereoselective. The anomeric opening with MeOH would still occur from the favoured axial 
position due to a transient oxonium ion species. It was also interesting to note that the oxidation step 
proceeded at a decreased rate, as seen by the slow consumption of one of the two spots, presumably from 
the less favourable axial hydroxyl position.
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The newly formed C=0 resonated at 8  204.9 ppm in the 125 MHz 13C NMR spectrum of 545 in 
C6 D6, consistent with a ketone carbonyl. There was also a sharp peak at 1722 cm"1 in the IR spectrum. 
HRMS confirmed the desired manipulation had taken place there being an [M+Na]+ ion at m/e 474.1923 
suggesting an empirical formula C2 3 H3 4 O7 S. The ketone 545 was then diluted with dry THF at low 
temperature, and n-butyllithium added to effect enolisation (Scheme 90). The naked lithium enoiate added 
to aldehyde 504 in THF as before and the desired dehydration was again observed when the reaction 
mixture was warmed. The enone 546 was isolated in 77% yield. HRMS showed the addition of the exocyclic 
olefin unit there being an [M+Cs]+ ion at m/e 867.2363 suggesting an empirical formula of C4 1 H5 4 0 8 SSi.
In continuation of our route, the acetonide enone 546 was subjected to a Luche reduction. Metal 
coordination with the anomeric methoxide over 45 minutes at room temperature and subsequent cooling to 
-78°C followed by the addition of sodium borohydride in three equal portions delivered the unstable p- 
hydroxy alkene 547. This was used directly for the next step to avoid any potential loss of product.
PhSO
OMe H' O
545
19.) "BuLi (2.5M, 1.5eq.), THF  
(0.015M), -78°C, 5 mins
then o  (2eq.)
hJ ^ otbdps
-RT, 20 mins 
77%
P h S 02
546
20 .)C eC I3.7H20 (1 0 e q .)f 
NaBH4 (5eq.), MeOH (0.05M),
-78°C 1h - RT 
80%
OTBDPS
PhSO-
OMe h
HO'"
547
OTBDPS
21.) Et3SiOTf (5eq.), 2,6-lutidine 
(10eq.), CH2CI2 (0.014M). -78°C - 
RT, 30 mins
82%
PhSO-
OMe h
TESO""
OTBDPS
Scheme 90 Completion of Masamunes C- ring synthon 4.
On exposure to an excess of triethylsilyl triflate in 0.06 M dichloromethane and 10 equivalents of 
2,6-lutidine at 0°C and allowing to warm to room temperature, the synthesis of the modified target 4 was 
completed in 57% yield over the two steps. This was completed in 3.06 % yield for the 21 step sequence, 
and 2.67% yield for the 20 step sequence from (E)-1,4-hexadiene 450. Although the overall synthesis 
required a longest linear synthesis of 25 steps and 27 synthetic transformations, this compared favourably 
with the route Masamune used in the synthesis of bryostatin 7 35, which had a longest linear synthesis of 21 
steps and 40 synthetic transformations.
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As was seen in 426, acetal 4 also showed slow bond rotation about C(18)/C(19) bond, significantly 
broadening the peaks at room temperature. At elevated temperatures however, it could be seen that these 
sharpened quite dramatically, and a high temperature 2-D NMR NOESY spectrum confirmed once again 
the desired stereochemistry. The C(34) exocyclic olefin triplet at 8  5.61 ppm showed significant correlation 
with the H(20) singlet at 8  4.68 ppm, and not the H(22) ring protons, however it was also interesting to note 
that there was a decrease in the correlation between the H(20) singlet and the anomeric methoxide. This 
could be a consequence of the slight change in the conformation of the ring, positioning H(20) in a more 
equatorial confirmation. HRMS confirmed that the reduction / protection sequence had been successful with 
an [M+Na]+ ion at m/e 873.4228 suggesting an empirical formula of C4 7 H7 o0 8 Si2 S.
It was interesting to note that even though Masamune and Nishiyama had both previously 
prepared structurally related O(20)-triethylsilylated C-ring phenylsulfone intermediates (4 and 115), neither 
had documented the occurrence of this restricted bond-rotational effect.
In conclusion, the shortest route to a fully elaborated and functionalised C-ring intermediate 426 so 
far in existence has been developed, with interesting slow bond rotation effects apparent. We have shown 
its usefulness in constructing a bare C-ring analogue 525 that has exhibited binding to the PKC-a CRD2 in 
similar concentrations to phorbol ester. The value of 525 has also been demonstrated in the construction of 
a more elaborate bryostatin analogue 526 that has yet to undergo biological NMR testing. Finally in our 
efforts towards the formal synthesis of bryostatin 7, the formation of the requisite C-ring synthon 4 has been 
completed.
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3.0 E xperim en ta l
Materials and Methods
Reactions were carried out under a nitrogen atmosphere with freshly distilled solvents unless 
otherwise noted. Hexanes refer to the distillate fraction of petroleum spirit that is collected at 40-60 °C and 
was distilled prior to use. All solvents were reagent grade. Dichloromethane, toluene, benzene and 
acetonitrile were distilled from calcium hydride under nitrogen. Diethyl ether and THF were distilled from 
sodium under nitrogen. All other reagents were used ‘as supplied’ from manufacturers unless otherwise 
stated. Flash chromatography was carried out according to Still et al. 1 3 4  with Kieselgel 60 40/60A (220-240 
mesh) silica gel. Precoated silica gel plates (250 pm) with a fluorescent indicator (E. Merck) were used for 
analytical thin layer chromatography. The plates were initially examined under UV light and then developed 
with either a sulfuric acid stain [Et0 H:H2 S0 4 :p-Me0 C6 H4 CH0  (95:4:1)] or iodine unless otherwise stated. 
Evaporation refers to the removal of solvents at < 40 °C on a Buchi rotary evaporator. 1H NMR spectra were 
acquired at 500 MHz with a Bruker DRX 500 and 13C NMR spectra were acquired at 125 MHz with a Bruker 
DRX 500. 2-D NMR spectra were also recorded on a Bruker DRX 500. Chemical shifts are reported in 5- 
values relative to tetramethylsilane (1H and i3 C) and all NMR spectra were recorded in deuterated solvent 
solutions. All infrared spectra were recorded on a Perkin-Elmer 1605 FT-IR spectrophotometer. Optical 
rotations were measured on an Optical Activity, Polaar 2000 automatic polarimeter. High resolution mass 
spectra were measured at the London School of Pharmacy on a V.G. 7070H or VG-ZAB instrument with a 
Finnigan Incos II data system.
3.1 Detailing the synthetic routes described in Schemes 53 and 54 135
In the following sub-section, compounds 450 to 435 had previously been prepared by Dr John 
Lennon 105,,/. However, the scale upon which he conducted many of his preparations of these compounds 
was often much smaller. The procedures described herein were all carried out on a larger scale or were 
adapted and improved in some way.
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(2/?,3/?)-hex-5-ene-2,3-diol 453
OH
OH
A 3 L conical flask equipped with an overhead mechanical stirrer was charged with H20  (1.2 L), t- 
butanol3 (1.2 L) and AD-mix-/?a (400 g, 0.6 eq). After 10 min of vigorous stirring at room temperature, the 
mixture was cooled to 0 °C when trans-1,4-hexadiene3  450 (40.0 g, 490 mmol) was added in one portion. 
After 72 h at 0 °C the reaction was quenched with solid sodium sulfite (145 g) and vigorously stirred at room 
temperature for 1 h. The organic layer was separated and aqueous layer extracted with EtOAc (9 x 200 
ml_). The combined organic layers were washed with brine (1 x 200 mL), dried over MgS04> filtered, and 
concentrated in vacuo. Purification of the residue by Si0 2  flash chromatography using hexanes/Et20  (2:1) 
as eluent afforded the volatile diol 453 (17.2 g, 51%) as a colourless free-flowing oil.
Spectral data agreed with those previously reported by Lennon 105"'.
Literature yield: 45-58%
(4/?,5/?)-4,5-Bis-(f-butyl-dimethylsilanyloxy)-hex-1 -ene 454
OTB S
OTBS
To a stirred solution of diol 453 (7.46 g, 64.2 mmol) and imidazole0  (13.12 g, 192 mmol) in dry 
DMFa (65 mL) was added f-butyldimethylchlorosilane° (24.2 g, 161 mmol) in one portion and the reactants 
heated at 85 °C. After 4 h, the reaction mixture was cooled to 0 °C, diluted with Et20  (50 mL) and quenched 
with solid NaHC03  followed by saturated aq. NaHC03. It was then extracted with Et20  (5 x 75 mL), the 
combined organic extracts washed with H20  (1 x 200 mL) and brine (1 x 200 mL), dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the residue by S i0 2  flash chromatography using neat 
hexanes as eluent afforded disilyl ether 454 (20.2 g, 91%) as a colourless free-flowing oil.
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Spectral data agreed with those previously reported by Lennon 105"'. 
Literature yield: 84%
(3/?,4/?)-3,4-Bis-(t-butyl-dimethylsilanyloxy)-pentanal 455
OTBS
O OTBS
To a cooled (0 °C) solution of alkene 454 (44.9 g, 130 mmol) in dry THF (200 mL) was added 
osmium tetroxide® (0.04 M solution in 1:1 acetone:H2 0 , 53 mL, 2.10 mmol). After 5 min sodium meta- 
periodate0  (167 g, 782 mmol) was added in one portion and after a 0.5 h at 0 °C, the reaction mixture was 
allowed to warm to RT. After 3.5 h, H20  (80 mL) was added, and the reaction mixture extracted with EtOAc 
( 6  x 200 mL). The combined organic extracts were washed with brine (1 x 200 mL), dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the residue by S i0 2  flash chromatography using 
hexanes/EtOAc (150:1) as eluent afforded aldehyde 455 (29.6 g, 65%) as a colourless oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 72%
(E)-(5/?,6/?)-5,6-Bis-(f-butyl-dimethylsilanyloxy)-hept-2-enoic acid ethyl ester 456
OTBS
EtO- OTBS
To a stirred solution of aldehyde 455 (24.0 g, 69.3 mmol) in dry CH2 CI2  (70 mL) was added
carbethoxymethylene triphenylphosphorane0 (35.0 g, 101 mmol) in one portion. After 48 h at room
temperature the reaction mixture was concentrated in vacuo. Et20  (-100 ml) was then added to precipitate
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the Ph3 P=0 solid by-product which was then removed by filtration. The filtrate was then concentrated in 
vacuo, and the residue purified by Si0 2  flash chromatography using hexanes/EtOAc (20:1) as eluent to 
afford allylic ester 456 (28.0 g, 97%) as a colourless oil.
Spectral data agreed with those previously reported by Lennon 105"'.
Literature yield: 93-95%
(£)-(5ft,6/?)-5,6-Bis-(f-butyl-dimethylsilanyloxy)-hept-2-en-1-ol 457
OTBS
HO. OTBS
To a cooled (-78 °C) solution of allylic ester 456 (28.0 g, 67.2 mmol) in dry CH2 CI2  (335 mL) was 
added diisobutylaluminiumhydride0  (1.5 M solution in PhMe, 99 mL, 148 mmol) dropwise over 0.5 h. The 
reaction mixture was allowed to warm to -60 °C over 1 h and maintained at this temperature for 2.5 h. It was 
then quenched by the careful dropwise addition of MeOH until all gas evolution ceased. The mixture was 
then diluted with CH2 CI2  (300 mL) and allowed to warm to 0 °C whereupon 10% aq. sodium potassium 
tartrate solution (300 mL) was added. After vigorous stirring at 0 °C for 1 h the solution was then stirred at 
room temperature for 1 h. The organic layer was separated and aqueous layer extracted with CH2 CI2  (5 x 
300 mL), then EtOAc (5 x 400 mL). The combined organic layers were dried over MgS04, filtered and 
concentrated in vacuo. Purification of the crude residue by Si0 2  flash chromatography using 
hexanes/EtOAc (9:1) as eluent afforded allylic alcohol 457 (23.8 g, 95%) as a viscous light yellow oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 87%
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{(2/?,3/?)-3-[(2/?,3/?)-2)3-Bis-(f-butyl-dimethylsilanyloxy)-butyl]-oxiranyl>-methanol 458
OTBS
HO. OTBS
To a cooled (-35 °C) solution of diethyl D-tartratea (1.63 mL, 9.60 mmol) in dry CH2 CI2  (120 mL) 
and flame activated 4A molecular sieves8 (20 g) was added titanium(IV) isopropoxide8  (2.31 ml, 7.76 mmol) 
and f-butyl hydroperoxide (8 . 8  M solution in CH2 CI2, 50.4 mL) sequentially. After ageing for 1 h, a solution of 
allylic alcohol 457 (18.0 g, 48.0 mmol) in dry CH2 CI2  (25 mL) was added dropwise over 18 mins and the 
mixture was stored at -33 °C for 7 d. The mixture was then warmed to 0 °C, and quenched by pouring in a 
solution of iron(II) sulfate heptahydrateb (80 g) and citric acid8  (18.1 g) in H20  (178 mL) and stirring 
vigorously for 0.5 h. The organic layer was removed and aqueous layer extracted with Et20  (4 x 200 mL) 
and the combined organic layers were vigorously stirred with 15% NaOH in brine (260 mL) at 0 °C for 1.5 h. 
The organic layer was separated and the aqueous layer again extracted with Et20  (5 x 50 mL). The 
combined organic layers were dried over MgS04, filtered, and concentrated in vacuo. Purification of the 
residue by Si0 2  flash chromatography using hexanes/EtOAc (40:1) as eluent afforded epoxy alcohol 458 
(18.1 g, 96%) as a colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105"'.
Literature yield: 89%
(3Sl5/?l6/?)-5,6-Bis-(f-butyl-dimethylsi!anyloxy)-heptane-1,3-diol 459
OTBS
HO- OTBS
To a cooled (-40 °C) solution of epoxy alcohol 458 (19.04 g, 48.7 mmol) in dry THF (10 mL) was 
added sodium b/s(methoxyethoxy)aluminium hydridef (3.5 M solution in PhMe, 70 mL, 244 mmol) diluted
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with THF (20 mL) dropwise over 19 min and the mixture was stored at -33 °C for 96 h. The mixture was 
then cooled to -78 °C, diluted with CH2 CI2  (200 mL) and quenched by the careful addition of MeOH until 
effervescence ceased. The mixture was warmed to 0 °C whereupon 10% aq. sodium potassium tartrate 
solution (200 mL) was added with vigorous stirring for 1.5 h. The organic layer was separated and the 
aqueous layer successively extracted with CH2 CI2  (5 x 150 mL). The combined organic layers were washed 
with brine (1 x 60 mL), dried over MgS04) filtered, and concentrated in vacuo. Purification of the residue by 
Si0 2  flash chromatography using hexanes/EtOAc (elution gradient 9:1, then 6:1) as eluent afforded 1,3-diol 
459 (16.5 g, 8 6 %) as a white solid.
Spectral data agreed with those previously reported by Lennon 105,//.
Literature yield: 83%
(S)-4-[(2/?,3R)-2l3-Bis-(f-butyl-dimethylsilanyloxy)-butyl]-2-(4-methoxy-phenyl)-[1,3]dioxane 460
OTBS
PMP'
OTBS
A mixture of 1,3-diol 459 (16.3 g, 41.6 mmol), p-anisaldehyde dimethylacetal9 (10.6 mL, 62.4 
mmol) and pyridinium p-toluenesulfonatea (1.9 g, 7.5 mmol) in dry DMFa (275 mL) were heated at 50 °C on 
a rotary evaporator under reduced pressure (28 mmHg) for 25 min. The reaction mixture was then cooled to 
room temperature and quenched by the slow addition of saturated aq. NaHC03  (—50 mL) and extracted with 
Et20  ( 6  x 150 mL). The combined organic layers were washed with brine (1 x 150 mL), dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the residue by S i0 2  flash chromatography using 
hexanes/EtOAc (9:1) as eluent afforded p-methoxybenzylidene acetal 460 (19.6 g, 92 %) as a colourless 
viscous oil.
Spectral data agreed with those previously reported by Lennon 105'".
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(3Sl5Rl6/?)-5,6-Bis-(f-butyl-dimethylsilanyloxy)-3-(4-methoxy-benzyloxy)-heptan-1-ol 461
PMBO, ^
QTBS
H O ^ 6 tb s
To a cooled (-78 °C) solution of p-methoxybenzy!idene acetal 460 (5.6 g, 11.0 mmol) in dry CH2 CI2  
(10 mL) was added diisobutylaluminiumhydride® (1.5 M solution in PhMe, 21.8 mL, 26.3 mmol) dropwise 
over 8  min and the reaction was allowed to warm to 0 °C over 4 h. After 30 min at 0 °C it was re-cooled to - 
78 °C, diluted with CH2 CI2  (60 mL) and quenched by the careful dropwise addition of MeOH until 
effervescence ceased. The mixture was warmed to 0 °C whereafter 10% aq. sodium potassium tartrate 
solution (90 mL) was added. After vigorous stirring for 1 h, the organic layer was separated and the 
aqueous layer extracted with CH2 CI2  (9 x 100 mL). The combined organic layers were washed with brine (1 
x 200 mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the crude residue by Si0 2  
flash chromatography using hexanes/EtOAc (40:1) as eluent afforded primary alcohol 461 (5.0 g, 89%; or 
82% for 2  steps) as a colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105,//.
Literature yield: 60-69% (2 steps)
(£)-(5S,7Rl8/?)-7,8-Bis-(f-butyl-dimethyl-silanyloxy)-5-(4-methoxy-benzyloxy)-non-2-enoic acid ethyl 
ester 463
OTBS
EtO. OTBS
To a cooled (-78 °C) solution of oxalyl chloride® (4.8 mL, 55.4 mmol) in dry CH2 CI2  (34 mL) was 
added DMSO® (7.86 mL, 110.8 mmol) dropwise over 8  min with concomitant gas evolution. After 50 min at - 
78 °C, a solution of 461 (5.7 g, 11.1 mmol) in dry CH2 CI2 (25 mL) was added dropwise over 13 min, and the
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reaction mixture then allowed to warm to -55 °C over 2 h. After 45 min at this temperature, Et3N (23.15 mL, 
166 mmol) was added dropwise over 1 1  min and the mixture stirred vigorously for 10 min. Dry CH2 CI2  (60 
mL) was then added and the reactants allowed to warm to RT. The reaction mixture was washed with brine 
(1 x 70 mL), dried over MgS04, filtered, and concentrated in vacuo to yield a thick dark yellow oil. The crude 
aldehyde 462 was azeotropically dried from C6 H6  ( 1 x 1 5  mL) and used for the next step without further 
purification.
To the crude aldehyde 462 (5.7 g, 11.1 mmol, assuming 100% conversion) in dry CH2 CI2  (11.2 
mL) was added carbethoxymethylene triphenylphosphoranec (7.7 g, 22.2 mmol) in one portion. After 15 h 
at room temperature, S i0 2  (-10 g) was added and the solvents removed in vacuo. Flash chromatography 
was then performed with hexanes/EtOAc (20:1) as eluent to afford a,|3-unsaturated ester 463 (5.8 g, 89%, 2 
steps) as a colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105/,/.
Literature yield: 70-75% (2 steps)
(2S,3/?,5Sl7/?,8/?)-7,8-Bis-(f-butyl-dimethyl-silanyloxy)-2)3-dihydroxy-5-(4-methoxy-benzyloxy)- 
nonanoic acid ethyl ester 464
OPMB OTBS
EtO.
OTBS
HO
OH
To a stirred suspension of H20  (50.0 mL) and f-butanola (60.0 mL) was added AD-mix /?a (55.7 g,
4.0 eq.) and methanesulfonamidec (3.8 g, 39.6 mmol). After 10 min of vigorous stirring at room temperature, 
the mixture was cooled to 0 °C whereupon a solution of a,p-unsaturated ester 463 (5.8 g, 9.9 mmol) in t- 
butanol3 (10 mL) was added in one portion. After 20 h the reaction was quenched with solid sodium sulfite 
(59.6 g) and vigorously stirred at room temperature for 1 h. The organic layer was separated and the 
aqueous layer extracted with hot EtOAc ( 8  x 30 mL). The combined organic layers were dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the crude residue by Si0 2  flash chromatography using
107
Chapter 3 :  Experimental
hexanes/EtOAc (elution gradient 20:1, then 3:1) as eluent afforded 1,2-diol 464 (5.7 g, 93%) as a light 
yellow viscous oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 8 6 %
(4S,5/?)-5-[(2S,4/?l5/?)-4l5-Bis-(f-butyl-dimethyl-silanyloxy)-2-(4-methoxy-benzyloxy)-hexyl]-2,2- 
dimethyl-[1,3]dioxolane-4-carboxylic acid ethyl ester 438
OPMB 9TBS
EtO.
OTBS
To a stirred solution of 1,2-diol 464 (13.7 g, 22.3 mmol) in acetoneb (48 mL) and 2,2- 
dimethoxypropane® (48 mL) was added pyridinium p-toluenesulfonatec (1.4 g, 5.6 mmol) in one portion, a 
condenser was fitted and the mixture heated to 40 °C. After 16 h the solvent was removed in vacuo. 
Purification of the residue by S i0 2 flash chromatography using hexanes/EtOAc (20:1) as eluent afforded 
acetonide 438 (13.7 g, 94%) as a colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 85-90%
3-{(4Sl5/?)-5-[(2S,4f?,5/?)-4f5-Bis-(f"butyl-dimethyl-silanyloxy)-2-(4-methoxy-benzyloxy)-hexyl]-2>2- 
dimethyl-[1,3]dioxolan-4-yl}-2,2-dimethyl-3-oxo-propionic acid methyl ester 436
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OPMB 9TBS
MeO.
OTBS
To a cooled (-78 °C) solution of dry diisopropylamine (7.9 mL, 56.0 mmol) and dry THF (8.5 mL) 
was added n-butyllithium3  (2.5 M solution in hexanes, 22.4 mL, 56.0 mmol) dropwise over 7 min. After 45 
min methyl isobutyrate3 (6.80 mL, 59.2 mmol) was added in one portion. After a further 40 min a solution of 
acetonide 438 (5.24 g, 8.0 mmol) in dry THF (19 mL) was added over 12 min. After 0.5 h the mixture was 
warmed to -20 °C and stirred for 1 h. The mixture was diluted with Et20  (80 mL), quenched by dropwise 
addition of saturated NH4CI (aq.) (~30 mL) and stirred for 20 min at room temperature. The organic layer 
was separated and the aqueous layer extracted with EtOAc (9 x 60 mL). The combined organic layers were 
washed with brine (1 x 50 mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the 
residue by Si0 2  flash chromatography using hexanes/EtOAc (4:1) as eluent afforded (3-keto ester 436 (5.4 
g, 95%) as a light yellow viscous oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 85%
3-{(4S,5/?)-5-[(2/?l4Rl5/?)-4l5-Dihydroxy-2-(4-methoxy-benzyloxy)-hexyl]-2l2-dimethyl-[1,3]dioxolan-4- 
yl}-2,2-dimethyl-3-oxo-propionic acid methyl ester 465
OPMB ? H
MeO.
OH
To a cooled (-40 °C) solution of p-keto ester 436 (5.4 g, 7.6 mmol) in dry THF (64 mL) in a 
polyethylene bottle was added hydrogen fluoride-pyridine complex (20 mL) dropwise via a polyethylene
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syringe over 5 min and the mixture was allowed to warm to -5 °C over 4 h. After a further 26 h at -5 °C, the 
reaction was quenched by the sequential addition of solid NaHC03l and saturated aq. NaHC03 solution, 
and diluted with EtOAc (20 mL). The organic layer was then separated and aqueous layer was extracted 
with EtOAc (10 x 50 mL). The combined organic layers were dried over MgS04l filtered, and concentrated 
in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (3:2, then 1:1) as 
eluent afforded diol 465 (3.25 g, 89%) as a colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105'".
Literature yield: 98%
3-{(4S,5/?)-5-[(2Sl4/?l5/?)-4l5-Bis-(2,2-dimethyl-propionyloxy)-2-(4-methoxy-benzyloxy)-hexyl]-2,2- 
dimethyl-[1,3]dioxolan-4-yl}-2,2-dimethyl-3-oxo-propionic acid methyl ester 466
OPMB ? Piv
MeO.
OPiv
To a cooled (0 °C) solution of diol 465 (702 mg, 1.5 mmol) in dry pyridine3 (2.4 mL) and dry CH2CI2 
(2.1 mL) was added trimethylacetylchloride0 (1.8 mL, 15.0 mmol) dropwise over 2 min, and the mixture was 
allowed to warm to room temperature. After 10 d the mixture was quenched by the addition of saturated aq. 
NaHC03 solution (~5 mL) and extracted with EtOAc (6 x 10 mL). The combined organic layers were 
washed with brine ( 1 x 1 5  mL), dried over MgS04, filtered, and concentrated in vacuo. The excess pyridine 
was then azeotropically removed with PhMe (2 x 10 mL). Purification of the residue by Si02 flash 
chromatography using hexanes/EtOAc (12:1) as eluent afforded the dipivaloate 466 (820 mg, 87%) as a 
colourless viscous oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 92%
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3-{(4Sl5/?)-5-[(2Sl4/?l5/?)’4 l5-Bis-(2,2-dimethyl-propionyloxy)-2-hydroxy-hexyl]-2,2-dimethyl-[1l3]- 
dioxolan-4-yl}-2,2-dimethyl-3-oxo-propionic acid methyl ester 467
OPivOH
MeO.
OPiv
To a stirred solution of dipivaloate 466 (5.73 g, 8.81 mmol) in CH2CI2 (68 mL) and H20  (3.8 mL) 
was added 2,3-dichloro-5,6-dicyanobenzoquinonea (4.0 g, 17.6 mmol) in one portion. After 85 min at room 
temperature the mixture was quenched with saturated aq. NaHC03 solution and filtered through a plug of 
CELITE™ with subsequent CH2CI2 washings, then H20  washings. The organic layer was separated and 
aqueous layer extracted with CH2CI2 (4 x 50 mL). The combined organic layers were dried over MgS04, 
filtered, and concentrated in vacuo. Purification of the crude residue by Si02 flash chromatography using 
hexanes/EtOAc (10:1) as eluent afforded 8-hydroxy ketone 467 (4.2 g, 89%) as a light yellow viscous oil.
Spectral data agreed with those previously reported by Lennon 105/".
Literature yield: 89-94%
2,2-Dimethyl-propionic acid (1 R,2R)-2-{2,2-ti\methy\-prop\ony\oxy)-Z-((2aS,5S,7RJaS)-7-hydroxy -3a- 
methoxy-3,3-dimethyl-2-oxo-hexahydro-furo[3,2-b]pyran-5-yl)-1 -methyl-propyl ester 435
OPivMe
OPiv
OH
To a 50 mL flask containing dry MeOH8 (6.2 mL) was added acetyl chloride8 (0.9 mL, 12.1 mmol). 
After 4 h at RT the solution of methanolic HCI was added to 8-hydroxy ketone 467 (552 mg, 1.1 mmol). The 
mixture was heated at 40 °C for 96 h, whereafter it was cooled to 0 °C and quenched by the addition of solid
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NaHC03 (~5 g). After C 02 evolution had subsided, the mixture was diluted with EtOAc (10 mL) and H20  (10 
mL). The organic layer was separated and the aqueous layer extracted with EtOAc ( 8 x 1 5  mL). The 
combined organic layers were washed with brine ( 1 x 1 5  ml), dried over MgS04, filtered, and concentrated 
in vacuo. Purification of the crude residue by Si02 flash chromatography using hexanes/EtOAc (20:1, then 
5:1) as eluent afforded methyl glycoside 435 (280 mg, 58%) as a clear viscous oil.
Spectral data agreed with those previously reported by Lennon 105'".
Literature yield: 56% (for 2 step procedure)
2,2-Dimethyl-propionic acid (1 R,2/?)-2-(2,2-dimethyl-propionyloxy)-1 -[(3aS,5S,7RJaS)-Za-methoxy-7- 
(4-methoxy-benzyloxy)-3,3-dimethyl-2-oxo-hexahydro-furo[3,2-b]pyran-5-ylmethyl]-propyl ester 
473
Me. OPiv
OPiv
OPMB
To a stirred solution of methyl glycoside 435 (306 mg, 0.66 mmol) in dry CH2CI2 (2.0 mL) was 
added a solution of p-methoxybenzyl trichloroacetimidate (940 mg, 3.3 mmol) in dry CH2CI2 (3.0 mL) in one 
portion. Pyridinium-p-toluene sulfonate0 (83 mg, 0.33 mmol) was then added in one portion. After 14 d of 
stirring, the mixture was diluted with CH2CI2 (13 mL) and quenched by dropwise addition of saturated aq. 
NaHC03 (~2 mL). The organic layer was separated and aqueous layer extracted with CH2CI2 ( 4 x 5  mL). 
The combined organic layers were washed with brine (1 x 10 mL), dried over MgS04, filtered, and 
concentrated in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc 
(gradient elution with neat hexanes, then 400:1, then 100:1, then 10:1) as eluent afforded p-methoxybenzyl 
ether 473 (272 mg, 70%) as a colourless viscous oil.
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IR (neat film): 2975 (m), 2937 (m), 2910 (m), 2873 (w), 1791 (s), 1730 (s), 1613 (w), 1514 (m), 1480 (w), 
1464 (w), 1391 (w), 1368 (w), 1281 (m), 1249 (m), 1210 (w), 1155 (s). 1099 (m), 1059 (m), 1037 (m), 993 
(w), 823 (w) cm'1.
1H NMR (500 MHz in CDCI3): 5 7.20 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 5.18 (m, 1H), 4.92 (m, 
1H), 4.51 (dd, J =  11.8, 19.4 Hz, 2H), 4.15 (d, J = 2.0 Hz, 1H), 3.94 (m, 1H), 3.86 (m, 1H), 3.76 (s, 3H), 3.27 
(s, 3H), 1.73-1.61 (complex m, 3H), 1.51 (m, 1H), 1.30 (s, 3H), 1.19 (s, 3H), 1.17 (s, 9H), 1.15 (s, 9H), 1.12 
(d, J = 6.5 Hz, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 178.8, 177.5, 177.3, 159.2, 129.7, 129.0, 113.7, 102.0, 73.1, 70.6, 70.4,
70.2, 69.5, 61.7, 55.2, 49.9, 48.6, 38.8, 38.7, 36.5, 30.2, 27.1, 27.0, 20.1, 18.2, 15.5 ppm.
HRMS (FAB, MNOBA matrix): for C32 H4 8 O10Na (M+Na)+, Calcd: 615.3180, Found: 615.3145.
(3aS,5/?>7/?,7aS)-5-((2R,3/?)-2J3-Dihydroxy-butyl)-3a-methoxy-7-(4-methoxy-benzyloxy)-3,3-dimethyl- 
hexahydro-furo[3,2-b]pyran-2-one 474
OH
OH
OPMB
To a stirred solution of p-methoxybenzyl ether 473 (500 mg, 0.86 mmol) in MeOH3 (7.8 mL) was 
added a fresh solution of sodium methoxide (1 M solution in MeOH, 28 mL, 11.9 mmol) in one portion. After 
72 h the mixture was neutralised (pH 7) by the slow addition of pre-washed (in MeOH) Amberlite 120 H+ 
resin. The resin was filtered off and the solvent removed in vacuo. Purification of the residue by Si02 flash 
chromatography using hexanes/EtOAc (2:1, then neat EtOAc) as eluent afforded 1,2-diol 474 (276 mg, 
73%) as a colourless oil.
[a ]D: +37.2° (c 0.18, CH2CI2).
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IR (neat film): 3446 (br), 2950 (s), 1783 (s), 1613 (m), 1514 (s), 1463 (m), 1390 (m), 1248 (s), 1037 (s), 
914 (m), 823 (m), 732 (s) cm'1.
1H NMR (500 MHz in CDCI3): 6 7.24 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.54 (s, 2H), 4.28 (t, J =
10.5 Hz, 1H), 4.17 (d, J =  1.6 Hz, 1H), 3.87 (m, 1H), 3.77 (s, 3H), 3.63 (m, 1H), 3.55 (m, 1H), 3.39 (s, 3H),
2.27 (broad s, 2H), 1.68 (d, J=  14.3 Hz, 1H), 1.59-1.48 (complex m, 3H), 1.30 (s, 3H), 1.24 (s, 3H), 1.17 (d, 
J = 6.2 Hz, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 179.1, 159.3, 130.0, 129.5, 113.9, 101.8, 73.3, 72.0, 71.2, 70.7, 69.4, 62.0,
55.2, 50.0, 48.6, 39.1, 30.1, 20.1,19.7,18.3 ppm.
HRMS (FAB, MNOBA matrix): for C22H320 8Na (M+Na)+, Calcd: 447.2006, Found: 447.1995.
(3aS,5Sl7/?,7aS)-3a-Methoxy-7-(4-methoxy-benzyloxy)-3,3-dimethyl-5-((4R,5R)-2l2,5-trimethyl-[1l3]- 
dioxolan-4-ylmethyl)-hexahydro-furo[3,2-b]pyran-2-one 475
Me.
OPMB
To a stirred solution of 1,2-diol 474 (56 mg, 0.13 mmol) in acetoneb (0.95 mL) and 2,2- 
dimethoxypropane® (0.95 mL) was added pyridinium p-toluenesulfonatec (8 mg, 30 pmol) in one portion, a 
condenser was fitted and the mixture was heated to 40 °C. After 20 min the solvent was removed in vacuo. 
Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (gradient elution 4:1, then 
3:1) as eluent afforded acetonide 475 (60 mg, 98%) as a colourless oil.
IR (neat film): 2981 (m), 1789 (s), 1613 (w), 1514 (m), 1464 (w), 1378 (w), 1247 (s), 1099 (m), 1039 (m)
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1H NMR (500 MHz in CDCI3): 8 7.25 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 4.55 (dd, J = 12.2, 14.8
Hz, 2H), 4.21 (m, 1H), 4.16 (d, J = 1.4 Hz, 1H), 3.86 (dd, J = 2.4, 4.9 Hz, 1H), 3.79 (m, 1H), 3.78 (s, 3H),
3.63 (m, 1H), 3.38 (s, 3H), 1.73 (d, J=  14.3 Hz, 1H), 1.62-1.44 (complex m, 3H), 1.35 (s, 3H), 1.320 (s, 3H),
1.316 (s, 3H), 1.24 (s, 3H), 1.21 (d, J = 6.0 Hz, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 179.0, 159.3, 129.7, 129.3, 113.8, 107.8, 101.8, 77.9, 76.8, 73.3, 70.7,
69.4, 62.3, 55.2, 49.6, 48.6, 37.8, 30.3, 27.3, 27.0, 20.1, 18.4, 16.9 ppm.
HRMS (FAB, MNOBA matrix): for C25H3608Na (M+Na)+, Calcd: 487.2330, Found: 487.2308.
(3aSl5/?>7/?,7aS)-5-((2R,3R)-2>3-Dihydroxy-butyl)-7-hydroxy-3a-methoxy-3,3-dimethyl-hexahydro- 
furo[3,2-b]pyran-2-one 477
Me. OH
OH
OH
To a stirred solution of dipivaloate 435 (2.3 g, 4.8 mmol) in MeOHa (40 mL) was added a fresh 
solution of sodium methoxide (1 M solution in MeOH, 170 mL, 72 mmol) in one portion. After 48 h the 
mixture was neutralised (pH 7) by the slow addition of pre-washed (in MeOH) Amberlite 120 H+ resin. The 
resin was filtered off, S i02 added and the solvent removed in vacuo. It was then added to a pre-packed 
column of S i02 and the column eluted using hexanes/EtOAc (1:2, then 20:1 EtOAc:MeOH). Triol 477 (1.4 g, 
99%) was obtained as a white crystalline solid.
IR (neat film): 3394 (br), 2977 (m), 2948 (m), 1768 (s), 1650 (w), 1461 (m), 1391 (m), 1285 (m), 1245 (m), 
1213 (m), 1157 (s), 1131 (s), 1096 (s), 1038 (s), 922 (m) 730 (m)cm’1.
115
Chapter 3 :  Experimental
1H NMR (500 MHz in CDCI3): 5 4.26 (m, 2H), 4.13 (d, J = 2.6 Hz, 1H), 3.64 (m, 1H), 3.57 (m, 1H), 3.41 (s, 
3H), 2.54 (broad s, 3H), 1.68 (m, 2H), 1.64-1.47 (complex m, 2H), 1.32 (s, 3H), 1.25 (s, 3H), 1.19 (d, J = 
6.22 Hz, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 178.8, 102.2, 73.8, 71.8, 71.3, 64.0, 61.0, 50.1, 48.6, 39.0, 32.9, 19.8, 18.3 
ppm.
HRMS (FAB, MNOBA matrix): for Ci4H240 7Na (M+Na)+, Calcd: 327.1407, Found: 327.1420.
(3aSl5R,7/?,7aS)-7-Benzyloxy-5-((2/?l3R)-2l3-bis-benzyloxy-butyl)-3a-methoxy-3l3-dimethyl- 
hexahydro-furo[3,2-b]pyran-2-one 478
OBnMe.
OBn
OBn
To a cooled (0 °C) solution of triol 477 (500 mg, 1.64 mmol) in dry DMFa (15 mL) was added 
sodium hydride0 (60% dispersion in mineral oil, 660 mg, 16.4 mmol) in 3 portions over a 2 min period, to 
avoid excess foaming. After 40 min, benzyl bromide8 (1.95 mL, 16.4 mmol) was added dropwise over 2 min 
and 10 min later, the mixture was allowed to warm to room temperature. After a further 1.5 h at RT the 
mixture was re-cooled to 0 °C and quenched by adding solid NaHC03 (~2 g) and dropwise addition of H20  
(~30 mL). The mixture was extracted with Et20  (9 x 20 mL) and the combined organic layers were dried 
over MgS04, filtered, and concentrated in vacuo. Purification of the crude residue by Si02 flash 
chromatography using hexanes/EtOAc (gradient elution with neat hexanes, then 20:1, then 10:1, then 5:1) 
as eluent afforded tris-benzyl ether 478 (713 mg, 76%) as a colourless oil.
[a ]D: +1.6° (c 1.865, CH2CI2).
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IR (neat film): 2976 (m), 2876 (m), 1786 (s), 1496 (w), 1455 (m), 1389 (m), 1211 (m), 1101 (s), 1061 (s), 
738 (s) cm'1.
1H NMR (500 MHz in CDCI3): 5 7.23 (m, 15H), 4.62 (d, J = 11.4 Hz, 1H), 4.56 (m, 3H), 4.47 (d, J = 11.8 Hz, 
1H), 4.41 (d, J =  11.4 Hz, 1H), 4.22 (dt, J = 2.3, 9.3 Hz, 1H), 4.16 (d, J =  1.7 Hz, 1H), 3.86 (m, 1H), 3.80 (m, 
1H), 3.74 (m, 1H), 3.23 (s, 3H), 1.80-1.73 (complex m, 2H), 1.59-1.48 (complex m, 2H), 1.30 (s, 3H), 1.21 
(s, 3H), 1.13 (d, J = 6.3 Hz, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 179.0, 138.5, 137.8, 128.1, 127.7, 127.6, 127.4, 101.9, 77.4, 74.7, 73.6,
72.0, 71.1, 70.9, 70.0, 62.6, 49.6, 48.6, 35.7, 30.0, 20.2, 18.4, 14.4 ppm.
HRMS (FAB, MNOBA matrix): for C35H4207Na (M+Na)+, Calcd: 597.2807, Found: 597.2828.
(2S,3S,4R,6S)-4-Benzyloxy-6-[(2/?,3R)-2,3-bis-benzyloxy-butyl]-2-(2-hydroxy-1l1-dimethyl-ethyl)-2- 
methoxy-tetrahydro-pyran-3-ol 479
OBnMe.
F O'HO.
OBn
HO
OBn
To a cooled (0 °C) solution of lithium aluminium hydride3 (1 M solution in Et20 , 1.74 mL, 1.74 
mmol) in dry THF (4 mL) was added a solution of tris-benzyl ether 478 (200 mg, 0.35 mmol) in dry THF 
(800 pL) dropwise over 2 min. After 5 min, the reaction mixture was allowed to warm to room temperature 
and stirred for 3.5 h. It was then re-cooled to 0 °C and EtOAc (5 mL) was added. Final quenching was 
accomplished by dropwise addition of MeOH until H2 gas evolution visibly ceased. The mixture was then 
stirred vigorously with saturated aq. sodium potassium tartrate0 (10 mL) for 45 min. The organic layer was 
separated and the aqueous layer extracted with EtOAc ( 8 x 1 0  mL). The combined organic layers were 
dried over MgS04, filtered, and concentrated in vacuo. The residue was purified by rapid Si02 flash
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chromatography using hexanes/EtOAc (2:1) as eluent. Diol 479 (176 mg, 88%) was obtained as a 
colourless viscous oil, that proved rather unstable.
1H NMR (500 MHz in C6D6): 8 7.41-7.04 (complex m, 15H), 4.59-4.42 (complex m, 6H), 4.30 (d, J = 11.7 
Hz, 1H), 4.07 (m, 2H), 3.70 (m, 2H), 3.53 (q, J = 10.8 Hz, 2H), 3.28 (s, 3H), 1.95 (complex m, 2H), 1.62 
(complex m, 2H), 1.20 (s, 3H), 1.17 (d, J = 6.3 Hz, 3H), 1.09 (s, 3H) ppm.
Benzoic acid 2-[(2S,3S>4R>6S)-4-benzyloxy-6-((2R,3R)-2J3-bis-benzyloxy-butyl)-3-hydroxy-2-methoxy- 
tetrahydro-pyran-2-yl]-2-methyl-propyl ester 483
OBnMe.
if O 'BzO.
OBn
HO'''
OBn
To a cooled (0 °C) solution of diol 479 (50 mg, 0.09 mmol) in dry CH2CI2 (1.2 mL) and pyridine8 
(1.2 mL) was added benzoyl chloride9 (100 pL, 0.9 mmol) dropwise over 1 min. After 2 min the mixture was 
diluted with CH2CI2 (~1 mL) and quenched by dropwise addition of saturated aq. NaHC03. The organic 
layer was separated and aqueous layer extracted with CH2CI2 ( 4 x 2  mL). The combined organic layers 
were dried over MgS04, filtered, and concentrated in vacuo. Purification of the residue by Si02 flash 
chromatography using hexanes/EtOAc (gradient elution with neat hexanes, then 6:1, then 3:1) as eluent 
afforded primary benzoate 483 (41 mg, 69%) as a colourless viscous oil.
13C NMR (125 MHz in C6D6): 8 172.3, 167.0, 148.4, 139.5, 133.6, 130.5, 130.0, 128.6, 128.5, 128.3, 127.8,
127.7, 127.5, 102.6, 77.4, 76.8, 75.2, 72.4, 71.2, 70.8, 67.5, 65.0, 51.3, 46.4, 36.8, 31.8, 30.4, 21.6, 21.0,
14.6 ppm.
HRMS (FAB, MNOBA matrix): for C42H5o08Na (M+Na)+, Calcd: 705.3373, Found: 705.3403.
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(S)-[(4R,6S)-6-[(2/?,3/?)-2,3-Bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy-phenyl)-[1,3]dioxan- 
4-yl]-hydroxy-acetic acid ethyl ester 490
EtO.
.OTBS
HO'"
"OTBS
PMP
To a cooled (0 °C) solution of 1,2-diol 464 (5.7 g, 9.4 mmol) in dry CH2CI2 (115 mL) and flame 
activated 4A molecular sieves3 (8 g) was added 2,3-dichloro-5,6-dicyanobezoquinone8 (2.6 g, 11.3 mmol) in 
one portion. After 2.5 h the mixture was diluted with CH2CI2 (100 mL), filtered through CELITE™ with 
CH2CI2 washings, and then washed with H20  (2 x 30 mL). The aqueous layers were back-extracted with 
CH2CI2 (2 x 20 mL), and the combined organic layers were dried over MgS04, filtered, and concentrated in 
vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (gradient elution 
100:1, then 20:1) as eluent afforded p-methoxybenzylidene acetal 490 (4.4 g, 76%) as a light yellow viscous 
oil.
[a]D: +26.6° (c 1.22, CH2CI2).
IR (neat film): 3524 (br), 2996 (s), 2857 (s), 1744 (m), 1616 (w), 1589 (w), 1518 (m), 1472 (m), 1389 (m), 
1302 (m), 1250 (s), 1105 (s), 1007 (m), 836 (s), 775 (s) cm-1.
1H NMR (500 MHz in CDCI3): 8 7.32 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 5.44 (s, 1H), 4.28 (q, J = 
7.1 Hz, 2H), 4.19 (dt, J = 2.3, 11.5 Hz, 1H),4.11 (dd, J = 2.4, 8.7 Hz, 1H), 3.96 (m, 2H), 3.81 (m, 1H), 3.78 
(s, 3H), 2.91 (d, J = 8.8 Hz, 2H), 1.92 (m, 2H), 1.53-1.42 (complex m, 2H), 1.30 (t, J =  7.1 Hz, 3H), 1.05 (d, 
J = 6.3 Hz, 3H), 0.87 (s, 9H), 0.85 (s, 9H), 0.021 (s, 3H), 0.016 (s, 6H), 0.00 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 172.2, 159.7, 130.9, 127.2, 113.3, 99.9, 77.3, 76.7, 73.1, 72.4, 70.3, 70.2,
61.7, 55.2, 36.1, 32.6, 25.8, 18.2, 18.0, 16.2, 14.3, -4.3, -4.6, -4.7, -4.8 ppm.
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HRMS (FAB, MNOBA matrix): for C3iH5608Si2Na (M+Na)+, Calcd: 635.3430, Found: 635.3411.
(S)-[(4/?,6S)-6-[(2/?,3/?)-2,3-Bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy-phenyl)-[1,3]dioxan- 
4-yl]-(f-butyl-dimethyi-silanyloxy)-acetic acid ethyl ester 491
EtO.
OTBS
TBSO'"
'OTBS
PMP
To a solution of a-hydroxy ester 490 (1.6 g, 2.6 mmol) in dry DMFa (10 mL) was added t- 
butyldimethylchlorosilane0 (1.0 g, 6.6 mmol) and imidazole0 (630 mg, 9.3 mmol) in one portion each 
sequentially. After 4.5 hrs the mixture was cooled to 0 °C, diluted with Et20  (20 mL) and quenched by 
dropwise addition of saturated aq. NaH0O3 solution (-10 mL). The organic layer was separated and 
aqueous layer extracted with Et20  ( 5 x 5  mL). The combined organic layers were washed with H20  ( 1 x10  
mL) then brine ( 1 x 1 0  mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the 
residue by Si02 flash chromatography using hexanes/EtOAc (100:1) as eluent afforded trisilyl ether 491 (1.9 
g, 99%) as a colourless oil.
[a ]D: +22.6° (c 0.7, CH2CI2).
1H NMR (500 MHz in CDCI3): 6 7.36 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.42 (s, 1H), 4.23 (d, J = 
6.0 Hz, 2H), 4.20 (q, J = 7.2 Hz, 3H), 4.05 (ddd, J = 2.3, 6.0, 11.4 Hz, 1H), 3.95 (d, J = 1.8, 4.4, 10.3 Hz, 
1H), 3.89 (t, J =  10.7 Hz, 1H), 3.78 (s, 3H), 3.77 (overlapping m, 1H), 1.88 (ddd, J =  1.7, 10.5, 13.9 Hz, 1H), 
1.59 (m, 2H), 1.41 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.04 (d, J = 6.3 Hz, 3H), 0.87 (s, 9H), 0.86 (s, 9H), 0.84 
(s, 9H) ppm.
13C NMR (125 MHz in CDCI3): 8 171.2, 159.6, 131.3, 127.5, 113.1, 100.3, 78.4, 76.2, 75.5, 72.3, 70.3, 70.2,
60.9, 55.2, 36.1, 32.7, 25.8, 25.7, 18.2, 18.1, 18.0, 16.2, 14.2, -4.3, -4.6, -4.7, -4.8, -4.96, -5.04 ppm.
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HRMS (FAB, MNOBA matrix): for C37H7o08Si3Na (M+Na)\ Calcd: 749.4300, Found: 749.4276.
(S)-[(4/?l6S)-6-[(2/?,3R)-2,3-Bis-(t-butyl-dimethyl-silany!oxy)-butyl]-2-(4-methoxy-phenyl)-[1,3]dioxan-
4-yl]-(f-butyl-dimethyi-silanyloxy)-acetaldehyde 489
OTBS
TBSO"
'OTBS
PMP
To a cooled (-78 °C) solution of trisilyl ether 491 (1.9 g, 2.6 mmol) in dry CH2CI2 (18.0 mL) was 
added diisobutylaluminiumhydride8 (1.5 M in PhMe, 2.2 mL, 2.6 mmol) dropwise over 5 min. After 1 h the 
mixture was quenched by the dropwise addition of MeOH (~10 mL) and warmed to 0 °C when 10% aq. 
sodium potassium tartrate solution (20 mL) and solid NaCI (5 g) were added with vigorous stirring. After 15 
min the organic layer was separated and aqueous layer was extracted with CH2CI2 ( 6 x 1 0  mL). The 
combined organic layers were washed with brine ( 1x 10  mL), dried over MgS04, filtered, and concentrated 
in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (100:1) as eluent 
afforded aldehyde 489 (1.7 g, 93%) as a colourless viscous oil, that proved rather unstable.
IR (neat film): 2955 (s), 2931 (s), 2888 (s), 2857 (s), 1738 (m), 1617 (m), 1591 (w), 1518 (m), 1469 (m), 
1440 (w), 1386 (m), 1343 (m), 1303 (m), 1252 (s), 1105 (s), 1068 (s), 1041 (s), 1008 (s), 939 (m), 880 (m), 
836 (s), 809 (m), 777 (s) cm’1.
1H NMR (500 MHz in CDCI3): 8 9.73 (d, J = 0.6 Hz, 1H), 7.36 (m, 2H), 6.83 (m, 2H), 5.41 (m, 1H), 4.22 (m, 
1H), 4.12 (m, 1H), 3.96-3.86 (complex m, 2H), 3.78 (s, 3H), 3.77 (overlapping m, 1H), 1.88 (m, 1H), 1.61- 
1.54 (complex m, 2H), 1.43 (m, 1H), 1.04 (d, J = 6.2 Hz, 3H), 0.87 (m, 27H), 0.03 (m, 18H) ppm.
13C NMR (125 MHz in CDCI3): 8 202.9, 171.1, 159.7, 131.4, 127.6, 113.1, 100.6, 79.4, 77.3, 72.5, 72.3,
70.3, 55.2, 36.1, 32.7, 25.8, 18.4, 18.0, 16.1, 14.2, -4.4, -4.7, -4.8, -5.0, -5.1 ppm.
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HRMS (FAB, MNOBA matrix): for CasHerC^ (M +H)\ Calcd: 683.4222, Found: 683.4195.
(1Rl2/?)-1-[(4/?,6S)-6-[(2Rl3R)-2,3-Bis-(t-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy-phenyl)-[1l3]- 
dioxan-4-yl]-1-(f-buty!-dimethyl-silanyloxy)-3,3-dimethyl-pent-4-en-2-ol 433
,OH
OTBS
TBSO'
OTBS
PMP
To a solution of aldehyde 489 (1.7 g, 2.4 mmol) in THF (6.1 mL) and H20  (6.1 mL) was added 
indium powder3 (560 mg, 4.9 mmol) in one portion. Then prenyl bromide3 (0.42 mL, 3.6 mmol) was added 
dropwise over 1 min. After 10 min the mixture was diluted with CH2CI2 (10 mL), the organic layer was 
separated and aqueous layer was extracted with CH2CI2 ( 5 x 5  mL). The combined organic layers were 
washed with brine ( 1 x 5  mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the 
residue by Si02 flash chromatography using hexanes/EtOAc (100:1) as eluent afforded p-hydroxy alkene 
493 (1.1 g, 59%) as a colourless syrup.
[a ]D: +26.3° (c 0.49, CH2CI2).
IR (neat film): 2956 (s), 2929 (s), 2858 (s), 1617 (w), 1518 (m), 1472 (m), 1389 (w), 1250 (s), 1098 (s), 
1006 (m), 835 (s), 775 (s) cm'1.
1H NMR (500 MHz in CDCI3): 8 7.35 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 5.83 (dd, J = 10.4, 18.0 
Hz, 1H), 5.38 (s, 1H), 4.99 (m, 2H), 3.93 (d, J = 5.0 Hz, 1H), 3.90 (ddd, J =  1.4, 4.4, 10.3 Hz, 1H), 3.84-3.74 
(overlapping m, 3H), 3.80 (s, 3H), 3.51 (d, J = 8.6 Hz, 1H), 3.07 (d, J = 8.6 Hz, 1H), 1.89 (m, 1H), 1.63-1.50 
(complex m, 2H), 1.39 (m, 1H), 1.03 (d, J = 6.3 Hz, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.88 (s, 9H), 0.87 (s, 
9H), 0.83 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H), 0.02 (s, 3H), 0.00 (s, 3H), -0.01 (s, 3H), -0.03 (s, 3H) ppm.
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13C NMR (125 MHz in CDCI3): 8 159.6, 145.3, 131.5, 127.5, 113.1, 112.3, 100.5, 78.7, 73.6, 72.9, 70.8,
70.4, 70.3, 55.2, 41.7, 36.3, 31.6, 26.0, 25.8, 24.3, 22.3, 18.3, 18.04, 17.99, 16.3, -3.2, -4.2, -4.6, -4.7, - 
4.76, -4.79 ppm.
HRMS (FAB, MNOBA matrix): for CasHe/OySia (M+H)+, Calcd: 753.4969, Found: 753.4977.
Benzoic acid (/?)-1-[(S)-[(4R,6S)-6-[(2R,3R)-2f3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy- 
phenyl)-[1,3] dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-2,2-dimethyl-but-3-enyl ester 487
OBz
,OTBS
TBSO'
'OTBS
PMP
To a stirred solution of (3-hydroxy alkene 493 (1.5 g, 2.0 mmol) in dry CH2CI2 (2.9 mL) and dry 
pyridine® (3.4 mL) was added 4-dimethylaminopyridinec (247 mg, 2.0 mmol) in one portion followed by 
dropwise addition of benzoyl chloride9 (2.3 mL, 20.2 mmol) over 1 min. A condenser was fitted and mixture 
heated to 80 °C for 72 h. The mixture was then allowed to cool to room temperature, diluted with CH2CI2 (10 
mL) and quenched by dropwise addition of saturated aq. NaHC03 solution (~5 mL) with vigorous stirring. 
After 15 min the organic layer was separated and aqueous layer was extracted with CH2CI2 ( 5 x 1 0  mL). 
The combined organic layers were washed with brine (1 x 10 mL), dried over MgS04, filtered, and 
concentrated in vacuo. Purification of the residue by S i02 flash chromatography using hexanes/EtOAc 
(100:1) as eluent afforded alkene 487 1.5 g (86%) as a colourless oil.
[a ]D: +21.0° (c 0.39, CH2CI2).
IR (neat film): 2956 (s), 2931 (s), 2888 (s), 2857 (s), 1720 (s), 1618 (m), 1518 (s), 1469 (s), 1385 (s), 1363 
(m), 1339 (m), 1311 (m), 1250 (s), 1173 (s), 1100 (s), 1007 (s), 912 (m), 830 (s), 776 (s), 710 (s) cm'1.
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1H NMR (500 MHz in CDCI3): 5 8.11 (dd, J = 1.2, 8.3 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.7 Hz, 
2H), 7.37 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.04 (dd, J = 10.8, 17.5 Hz, 1H), 5.32 (s, 1H), 5.08 
(m, 2H), 5.05 (d, J = 1.5 Hz, 1H), 4.03 (dd, J = 1.9, 6.8 Hz, 1H), 3.89 (m, 1H), 3.84 (complex m, 2H), 3.80
(s, 3H), 3.77 (m, 1H), 1.81 (m, 2H), 1.43 (m, 2H), 1.16 (s, 3H), 1.14 (s, 3H), 1.05 (d, J = 6.3 Hz, 3H), 0.88
(s, 9H), 0.85 (s, 9H), 0.79 (s, 9H), 0.00 (s, 6H), -0.01 (s, 3H), -0.02 (s, 6H), -0.10 (s, 3H) ppm.
13C NMR (125 MHz in CDCfe): 8 166.0, 159.6, 145.0, 132.8, 131.5, 130.5, 129.9, 128.3, 128.0, 113.1,
18.1, 18.0, 16.3, -3.3, -4.3, -4.4, -4.6, -4.7, -4.8 ppm.
LRMS (FAB, MNOBA matrix): for C47H8o08Si3, [M]+ 857.
Benzoic acid (/?)-1-[(S)-[(4/?,6S)-6-[(2R,3R)-2,3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy- 
phenyl)-[1,3]dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-3,4-dihydroxy-2,2-dimethyl-butyl ester 
494
To a stirred solution of alkene 487 (1.2 g, 1.4 mmol) in acetoneb (4.2 mL) and H20  (4.2 mL) was 
added osmium tetroxide® (3.5 mL, 0.14 mmol of a 0.04 M solution in (1:1) acetone:H20 ) in one portion. 
Then 4-methylmorpholine-A/-oxidea (244 mg, 2.1 mmol) was added in one portion followed by addition of f- 
butanol® (10 mL) in one portion. After 96 h the mixture was quenched by addition of sodium sulfite (25 g) 
with vigorous stirring. After 1.5 h the organic layer was separated and aqueous layer was extracted with 
EtOAc (9 x 20 mL). The combined organic layers were dried over MgS04, filtered, and concentrated in 
vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (6:1) as eluent 
afforded 1,2-diol 494 (991 mg, 80%) as a white foam.
PMP
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[a ]D: +22.3° (c 0.965, CH2CI2).
IR (neat film): 3424 (br), 2955 (s), 2931 (s), 2887 (s), 2857 (s), 1719 (s), 1617 (s), 1518 (s), 1470 (s), 1391 
(s), 1249 (s), 1100 (s), 1007 (s), 910 (s), 829 (s), 777 (s), 734 (s) cm'1.
LRMS (FAB, MNOBA matrix): for C47 H8 2O10Si3 , [M+Na-H+]+ 913.
Benzoic acid (R)-1-[(S)-[(4R,6S)-6-[(2R,3R)-2,3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy- 
phenyl)-[1,3]dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-2,2-dimethyl-3-oxo-propyl ester 495
,OBz
OTBS
TBS
"OTBS
PMP
To a cooled (0 °C) solution of 1,2-diol 494 (1.2 g, 1.3 mmol) in dry THF (10 mL) was added lead 
tetraacetate3 (1.2 g, 2.6 mmol) in one portion. After 10 min the bright yellow solution was diluted with Et20  
(10 mL) followed by addition of solid NaHC03 (-1.2 g) then dropwise addition of saturated aq. NaHC03 
solution (-5  mL). The organic layer was separated and aqueous layer was extracted with Et20  ( 4 x 5  mL). 
The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo. Purification of the 
residue by Si02 flash chromatography using hexanes/EtOAc (9:1) as eluent afforded aldehyde 495 (1.1 g, 
94%) as a white crystalline solid.
IR (neat film): 3422 (br), 2955 (s), 2931 (s), 2888 (s), 2857 (s), 1721 (s), 1700 (s), 1601 (s), 1579 (m), 1512 
(m), 1471 (s), 1386 (m), 1317 (m), 1264 (s), 1160 (s), 1106 (s), 1031 (s), 836 (s), 776 (s), 711 (s) cm'1.
LRMS (FAB, MNOBA matrix): for C46H7809Si3, [M f 861.
125
Chapter 3 :  Experimental
Benzoic acid (/?)-1 -[(S)-[(4R,6S)-6-[(2R,3R)-2,3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4- 
methoxy-phenyl)-[1,3]dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-3-hydroxy-2,2-dimethyl- 
propyl ester 496
HO. ,OBz
OTBS
TBSO""
OTBS
PMP
To a cooled (-10 °C) solution of aldehyde 495 (616 mg, 720 pmol) in MeOHa (3.6 mL) was added 
sodium borohydride0 (136 mg, 3.6 mmol) in 3 equal portions to avoid excess foaming. After 15 min the 
mixture was quenched by dropwise addition of H20  (-10 mL), diluted with EtOAc (10 mL) and stirred 
vigorously for 10 min. The organic layer was separated and aqueous layer was extracted with EtOAc (5 x 
15 mL). The combined organic layers were washed with brine ( 1 x 1 5  mL), dried over MgS04, filtered, and 
concentrated in vacuo. Purification of the residue by S i02 flash chromatography using hexanes/EtOAc 
(elution gradient 40:1, then 15:1) as eluent afforded alcohol 496 (601 mg, 97%) as a white foam.
[a ]D:+15.1°(c 0.425, CH2CI2).
IR (neat film): 34712 (br), 2955 (s), 2888 (s), 2857 (s), 1720 (m), 1617 (w), 1518 (m), 1470 (m), 1389 (m), 
1251 (s), 1100 (s), 1065 (s), 1008 (s), 832 (s), 776 (s), 711 (m) cm*1.
1H NMR (500 MHz in CDCI3): 6 8.09 (dd, J = 1.2, 8.3 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.8 Hz, 
2H), 7.33 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.31 (s, 1H), 5.17 (d, J =  1.9 Hz, 1H), 4.13 (dd, J =
1.6, 6.9 Hz, 1H), 3.89 (m, 1H), 3.83 (ddd, J = 1.5, 4.4, 10.3 Hz, 1H), 3.79 (s, 3H), 3.74 (complex m, 2H),
3.28 (q, J =  11.9 Hz, 2H), 1.78 (m, 1H), 1.69 (m, 1H), 1.45-1.33 (complex m, 2H), 1.10 (s, 3H), 1.00 (d, J =
6.3 Hz, 3H), 0.97 (s, 3H), 0.85 (s, 9H), 0.82 (s, 18H), 0.05 (s, 3H), -0.03 (s, 6H), -0.06 (s, 9H) ppm.
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13C NMR (125 MHz in CDCI3): 8 166.6, 159.6, 133.1, 131.1, 129.9, 128.5, 128.0, 113.1, 101.4, 79.1, 75.1,
4.6, -4.7, -4.8 ppm.
LRMS (FAB, MNOBA matrix): for C46H8o09Si3, [M]+ 861.
Benzoic acid (R)-1-[(S)-[(4R>6S)-6-[(2/?,3R)-2,3-bis-(f-butyl-dimethyl-silanyIoxy)-butyl]-2-(4-methoxy- 
phenyl)-[1,3]dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-2,2-dimethyl-3-phenylsulfanyl-propyl 
ester 497
To a stirred solution of alcohol 496 (839 mg, 997 pmol) in dry DMFa (5.0 mL) was added phenyl 
disulfide3 (2.18 g, 10.0 mmol) in one portion followed by addition of tri-n-butylphosphinec (2.5 mL, 10.0 
mmol) in one portion. A condenser was fitted and mixture heated to 75 °C. After 14 h the mixture was 
cooled to room temperature, diluted with Et20  (10 mL) and quenched by dropwise addition of H20  (-10  
mL). The organic layer was separated and aqueous layer extracted with Et20  ( 5 x 1 0  mL). The combined 
organic layers were washed with brine ( 1 x 1 5  mL), dried over MgS04, filtered, and concentrated in vacuo. 
Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (elution gradient neat 
Hexanes then 20:1, then 9:1) as eluent afforded thiophenyl ether 497 (846 mg, 91%) as a white foam.
[a ]D: +54.0° (c 0.48, CH2CI2).
IR (neat film): 2955 (s), 2930 (s), 2889 (s), 2856 (s), 1720 (s), 1617 (w), 1584 (w), 1519 (w), 1470 (m), 
1388 (w), 1251 (s), 1101 (s), 1066 (m), 1007 (m), 832 (s), 776 (s) cm'1.
PMP
127
Chapter 3 :  Experimental
1H NMR (500 MHz in CDCI3): 8 8.07 (dd, J = 1.2, 8.2 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.8 Hz, 
2H), 7.33 (d, J=  8.7 Hz, 2H), 7.30 (dd, J =  1.1, 8.3 Hz, 2H), 7.18 (t, J = 7.6 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 
6.81 (d, J = 8.8 Hz, 2H), 5.27 (s, 1H), 5.14 (d, J = 1.5 Hz, 1H), 4.08 (dd, J = 1.3, 7.1 Hz, 1H), 3.87-3.78 
(complex m, 3H), 3.79 (s, 3H), 3.73 (m, 1H), 3.10 (q, J =  12.6 Hz, 2H), 1. 82 (m, 2H), 1.43 (m, 2H), 1.17 (s, 
3H), 1.15 (s, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.84 (s, 9H), 0.83 (s, 9H), 0.75 (s, 9H), -0.02 (s, 3H), -0.04 (s, 
3H), -0.05 (s, 3H), -0.06 (s, 6H), -0.13 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 165.9, 159.2, 137.7, 132.9, 131.4, 130.2, 129.9, 129.6, 129.1, 128.3,
128.2, 125.8, 113.0, 101.3, 79.5, 76.1, 73.9, 73.0, 70.3, 70.0, 55.2, 44.9, 39.8, 36.2, 33.5, 29.7, 25.9, 25.8,
24.2, 24.0, 18.5, 18.2, 18.0, 16.2, -3.2, -4.3, -4.4, -4.6, -4.7, -4.8 ppm.
LRMS (FAB, MNOBA matrix): for C52H8408Si3S, [M+H]+ 953.
Benzoic acid (/?)-3-benzenesulfonyl-1-[(S)-[(4/?,6S)-6-[(2R,3/?)-2,3-bis-(f-butyl-dimethyl-silanyloxy)- 
butyl]-2-(4-methoxy-phenyl)-[1,3]dioxan-4-yl]-(f-butyl-dimethyl-silanyloxy)-methyl]-2,2-dimethyl- 
propyl ester 498
PhSO- ,OBz
OTBS
TBS O'
'"OTBS
PMP
To a stirred solution of thiophenyl ether 497 (846 mg, 906 pmol) in EtOAcb (4.5 mL) was added 
sodium hydrogencarbonateb (457 mg, 5.4 mmol) in one portion. Then 3-chloroperoxy-benzoic acid3 (543 
mg, 2.3 mmol) was added in one portion. After 20 min the reaction mixture was diluted with Et20  (10 mL) 
and quenched by dropwise addition of saturated aq. NaHC03 solution (~5 mL). The organic layer was then 
washed with saturated aq. NaH0O3 solution (1 x 10 mL), brine (1 x 10 mL) and the combined aqueous 
layers were washed with Et20  ( 5 x 5  mL). The combined organic layers were dried over MgS04, filtered,
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and concentrated in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc 
(9:1) as eluent afforded phenyl sulfone 498 (778 mg, 89%) as a white foam.
[a ]D: +22.0° (c 0.92, CH2CI2).
IR (neat film): 2955 (s), 2930 (s), 2887 (s), 2857 (s), 1722 (s), 1617 (s), 1518 (s), 1470 (s), 1392 (s), 1317 
(s), 1257 (s), 1151 (s), 1104 (s), 1008 (s), 912 (s), 8289 (s), 777 (s), 733 (s), 687 (s) cm'1.
1H NMR (500 MHz in CDCI3): 8 8.04 (dd, J = 1.2, 8.2 Hz, 2H), 7.78 (d, J = 7.6 Hz, 2H), 7.57 (m, 2H), 7.46 
(m, 4H), 7.32 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.25 (s, 1H), 5.02 (d, J = 1.2 Hz, 1H), 4.06 (d, J =
6.3 Hz, 1H), 3.84 (ddd, J =  1.5, 4.4,10.3 Hz, 1H), 3.79 (s, 3H), 3.75 (m, 3H), 3.37 (q, J=  14.3 Hz, 2H), 1. 80 
(m, 1H), 1.72 (m, 1H), 1.43 (s, 3H), 1.39 (s, 3H), 1.39 (overlapping m, 2H), 1.01 (d, J = 6.3 Hz, 3H), 0.83 (s, 
9H), 0.82 (s, 9H), 0.61 (s, 9H), -0.03(s, 3H), -0.06 (s, 6H), -0.07 (s, 3H), -0.12 (s, 3H), -0.15 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 165.7, 159.7, 141.9, 133.3, 133.2, 131.2, 129.9, 129.8, 129.1, 128.5,
128.1, 127.6, 113.1, 101.3, 77.7, 73.9, 72.3, 70.2, 70.0, 62.8, 55.2, 39.6, 36.1, 33.4, 25.8, 25.7, 24.7, 24.2,
18.3, 18.0, 17.9, 16.2, -3.3, -4.3, -4.4, -4.7, -4.8, -4.9 ppm.
(1/?,2/?)-4-Benzenesulfonyl-1-[(4Rl6S)-6-[(2/?,3R)-2l3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4- 
methoxy-phenyl)-[1,3]dioxan-4-yl]-1 -(f-butyl-dimethyl-silanyloxy)-3,3-dimethyl-butan-2-ol 499
,OH
OTBS
TBSO'
'OTBS
PMP
To a cooled (-78 °C) solution of phenyl sulfone 498 (488 mg, 495 pmol) in dry CH2CI2 (5.0 mL) was 
added diisobutylaluminiumhydride3 (1.5 M solution PhMe, 0.73 mL, 1.1 mmol) dropwise over 2 min. After 10 
min the mixture was quenched by dropwise addition of MeOH (~5 mL), diluted with CH2CI2 (5.0 mL) and
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warmed to 0 °C. The mixture was then vigorously stirred with 10% aq. sodium potassium tartrate0 solution 
(10 mL) for 0.5 h then warmed to room temperature and stirred for a further 0.5 h. The organic layer was 
separated and aqueous layer extracted with CH2CI2 ( 9 x 1 0  mL). The combined organic layers were dried 
over MgS04f filtered, and concentrated in vacuo. Purification of the residue by Si02 flash chromatography 
using hexanes/EtOAc (30:1, then 20:1) as eluent afforded p-hydroxy sulfone 499 (422 mg, 97%) as a white 
crystalline solid.
IR (neat film): 3509 (m), 2955 (s), 2931 (s), 2857 (s), 1617 (s), 1589 (w), 1518 (s), 1469 (s), 1392 (s), 1317 
(s), 1252 (s), 1102 (s), 1006 (s), 838 (s), 777 (s), 733 (s), 687 (m) cm'1.
1H NMR (500 MHz in CDCI3): 8 7.86 (dd, J = 1.2, 8.4 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.7 Hz, 
1H), 7.33 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 5.38 (s, 1H), 3.98 (d, J = 5.1 Hz, 1H), 3.90 (ddd, J =
1.3, 4.4, 10.4 Hz, 1H), 3.84-3.76 (complex m, 3H), 3.79 (s, 3H), 3.47 (d, J = 7.5 Hz, 1H), 3.17 (q, J = 14.2 
Hz, 2H), 3.14 (d, J = 8.0 Hz, 1H), 1.87 (m, 1H), 1.45 (m, 2H), 1.37 (m, 1H), 1.29 (s, 3H), 1.14 (s, 3H), 1.02 
(d, J = 6.3 Hz, 3H), 0.87 (s, 9H), 0.83 (s, 9H), 0.81 (s, 9H), 0.08(s, 3H), 0.06 (s, 3H), 0.02 (s, 3H), 0.01 (s, 
3H), 0.00 (s, 3H), -0.02 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 159.6, 142.0, 133.2, 131.1, 129.1, 127.7, 127.3, 113.2, 100.4, 78.1, 77.2,
73.2, 72.7, 70.5, 70.3, 69.6, 63.4, 55.1, 39.7, 36.1, 31.2, 25.8, 25.6, 22.9, 22.0, 18.1, 18.0, 16.2, -3.2, -4.2, -
4.6, -4.7, -4.8, -4.9 ppm.
HRMS (FAB, MNOBA matrix): for C45H8o09Si3SNa (M +Na)\ Calcd: 903.4748, Found: 903.4729.
(S)-4-BenzenesulfonyM-[(4/?,6S)-6-[(2R,3/?)-2,3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-2-(4-methoxy- 
phenyl)-[1,3]dioxan-4-yl]-1 -(f-butyl-dimethyl-silanyloxy)-3,3-dimethyl-butan-2-one 486
130
Chapter 3 :  Experimental
PhSO
OTBS
TBSO'
""OTBS
PMP
To a cooled (-78 °C) solution of dry CH2CI2 (6.0 mL) and DMSOa (0.70 mL, 9.6 mmol) was added 
trifluoroacetic anhydride3 (1.35 mL, 9.6 mmol) dropwise over 3 min. After 75 min a solution of p-hydroxy 
sulfone 499 (422 mg, 429 pmol) in dry CH2CI2 (4.0 mL) was added dropwise over 8 min. After 0.5 h dry 
Et3N (3.4 mL, 23.9 mmol) was added dropwise over 4 min and the reaction mixture was warmed to 0 °C 
when Et20  (20 mL) and H20  (10 mL) were added. The organic layer was separated and aqueous layer 
extracted with Et20  (6 x 10 mL). The combined organic layers were dried over MgS04, filtered, and 
concentrated in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc 
(10:1) as eluent afforded p-keto sulfone 486 (406 mg, 96%) as a white foam.
[a ]D: +38.3° (c 0.815, CH2CI2).
IR (neat film): 2955 (s), 2931 (s), 2888 (s), 2857 (s), 1717 (m), 1617 (m), 1518 (m), 1469 (m), 1390 (m), 
1361 (m), 1315 (m), 1253 (s), 1150 (s), 1104 (s), 1005 (s), 836 (s), 777 (s), 734 (m), 687 (w) cm'1.
1H NMR (500 MHz in CDCI3): 6 7.81 (d, J = 7.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 
7.33 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.35 (s, 1H), 4.75 (d, J = 6.2 Hz, 1H), 4.10 (ddd, J = 2.3,
6.2,11.3 Hz, 1H), 3.85 (complex m, 2H), 3.80 (s, 3H), 3.74 (m, 1H), 3.44 (q, J =  14.1 Hz, 2H), 1.82 (m, 1H), 
1.56 (s, 3H), 1.53 (m, 1H), 1.45 (s, 3H), 1.42 (m, 2H), 1.01 (d, J = 6.3 Hz, 3H), 0.85 (s, 9H), 0.83 (s, 9H), 
0.82 (s, 9H), 0.04(s, 3H), 0.00 (s, 3H), -0.02 (s, 3H), -0.03 (s, 3H), -0.04 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 5 209.7, 159.8, 141.7, 133.4, 131.1, 129.2, 127.8, 127.5, 113.2, 101.1, 78.7,
76.1, 72.5, 70.3, 70.0, 64.0, 55.2, 47.2, 36.1, 32.7, 26.0, 25.8, 24.3, 24.2, 18.4, 18.0, 16.2, -4.1, -4.3, -4.4, -
4.5, -4.6, -4.7 ppm.
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HRMS (FAB, MNOBA matrix): for C45H7809Si3SNa (M+Na)+, Calcd: 901.4585, Found: 901.4572.
2,2-Dimethyl-3-phenylsulfanyl-propan-1 -ol 509
PhS OH
To a stirred solution of 2,2-dimethyl-1,3-propane diol9 11 (13.0 g, 125 mmol) and phenyl disulfide3 
(30.0 g, 137 mmol) in dry DMF3 (625 mL) was added tri-/7-butylphosphinec (40.1 mL, 150 mmol) dropwise 
over 8 min and the mixture was stirred vigorously for 14 d. The reaction mixture was then cooled to 0 °C 
and quenched by addition of H20  (500 mL). The organic layer was separated and aqueous layer extracted 
with EtOAc (7 x 250 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over 
Na2S 04, filtered and concentrated in vacuo. Purification of the residue by Si02 flash chromatography using 
hexanes/EtOAc (elution gradient neat hexanes, then 10:1, then 5:1) as eluent afforded thioether 509 (15.4 
g, 63%) as a light orange free-flowing oil.
Data agreed with those previously reported4,1,1.
Literature yield: 85% (for a 2-step procedure).
3-Benzenesulfonyl-2,2-dimethyl-propan-1 -ol 510
*
PhS02 OH
To a stirred solution of thioether 509 (15.4 g, 78.2 mmol) in dry CH2CI2 (390 mL) was added 
sodium bicarbonate6 (32.9 g, 391 mmol) in one portion with vigorous stirring. After 15 min the mixture was 
cooled to 0 °C when 4-chloroperoxybenzoic acid3 (52.5 g, 219 mmol) was added in 6 equal portions with 
vigorous stirring, and after 1 h the mixture was allowed to warm to 0 °C. After 5 d the mixture was quenched
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by pouring into a solution of aq. Na2S20 3 (200 mL) with vigorous stirring for 2 h. Then EtOAc (2 L) was
added, the organic layer was separated and aqueous layer extracted with CH2CI2 (7 x 250 mL). The
combined organic layers were dried over Na2S 04, filtered, and concentrated in vacuo. Purification of the 
residue by Si02 flash chromatography using hexanes/EtOAc (elution gradient 10:1, then 4:1) as eluent
afforded sulfone 510 (16.0 g, 90%) as a light orange viscous oil.
3-Benzenesulfonyl-2,2-dimethyl-propionic acid 508
OH
To a cooled (0 °C) solution of sulfone 510 (8.4 g, 36.6 mmol) in MeCN (100 mL), CCI4a (100 mL) 
and H20  (150 mL) was added sodium-mete-periodate0 (8.6 g, 40.3 mmol) and ruthenium trichloride0 (760 
mg, 3.7 mmol) in one portion each sequentially. After 1 h the mixture was allowed to warm to room 
temperature, and after a further 12 h, sodium-mefa-periodate0 (3.9 g, 20.2 mmol) was added in one portion. 
After 24 h the mixture was quenched by diluting with H20  (200 mL) and extracted with CH2CI2 (6 x 250 mL). 
The combined organic layers were dried over Na2S 04, filtered, and concentrated in vacuo. Purification of 
the residue by Si02 flash chromatography using hexanes/EtOAc (elution gradient 2:1, then 1:1, then 1:2) as 
eluent afforded acid 508 (7.5 g, 85%) as a white solid.
Data agreed with those previously reported 136.
3-Benzenesulfonyl-2,2-dimethyl-propionic acid methyl ester 511
OMe
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To a stirred solution of acid 508 (13.1 g, 54.3 mmol) in dry DMFa (185 mL) was added potassium 
carbonate15 (37.4 g, 271 mmol) in one portion. After 5 min of vigorous stirring, methyl iodide3 (33.7 mL, 542 
mmol) was added dropwise over 5 min. After 12 h the reaction was diluted with H20  (350 mL), the organic 
layer was separated and aqueous layer extracted with EtOAc (5 x 200 mL). The combined organic layers 
were dried over Na2S 04, filtered, and concentrated in vacuo. Purification of the residue by Si02 flash 
chromatography using hexanes/EtOAc (elution gradient neat hexanes, then 2:1) as eluent afforded methyl 
ester 511 (13.2 g, 95%) as a viscous light yellow oil.
Data agreed with those previously reported by3.
Literature yield: 83% (for a 2-step procedure).
(4-Benzenesulfonyl-3,3-dimethyl-2-oxo-butyl)-phosphonic acid dimethyl ester 507
To a cooled (-78 °C) of dimethyl methylphoshonate3 (4.6 mL, 42.3 mmol) in dry THF (40 mL) was 
added n-butyl lithium3 (1.6 M in hexanes, 26.5 mL, 42.3 mmol) via a dropping funnel over 40 min. After 50 
min, a solution of methyl ester 511 (4.3 g, 16.9 mmol) in dry THF (19 mL) was added to the mixture via a 
dropping funnel over 40 min. After 3.5 h the mixture was quenched by dropwise addition of saturated aq. 
NH4CI (—50 mL), and warmed to room temperature. The organic layer was separated and aqueous layer 
extracted with EtOAc (4 x 25 mL). The combined organic layers were washed with brine (1 x 20 mL), dried 
over MgS04, filtered, and concentrated in vacuo. Purification of the residue by Si02 flash chromatography 
using hexanes/EtOAc (elution gradient 5:1, then 1:1) as eluent afforded phosphonate 507 (4.9 g, 83%) as a 
viscous light yellow oil.
IR (neat film): 3424 (br), 2959 (m), 1709 (m), 1641 (w), 1448 (m), 1307 (m), 1248 (m), 1150 (m), 1032 (s)
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1H NMR (500 MHz in CDCI3): 8 7.76 (d, J = 7.2 Hz, 2H), 7.54 (t, J = 7.5Hz, 1H), 7.45 (t, J = 7.7Hz, 2H), 
3.71 (s, 3H), 3.69 (s, 3H), 3.39 (s, 2H), 3.28 (d, J = 21.6Hz, 2H), 1.37 (s, 6H) ppm.
13C NMR (125 MHz in CDCI3): 8 204.9, 140.8, 133.5, 129.2, 127.4, 65.1, 52.9, 49.4, 47.4, 36.7, 35.3, 24.8 
ppm.
HRMS (FAB, MNOBA matrix): for C14H2206SP (M+H)\ Calcd: 349.0869, Found: 349.0875.
(E)-(7S,9R)10/?)-1-Benzenesulfonyl-9,10-bis-(f-butyl-dimethyl-silanyloxy)-7-(4-methoxy-benzyloxy)-
2,2-dimethyl-undec-4-en-3-one 506
PhSO- PMBO/, OTBS
'OTBS
To a stirred solution of phosphonate 507 (5.8 g, 16.5 mmol) in dry MeCN (45 mL) and lithium 
chlorided (1.22 g, 28.7 mmol) was added diisopropylethylamine8 (12.5 mL, 71.8 mmol) dropwise over 5 min. 
After a further 5 min, a solution of crude aldehyde 462 (assumed 100% yield, 7.34 g, 14.4 mmol) in dry 
MeCN (45 ml) was added dropwise over 5 min. After 48 h the mixture was cooled to 0 °C, diluted with 
EtOAc (200 mL) and quenched by dropwise addition of 10% aq. HCI (-200 mL) until the pH reached 7. The 
organic layer was separated and aqueous layer extracted with EtOAc (5 x 50 mL). The combined organic 
layers were washed with brine (1 x 100 mL), dried over MgS04, filtered, and concentrated in vacuo. 
Purification of the residue by Si02 flash chromatography using hexanes/EtOAc (elution gradient 9:1, then 
5:1) as eluent afforded enone 506 (8.6 g, 82%, 2 steps based on alcohol 461) as a viscous light orange oil.
[a ]D: +13.2° (c 0.635, CH2CI2).
IR (neat film): 2931 (s), 2857 (s), 1693 (m), 1621 (m), 1513 (m), 1469 (m), 1388 (w), 1317 (m), 1250 (s), 
1152 (s), 1039 (s), 934 (s), 775 (s) cm’1.
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1H NMR (500 MHz in CDCI3): 5 7.88 (d, J = 7.6 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 
7.21 (d, J = 8.5 Hz, 2H), 7.00 (dt, J = 7.4, 15.2 Hz, 1H), 6.82 (d, J =  8.5 Hz, 2H), 6.55 (d, J =  15.3 Hz, 1H), 
4.43 (q, J =11.0 Hz, 2H), 3.83 -  3.71 (complex multiplet, 3H), 3.76 (s, 3H), 3.45 (s, 2H), 2.51 (t, J = 6.4 Hz, 
2H), 1.93 (dd, J = 8.8, 14.1 Hz, 1H), 1.42 (s, 3H), 1.41 (s, 3H), 1.37 (multiplet, 1H), 1.02 (d, J=  6.2 Hz, 3H), 
0.85 (s, 9H), 0.84 (s, 9H), 0.02 (s, 3H), 0.01 (s, 6H), 0.00 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 8 200.2, 158.9, 146.0, 141.4, 133.4, 130.8, 129.2, 128.9, 128.7, 127.6, 
124.8, 113.8, 113.6, 74.9, 70.4, 69.7, 63.7, 55.2, 45.8, 37.9, 35.1, 25.9, 25.7, 24.5, 24.4, 17.9, 16.1, -4.4, -
4.6, -4.7, -4.8 ppm.
HRMS (FAB, MNOBA matrix): for C39H6407Si2SNa (M+Na)+, Calcd: 755.3827, Found: 755.3809.
(7S,9R,10/?)-1 -Benzenesulfonyl-9,10-bis-(f-butyl-dimethyl-silanyloxy)-7-(4-methoxy-benzyloxy)-2,2- 
dimethyl-undecan-3-one 512
PhS02^  P M B Q ,,^ \^ O T B S
'" /J  1
^ '''O T B S
O
To a stirred solution of enone 506 (8.0 g, 10.9 mmol) in EtOAcb (110 mL) was added palladium 
hydroxide8 (20% on carbon) (1.5 g, 2.2 mmol) in one portion, then the reaction flask was evacuated and 
filled with a hydrogen atmosphere. After 1.5 h the mixture was filtered to remove the carbon particulates, 
with subsequent MeOH washes, and the residue was concentrated in vacuo. Purification of the residue by 
Si02 flash chromatography using hexanes/EtOAc (elution gradient 9:1, then 7:1, then 5:1) as eluent 
afforded ketone 512 (7.6 g, 94%) as a viscous colourless oil.
IR (neat film): 2855 (s), 2857 (s), 1709 (m), 1613 (w), 1513 (m), 1469 (m), 1387 (w), 1315 (m), 1250 (s), 
1152 (s), 1088 (s), 983 (s), 775 (s), cm'1.
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1H NMR (500 MHz in CDCI3): 5 7.87 (d, J = 7.2 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.6 Hz, 2H), 
7.25 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.40 (q, J = 11.1 Hz, 2H), 3.83 (m, 1H), 3.78 (m, 1H), 3.77 
(s, 3H overlapping multiplet), 3.59 (m, 1H), 3.47 (s, 2H), 2.60 (t, J = 6.9 Hz, 2H), 1.91 (dd, J = 9.1, 14.1 Hz, 
1H), 1 .6 8 -1 .5 3  (m, 4H), 1.39 (m, 1H), 1.373 (s, 3H), 1.366 (s, 3H), 1.04 (d, J =  6.2 Hz, 3H), 0.86 (s, 9H), 
0.85 (s, 9H), 0.02 (s, 3H), 0.010 (s, 6H), 0.008 (s, 3H) ppm.
13C NMR (125 MHz in CDCI3): 5 212.3, 158.7, 141.3, 133.5, 131.5, 129.2, 128.7, 127.6, 113.7, 113.5, 75.6,
72.1, 70.5, 68.9, 64.6, 55.2, 46.5, 37.2, 34.6, 33.4, 25.8, 24.9, 19.1, 18.0, 16.3, -4.4, -4.6, -4.7, -4.8 ppm. 
HRMS (FAB, MNOBA matrix): for C39H6607Si2SNa (M+Na)+, Calcd: 757.3991, Found: 757.3966.
(7S)9Rl10/?)-1-Benzenesulfonyl-9,10-bis-(f-butyl-dimethyl-silanyloxy)-7-hydroxy-2,2-dimethyl- 
undecan-3-one 513
PhSO-
OH
,OTB S
'OTBS
To a cooled (0 °C) solution of ketone 512 (270 mg, 367 pmol) in CH2CI2 (4.9 mL) and H20  (270 
pL) was added 2,3-dichloro-5,6-dicyanobenzoquinonea (125 mg, 551 nmol) in one portion turning mixture 
green. After 0.5 h the now orange mixture was quenched by dropwise addition of saturated aq. NaHC03 
(-30 mL) and filtered through CELITE™ with subsequent CH2CI2 washes. The organic layer was separated 
and aqueous layer extracted with CH2CI2 ( 3 x15  mL). The combined organic layers were washed with brine 
( 1 x15  mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the residue by S i02 flash 
chromatography using hexanes/EtOAc (elution gradient 10:1, then 5:1) as eluent afforded 5-hydroxy ketone 
513 (224 mg, 99%) as a viscous colourless oil.
[a ]D: +18.9° (c 1.25, CH2CI2).
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IR (neat film): 3538 (m), 3460 (m), 2954 (s), 2857 (s), 1708 (s), 1472 (s). 1390 (m), 1308 (s), 1255 (s), 
1155 (s), 1095 (s), 908 (s), 779 (s) cm'1.
1H NMR (500 MHz in C6D6): 8 7.83 (d, J = 6.6 Hz, 2H), 6.93 (m, 3H), 4.07 (dt, J = 4.4, 8.6 Hz, 1H), 3.97 (m, 
1H), 3.85 (m, 1H), 3.15 (s, 3H), 2.50 (d, J = 4.2 Hz, 1H), 2.41 (m, 2H), 1.94-1.78 (complex m, 3H), 1.63 
(ddd, J = 1.8, 7.7, 14.2 Hz, 1H), 1.47 (m, 1H), 1.25 (d, J = 6.3 Hz, 3H), 1.11 (s, 6H), 0.98 (s, 9H), 0.97 (s, 
9H), 0.16 (s, 3H), 0.126 (s, 3H), 0.117 (s, 3H), 0.07 (s, 3H) ppm.
13C NMR (125 MHz in C6D6): 8 211.7, 142.4, 133.0, 129.0, 128.5, 127.5, 73.4, 71.6, 68.4, 65.0, 46.5, 39.3, 
37.9, 37.0, 26.0, 25.9, 25.0, 24.9, 20.1, 18.2, 16.7, -4.1, -4.3, -4.6, -4.8 ppm.
HRMS (FAB, MNOBA matrix): for CsiHgaOeSizSNa (M+Na)\ Calcd: 637.3369, Found: 637.3390.
(S)-6-(2-BenzenesulfonyM,1-dimethyl-ethyl)-2-[(2/?,3/?)-2,3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]- 
3,4-dihydro-2H-pyran 505
PhSO
>OTBS
'OTBS
To a solution of 8-hydroxy ketone 513 (2.3 g, 3.7 mmol) in C6H6 (125 mL) was added 
camphorsulfonic acid3 (43 mg, 184 pmol) in one portion when Dean-Stark apparatus was fitted and mixture 
was heated to 85 °C. After 45 min the mixture was allowed to cool to room temperature then quenched by 
dropwise addition of pyridine (-0.5 mL) and the crude mixture was concentrated in vacuo. Purification of the 
residue by Si02 flash chromatography using hexanes/EtOAc (10:1) as eluent afforded glycal 505 (1.97 g, 
90%) as a white solid.
IR (neat film): 2954 (s), 2940 (s), 2856 (s), 1670 (m), 1470 (m), 1382 (m), 1314 (m), 1254 (m), 1134 (m), 
1058 (s), 1008 (m), 833 (s), 776 (s) cm*1
138
Chapter 3 :  Experimental
1H NMR (500 MHz in C6 D6): 5 7.84 (d, J = 7.9 Hz, 2H), 6.99 (m, 3H), 4.43 (dd, J = 2.5, 4.7 Hz, 1H), 3.96 
(m, 1H), 3.86 (m, 2H), 3.27 (q, 14.1 Hz, 2H), 1.93 (m, 1H), 1.80 (m, 1H), 1.62 (m, 1H), 1.47 (s, 3H), 1.38 (s, 
3H), 1.33 (m, 2H), 1.14 (d, J = 6.3 Hz, 3H), 1.00 (m, 1H), 0.95 (s, 9H), 0.91 (s, 9H), 0.09 (s, 3H), 0.07 (s, 
3H), 0.04 (s, 3H), 0.02 (s, 3H) ppm.
13C NMR (125 MHz in C6 D6): 8  157.1, 142.9, 132.8, 128.8, 127.9, 94.2, 72.2, 71.9, 70.8, 64.2, 38.9, 36.1,
28.1, 26.7, 26.0, 25.5, 20.6, 18.2, 16.4, -4.1, -4.4, -4.5 ppm
HRMS (FAB, MNOBA matrix): for C3 iH 5 6 0 5 Si2SNa (M+Na)+, Calcd: 619.3273, Found: 619.3285. 
Preparation of dimethyldioxirane
To a cooled solution (0 °C) of H20  (191 mL, 10.6 mol) and acetoneb (144 mL, 1.96 mol) was 
added sodium hydrogen carbonate15 (43.5 g, 0.52 mol) with vigorous stirring. Then Oxone™ 8  (90 g, 0.15 
mol) was added in 5 equal portions in 3-4 minute intervals. The mixture was then allowed to warm to room 
temperature and the apparatus placed under reduced pressure. The DMDO solution was then collected at - 
78 °C using a cold finger. When no more solution was removed the mixture was dried over K2 C 03 , filtered 
into a cooled (0°C) flask and stored at -33 °C as a pale yellow solution, smelling of bleach.
Typical yields 120-130 m L126.
(2S,3S,6S)-2-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-6-[(2R,3R)-2,3-bis-(f-butyl-dimethyl-silanyloxy)- 
butyl]-2-methoxy-tetrahydro-pyran-3-ol 516
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PhSO-
OMe H
' " ' j OTBS
HO'" OTBS
To a cooled (0 °C) solution of glycal 505 (1.47 g, 2.5 mmol) in MeOHa (120 mL) was added flame 
activated 4A molecular sieves9  (20 g). Then freshly distilled DMDO (-0.07 M in acetone, 45.8 mL, 3.2 
mmol) was added dropwise over 5 min. After 10 min, pyridinium-p-to!uenesulfonatec (124 mg, 493 pmol) 
was added in one portion and mixture was allowed to warm to room temperature. After 15 min the mixture 
was quenched by the dropwise addition of saturated aq. NaHC03  (-50 mL) then diluted with EtOAc (50 mL) 
and H20  (200 mL). The organic layer was separated and aqueous layer extracted with EtOAc (3 x 50 mL). 
The combined organic layers were washed with brine (1 x 50 mL), dried over Na2 S 04, filtered, and 
concentrated in vacuo. Rapid purification of the residue by S i0 2  flash chromatography using 
hexanes/EtOAc (elution gradient 6:1, then 4:1) as eluent afforded alcohol 516 (1.46 g, 92%) as a white 
foam.
IR (neat film): 3492 (br), 2955 (s), 2657 (s), 1472 (m), 1389 (m), 1305 (m), 1257 (m), 1148 (s), 1097 (s), 
836 (s), 775 (m) cm'1.
1H NMR (500 MHz in C6 D6): 8  7.94 (dd, J = 1.9, 7.7 Hz, 2H), 6.91 (m, 3H), 4.07 (d, J = 14.4 Hz, 1H), 3.93 
(m, 2H), 3.62 (m, 1H), 3.55 (dt, J = 5.2, 11.1 Hz, 1H), 3.45 (d, J =  14.4 Hz, 1H), 3.32 (s, 3H), 1.98 (ddd, J =
2.6, 8.2, 14.1 Hz, 1H), 1.84 (s, 3H), 1.61 (s, 3H), 1.50-1.35 (complex multiplet, 5H), 1.14 (d, J = 6.0 Hz, 
3H), 0.97 (m, 1H), 0.97 (s, 9H), 0.95 (s, 9H), 0.09 (s, 6 H), 0.07 (s, 3H), 0.06 (s, 3H) ppm.
13C NMR (125 MHz in C6 D6): 8  143.8, 132.6, 129.1, 128.5, 100.7, 73.0, 70.8, 6 8 .8 , 63.9, 51.3, 44.7, 37.7,
31.7, 29.9, 26.05, 25.97, 25.8, 23.2, 18.3, 18.2, 16.3, -3.5, -4.4, -4.6, -4.7 ppm
(2S,6S)-2-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-6-[(2/?,3/?)-2,3-bis-(f-butyl-dimethyl-silanyloxy)- 
butyl]-2-methoxy-dihydro-pyran-3-one 503
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PhSO.
OMe h
.OTBS
'OTBS
To a solution of alcohol 516 (338 mg, 524 pmol) in dry D M F a (5.2 mL) was added pyridinium 
dichromate3 (394 mg, 1.05 mmol) in one portion. After 14 h the mixture was diluted with H20  (5 mL), the 
organic layer was separated and aqueous layer extracted with EtOAc ( 3 x 1 0  mL). The combined organic 
layers were dried over Na2 S 04, filtered, and concentrated in vacuo. Purification of the residue by Si0 2  flash 
chromatography using hexanes/EtOAc (15:1) as eluent afforded ketone 503 (216 mg, 64%) as a light yellow
oil.
[a ]D: +3.1° (c 0.8, CH2 CI2).
IR (neat film): 2955 (s), 2657 (s), 1724 (s), 1470 (m), 1388 (w), 1327 (m), 1256 (m), 1411 (s), 1008 (m), 
996 (s), 776 (s) cm'1.
1H NMR (500 MHz In CDCI3): 5 7.89 (d, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.51 (t, J = 7.4Hz, 2H), 
4.13 (m, 1H), 3.77 (m, 2H), 3.55 (d, J =  14.4 Hz, 1H), 3.30 (s, 3H), 3.27 (d, J =  14.5 Hz, 1H), 2.46 (m, 2H), 
2.03-1.87 (complex multiplet, 3H), 1.42 (s, 3H), 1.39 (m, 1H), 1.33 (s, 3H), 1.03 (d, J = 6.1 Hz, 3H), 0.85 (s, 
9H), 0.84 (s, 9H), 0.02 (s, 6 H), 0.00 (s, 6 H) ppm.
13C NMR (125 MHz in CDCI3): 5 207.4, 142.4, 133.1, 129.4, 129.1, 127.5, 102.9, 71.8, 70.3, 69.4, 61.2,
53.2, 43.9, 37.9, 36.8, 30.2, 25.8, 25.7, 21.7, 21.5, 17.99, 17.96, 16.0, -4.0, -4.5, -4.76, -4.84 ppm.
HRMS (FAB, MNOBA matrix): fo r C 32H 58 0 7S i2S N a  ( M + N a ) \  C a lc d : 665.3363, F ou nd : 665.3340. 
2-(f-Butyl-diphenyl-silanyloxy)-ethanol 520
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ho / ^ otbdps
To a cooled (0 °C) solution of dry THF (155 mL) and sodium hydride0  (60% dispersion in mineral 
oil, 741 mg, 18.5 mmol) was added ethylene glycolb 519 (900 pL, 16.1 mmol) dropwise over 5 min and the 
mixture was allowed to warm to room temperature over 45 min. Then f-butyl-diphenylchlorosilane° (4.8 mL,
18.5 mmol) was added dropwise over 1 min. After 2 h the mixture was quenched by the dropwise addition 
of saturated aq. NH4CI (~20 mL), the organic layer was separated and the aqueous layer was extracted with 
Et20  ( 3x15  mL). The combined organic layers were dried over MgS04, filtered, and concentrated in vacuo. 
Purification using Kugelrohr distillation afforded alcohol 520 as a colourless viscous oil.
Data agreed with those previously reported by Marshall127.
(f-Butyl-diphenyl-silanyloxy)-acetaldehyde 504
O
uA^OTBDPS
H
To a cooled (-78 °C) solution of dry CH2 CI2  (61 mL) and oxalyl chloride3  (1.6 mL, 17.7 mmol) was 
added DMSO3  (2.5 mL, 35.4 mmol) over 2 min. After 5 min a solution of alcohol 520 (assumed 100%, 4.84 
g, 16.1 mmol) in CH2 CI2  (10 mL) was added dropwise over 6  min. After a further 15 min, Et3N (11.0 mL, 79 
mmol) was added dropwise over 4 min and the reaction was allowed to warm to room temperature. The 
solvent was removed in vacuo and then triturated with a solution of 4:1 hexanes/EtOAc (3 x 250 mL). The 
combined organic washings were filtered through a plug of S i0 2  then concentrated in vacuo. Purification 
using Kugelrohr distillation afforded aldehyde 504 (3.93 g, 82%, 2 steps) as a colourless free-flowing oil.
Data agreed with those previously reported by Marshall127.
Literature yield: 84% (for 2 steps)
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(2S,6S)-2-(2-BenzenesulfonyM,1-dimethyl-ethyl)-6-[(2/?,3/?)-2,3-bis-(f-butyl-dimethyl-silanyloxy)- 
butyl]-4-[2-(f-butyl-methyl-phenyl-silanyloxy)-eth-(E)-ylidene]-2-methoxy-dihydro-pyran-3-one 502
PhSO-
OMe h
OTBS
^  'OTBS 
OTBDPS
To a cooled (-78 °C) solution of ketone 503 (495 mg, 770 pmol) in dry THF (38 mL) was added n- 
butyllithium3  (2.5 M in hexanes, 0.46 mL, 1.12 mmol) dropwise over 2 min turning the reaction bright yellow. 
After 5 min a pre-cooled (-78 °C) solution of aldehyde 504 (1.15 g, 3.85 mmol) in dry THF (12 mL) was 
added to the mixture via a cannula over 1 min. After 5 min the flask was warmed to room temperature and 
after a further 20 min the mixture was re-cooled to 0 °C and quenched by the dropwise addition of saturated 
aq. NH4CI solution (-10 mL) and diluted with H20  (10 mL) and EtOAc (10 mL) with vigorous stirring. After 5 
min, the organic layer was separated and aqueous layer was extracted with EtOAc (1 x 20 mL). The 
combined organic layers were washed with brine (1 x 20 mL), dried over Na2 S 04, filtered, and concentrated 
in vacuo. Purification of the residue by Si0 2  flash chromatography using hexanes/EtOAc (elution gradient 
20:1, then 10:1, then 5:1) as eluent afforded enone 502 (547 mg, 77%) as a colourless oil.
[a ]D: -18.9° (c 0.38, CH2 CI2).
IR (neat film): 3074 (w), 2955 (s), 2930 (s), 2857 (s), 1698 (w), 1619 (w), 1472 (m), 1428 (m), 1306 (w), 
1258 (w), 1147 (m), 1112 (s), 823 (m), 701 (s) cm' 1
1H NMR (500 MHz in C6 D6): 5 7.85 (d, J = 8.2Hz, 2H), 7.71 (m, 4H), 7.22 (m, 6 H), 7.11 (m, 1H), 6 . 8 6  (m, 
3H), 4.13 (dd, J = 4.7, 14.3 Hz, 2H), 4.08 (m, 1H), 3.99 (m, 1H), 3.93 (m, 2H), 3.69 (d, J = 14.4 Hz, 1H), 
3.21 (s, 3H), 2.02-1.88 (complex multiplet, 3H), 1.80 (s, 3H), 1.64 (s, 3H), 1.33 (m, 1H),1.16 (d, J = 6.2 Hz, 
3H), 0.97 (s, 9H), 0.89 (s, 9H), 0.09 (s, 3H), 0.072 (s, 3H), 0.069 (s, 3H), 0.01 (s, 3H) ppm.
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13C NMR (125 MHz in C6 D6): 5 195.4, 143.5, 140.7, 135.9, 133.5, 133.3, 132.6, 130.4, 130.2, 129.0, 128.3,
104.2, 72.3, 70.5, 69.7, 61.7, 61.5, 53.6, 44.9, 37.3, 33.7, 26.8, 26.00, 25.96, 21.9, 21.7, 19.6, 18.20, 18.19,
16.3, -3.6, -4.58,-4.62 ppm.
HRMS (FAB, MNOBA matrix): for CsoHtaOaSiaSNa (M+Na)+, Calcd: 945.4633, Found: 945.4623.
(2Sl3Sl6S)-2-(2-Benzenesuifonyl-1,1-dimethyl-ethyl)-6-[(2Rl3/?)-2,3-bis-(f-butyl-dimethyl-siIanyloxy)- 
butyl]-4-[2-(f-butyl-methyl-phenyl-silanyloxy)-eth-(E)-ylidene]-2-methoxy-tetrahydro-pyran-3-ol 522
OMe H
,OTBS
HO'" ^  OTB S 
OTBDPS
To a stirred solution of enone 502 (100 mg, 108 pmol) in dry methanol3 (2.2 ml_) was added 
ceriumtrichloride heptahydrate3 (403 mg, 1.1 mmol) in one portion with vigorous stirring. After 45 min the 
mixture was cooled to -78 °C when sodium borohydride0  (20 mg, 542 pmol) was added in one portion with 
associated gas evolution. After 15 min the mixture was warmed to -20 °C and after a further 10 min the 
mixture was stirred at room temperature. After 10 min, the mixture was re-cooled to -20 °C and quenched 
by dropwise addition of saturated aq. NaHC03  (~3 mL) and diluted with EtOAc (5 mL). The organic layer 
was separated and aqueous layer extracted with EtOAc ( 2 x 5  mL). The combined organic layers were 
washed with brine ( 1 x 1 0  mL), dried over Na2 S 04, filtered, and concentrated in vacuo. The boronic acid 
residues were then azeotropically removed with MeOH ( 1 x 1 0  mL). Rapid purification of the residue by 
Si0 2  flash chromatography using hexanes/EtOAc (elution gradient 10:1, then 5:1) as eluent afforded a- 
hydroxy alkene 522 (80 mg, 80%) as a white foam, that proved rather unstable.
IR (neat film): 3478 (br), 2955 (s), 2856 (s), 1472 (m), 1389 (m), 1305 (m), 1256 (m), 1145 (m), 1112 (s), 
836 (m), 775 (m), 703 (m) cm* 1
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1H NMR (500 MHz in C6 D6): 8  7.97 (m, 2H), 7.76 (m, 4H), 7.26 (m, 6 H), 6.96 (m, 3H), 5.60 (t, J = 6.0 Hz, 
1H), 4.20 (m, 3H), 4.03 (d, J = 4.4 Hz, 1H), 3.96 (m, 3H), 3.60 (d, J =  14.4 Hz, 1H), 3.24 (s, 3H), 1.98 (dd, J 
= 9.6, 12.9 Hz, 1H), 1.86 (m, 2H), 1.74 (s, 6 H), 1.51 (m, 1H), 1.33 (m, 1H), 1.18 (s, 3H), 1.16 (s, 9H), 0.96 
(s, 9H), 0.92 (s, 9H), 0.109 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H) ppm.
13C NMR (125 MHz in C6 D6): 5 143.9, 136.9, 135.9, 134.0, 132.5, 130.06, 130.04, 129.0, 128.5, 126.5, 
102.7, 72.6, 72.3, 70.8, 68.2, 63.2, 60.2, 52.8, 45.4, 36.8, 30.6, 27.0, 26.07, 26.05, 23.6, 22.7, 19.3, 18.3,
16.4, -3.9, -4.3, -4.5, -4.6 ppm.
(2Sl3Sl6S)-2-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-6-[(2Rl3R)-2l3-bis-(f-butyl-dimethyl-silanyloxy)- 
butyl]-4-[2-(f-butyl-methyl-phenyl-silanyloxy)-eth-(E)-ylidene]-2-methoxy-3-triethylsilanyloxy- 
tetrahydro-pyran 426
OTBSOMe h
OTBS
TESO'
OTBDPS
To a cooled (0 °C) solution of a-hydroxy alkene 522 (104 mg, 1 1 2  pmol) in dry CH2 CI2  (4.0 mL) 
and freshly 2,6-lutidine (130 pL, 1.12 mmol) was added triethylsilyl triflate3 (80 pL, 337 pmol) dropwise over 
2 min and the mixture was allowed to warm to room temperature. After 40 min, the mixture was cooled to 0 
°C and quenched by dropwise addition of saturated aq. NaHC03  (-5  mL) then solid NaHC03  and diluting 
with EtOAc (10 mL). The organic layer was separated and aqueous layer extracted with EtOAc ( 2 x 5  mL). 
The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2 S 04, filtered, and 
concentrated in vacuo. Purification of the residue by S i0 2 flash chromatography using hexanes/EtOAc 
(12:1) as eluent afforded triethysilylether 426 (96 mg, 82%) as a very light yellow oil.
[a ]D: +2.9° (c 0.855, CH2 CI2).
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IR (neat film): 3051 (w), 2955 (s), 2931 (s), 2856 (s), 1730 (w), 1589 (w), 1469 (s), 1427 (m), 1385 (m), 
1314 (m), 1255 (s), 1149 (s), 1110 (s), 1085 (s), 1006 (m), 959 (m), 831 (s), 776 (m), 740 (m), 704 (m) cm' 1
1H NMR (500 MHz in C6 D6  at +70°C): (data quoted for major isomer) 8  8.00 (d, J = 7.5 Hz, 2H), 7.77 (m, 
4H), 7.26 (m, 6 H), 7.04 (m, 3H), 5.76 (t, J = 6.2 Hz, 1H), 4.46 (s, 1H), 4.30 (a, J = 6.2 Hz, 2H), 4.07 (m, 1H), 
3.99 (d, J = 14.2 Hz, 1H), 3.96 (overlapping m, 2H), 3.73 (d, J = 14.2 Hz, 1H), 3.32 (s, 3H), 2.13-2.04 
(complex m, 3H), 1.81 (s, 3H), 1.75 (s, 3H), 1.16 (s, 9H), 0.96 (s, 9H), 0.94 (complex m, 12H), 0.91 (s, 9H),
0.64 (q, J = 7.9 Hz, 6 H), 0.11 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H) ppm.
HRMS (FAB, MNOBA matrix): for CseHjwC^SCs (M+Cs)+, Calcd: 1171.4840, Found: 1171.4801.
Acetic acid (2S,3S,6S)-2-(2-benzenesulfonyl-1,1 -dimethyl-ethyl)-6-[(2R,3R)-2,3-bis-(f-butyl-dimethyl- 
silanyloxy)-butyl]-4-[1-(f-butyl-diphenyl-silanyloxy)-meth-(E)-ylidene]-2-methoxy-tetrahydro-pyran-3- 
yl ester 527
PhS0 2 OTBSOMe h
OTBS
AcO'"
OTBDPS
To a cooled (0 °C) solution of alcohol 522 (48 mg, 52 pmol) in dry CH2 CI2  (1.0 mL) and pyridine3  
(20 pL, 259 pmol) was added acetic anhydride3  (25 pL, 259 pmol) dropwise over 1 min. Then 
dimethylaminopyridine0  (30 mg, 26 pmol) was added in one portion and the mixture was removed from the 
ice bath. After 10 min the mixture was re-cooled to 0 °C and quenched by the addition of solid NaHC03  
followed by dropwise addition of saturated aq. NaHC03  (-2  mL), diluted with CH2 CI2  (~5 mL) and stirred 
vigorously for 10 min. The organic layer was separated and aqueous layer extracted with EtOAc ( 3 x 5  mL). 
The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2 S 04, filtered, and 
concentrated in vacuo. Purification of the residue by Si0 2  flash chromatography using hexanes/EtOAc 
(10:1) as eluent afforded acetate 527 (31 mg, 62%) as a very light orange oil.
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IR (neat film): 2955 (s), 2857 (s), 1747 (s), 1470 (m), 1428 (m), 1372 (m), 1315 (m), 1255 (m), 1227 (m), 
1149 (m), 1109 (s), 961 (m), 833 (m), 777 (m), 705 (m) cm’ 1
1H NMR (500 MHz in C6 D6): 8  7.93 (m, 2H), 7.73 (m, 4H), 7.25 (m, 6 H), 6.97 (m, 3H), 6.04 (t, J = 5.5 Hz, 
1H), 5.80 (s, 1H), 4.15 (ddd, J = 6.1, 13.1, 26.1 Hz, 2H), 4.05 (m, 1H), 3.91 (m, 3H), 3.52 (d, J =  14.3 Hz, 
1H), 3.19 (s, 3H), 1.94 (m, 2H), 1.84 (m, 1H), 1.78 (s, 3H), 1.76 (s, 3H), 1.69 (s, 3H), 1.31 (m, 1H), 1.15 (d, 
J = 6.1 Hz, 3H), 1.13 (s, 9H), 0.92 (s, 9H), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H) 
ppm.
13C NMR (125 MHz in C6 D6): 8  168.6, 143.6, 135.9, 134.0, 133.9, 132.8, 130.0, 129.9, 129.1, 128.3, 102.4,
72.2, 72.0, 70.6, 68.0, 63.1, 60.1, 53.0, 45.2, 36.6, 31.2, 30.1, 26.9, 26.0, 25.9, 23.5, 22.6, 21.0, 19.3, 
18.23, 18.19, 16.3, -4.3, -4.4, -4.55, -4.64 ppm.
HRMS (FAB, MNOBA matrix): for C52H8209Si3SNa (M+Na)+, Calcd: 989.4904, Found: 989.4885.
Acetic acid (2S,3S,6S)-2-(2-benzenesulfonyl-1,1 -dimethyl-ethyl)-6-((2/?,3R)-2,3-dihydroxy-butyl)-2- 
hydroxy-4-[2-hydroxy-eth-(£)-ylidene]-tetrahydro-pyran-3-yl ester 525
PhS02
OH H
,OH
AcO''' OH
OH
To a stirred solution of acetate 527 (163 mg, 170 pmol) in MeCN (1.8 mL) and THF (1.8 mL) in a 
polyethylene container was added hydrogen fluorideb solution (40% aq., 1.8 mL, 0.7 mmol) dropwise over 1 
min. After 2 h the mixture was quenched by slow addition of solid NaHC03  and saturated aq. NaHC03  
solution (-2  mL), diluted with EtOAc (~5 mL) and stirred vigorously until gas evolution ceased. The organic 
layer was separated and aqueous layer extracted with EtOAc ( 3 x 5  mL). The combined organic layers were 
dried over Na2 S 0 4, filtered, and concentrated in vacuo. Purification of the residue by Si0 2  flash
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chromatography using chloroform/ethanol (10:1) as eluent afforded tetraol 525 (70 mg, 85%) as a white 
crystalline solid. Due to the existence of two forms of the product, spectral data was difficult to achieve.
[a ]D: +31.7° (c 0.375, CH2 CI2).
HRMS (FAB, MNOBA matrix): for C^H^OgSNa (M+Na)+, Calcd: 509.1803, Found: 509.1821.
Benzoic acid 2-benzenesulfonyl-3-{6-[(2R>3/?)-2l3-bis-(f-butyl-dimethyl-silanyloxy)-butyl]-5,6- 
dihydro-4H-pyran-2-yl}-1-cyclohexyl-3-methyl-butyl ester 530
BzO'
,OTBS
OTBS
To a cooled (-78 °C) solution of glycal 505 (200 mg, 335 pmol) in dry THF (2.7 mL) was added n- 
butyl lithium8  (2.5 M in hexanes, 155 pL, 390 pmol) dropwise over 1 min turning the mixture bright yellow. 
After 22 min cyclohexanecarboxaldehyde8  (50 pL, 400 pmol) was added dropwise over 1 min turning 
mixture colourless. Immediately benzoyl chloride9  (190 pL, 1.68 mmol) was added in one portion followed 
by addition of dry Et3N (280 pL, 2.01 mmol) and dimethylaminopyridine0 (410 mg, 340 pmol) in one portion 
each sequentially. The mixture was then warmed to 0 °C and after 10 min warmed to room temperature. 
After a further 40 min the mixture was re-cooled to 0 °C and quenched by dropwise addition of saturated aq. 
NaHC03  (~2 mL), diluted with EtOAc (10 mL) and H20  (15 mL) and stirred vigorously for 10 min. The 
organic layer was separated and aqueous layer extracted with EtOAc ( 3 x 1 0  mL). The combined organic 
layers were washed with brine (1 x 15 mL), dried over Na2 S0 4 , filtered, and concentrated in vacuo. 
Purification of the residue by Si0 2  flash chromatography using hexanes/EtOAc (20:1) as eluent afforded 
benzoyl sulfones 530 (246 mg, 90%) as a light yellow oil.
The compound was then used directly for the next without full characterisation.
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HRMS (FAB, MNOBA matrix): for C4 5 H7 3 0 7 Si2 S (M+H)\ Calcd: 813.4645, Found: 813.4616.
2-[(2/?,3/?)-2>3-Bis-(f-butyl-dimethyl-silanyloxy)-butyl]-6-((£)-3-cyclohexyl-1l1-dimethyl-allyl)-3,4- 
dihydro-2H-pyran 531
OTBS
""OTBS
To a cooled (0 °C) solution of benzoyl sulfones 530 (267 mg, 330 pmol) in EtOHb (32.8 mL) was 
added magnesium powder8  (-50 mesh) (40 mg, 1.64 mmol) and mercury(II) chlorideh (22 mg, 82 pmol) in 
one portion each sequentially, and mixture allowed to warm to room temperature. After 12 h the mixture 
was quenched by addition of solid NaHC03  then dropwise addition of saturated aq. NaHC03  (~5 mL), and 
stirred vigorously for 15 min. The organic layer was separated and aqueous layer extracted with EtOAc (3 x 
15 mL). The combined organic layers were washed with brine ( 1 x 1 0  mL), dried over Na2 S 04, filtered, and 
concentrated in vacuo. Purification of the residue by Si0 2  flash chromatography using hexanes/EtOAc (9:1) 
as eluent afforded alkene 531 (144 mg, 80%) as a colourless viscous oil.
1H NMR (500 MHz in C6 D6): 8  5.77 (dd, J=  1.1, 15.8 Hz, 1H), 5.50 (dd, J = 6.9, 15.8 Hz, 1H), 4.66 (dd, J =
2.4, 4.6 Hz, 1H), 4.20 (ddd, J = 1.3, 4.3, 10.3 Hz, 1H), 4.08 (m, 1H), 2.14 (m, 1H), 2.00 (m, 2H), 1.88 (m, 
1H), 1.77 (m, 2H), 1.69 (m, 2H), 1.62-1.41 (complex m, 4H), 1.39 (s, 3H), 1.37 (s, 3H), 1.34 (m, 1H), 1.28 
(m, 1H), 1.22 (d, J = 6.3 Hz, 3H), 1.19-1.04 (complex m, 3H), 1.01 (s, 9H), 0.99 (s, 9H), 0.21 (s, 3H), 0.17 
(s, 6 H), 0.11 (s, 3H) ppm.
13C NMR (125 MHz in C6D6): 8 160.1, 136.0, 132.7, 128.5, 93.0, 72.0, 71.8, 71.0, 41.3, 40.7, 36.2, 33.75,
33.69, 28.9, 26.65, 26.59, 26.5, 26.4, 26.3, 26.1, 21.0, 18.3, 18.2, 16.5, -4.1, -4.2, -4.3, -4.5 ppm.
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HRMS (FAB, MNOBA matrix): for C32H6303Si2 (M+H)+, Calcd: 551.4333, Found: 551.4316.
(2R,6S)-4-[2-(f-Butyl-diphenyl-silanyloxy)-eth-(E)-ylidene]-2-(4-methoxy-benzyloxymethy!)-6- 
triethylsilanyloxymethyl-tetrahydro-pyran 532
OTES
TBDPSO
OPMB
To a cooled (-20 °C) solution of primary alcohol 428 (190 mg, 350 pmol) in dry CH2 CI2  (4.4 mL) 
and 2,6-lutidine (20 pL, 1.74 mmol) was added triethylsilyl triflate3 (120 pL, 520 pmol) dropwise over 2 min. 
After 5 min, the mixture was quenched by the dropwise addition of saturated aq. NaHC03  (~2 mL) then 
solid NaHC03l diluted with EtOAc (10 mL) and vigorously stirred for 10 min. The organic layer was 
separated and aqueous layer extracted with EtOAc ( 3 x 5  mL). The combined organic layers were dried 
over MgS04, filtered, and concentrated in vacuo. Purification of the residue by S i0 2  flash chromatography 
using hexanes/EtOAc (20:1) as eluent afforded triethysilylether 532 (224 mg, 97%) as a light yellow oil.
[a ]D: +6 .2 ° (c 1.57, CH2 CI2).
IR (neat film): 3070 (w), 2955 (s), 2876 (s), 1613 (m), 1588 (w), 1513 (s), 1461 (m), 1427 (m), 1360 (m), 
1302 (m), 1248 (s), 1175 (m), 1110 (s), 1040 (s), 823 (m), 741 (s), 704 (s), 613 (m) cm'1.
1H NMR (500 MHz in CDCI3): 5 7.66 (d, J = 6.5 Hz, 4H), 7.37 (m, 6 H), 7.21 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 
8.7 Hz, 2H), 5.46 (t, J = 6.5 Hz, 1H), 4.45 (q, J = 11. 8  Hz, 2H), 4.20 (m, 2H), 3.78 (s, 3H), 3.72 (dd, J = 5.1, 
10.3 Hz, 1H), 3.53 (dd, J = 5.9, 10.3 Hz, 1H), 3.41-3.31 (complex m, 4H), 2.21 (d, J =  13.5 Hz, 2H), 1.94 (t, 
J = 12.5 Hz, 1H), 1.63 (t, J = 12.3 Hz, 1H), 1.03 (s, 9H), 0.95 (t, J = 7.9 Hz, 9H), 0.60 (q, J = 8.0 Hz, 6 H) 
ppm.
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13C NMR (125 MHz in CDCI3): 8  159.1, 135.6, 133.9, 130.3, 129.6, 129.5, 129.3, 127.6, 123.5, 113.7, 78.7,
76.6, 73.0, 72.8, 66.1, 60.0, 55.2, 38.4, 31.5, 26.8, 19.1, 6.7, 4.4 ppm.
LRMS (FAB, MNOBA matrix): for C3 9 H5 6 0 5 Si2 , [M-2H]+ 659.
{(2/?,6S)-4-[2-(t-Butyl-diphenyl-silanyloxy)-eth-(E)-ylidene]-6-triethylsilanyloxymethyl-tetrahydro- 
pyran-2-yl}-methanol 533
OTES
TBDPSO
OH
To a cooled (0 °C) solution of triethysilylether 532 (224 mg, 340 pmol) in CH2 CI2  (4.2 mL) and H20  
(230 pL) was added 2,3-dichloro-5,6-dicyanobenzoquinonea (115 mg, 510 pmol) in one portion turning 
mixture green. After 1.5 h the now orange mixture was quenched by dropwise addition of saturated aq. 
NaHC03  (~5 mL), filtered through CELITE™ with subsequent CH2 CI2  washes. The organic layer was 
separated and aqueous layer extracted with CH2 CI2  ( 3 x 5  mL). The combined organic layers were washed 
with brine ( 1 x 5  mL), dried over MgS04, filtered, and concentrated in vacuo. Purification of the residue by 
Si0 2  flash chromatography using hexanes/EtOAc (gradient elution 40:1, then 30:1, then 20:1, then 5:1) as 
eluent afforded primary alcohol 533 (153 mg, 81%) as a light yellow oil.
IR (neat film): 3395 (br), 2955 (s), 2877 (s), 1460 (w), 1427 (m), 1110 (s), 1068 (s), 823 (m), 787 (m), 741 
(m), 703 (s), 612 (m), 505 (m) cm"1.
1H NMR (500 MHz in CDCI3): 8  7.66 (d, J = 7.5 Hz, 4H), 7.42-7.34 (m, 6 H), 5.47 (t, J = 6.5 Hz, 1H), 4.20 
(m, 2H), 3.66 (dd, J = 5.6, 10.6 Hz, 1H), 3.53 (m, 2H), 3.41 (m, 2H), 3.23 (m, 1H), 2.14 (d, J =  13.4 Hz, 1H), 
2.09 (d, J =  13.5 Hz, 1H), 1.94 (t, J =  12.4 Hz, 1H), 1.62 (t, J = 12.6 Hz, 1H), 1.62 (underlying m, 1H), 1.02 
(s, 9H), 0.95 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 8.0 Hz, 6 H) ppm.
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13C NMR (125 MHz in CDCI3): 8  135.6, 135.3, 133.8, 129.6, 127.6, 123.8, 78.8, 77.5, 66.1, 65.9, 60.0, 38.2,
30.5, 26.9, 19.1,6.7, 4.4 ppm.
LRMS (FAB, MNOBA matrix): for C3 iH4 8 0 4 Si2 , [M-OH]+ 539.
(2Sl3S,6S)-6-[(2/?)3/?)-2l3-Bis-(f-butyl-dimethyl-silanyloxy)-butyl]-4-[2-(f-Butyl-diphenyl-silanyloxy)- 
eth-(E)-ylidene]-2-((E)-3-{(2f?,6S)-4-[2-(f-Butyl-diphenyl-silanyloxy)-eth-(£)-ylidene]-6-hydroxymethyl- 
tetrahydro-pyran-2-yl}-1,1-dimethyl-allyl)-2-methoxy-3-triethylsilanyloxy-tetrahydro-pyran 535
OH
TBDPSO
OTBSOMe H
OTBS
TESO'
OTBDPS
To a solution of primary alcohol 533 (90 mg, 160 pmol) in dry MeCN (3.25 mL) and flame activated 
4A molecular sieves ( ~ 1  g) was added tertapropylammonium perruthenate0 ( 6  mg, 16 pmol) and 4- 
methylmorpholine N-oxide® (38 mg, 320 pmol) sequentially. After 25 min the mixture was diluted with 
CH2 CI2  (~10 mL), then filtered through a pad of CELITE™, then a pad of S i0 2  with CH2 CI2  washings. The 
crude aldehyde 529 was then concentrated in vacuo and used immediately without further purification.
To a cooled (-78 °C) solution of phenylsulfone 426 (200 mg, 193 pmol) in double distilled THF (1.9 mL) was 
added phenyllithium3  (1.8 M in hexanes, 140 pL, 240 pmol) dropwise over 1 min turning mixture lime green. 
The reaction was allowed to warm to -50 °C over 20 min, and after a further 20 min at -50 °C the mixture 
was re-cooled to -78 °C when a solution of freshly aldehyde 529 (assumed 100%, 90 mg, 160 pmol) in 
double distilled THF (1.1 mL) was added to the mixture dropwise over 3 min. After 35 min the reaction was 
allowed to warm to room temperature and after a further 2 h the mixture was re-cooled to -78 °C, quenched 
by the dropwise addition of saturated aq. NH4CI (~5 mL) solution and diluted with and EtOAc (5 mL) and 
H20  (5 mL) with vigorous stirring. The organic layer was separated and aqueous layer was extracted with
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EtOAc ( 3 x 5  mL). The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2 S 04, 
filtered, and concentrated in vacuo. Purification of the residue by Si0 2  flash chromatography using 
hexanes/EtOAc (30:1, then neat EtOAc) as eluent afforded a-hydroxysulfones 534 (80 mg, 26%) (63% 
based on recovered starting material) as a light yellow oil. Due to the diastereomeric mixture of products, 
the material was used without full characterisation.
To a cooled (-20 °C) solution of a-hydroxysulfones 534 (80 mg, 50 pmol) in MeOHb (2.0 mL) and 
EtOAcb (1.0 mL) was added freshly made sodium-mercury amalgam (6 %, 500 mg), and disodium hydrogen 
orthophosphate (250 mg) in one portion each sequentially. After 1 h sodium-mercury amalgam (6 %, 1.0 g) 
and disodium hydrogen orthophosphate (500 mg) were added in one portion each sequentially. After a 
further 3.5 h a third addition of sodium-mercury amalgam (6 %, 1.0 g) and disodium hydrogen 
orthophosphate (500 mg) was carried out in one portion each sequentially, and the mixture was allowed to 
warm to 0 °C over 0.5 h. After 1.5 h the mixture was filtered through a pad of CELITE™ with subsequent 
EtOAc washings, transferred to a separating funnel and washed with saturated aq. NH4CI solution ( 1 x 5  
mL). The aqueous layer was then back-extracted with EtOAc ( 1 x 5  mL), and the combined organic layers 
were washed with saturated brine solution ( 1 x 1 0  mL), dried over Na2 S 04, filtered, and concentrated in 
vacuo Purification of the residue by Si0 2  flash chromatography using hexanes/EtOAc (20:1) as eluent 
afforded primary alcohol 535 (21 mg, 32%) as a colourless oil.
IR (neat film): 3481 (w), 2955 (s), 2931 (s), 2857 (s), 1472 (m), 1428 (m), 1378 (m), 1360 (w), 1256 (m), 
1111 (s), 1006 (m), 825 (m), 808 (m), 775 (m), 739 (m), 702 (s), 614 (w) cm'1.
1H NMR (500 MHz in C6 D6): 8  7.81 (m, 8 H), 7.27 (m, 12H), 6.40 (d, J = 15.9 Hz, 1H), 5.81 (t, J = 5.4 Hz, 
1H), 5.58 (dd, J = 6.5, 22.6 Hz, 1H), 5.56 (o verlap p in g  m , 1H), 4.44 (s, 1H), 4.37 (t, J = 6.2 Hz, 2H), 4.32 (d, 
J = 6.3 Hz, 2H), 4.16 (dd, J = 3.9, 9.1 Hz, 1H), 4.11 (t, J = 10.4 Hz, 1H), 3.99 (m, 1H), 3.79 (dd, J = 6.3, 
10.1 Hz, 1H), 3.46 (c o m p le x  m , 2H), 3.36 (s, 3H), 3.35 (o v erlap p in g  m , 1H), 2.40 (d, J =  13.7 Hz, 1H), 2.19 
(co m p le x  m , 2H), 2.08 (dd, J = 2.8, 13.9 Hz, 1H), 1.98 (t, J -  12.3 Hz, 1H), 1.75 (m , 3H), 1.51 (o verlap p in g  
m, 1H), 1.50 (s, 3H), 1.46 (s, 3H), 1.23 (d, J = 6.2 Hz, 3H), 1.20 (s, 9H), 1.19 (s, 9H), 1.04 (t, J = 8.0 Hz, 
9H), 1.00 (s, 9H), 0.97 (s, 9H), 0.71 (q, J = 7.7 Hz, 6 H), 0.19 (s, 3H), 0.18 (s, 3H), 0.16 (s, 3H), 0.11 (s, 3H) 
ppm .
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13C NMR (125 MHz in C6 D6): 8  140.1, 137.7, 136.0, 135.9, 134.3, 130.0, 128.5, 128.3, 128.1, 127.9, 127.6, 
127.1, 123.9, 103.3, 78.9, 78.8, 74.9, 72.3, 70.9, 68.0, 66.1, 60.4, 52.0, 46.2, 37.6, 37.5, 31.6, 30.2, 27.1,
27.0, 26.1, 25.3, 24.9, 19.4, 18.3, 16.5, 7.4, 5.5, -3.8, -4.3, -4.4, -4.5 ppm.
HRMS (FAB, MNOBA matrix): for CysH^oOgSigNa (M+Na)\ Calcd: 1327.7640, Found: 1327.7676.
Benzoic acid (2S,6R)-6-((£)-3-{(2Sl3S>6S)-6-((2R,3R)-2,3- Bis-(f-butyl-dimethyl-silanyloxy)-butyl)-3- 
triethylsilanyloxy -4-[2-(f-Butyl-diphenyl-silanyloxy)-eth-(E)-ylidene]-2-methoxy-tetrahydro-pyran-2- 
yl}-3-methyl-but-1-enyl)-4-[2-(f-Butyl-diphenyl-silanyloxy)-eth-(E)-ylidene]-tetrahydro-pyran-2-yl- 
methyl ester 536
OBz
TBDPSO
OTBSOMe H
OTBS
TESO"
OTBDPS
To a cooled (-50 °C) solution of primary alcohol 535 (15 mg, 1 2  pmol) in dry CH2 CI2  (750 pL) and 
dry pyridine3  (50 pL) was added 4-dimethylaminopyridinec (1 mg, 12 pmol) in one portion followed by 
dropwise addition of benzoyl chloride9  (25 pL, 12 pmol) over 0.5 min. After 15 min the mixture was 
quenched by dropwise addition of saturated aq. NaHC03  solution (~2 mL) and diluted with EtOAc (5 mL) 
with vigorous stirring. After 5 min the organic layer was separated and aqueous layer was extracted with 
EtOAc ( 3 x 5  mL). The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2 S 04, 
filtered, and concentrated in vacuo. Purification of the residue by Si0 2  flash chromatography using 
hexanes/EtOAc (20:1) as eluent afforded primary benzoate 536 (11 mg, 69%) as a light yellow oil.
IR (neat film): 2956 (s), 2931 (s), 2857 (s), 1725 (s), 1472 (m), 1428 (m), 1379 (w), 1360 (w), 1272 (s), 
1112 (s), 1027 (m), 1006 (m), 825 (m), 807.7 (m), 776 (m), 740 (m), 702 (s), 614 (w) cm'1.
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1H NMR (500 MHz in C6 D6): 8  8.17 (d, J = 7.2 Hz, 2H), 7.81 (m , 8 H), 7.28 (m , 12H), 7.11 (t. J = 7.3 Hz, 1H),
7.05 (t, J = 7.5 Hz, 2H), 6.43 (d, J =  16.1 Hz, 1H), 5.81 (t, J = 5.7 Hz, 1H), 5.61 (dd, J =  5.9, 16.0 Hz, 1H), 
5.56 (t, J = 6.3 Hz, 1H), 4.46 (s, 1H), 4.42-4.26 (co m p le x  m , 6 H), 4.16 (dd, J = 3.8, 9.4 Hz, 1H), 4.11 (t, J 
= 10.4 Hz, 1H), 3.99 (m , 1H), 3.79 (dd, J = 5.9, 10.4 Hz, 1H), 3.62 (m , 1H), 3.37 (s, 3H), 2.40 (d, J = 13.4 
Hz, 1H), 2.22 (t, J =  12.7 Hz, 1H), 2.15 (dd, J = 9.9, 13.3 Hz, 1H), 2.07 (dd, J = 2.4, 13.7 Hz, 1H), 1.98 (t, J 
= 12.5 Hz, 1H), 1.76 (t, J =  12.4 Hz 3H), 1.58 (m , 1H), 1.49 (s, 3H), 1.45 (s, 3H), 1.23 (d, J = 6.3 Hz, 3H), 
1.20 (s, 9H), 1.18 (s, 9H), 1.03 (t, J = 8.0 Hz, 9H), 1.00 (s, 9H), 0.96 (s, 9H), 0.71 (m, 6 H), 0.18 (s, 6 H), 0.15 
(s, 3H), 0.10 (s, 3H) ppm .
13C NMR (125 MHz in C6 D6): 8  167.5, 166.1, 139.6, 136.0, 135.9, 132.9, 130.7, 130.0, 129.0, 128.5, 128.1, 
127.9, 127.1, 124.3, 103.3, 78.8, 76.2, 74.8, 72.3, 70.9, 68.0, 67.9, 67.5, 60.4, 52.0, 46.1, 39.2, 38.3, 35.7,
30.8, 29.3, 27.1, 27.0, 26.2, 26.1, 25.2, 24.1, 23.3, 19.4, 18.3, 16.5, 14.2, 11.1, 7.4, 5.5, -3.9, -4.3, -4.4, -4.5 
ppm.
HRMS (FAB, MNOBA matrix): for C8 2 H1 2 4 0 ioSi5 Na (M+Na)+, Calcd: 1431.7987, Found: 1431.7939.
Benzoic acid (2S,6R)-6-((£)-3-{(2S,3Sl6S)-6-((2R,3/?)-2,3-dihydroxy-butyl)-2>3-dihydroxy-4-[2-hydroxy- 
eth-(E)-ylidene]-tetrahydro-pyran-2-yl}-3-methyl-but-1-enyl)-4-[2-hydroxy-eth-(E)-ylidene]-tetrahydro- 
pyran-2-yl-methyl ester 526
OBz
HO
OHOH H
OH
HO'
OH
To a cooled (-20 °C) solution of primary benzoate 536 (11 mg, 8  pmol) in MeCN (130 pL) and THF
(200 pL) in a polyethylene container was added hydrogen fluorideb solution (40% aq., 130 pL, 47 pmol)
dropwise over 1 min and the mixture was allowed to warm to 0 °C over 45 min. After 12 h the mixture was
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quenched by slow addition of solid NaHC03 and saturated aq. NaHC03 solution (~2 mL), diluted with 
EtOAc (5 mL) and stirred vigorously, until gas evolution ceased. The organic layer was separated and 
aqueous layer extracted with EtOAc ( 3 x 5  mL). The combined organic layers were dried over Na2S 04, 
filtered, and concentrated in vacuo. Purification of the residue by S i02 flash chromatography using 
CHCIs/EtOH (elution gradient 7:1 then 3:1) as eluent afforded hexanol 526 (4 mg, 89%) as a white 
crystalline solid.
[a ]D: +23.9° (c 0.046, CH2CI2).
1H NMR (500 MHz in CD3OD): 8 8.02 (dd, J = 1.3, 8.4 Hz, 2H), 7.60 (t, J = 7.5 Hz, 1H), 7.47 (t, J = 7.8 
Hz, 2H), 6.14 (dd, J = 0.9, 16.0 Hz, 1H), 5.88 (t, J = 6.9 Hz, 1H), 5.51 (dd, J = 6.6, 16.0 Hz, 1H), 5.51 
(overlapping m, 1H), 4.38 (ddd, J = 3.7, 6.7, 12.3 Hz, 1H), 4.34 (d, J = 4.9 Hz, 2H), 4.24 (m, 2H), 4.20-4.08 
(complex m, 4H), 3.83 (m, 1H), 3.76 (m, 1H), 3.49 (qu, J = 6.5 Hz, 1H), 2.75 (d, J =  15.1 Hz, 1H), 2.65 (d, J 
= 13.7 Hz, 1H), 2.50 (m, 1H), 2.24 (d, J =  12.4 Hz, 1H), 2.17 (t, J = 13.0 Hz, 1H), 1.88 (m, 1H), 1.75 (dt, J =
5.4,12.5 Hz, 1H), 1.19 (s, 3H), 1.12 (s, 3H), 1.03 (d, J = 6.4 Hz, 3H) ppm.
13C NMR (125 MHz in CD3OD): 8 167.9, 142.6, 140.9, 137.9, 134.3, 131.4, 130.6, 129.6, 128.0, 124.7,
121.0, 101.4, 80.6, 77.4, 73.3, 72.5, 68.4, 58.9, 58.3, 45.9, 39.0, 36.1, 33.2, 31.4, 23.8, 23.4, 18.0 ppm.
HRMS (FAB, MNOBA matrix): for C31H420 9Na (M+Na-H20 )+, Calcd: 581.2719, Found: 581.2727.
(2S,6S)-2-(2-BenzenesulfonyM,1-dimethyl-ethyl)-6-((2/?,3R)-2,3-dihydroxy-butyl)-4-[2-hydroxy-eth- 
(E)-ylidene]-2-methoxy-dihydro-pyran-3-one 538
PhSO;
OMe H
OH
'"OH
OH
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To a cooled (-40 °C) solution of enone 502 (314 mg, 340 pmol) in dry THF (17 mL) in a 
polyethylene bottle was added hydrogen fluoride-pyridine complex (5.4 mL) dropwise via a polyethylene 
syringe over 3 min and the mixture was allowed to warm to 0 °C over 1 hr. After a further 12 h the reaction 
was quenched by addition of solid NaHC03 and saturated aq. NaHC03 (-50 mL), diluted with EtOAc (35 
mL) and stirred vigorously untii effervescence ceased. The organic layer was separated and aqueous layer 
was extracted with EtOAc (7 x 25 mL). The combined organic layers were dried over Na2S 04, filtered, and 
concentrated in vacuo. Purification of the residue by Si02 flash chromatography using CHCIs/MeOH (7:1) as 
eluent afforded triol 538 (88 mg, 57%) as a viscous light orange oil.
IR (neat film): 3388 (br), 2976 (w), 2936 (w), 1696 (m), 1621 (m), 1448 (m), 1304 (s), 1145 (s), 1065 (s), 
726 (m), 688 (m) cm'1.
1H NMR (500 MHz in CD3OD): 8 7.88 (d, J = 7.2 Hz, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.62 (t, J = 7.6 Hz, 2H), 
6.76 (m, 1H), 4.32-4.15 (complex m, 3H), 3.70 (m, 1H), 3.59 (m, 1H), 3.40 (d, J = 2.2 Hz, 2H), 3.26 (s, 3H), 
2.64 (d, J =  16.4 Hz, 1H), 2.51 (m, 1H), 1.77-1.63 (complex m, 2H), 1.28 (s, 3H), 1.18 (s, 3H), 1.15 (d, J = 
6.4 Hz, 3H) ppm.
13C NMR (125 MHz in CD3OD): 8 197.9, 143.5, 141.9, 135.2, 134.7, 130.5, 128.6, 105.1, 72.2, 71.9, 71.7,
62.2, 59.7, 52.9, 45.2, 39.8, 34.4, 21.81, 21.76, 18.9 ppm.
HRMS (FAB, MNOBA matrix): for C22H320 8SNa (M+Na)+, Calcd: 479.1730, Found: 479.1716.
Acetic acid (1 R,2R)-2-acetoxy-1 -[(2S,6S)-4-[2-acetoxy-eth-(E)-ylidene]-6-(2-benzene-sulfonyl-1,1 - 
dimethyl-ethyl)-6-methoxy-5-oxo-tetrahydro-pyran-2-ylmethyl]-propyl ester 538a
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OMe H
OAc
'OAc
OAc
To a cooled (0 °C) solution of alcohol 538 (5 mg, 11 nmol) in dry CH2CI2 (1.0 mL) and pyridine3 (13 
pL, 160 pmol) was added acetic anhydride3 (16 pL, 160 pmol) dropwise over 1 min. Then 
dimethylaminopyridine0 (1 mg, 5 pmol) was added in one portion and the mixture was removed from the ice 
bath. After 1.5 h the reaction was re-cooled to 0 °C and quenched by the dropwise addition of saturated aq. 
NaHC03 (~2 mL), diluted with EtOAc (10 mL) and stirred vigorously for 10 min. The organic layer was 
separated and aqueous layer extracted with EtOAc ( 3 x 5  mL). The combined organic layers were washed 
with brine ( 1 x 5  mL), dried over Na2S 04, filtered, and concentrated in vacuo. Purification of the residue by 
S i02 flash chromatography using hexanes/EtOAc (1:1) as eluent afforded fr/s-acetate 538a (4 mg, 63%) as 
a colourless viscous oil.
HRMS (FAB, MNOBA matrix): for CzsHasOnSNa (M+Na)+, Calcd: 605.2050, Found: 605.2033.
(2/?,3/?)-1-[(S)-6-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-3)4-dihydro-2H-pyran-2-yl]-butane-2l3-diol
542
PhSO-
OH
OH
To a cooled (0 °C) solution of glycal 505 (1.97 g, 3.3 mmol) in THF (19.4 mL) was added 
tetrabutylammonium fluoride3 (1 M in THF, 9.2 mL, 9.2 mmol) dropwise over 2 min and mixture was allowed 
to warm slowly to room temperature. After 12 h, Si02 was added and the solvent removed in vacuo. It was 
then added to a pre-packed column of Si02 and the column eluted using hexanes/EtOAc (elution gradient 
1:2, then 1:4, then neat EtOAc) as eluent afforded diol 542 (1.16 g, 95%) as a viscous colourless oil.
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[a ]D: +34.3° (c 0.705, CH2CI2).
IR (neat film): 3489 (br, s), 2970 (s), 2924 (s), 1670 (s), 1447 (s), 1386 (m), 1307 (s), 1232 (m), 1149 (s), 
1086 (s), 812 (m), 751 (m)cm'1.
1H NMR (500 MHz in C6D6): 8 7.89 (d, J = 8.0 Hz, 2H), 7.07 (m, 3H), 4.56 (dd, J = 2.2, 4.5 Hz, 1H), 4.03 (t, 
J = 10.6 Hz, 1H), 3.97 (d, J = 3.8 Hz, 1H), 3.85 (m, 1H), 3.69 (m, 1H), 3.45 (s, 1H), 3.31 (d, J = 14.0 Hz, 
1H), 2.86 (d, J = 14.0 Hz, 1H), 1.89 (m, 1H), 1.74 (m, 1H), 1.59-1.49 (complex m, 2H), 1.41 (m, 1H), 1.28 
(m, 1H), 1.28 (s, overlapping m, 3H), 1.22 (d, J -  6.3 Hz, 3H), 1.11 (s, 3H) ppm.
13C NMR (125 MHz in C6D6): 8 156.2, 142.1, 133.2, 129.2, 128.3, 95.5, 72.6, 72.1, 71.3, 64.1, 39.3, 38.6,
28.6, 28.1, 25.6, 21.1, 19.5 ppm.
HRMS (FAB, MNOBA matrix): for C1 9 H2 9 0 5S (M+H)+, Calcd: 369.1748, Found: 369.1736.
(S)-6-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-2-((4R,5/?)-2,2,5-trimethyl-[1>3]dioxolan-4-ylmethyl)-3,4- 
dihydro-2H-pyran 543
PhS02
To a stirred solution of 1,2-diol 542 (1.16 g, 3.15 mmol) in acetone15 (24.2 mL) and 2,2- 
dimethoxypropane3 (24.2 mL, 9.4 mmol) was added pyridinium p-toluenesulfonatec (198 mg, 780 pmol) in 
one portion and the mixture was heated to 40 °C. After 15 min the mixture was cooled to room temperature 
and the solvent was removed in vacuo. Purification of the residue by S i02 flash chromatography using 
hexanes/EtOAc (2:1) as eluent afforded acetonide 543 (1.25 g, 97%) as a viscous colourless oil.
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[a ]D: +42.2° (c 1.72, CH2CI2).
IR (neat film): 3065 (m), 2981 (s), 2932 (s), 1670 (s), 1447 (s), 1378 (s), 1308 (s), 1236 (s), 1151 (s), 1090 
(s), 1003 (m), 931 (m), 846 (m), 750 (m) cm'1.
1H NMR (500 MHz in C6D6): 5 7.82 (d, J = 7.9 Hz, 2H), 7.03 (m, 3H), 4.42 (t, J = 3.6 Hz, 1H), 3.69 (m, 1H), 
3.58 (m, 1H), 3.51 (m, 1H), 3.27 (d, J = 14.3 Hz, 1H), 3.14 (d, J = 14.3 Hz, 1H), 1.66 (m, 2H), 1.44-1.33 
(complex m, 2H), 1.37 (s overlapping m, 3H), 1.36 (s overlapping m, 3H), 1.30 (s, 3H), 1.25 (m, 1H), 1.23 
(s, overlapping m, 3H), 1.07 (m, 1H), 1.07 (d overlapping m, J = 6.0 Hz, 3H) ppm.
13C NMR (125 MHz in C6D6): 8 156.0, 142.4, 132.8, 128.8, 137.9, 107.8, 94.8, 79.0, 77.2, 72.4, 63.8, 63.7,
38.4, 38.2, 27.6, 27.5, 26.9, 25.7, 20.3, 17.2 ppm.
HRMS (FAB, MNOBA matrix): for C22H330 5S (M +H)\ Calcd: 409.2054, Found: 409.2049.
(2S,6S)-2-(2-Benzenesulfonyl-1,1-dimethyl-ethyl)-2-methoxy-6-((4/?,5R)-2,2l5-trimethyl-[1,3]dioxolan- 
4-ylmethyl)-dihydro-pyran-3-one 545
PhSO-
OMe h
To a cooled (0 °C) solution of glycal 543 (30 mg, 70 pmol) in MeOHa (1.8 mL) and 2,2-
dimethoxypropane3 (1.8 mL) was added flame activated 4A molecular sieves9 (-2  g). Then freshly distilled
DMDO (-0.07 M in acetone, 2.6 mL, 180 pmol) was added dropwise over 2 min. After 12 min, a stock
solution of pyridinium-p-toluenesulfonatec (46 mg in 50 mL) (0.2 mL) was added in one portion and mixture
was warmed to room temperature. After 10 min the reaction was re-cooled to 0 °C, quenched by the
dropwise addition of saturated aq. NaHC03 (-5  mL) then diluted with EtOAc (10 mL) and H20  (10 mL). The
organic layer was separated and aqueous layer extracted with EtOAc ( 4 x 5  mL). The combined organic
160
Chapter 3 :  Experimental
layers were dried over Na2S 04, filtered, and concentrated in vacuo. Due to the unstable nature of this 
intermediate, we were unable to obtain analytical data, instead using the compound directly for the next 
step.
To a solution of crude alcohol 544 (assumed 100%, 34 mg, 70 pmol) in dry DMFa (750 pL) was 
added pyridinium dichromate3 (83 mg, 220 pmol) in one portion. After 12 h a second addition of pyridinium 
dichromate3 (28 mg, 70 pmol) was added in one portion. After a further 8 h the mixture was diluted with H20  
(5 mL) and Et20  (5 mL). The organic layer was separated and aqueous layer extracted with Et20  ( 5 x 3  
mL). The combined organic layers were washed with brine ( 1 x 5  mL), dried over NaS04, filtered, and 
concentrated in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc 
(elution gradient 10:1, then 5:1, then 2:1, then 1:1) as eluent afforded ketone 545 (19 mg, 58%, 2 steps) as 
a light yellow oil.
[a ]D: +23.2° (c 1.52, CH2CI2).
IR (neat film): 2984 (s), 2937 (s), 1722 (s), 1447 (m), 1379 (m), 1307 (s), 1235, (m), 1149 (s), 1114 (s), 
1087 (s), 1046 (s), 996 (m), 841 (m), 724 (s), 690 (m) cm'1.
1H NMR (500 MHz in C6D6): 6 7.81 (d, J = 6.9 Hz, 2H), 6.93 (t, J = 7.3 Hz, 1H), 6.88 (t, J = 7.3 Hz, 2H), 
3.93 (m, 1H), 3.88 (d, J =  14.4 Hz, 1H), 3.80 (m, 1H), 3.51 (m, 1H), 3.45 (d, J =  14.3 Hz, 1H), 3.17 (s, 3H), 
2.17-2.05 (complex m, 2H), 1.62 (s, 3H), 1.59 (s, 3H), 1.53 (m, 1H), 1.44 (m, 1H), 1.36 (s, 3H), 1.31 (s, 3H), 
1.31-1.22 (complex m, 2H), 1.16 (d, J -  6.0 Hz, 3H) ppm.
13C NMR (125 MHz in C6D6): 8 204.9, 143.1, 132.5, 128.8, 128.3, 107.5, 102.6, 78.4, 76.9, 70.6, 62.0, 51.6,
43.9, 38.2, 37.3, 29.9, 27.2, 27.1, 22.5, 22.1, 16.9 ppm.
HRMS (FAB, MNOBA matrix): for CzsH^OySNa (M+Na)+, Calcd: 474.1940, Found: 474.1923.
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(2S,6S)-2-(2-BenzenesulfonyM,1-dimethyl-ethyl)-4-[2-(f-butyl-diphenyl-silanyloxy)-eth-(E)-ylidene]-2- 
methoxy-6-((4/?,5R)-2,2,5-trimethyl-[1,3]dioxolan-4-ylmethyl)-dihydro-pyran-3-one 546
PhSO-
OTBDPS
To a cooled (-78 °C) solution of ketone 545 (88 mg, 190 pmol) in dry THF (9.7 mL) was added n- 
butyllithium8 (2.5 M in hexanes, 150 pL, 390 nmol) dropwise over 1 min turning mixture bright yellow. After 
13 min a solution of aldehyde 504 (144 mg, 480 pmol) in dry THF (3.2 mL) was added to the mixture 
dropwise over 1 min. After 15 min the reaction was warmed to 0 °C and after a further 10 min the mixture 
was quenched by the dropwise addition of saturated aq. NH4CI (~5 mL) and diluted with EtOAc (5 mL) with 
vigorous stirring. The organic layer was separated and aqueous layer was extracted with EtOAc ( 3 x 5  mL). 
The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2S 0 4, filtered, and 
concentrated in vacuo. Purification of the residue by Si02 flash chromatography using hexanes/EtOAc 
(elution gradient 10:1, then 5:1) as eluent afforded enone 546 (107 mg, 75%) as a light yellow oil.
[a ]D: -16.7° (c 0.57, CH2CI2).
IR (neat film): 3070 (w), 2934 (m), 2858 (m), 1699 (m), 1625 (m), 1472 (m), 1430 (m), 1378 (m), 1316 (m), 
1237 (m), 1148 (s), 1112 (s), 704 (s) cm'1.
1H NMR (500 MHz in C6D6): 5 7.82 (d, J = 8.3 Hz, 2H), 7.74 (m, 4H), 7.24 (m, 6H), 7.08 (t, J = 5.6 Hz, 1H), 
6.88 (t, J = 7.3 Hz, 1H), 6.82 (7.4 Hz, 2H), 4.15 (ddd, J = 5.7, 15.9, 30.5 Hz, 2H), 3.95 (m, 1H), 3.78 (m, 
1H), 3.76 (Abq overlapping m, J -  14.5 Hz, 2H), 3.51 (m, 1H), 3.19 (s, 3H), 1.93-1.79 (complex m, 2H), 1.73 
(s, 3H), 1.62 (s, 3H), 1.35 (s, 3H), 1.34 (m, 1H), 1.30 (s, 3H), 1.15 (m, 1H), 1.13 (s overlapping m, 9H), 1.09, 
(d, J =  6.0 Hz, 3H) ppm.
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13C NMR (125 MHz in C6D6): 8 195.6, 143.4, 139.8, 135.9, 133.5, 132.6, 130.3, 129.2, 128.5, 127.6, 108.0,
104.4, 78.5, 77.2, 71.0, 61.6, 61.5, 52.2, 44.6, 38.5, 33.4, 27.5, 27.4, 26.8, 22.0, 21.6, 19.3, 17.1 ppm.
HRMS (FAB, MNOBA matrix): for C^HwOaSSiCs (M+Cs)\ Calcd: 867.2386, Found: 867.2363.
(2Sl3Sl6S)-2-(2-Benzenesulfonyl-1l1-dimethyl-ethyl)-4-[2-(f-butyl-diphenyl-silanyloxy)-eth-(£)- 
ylidene]-2-methoxy-3-triethylsilanyloxy-6-((4fi,5R)-2,2,5-trimethyl-[1,3]dioxolan-4-ylmethyl)- 
tetrahydro-pyran 4
PhSO-
TESO"'
OTBDPS
To a stirred solution of enone 546 (120 mg, 160 pmol) in dry MeOHa (10 mL) was added 
ceriumtrichloride heptahydrate8 (610 mg, 1.6 mmol) in one portion with vigorous stirring. After 45 min the 
mixture was cooled to -78 °C when sodium borohydride0 (31 mg, 820 pmol) was added in 3 equal portions 
in 6 min intervals, with associated gas evolution. After 20 min the reaction was allowed to warm to room 
temperature. After a further 15 min, the mixture was re-cooled to 0 °C and quenched by dropwise addition 
of saturated aq. NaHC03 (~5 mL) and diluted with H20  (10 mL) and EtOAc (10 mL) with vigorous stirring. 
The organic layer was separated and aqueous layer extracted with EtOAc ( 3 x 5  mL). The combined 
organic layers were washed with brine ( 1 x 5  mL), dried over Na2S 04, filtered, and concentrated in vacuo. 
Rapid purification of the residue by Si02 flash chromatography using hexanes/EtOAc (elution gradient 5:1, 
then 3:1) as eluent afforded a-hydroxy alkene 547 (83 mg, 69%) as a white foam. Due to the unstable 
nature of this intermediate, we were unable to obtain analytical data, instead using the compound directly 
for the next step.
To a cooled (0 °C) solution of a-hydroxy alkene 547 (83 mg, 110 pmol) in dry CH2CI2 (2.0 mL) and 
freshly distilled 2,6-lutidine (130 pL, 1.1 mmol) was added triethylsilyl triflate8 (80 pL, 340 pmol) dropwise 
over 1 min and the mixture was allowed to warm to room temperature. After 1.5 h, the reaction was re­
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cooled to 0 °C and quenched by dropwise addition of saturated aq. NaHC03 (~5 mL) then solid NaHC03 
and diluting with EtOAc (5 mL). The organic layer was separated and aqueous layer extracted with EtOAc 
( 3 x 5  mL). The combined organic layers were washed with brine ( 1 x 5  mL), dried over Na2S 04> filtered, 
and concentrated in vacuo. Purification of the residue by S i02 flash chromatography using hexanes/EtOAc 
(neat hexane, then 10:1) as eluent afforded triethysilylether 4 (79 mg, 82%) as a very light yellow oil.
Spectral data agreed with those previously reported by Masamune35".
HRMS (FAB, MNOBA matrix): for C47H7o08Si2SNa (M+Na)+, Calcd: 873.4254, Found: 873.4228.
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Com m on A bbreviations U sed in the  Text
AD Asymmetric dihydroxylation
AE Asymmetric epoxidation
AIBN a, a-Azoiosbutyronitrile
All Ally!
BINAP 2,2’-Bis(diphenylphosphino)-1,1,-binapthy!
Bn Benzyl
Boc f-Butoxycarbonyl
BOM Benzyloxymethyl
BOM Benzyloxymethyl
Bz Benzoyl
CAN Ceric ammonium nitrate
CBS Corey-Bakshui-Shibata
CRD Cysteine rich domain
CSA Camphorsulfonic acid
DBU 1,8-Diazobicyclo[5.4.0]undec-7-ene
DCC 1,3-Dicyclohexylcarbodimide
DDQ 2,3-Dichloro-5,6-dicyanobenzoquinone
DEAD Diethyl azodicarboxylate
DHP Dihydropyran
DIBAL Diisobutylaluminium hydride
DIC Diisopropylcarbodiimide
DIP-CI Chlorodiisopenylcamphenylborane
DMAP 4-Dimethylaminopyridine
DMB 3,5-Dimethoxybenzyl
DMDO Dimethyldioxirane
DMF Dimethylformamide
DMP 3,5-Dimethoxyphenyl
DMSO Dimethylsulfoxide
FAB Fast atom bombardment
Fmoc 9-Fluorenylmethoxycarbonyl
HDA Hetero-Diels-Alder
HMPA Hexamethylphosphoramide
HRMS High resolution mass spectrometry
Ipc Isopenylcamphenyl
IR Infra red
KHMDS Potassiumhexamethyl disilylamide
LDA Lithium diisopropylamine
LRMS Low resolution mass spectrometry
M Molar
m-CPBA mefa-Chloroperoxybenzoic acid
MEM 2-Methoxyethoxymethyl
MHz Megahertz
MMPP Magnesium monoperoxyphthalate hexahydrate
Ms Methanesulphonyl
MS Molecular sieves
NaH Sodium hydride
NaHMDS Sodiumhexamethyl disilylamide
NMO A/-Methylmorpholine-A/-oxide
NMR Nuclear magnetic resonance
nOe Nuclear overhauser effect
o-Tol o-Toluyl
PA Phorbol-13-acetate
PB Phorbol-12,13-butyrate
Ph Phenyl
Piv Pivaloyl
PKC Protein kinase C
PMB p-Methoxybenzyl
PMP p-Methoxyphenyl
ppm Parts per million
PPTS Pyridinium p-toluene sulfonate
p-TsOH p-Toluenesulfonic acid
Py Pyridine
REDAL Sodium bis(2-methoxyethoxy) aluminium hydride
SAM S-adenosylmethionine
SEMCI [2-(Trimethylsilyl)ethoxy]methyl chloride
TBAF tetrabutylammonium fluoride
TBDPS f-Butyldiphenylsilyl
TBS f-Butyldimethylsilyl
TES Triethylsilyl
Tf Trifluoromethane sulfonte
TFA Trifluoroacetic acid
TFAA Trifluoroacetic anhydride
THF Tetrahydrofuran
THP Tetrahydropyran
TLC Thin layer chromatography
TMS Trimethylsilyl
TMSOMe Trimethylsilyl methoxide
TMSOTf Trimethylsilyl triflate
Tol p-Toluyl
TPAP Tetra-n-propylammonium perruthenate
Tr Trityl
Ts Toluenesulfonyl
WHE Wadsworth-Horner-Emmons
Appendix 1
The following pages contain the spectral data for compounds described in the experimental 
section on pages 100 to 164.
(File : 0TSE442 Ident: 3 6_3 8 Win 1000PPM Acq: 12-FEB-2001 14:50:bO +2:00 Cal :FABLM0 802U'1_1 
ZAB-SE4F FAB+ Magnet BpM:121 BpI:16657067 TIC:52518444 Flags:HALL 
File Text:II-MF-144 FABMS MATRIX MNOBA + NA
396
OPiv
o = \ OPiv
OPMB 561
•  ° E 0
650 7 00 m/z
1 0 0 .0
% T
90.0
80.0
822.6
70.0 136ll 
p .5  I
1390.:
16132872.8
2910.4 992.360.0 1210.2
2937.4 1463.9
1480.350.0
2975.0 1514.0 058.8
[9.340.0
1248
1280.6OPiv 1036.7
30.0
OPiv
1730.0OPMB 1155.320.0
10.0
0.0
4000.0 3500.0 3000.0 2500.0
DEFAULT. IRS.
Date: 06/02/01 Time:
Type: HYPER IR User:
Abscissa: 1/cm Ordinate:
Min: 500.49 Max:
Ndp: 3629
Gain: auto
2000.0 1750.0 1500.0 1250.0 1000.0
12:12:55 NScans: 20
A20923500085 Shimadz Detector: 
%T Apodization: Happ
3999.12 Range: 1/cm
standard
Data Interval: 0.96434 
Aperture: auto
Resolution: 2.0
Mirror Speed: 2.8(low)
750.0 500.0
1/cm
II-MF-144
HMQC
CDC13
ppm
IS
20
40
60
80
-100
-120
-140
OPivMe.
-160OPiv
OPMB
-180
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
II-MF-144
DEPT
CDC13
Me. OPiv
OPiv
OPMB
" I  r f  |   ■)............T n „ | r .................. . | r ........................., ............................, ........................... , ........................... , .............................. ,
80 70 60 50 40 30 20 10 0 ppm
II-MF-144
CARBON
CDC13
Me. OPiv
OPiv
OPMB
j u
80 60 40 20 0 ppm
II-MF-144
COSY
CDC13
LA _x 1  1 _a I_ ppm 
- 1 . 0
-1. 5
- 2 . 0
-2.5
-3.0
-3.5
-4.0
-4.5
-5.0
-5.5
- 6 . 0
6.5
-7.0
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
O
OPivMe.
OPiv
OPMB
T"1— i—ri—i—r T T 1---- 1---- 1----1---- 1---- 1---- 1---- 1---- 1---- 1---- 1---- 1----1-
II-MF-144
PROTON
CDC-13
p™
Me. OPiv
OPiv
OPMB
PERKIN ELMER
OPMB
73.00
%T
1000 cur1
B.60
4000 3500 3000 2500 2000 1500
0 2 /0 1 /0 3  11: 19
Y: 64 scans, 1 6 .0 c m -l, apod none, f l a t
File': 01SE4060 Ident:138-58 Win 1007)PPM Acq: 1-NOV-2 001 09:49:37 Cal:FABLM01llUl_l 
ZAB-SE4F FAB+ Magnet BpM:557 BpI:11677696 TIC:189155936 Flags:HALL 
File Text:II-MF-141 FABMS MATRIX MNOBA + NA
_1.2E7
1 0 0 %
:_1.1E7
- 1.1E7
-9.9E6
^9 . 3E6
-8.8E6
- 8 . 2E6
-_1. 6E6
1.7 . 0E6
. 4E6
n5.8E6
-5.3E6
OPMB
:_4 . 7E6
^4.1E6
- 3 .5E6
-2.9E6
- 2 .3E6
-1.8E6
-1.2E6
-5.8E5
541
i t  J , .  l l i l L i i l  i d . l j ^O.OEOKaJLm L i
200 220 240 260 280 32 0 340 360 380 400 420 440 460 4&0 50 0 520 540 560 580 600 m/z
PERKIN ELMER
100.00-]
XT
1i
I
);
!
CXI
■rri
to
cu
iI
Me.ii
j GOCOi
o
03
CO
r -OPMB
T
4000 3500 3000 2500 2000 1500 1000 cm"1 500
0 1 /0 3 /0 5  12: 15 
Y: 64 scans, 4 .0 c m -i
F i l e  :'0T'SE1692 Ident:4_10 Win 1000PPM Acq: 1-MAY-2 0 01 11:49:49 +0:25 Cal: FABMM010 50'l_i 
ZAB-SE4F FAB+ Magnet BpM:121 BpI:17857684 TIC:54860280 Flags:HALL 
File Text:II-MF-145 FABMS MATRIX MNOBA + NA
487100%
- 2 .9E5
i_2 .8E5
- 2.6E5
- 2.5E5
1.2 . 3E5
- 2 .2E5
1.2 . 0E5
^ 1 . 9 E 5OPMB
i_l.6E5
:_1.4E5
^1.2E5
9.3E4
1.7. 8E4
:_6.2E4
-4.7E4
:_3.1E4
-1.6E47 0 7 1 ^ i . 764
0 . 0E0 
800 m/z
II-MF-145
HMQC
CDC13
Me.
OPMBi
i
ii JLlX L a____ i jiM uiHu, ppm
20
40
60
80
-100
-120
-140
-160
-180
T ri—i—rn ri—rt— i— rt— i—i—r1—i—i—r i—i—i—r
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
I I - M F - 1 4 5
D E P T
C D C 1 3
minmm
Me.
OPMB
80 70 60 50 40 30 20 10 0 ppm
II-MF-145
CARBON
CDC13
!
Me.ii
!I|
II!I
OPMB
II-MF-145
COSY
CDC13
jLL jL l JA_a X
I
OPMB
ppm 
r 1. 0
7 1 . 5
7 2 . 0
7 2 . 5
7 3 . 0
-3.5
-4.0
4.5
7 5 . 0
-5.5
r 6 . 0
-6.5
7.0
1 1 ■ 1 • ' l 1 ' 1 1 l 1 1 1 1 I 1 1 1 1 I ' 1 1 ' I ' I 1 1 ' ' I ' 1 1 1 1 ■ ■ ■ ‘ 1 ' ’ ' ‘ 1 ‘ ‘ 1 ' ' ' ' 1 1 ‘
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
II-MF-145
PROTON
CDC13
lI Me.
i
OPMB
 j l L _ n
File:01SE928 Ident:44_49-15 Win 1000PPM Acq: 9-MAR-2001 11:07:50 +2:30 Cal:FABLM0903 01_1 
ZAB-SE4F FAB+ Magnet BpM:121 BpI:5528406 TIC:23462890 Flags:HALL 
File Text:II-MF-151 FABMS MATRIX MNOBA + NA
1 0 0 & 3 2 7
95i 
901  
85i 
80J 
751 
701 
651 
601 
551 
501 
451 
401 
3 51 
3 01 
251
2 0 i
15i 
101
51
01
I
OH
I
1
OH
O ' "
OH
202
189 
193
ill
303
283
207 221
215
180 2 00
22
ik
231 
6
243
220 240
249 
255
267
60
71
260
87
292
309 321
13
A
280 360
375
331
341 355
349
320 340
371
363 
l U
380 392
388
360
J_1l
3 . 1E5 
L3.0E5 
12.8E5 
12.6E5 
12.5E5 
12.3E5 
12.2E5 
12.0E5 
11.9E5 
1.7E5 
11.6E5 
11.4E5 
11.2E5 
11.1E5 
19.3E4 
17.8E4 
16.2E4 
14.7E4 
13.1E4 
11.6E4 
0.0E0
380 400 m /z
PERKIN ELMER
1 0 6 .7 8 -
3 1 .7 1
4000 3500 3000 2500 2000
0 2 /0 9 /2 4  1 6 :2 9
X: 64  scans. 1 6 .0cm -1, apod none, f l a t
1
in
CD
in
cvi
o
ci
— I—  
1500
— I—  
1000
-------------- r~
cnr1 500
II-MF-151
CDC13
HMQC
- A iMMu L  J ' Ul_ ppm
20
40
60
80
-100
OHMe.
-120OH
OH
-140
-160
-180
-i— i— rT t— i— rT
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppm
I I - M F - 1 5 1
C D C 1 3
D E P T
OHMe,
OH
OH
II-MF-151
CDC13
CARBON
OHMe,
OH
OH
i^ l! tm I i
II-MF-151
CDC13
COSY
OHMe.
OH
OH
II-MF-151
CDC13
PROTON
OHMe,
OH
OH
' 1 i 1 1 ' 
1
1 ' ‘ T | 
0
...........I
ppm
' ’ ' I 1 1 1 
234
File: 01SE929 Iden't:60_67 wi'n 1000PPM Acq: 9-MAR-2001 11:34:46 +3:24 Cal: FABLMU9 U3U1_1 
ZAB-SE4F FAB+ Magnet BpM:597 BpI: 1447872 TIC -.37180136 Flags :HALL 
File Text:II-MF-179 FABMS MATRIX MNOBA + NA
597 _1.4E6
1.1.4E6
-1.3E6
1.1.2E6
:_1.2E6
-1.1E6
1.1.0E6
:_9.4E5
1.8 . 7E5
:i8.0E5
1.7 .2E5
-6.5E5
1.5 . 8E5
:_5.1E5
-4.3E5
1.3. 6E5
-2.9E5
^2.2E5
1.1. 4E5
343 361 :_7 . 2E4467 4905
iiiyyniiii L0.0E0 
650 m/z
54
PERKIN ELMER
8 3 .7 4 -
%T
Of.
.  ID  
ID
[ \  CD 
CD OJ 
CU
OBnMe,
OBn
OBn
21 .4 5
3500 3000 2500 2000
0 1 /1 2 /0 6  11 :23
X: 64 scans, 1 6 .0 c m -!, apod none
1500 1000
II-MF-179
DEPT
CDC13
OBnMe.
OBn
O ' "
OBn
II-MF-179
CARBON
CDC13
OBnMe.
OBn
OBn
iAjUL
100 80 60 40 20 ppm
II-MF-179
COSY
CDC13
ill Jill a1 Jk .  . A _A_A_JuAA
OBnMe.
OBn
OBn
"i—r t—rt—i—r
ppm 
- 1.0
-1.5 
- 2 . 0  
r2.5 
7 3 .0 
7 3 . 5 
-4.0 
-4.5 
7 5 . 0 
-5.5 
r 6 . 0  
-6.5 
77.0 
r 7 . 5  
1 ppm
II-MF-179
PROTON
CDC13
OBnMe.
OBn
OBn
II-MF-160
C6D6
PROTON
Me OBn
HO.
OBnHO"
OBn
* l— — ] 1 1 1 1 | 1 I 1 i | i i---1-- 1---1---1---1---1---1---1-- 1---1---1---1---1---1---1---1-- 1---1---1---1---1---1-- 1-- 1---1-- 1-- 1---1---1---1-- 1-- 1---1---1---1---1---1-- 1---1---1---1---1---1---r---1---1---1---1---1---1---1---1---1---1---1-- 1-- 1-- 1---1---1
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
File:01SE935 Ident:72_7 9 Win lOOOPPM Acq: 9-MAR-2001 12:19:44 +4:02 Cal:FABLM0 9 03 01_1 
ZAB-SE4F FAB+ Magnet BpM:105 BpI:16184320 TIC:122157408 Flags:HALL
File Text:II-MF-191 FABMS MATRIX MNOBA + NA 
100%, , -3  . 0E5469
L2.8E595.
2 . 7E5
L2.5E5OBnMe.85.
BzO. L2.4E519801 298 OBn
H O '' 2 . 2E57 5 ! 705
OBn L2.1E570 1
691
1. 9E56 5 l
11.8E560!
489
599 L1.6E555.
1.5E526501
11.3E5451 31 499329 451
L1.2E551
345
1.0E5351
585 L8.9E4361
7 . 4E4479 61251
543 569 
559
407 15.9E4377201
673 733 14.4E4629 651151 529 663 3.0E4r,471 0 1 175,8 784
11.5E4
L0.0E0
m/z800750
II-MF-191
C6D6
COSY
j
J
II-MF-191
C6D6
CARBON
OBnMe.
BzO.
1
OBn
I
OBni
X m f X X
II-MF-191
C6D6
PROTON
Me, OBn
BzO,
OBn
HO'''
OBn
1 I ■ ■ ■ ■ i ■ ■ ■ ■ i ■ ■ ■ ■ i ■ ■ ■ ■ i ■ ■ ■ ■ i ■ • ■ ■ i ■ ■ 1 1 l 1 1 1 ■ i ■ ■ • 1 I 1 1 1 1 ■ l r  ■ ■ 1 - - |  . ■ ■ ■ .  i 1 ...............  1 1 I 1 1 1 1 l
8 . 5  8 . 0  7 . 5  7 . 0  6 . 5  6 . 0  5 . 5  5 . 0  4 . 5  4 . 0  3 . 5  3 . 0  2 . 5  2 . 0  1 . 5  1 . 0  ppm
PERKIN ELMER
I
iO O .O O -f
%T
3
j
EtO.
,OTBS
'OTB Sin ®
PMP
CD
OJ
o . oo --------- — —f ------------------ 7  r  ■ $ ■
4000 3500 3000 2500 2000
0 1 /0 3 /0 5  1 1 :5 3  
X: 54  scans, 4 .0 c m -l
17
44
.
| CD 
CD!in
!
O
CD
CO
o
r^o
cn
CD K
in
co
OJ
— I
1500
oin
OJ
CD
I----
1000
File : 01SE441 IdentrlO Acq: 12-FEB-2001" '14:45:3V +0:35 Cal: FABLM08U2UI_I 
ZAB-SE4F FAB+ Magnet BpI:3005444 TIC:44970784 Flags:HALL 
File Text:II-MF-59 FABMS MATRIX MNOBA + NA 
100% 635
9 5 l
,_3 . 0E6
2 . 9E6
2 . 7E6
2.6E68 5 j:
L2.4E6801
L2.3E675.
2 . 1E6701
L1.2E640,
1.1E635.
9.0E530.
7.5E530325.
L6.0E52 0 .
L4.5E515.
3.0E5101
213 1.5E5
766 798 835 880 f n npn.^ ■■r .v.Tr -  U . UC-U
i 0 800 850 960
7502 V - 289 327
^ 4 L 4 ' f >»w m/z
II-MF-170
HMQC
CDC13
EtO-
,OTBS
HO'
'OTBS
PMP
JL  JL ppm
20
40
60
80
-100
-120
-140
-160
i—rTTTt—i—r
0 ppm
II-MF-170
DEPT
CDC13
EtO.
,OTBS
HO"'
"OTBS
PMP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
II-MF-170
CARBON
CDC13
EtO.
.OTBSHO'"
OTBS
PMP
wp^ jnwmnii
II-MF-170
COSY
CDC13
1 __ I
BCL ^ 0
^ O T B S
HO"
O O \ 'OTBS
PMP
□  a
Q
JlL
□
ED
t— i— |— i— i i i i i i i— i— |— i— i— r- ~rT r
0
ppm
r 0 . 0
7 0 . 5
- 1.0
- 1 . 5
- 2 . 0
- 2 . 5
- 3 . 0
r 3 . 5
- 4 . 0
7 4 . 5
- 5 . 0
r 5 . 5
- 6 . 0
7 6 . 5
- 7 . 0
- 7 . 5
ppm
II-MF-17 0
PROTON
CDC13
EtO.
.OTBSHO
'OTBS
PMP
9 8 7 6
File: 01SE440 Ident: 8_12'"win 1000PPM Acq:12-FEB-2001 14:34:39 +0:35 Cal:FABLM0802UI_1 
ZAB-SE4F FAB+ Magnet BpM:115 BpI:1860301 TIC:42214248 Flags:HALL 
File Text:MF-II FABMS MATRIX MNOBA + NA
1 0 0 |  3 0 3  w------------------------------------------------ x l O . O O -----------------------------------------
9 5 i  
9 0 i  
85J  
80J  
75J  
70i
65i
60J  
5 5 i  
5 0 i  
4 5  j  
4 0 i  
35_i 
3 0.:
25i
2 0 i  
15J 
10 i
5 j  I 4 4 1
EtO-
.OTBS
TBSO'
'OTBS
PMP
750
669
i d  1 ’ 400 450 !
pl.lE6 
11.0E6 
L9.7E5 
L9.1E5 
18.6E5 
L8.0E5 
L7.5E5 
L7.0E5 
16.4E5 
15.9E5 
L5.4E5 
L4.8E5 
L4.3E5 
13.8E5 
L3.2E5 
L2.7E5 
12.1E5 
L1.6E5 
L1.1E5 
15.4E4
0 . 0E0 
0 m/ z
MFII
HMQC
CDC13
ppm
>
20
40
60
80
-100
-120
-140
-160
“i—rt—r
7 6 5 4 3 2 1 0  ppm
I
EtO.
OTBS
TBS O'
'OTBS
PMP
MFII
CDC13
COSY
3
□
EtO.
OTBS
TBSO'
'OTBS
i
i PMP
' 1 I ’
4
a jL /N—_ 0 L ppm
o
’S t*
< r
* 9
0 H m &
8 it 9  8
DO 0 S
'  a 0S 2  o
o a 3^
S3 o «
•
a o
V
O •
-i— i— i— i— i— i— i— i— i—i—i—l—i—i—l—i— i— i— 1—r -T--1--1--1--1--T" I1 T i l  l- i i i i i i i i i i i ■
4 . 0
- 5 . 5  
- 6 . 0  
6 . 5  
- 7 . 0  
- 7 . 5
ppm
MFII
DEPT
CDC13
EtO-
,OTBS
TBSO"
'OTBS
PMP
| i i i i i r r r  i | i i i i i i i i i j i i i i i > i i i | it t t  h t t i j i » i m  r n  p  i i 11 i-r r r -j rr i i i i i i r  j i i i i i i rvi -| i r i i i > rT TTTT rT T T T T T T T T  »"rr m i i j i i i i r r » » i i i i i r  i r > j ri i i i i r » r | tm t t  i i r » j-i ri i i i n i | i i i \  ^ i » > r  j i i r i i i n  i j i i » i » r i-TT|Tr r r f f t  i"rp-m Tr r i i j i i m  i t"i » j
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
MFII
CARBON
CDC13
MFII
PROTON
CDC13
Eto.
.OTBSTBSO
'OTBS
! PMP
ltd
9 8 7 6 4 3 2 1 0 ppm
PB9CIN ELMER
80.51
XT
to
o
r*
CM
m
O)
D)
m
o
GOO
OTBSTBSO' 3)
3
SI I 
•
I i
'OTBS
PMP
H I I i 
i i
cu
11
cu4.59
4000 3500 3000 2500 2000 1500 1000 cm'1
02/07/13 16: 19
X: 16 scans, 16.0cm-1, apod none, flat
File : 02SE2 855 ldent:8_13 win 1000PPM A c q  : 19-JUL-2 002 08:32:34 +0:36 Cal : FABLMI 9 U7 OT 
ZAB-SE4F FAB+ Magnet BpM:137 Bpl:22837932 TIC:987213632 Flags:HALL 
File Text:II-MF-37 FABMS MATRIX MNOBA + NA 
100%. 327
OTBS
TBSO'"
'OTBS
PMP
669
625
547 591
550 600 650
683
705
750
726
I700
781802
1.7E6 
11.6E6 
L1.5E6 
11.5E6 
L1.4E6 
11.3E6 
Ll.2E6 
11.1E6 
L1.0E6 
19.4E5 
L8.6E5 
L7.7E5 
L6.9E5 
16.0E5 
15.1E5 
L4.3E5 
13.4E5 
12.6E5 
11.7E5 
18.6E4
750 800 850
.0 . 0E0
m/ z
II-MF-3 7
CDC13
D E P T
OTBS
TBS O'
"OTBS
PMP
I ’ I ’ ! 1----------J--------- ’--------- 1----------•--------- \~
220 200 180 160 140 120
NywfWW* UUirmr
100 80 60 40 20 0 ppm
II-MF-37
CDC13
CARBON
OTBS
TBSO'
'OTBS
PMP
i 1 *4
II-MF-37
CDC13
PROTON
OTBS
TBS O'I
OTBS
PMP
r
9 8
r
t— i— i— r  I T I ' ' -----
0 ppm
T
34 2 1
PERK IN ELMER
7 9 .0
XT
OH
CVi
OTBS
TBSO"
OTBS
PMP
o
3500 3000 2500 2000 1500 1000
0 1 /0 4 /2 7  15 :51  
Z: 64 scans. 4 .0 c rc ~ i, apod none, f l a t
iFile : 02SE2854 Ident:20_23 Win 1000PPM Acq: '19 - JUL-2 U U2 08:27:03 +1:13 Cal: FABLMI9 07 02. 
ZAB-SE4F FAB+ Magnet BpM:115 BpI:14973952 TIC:282465568 Flags:HALL 
File Text:II-MF-38 FABMS MATRIX MNOBA + NA 
369 _3 . 6E5100%
3^.5E5
3^.3E5
:_3 . 1E5
-_2 . 9E5
- 2 .7E5
-2.6E5
TBSO -_2 . 4E5
2^.2E5
- 2  .0E5
- 1.8E5
. 6E5
:_1.5E5
1^. 3E5
-_ 1 . 1E5
9^.1E4
z-1 .3E4
5^.5E4
1.3. 6E4
l1.8E4
- 0.0E0
II-MF-38
CDC13
HMQC
OH
OTBS
TBSO'
OTBS
PMP
JU L J JL J U L ppm
20
40
60
80
hlOO
h 120
h  1 4 0
b  1 6 0
t—i—i—rt—|—i—i—i—r r■j— i i i— i— r—i— i i i | i i i—r
0 ppm
II-MF-3 8
CDC13
D E P T
,OH
,OTBS
TBSO'
'"OTBS
PMP
II-MF-38
CDC13
CARBON
.OH
OTBS
TBSO'
OTBS
PMP
v- A
II-MF-3 8
CDC13
COSY
^ O T B S
TBSO"
O y O  „ ^'OTBS
PMP
JU L J iL
0
&
-j—|—i—i—i—i—i—i—i—i—rT_TTn
6
t - i________|_ j L
Q;
s
a
8
i ppm
rO
- 1
-  2
-4
- 5
-7
0 ppm
II-MF-3 8
CDC13
PROTON
OH
OTBS
TBS O'
OTBS
PMP
1 i ‘ ‘ 1 i ■ ■ ’ ■ i ■ ■ 1 ' i ■ • 1 ■ i ■ ’ ■ ■ I ■ • ■ ■ i ■ • ■ ■ i ■ • ■ 1 I ' ' ' I ' 1 1 '' I ' '  I ' ' ' 1 I ' ' 1 ' I ' '' , _1" 'I ' 1 ' ' I ' ' ‘ ' I
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
01031002: Scan Avg 163-167 (37.83 - 38.77 min) - Back 
Base: 73.00 Int: 319218 Sample: VG70-SE Positive Ion FAB
320000
300000H
250000
2 0 0 0 0 0 -
150000
100000 -
50000
105
133
u
100 2 00
3 03
Sample: II-MF-73
,OBz
OTBS
TBSO'
"OTBS
PMP
i ■ 1 ■
531 
  , Jjb. .-kuL.
6 f 3 ' 7 9 9  8 f 7
300 400 500 600 700
m/z
800 900
n
1000
II-MF-73
HMQC
CDC13
,OBz
OTBS
TBS O'
'"OTBS
PMP
J JlL L N ppm
P t—r TP t—i—rt—r t—i—r P
-  20
- 40
L 60
- 80
-100
-120
-140
-160
0 ppm
II-MF-73
DEPT
CDC13 ,OBz
OTBS
TBSO'
'OTBS
PMP
TT T  i i j i i r r r r m  | T T t  TTT TTT*| i i i i i i i i I j  i n  I I I  i i i I 1 i i i i i I i i j m  i TTTT n  i~r n  i m m | i i m m 11 i j i v i i i i i  i i’ | m T-r-ri  i i i | m m i it  i »-| t  i m m i 11 j i i i r i ri  i i j i IT I U N  Tj i i i I I i i i i j t t  i i i i i i . j i . i i i . i . . j . i i i ■ ■ i i ■ j ■ ■ ■ ■ ■ ■ ■ ■ ■ j i
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
PERKIN ELMER
4000 3500
02/ 07/22  18:42
Y: 64 scans. 16.0cm-i, apod none, f l a t
II-MF-73
CARBON
CDC13
,OBz
OTBS
TBS O'
'OTBS
PMP
II-MF-73
COSY
CDC13
,OBz
OTBS
TBSO'"
'OTBS
PMP
J
i , i l .  I
O B
o acr
09
O  a
u
i 1 i ~i—i—i—i i i
- i l .
<5? &
dS
ppm
L 0
- 1
- 2
-4
-5
- 6
-7
0 ppm
II-MF-73
PROTON
CDC13
,OBz
,OTBS
TBSO"
'OTBS
PMP
9 8 7 6 5
J L A l J l I J
“ I 1---- 1---- 1---- 1-----1---- 1---- 1---- 1---- 1---- 1---- 1----1---- 1---- 1---- 1---- 1---- 1---- 1---- 1---- 1---- 1---- 1---- T“”1—i—i—I—i—i—i—i " r~
0 ppm
File : OlIS E2 994 Ident: 2_10'"Win 1000PPM Acq:28-NOV-2UOO 15:18:00 +0:42 Cal :FABMM2 8110U_I 
ZAB-SE4F FAB+ Magnet BpM:133 BpI:52712788 TIC:151847 9872 Flags:HALL 
File Text:II-MF-112 FABMS MATRIX MNOBA + NA 
100%. 133
OBz
HO’
,OTBSHO
TBS 'OTB S
PMP
913
“f — r
473
v 521I----
605
500
697 755 7 9 9
—*1— r -v -1*i—f * r — p
700 80O f t
0 3 9
5.3E7 
L5.0E7 
L4.7E7 
L4.5E7 
L4.2E7 
L4.0E7 
L3.7E7 
L3.4E7 
L3.2E7 
L2.9E7 
L2.6E7 
L2.4E7 
L2.1E7 
Ll.8E7 
L1.6E7 
L1.3E7 
L1.1E7 
L7.9E6 
L5.3E6 
12.6E6 
10.0E0
900 1000 m/z
PERKIN BJM&t
102.95—
-3.00
cu
cn
4000 3500
.— j—
3000
— j—
2500
— t -  
2000
02 /08 /01  11:33
X: 64 scans, 16.0cm-l, apod none, f l a t
,OBz
HO'
OTBSHO
TBS
OTBS
PMP
II-MF-85
HMQC
CDC13
ppm
20
40
60
80
-100
-120
-140
OBz
HO'
-160OTBSHO
TBS
-180
PMP
t—rt—i—r-i—i—r-i—i—i—i—i—r t—r TTt—r t—i—rt—r
0 ppm
II-MF-85
DEPT
CDC13
,OBz
HO'
,OTBSHO
TBS 'OTBS
PMP
u1Llu.j1 .iL JUaJ i
—  i.............. i ......... i ............ i ............ r
190 180 170 160 150 140 130 120 110 100 90 80 70
r r y
60 50 40 30 20 10 ppm
II-MF-85
CARBON
CDC13
,OBz
HO'
OTBSHO
TBS 'OTBS
PMP
j—  | . | ,-----------------,-----------------,-----------------1—
2 0 0  1 8 0  1 6 0  1 4 0  1 2 0
II-MF-85
PROTON
CDC13
,OBz
,OTBSHO
TBS 'OTBS
PMP
■ i •
9
“I 1---1---f- "1— i [ i—i—i—i—r ’’T
4 3 2 1 0 ppm
iFile:00SE29 9 8  Ident:5_8 Win 1000PPM Acq:28-NOV-2UUO 1 6 : 1 5 : 1 2  + 0 : 4 5  Cal:F A B M M 2 8 1 1 0 0 _ 1  
ZAB-SE4F FAB+ Magnet BpM:303 BpI:59797504 TIC:14917 95328 Flags:HALL 
File Text:II-MF-118 FABMS MATRIX MNOBA + NA 
100%, 303
95_i
901
851
801
151
101
651
601
551
501
451
401
351
301
2 51
2 01
15 J
10J
51
251
337
H ^ X ^ O B z
° o ' V r
^ O T B S
TBS 0 ^ 0  „  
PMP
"'OTBS
451
1 1
200
■r  'Y ‘ r  - f
400
[ 479 533 591
665
I
' eAo '  ' V A o
723
‘“-f*'—r-*i— r
801 
8  6  0 '
881 
— 1T960
6.0E7
L5.7E7
L5.4E7
L5.1E7
L4.8E7
L4.5E7
L4.2E7
L3.9E7
L3.6E7
L3.3E7
L3.0E7
L2.7E7
12.4E7
L2.1E7
L1.8E7
L1.5E7
L1.2E7
L9.0E6
L6.0E6
L3.0E6
1— 1------1------1------1------1------1------1------1— J r
1000 1100 12
L0.0E0 
00 m/z
PEf&ClN BLM5F7
109.18
2 . 9 7 - ^ t -
4000
0 2 /0 8 /0 5  10: 
Z: 84 scans.
— j—  
3500
17
16.0cm
34
22
.3
II-MF-82
DEPT
CDC13
-f, l*J» uIILl Ip
OBz
OTBS
TBS
"OTBS
PMP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
II-MF-82
CARBON
CDC13
OBz
OTBS
TBS
'OTBS
PMP
80 60 40 20 ppm
II-MF-82
COSY
CDC13
L 1 1 ppm
Q  O
i
,OBz
OTBS
TBS
OTBS
PMP
r i"v r I   " ' » i  i i~'i i » n  | i » i " i  n -TH ~ r T
10 0 ppm
II-MF-82
PROTON
CDC13
OBz
,OTBS
TBS OTBS
PMP
i ....................   I  | . . .  ............ | ------------  j
9 8 7 6 5
02/08/06 
12: 05
Y: 
64 
scans, 
1
6
.0cm
-1, 
apod 
none, 
fla
t
0 )
(ft 
*  ®
O  ”f ‘
o  I
u> i 
ot o  o
tooo *1
,,!_____ ..U .— .__ I
ro
utoo
roooo
i
4
4
oioo -I
o
O  * 1  o
o
3
3471 .7
29 55 .3  —
-<
1719.6  —
1617.3  —
1518.4
1470 .3
1 3 8 9 .3 -
aaasc
1064.8  ------------
1008
- S i
— 8 3 3 ^ 3 -' 
7 7 6 .3 -
s^-aKsessst.
7 1 0 .6 * i iu i nrwagir/:
111.354
II-MF-83
HMQC
CDC13
j jjUb L -UUL_jJUik_ ppm
20
40
60
3
80
-100
-120
-140
HO. OBz
OTBS
TBS O'' -160
'OTBS
T
PMP ppm
I I - M F - 8 3
C O S Y
C D C 1 3
HO. ,OBz
OTBS
TBSO"
'OTBS
PMP
I_ 1 1 X 1  JL 1 1  JL A Jt , UlM.. Jfc J * J \ L  A j .
0
a g k r
°v 0
R < r
a  o
@  D
J B V
0
o
♦
•
m O
o ’ m
a «<S 
•  V
O  a
ppm
- o
- 1
- 2
- 3
- 4
- 5
L 6
- 1
0 ppm
II-MF-83
DEPT
CDC13
HO. OBz
OTBS
TBS O'
"OTBS
PMP
JiUl tvi JJU-
80 70 60 50 40 30 20 10 0 ppm
II-MF-83
CARBON
CDC13
,OBzHO.
,OTBS
TBS O''
"OTBS
PMP
200 180 160 140 120 100
n Lm l
I ’
0 ppm80 60 40 20
II-MF-83
PROTON
CDC13
,OBzHO.
OTBS
TBSO'"
'OTBS
PMP
u l.
n  r _ r  ■ ' ' 1 ' ‘ 1 I ' 1' '    I 1 ' 1  I ............................................. I ............................................. I ............................................ I ............................................. I ............................................. I ............................................. I ..................................................I
9 8 7 6 5 4 3 2 1 0  ppm
File:00SE2999 Ident: 7_9" Win 1000PPM Acq:28-NOV-2 000 16:20:b7 +0:54 Cal:FABMM2 8110 0_1 
ZAB-SE4F FAB+ Magnet BpM:303 BpI:57420460 TIC:1478313856 Flags:HALL 
File Text:II-MF-122 FABMS MATRIX MNOBA + NA 
10 OS, 303
95i
90J
85i
80i
1 5 l
7 0_i
65J
60i
55_i
50i
45i
40i
35J
30i
25J
2 0i
151
10J
5J
X
^OBz
TBSO""
^ O T B S
O y 0  -
PMP
'''OTBS
883
,593
6 4 o'
667
_ L
7~5 o
725
825
-t— r
993
900 1000
-i— i— i— r
5.7E7 
L5.5E7 
L5.2E7 
14.9E7 
L4.6E7 
L4.3E7 
L4.0E7 
L3.7E7 
L3.4E7 
L3.2E7 
12.9E7 
L2.6E7 
L2.3E7 
L2.0E7 
L1.7E7 
L1.4E7 
L1.1E7 
L8 .6E6 
15.7E6 
L2.9E6 
L0.0E0
1100 1200 m/z
04081002: Scan 139 (32.23 min)
Base: 73.00 Int: 5.51684e+006 Sample: VG70-SE Positive Ion FAB
6000000 n
735500000
5000000-
4500000
Sample: II-MF-110
4000000 -
3500000
OBzPhS
3033000000 - OTBS
TBSO"
'OTBS2500000
PMP
2 0 0 0 0 0 0  -
1500000
1 0 0 0 0 0 0  -
759500000
251 10,59
12501000500
m/z
116.77
%T
I CD
rtn
ro *
to
CD
03
CD
v l
O)
03
03
113
CD
CVI
OJ
PhS ,OBz
OTBS
TBSO'"
'OTBS
PMP
4 3 .3 2
100015004000 3500 3000 20002500
0 2 /0 8 /2 2  08: 29
Y: 64 scans, 1 6 .0 c m -l, apod none, f l a t
II-MF-110
HMQC
CDC13
PhS OBz
OTBSTBSO"
'OTBS
PMP
II-MF-110
DEPT
CDC13
l l
PhS OBz
OTBS
TBS O''
'OTBS
PMP
" ' l ‘ ................I ................. I .................. I ................... I .................. I ..................I ...................I ................. I ................ ' I .................. I .................. I " " .......... I ' " ............I .................. I ..........I1i-r.T . ■ r , r, , | ............................|......................-M-jTrnr................j ...........................,.............................j
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
II-MF-110
CARBON
CDC13
PhS OBz
OTBS
TBSO'
'OTBS
PMP
M imm
II-MF-110
COSY
CDC13
II-MF-110
PROTON
CDC13
PhS OBz
.OTBS
TBSO'"
'OTBS
PMP
9 8
T ~ T
6 5
/
i A ,  il uJ iL J
' ' ' 'T
ppm
108.26
%T
-1 .8 4 — f—  
200025004000 3500 3000
0 2 /0 8 /2 8  09: 14
Y: 64 scans. 1 6 .0 c m -l, apod none, f l a t
■■
17
21
T®
PhSO
— j—  
1000
File:00SE2995 Ident:4_6 Win 1000PPM Acq:28-NOV-2UOO 15:43:38 + 0:36 Cal:FABMM2811UU_1 
ZAB-SE4F FAB+ Magnet BpM:115 BpI:54990168 TIC:890109888 Flags:HALL 
File Text:II-MF-114 FABMS MATRIX MNOBA + NA 
100& 303
95 j
90i
85i
80_i
7 5 i
7 0_i
65i
60i
55J
50i
45J
40i
35J
3 0i
25i
2 0i
15i
1 0i 1008
5j:
PhSO. OBz
OTBSTBSO'
'OTBS
PMP
200
Y t
00
463
r l^ U
500
603
etftT
659 718
791
L
700 857
849 953
557 1000 - r - T - f
1117 
W
1100
2 . 7E7 
L2.6E7 
L2.5E7 
L2.3E7 
L2.2E7 
L2.1E7 
L1.9E7 
L1.8E7 
L1.6E7 
L1.5E7 
L1.4E7 
L1.2E7 
L1.1E7 
L9.6E6 
L8.2E6 
L6 .8E6 
L5.5E6 
L4.1E6 
L2 .7E6 
L1.4E6
12
Lo .oeo
00 m/z
II-MF-125
HMQC
CDC13
PhSO OBz
OTBS
TBSO'
'OTBS
PMP
ppm
•i
20
40
60
80
-100
-120
-140
-160
i i i i—| i r ■ i -i-1 t i i i - T —
1 0 ppm
II-MF-125
DEPT
CDC13
,OBz
OTBSTBS O'
"OTBS
PMP
I r,'i  i  r"''1'' I M  'H  T'» i i » i i » » I I I I I i  r
190 180 170 160 150 140 130 120 110 100 90 70 60 50 40 30 20 10 0 ppm
II-MF-125
CARBON
CDC13
PhSO OBz
OTBS
TBSO'"
OTBS
PMP
J U l
II-MF-12 5
COSY
CDC13
JUL_ ppm
D
5
- 2
-3
a
-4
OBz
OTBS
TBSO'"
'OTBS -7
PMP
i—rt—rt—rt—i—r T
8 7 6 5 4 3 2 1 0  ppm
II-MF-12 5
PROTON
CDC13
PhSO .OBz
OTBS
TBSO'
'OTBS
PMP
9 8 7 6 5 4 3 2 1 0  ppm
File:00SE2996 Ident:2_3 Win 1000PPM' Acq:28-NOV-2OOO 1 5 : 5 1 : 0 2  + 0 : 2 1  Cal:FABMM2 8IIUU_± 
ZAB-SE4F FAB+ Magnet BpM:133 BpI:58376192 TIC:1535988352 Flags:HALL 
File Text:II-MF-115 FABMS MATRIX MNOBA + NA 
100^ 303
9 5 l
9 0 J
8 5 l
801
75^
7 01
6 5 l
6 0 l
551
501
451
401
351
301
251
201
151
101
51
227
,OHP hS02
OTBS
TBSO"
OTBS
PMP
903
I ,404
4 8 1 555 613
s i o ’ 'T '6*i
669
l— r  " i — r *
731 793
i ^ n — r
1013
— -1* I—-I I— f—I— r —I—
0 800 9 0 (
- i — i— r J ,
1118 -1—1---r
5.0E7 
L4.7E7 
L4.5E7 
14.2E7 
14.0E7 
13.7E7 
13.5E7 
13.2E7 
13.0E7 
12.7E7 
12.5E7 
12.2E7 
12.0E7 
11.7E7 
11.5E7 
11.2E7 
11.0E7 
17.5E6 
15.0E6 
12.5E6
1000 1100 12
10.0E0 
00 m/z
PERKtN ELMER
PhS0 2
4000 3500 3000 2500 2000 1500 1000 ctfT1 500
02 /09 /27  10:33 
X: 64 scans, 16.0cm -l. apod none, f l a t
II-MF-115
CDC13
HMQC
j u A  * iLA
II-MF-115
CDC13
DEPT
OH
OTBS
TBSO"
'OTBS
PMP
II-MF-115
CDC13
CARBON
,OHPhS0 2
OTBS
TBSO"
'OTBS
PMP
II-MF-115
CDC13
COSY
,OH
OTBS
TBSO'
"OTBS
PMP
II-MF-115
CDC13
PROTON
PhSO ,OH
OTBS
TBSO'
'"OTBS
PMP
I ‘ ‘ ‘ i ’ ‘ ■ i • ■ ■ • i ■  ■ ' i ' 1 • ' I 1 1 1 1 I ’ 1 1 I 1 r 1 ’ 1—1 ■ ■ ■ | 1 ■ ■ • | ■ ■ ■ ■ | - | - | ■ 1 | ■
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
File:00SE2997 Ident:4_7 Win 1000PPM Acq:28-NOV-2 00 0 16:09:07 +0:39 Cal:FABMM2 8110 0_1 
ZAB-SE4F FAB+ Magnet BpM:115 Bpl:47316992 TIC:952103168 Flags:HALL 
File Text:II-MF-117 FABMS MATRIX MNOBA + NA 
100%, 303
9 5 l
9 0 l
851
801
7 5 l
7 0 1
65l
60l
551
501
45l
401
35l
30l
25l
201
15i 
101
51
225
251
PhS02^ C ,
TBSO"" v^O T B S
° Y °  - ""OTBS
PMP
901
479
+4a
553 
1f ' t
611 
1_
686
X. 759
500 660 7(5o sio
821 33
1011
.036
U .
1 1162
2 . 5E7 
L2.4E7 
L2.3E7 
12.2E7 
12.0E7 
L1.9E7 
H.8E7 
11.6E7 
11.5E7 
11.4E7 
11.3E7 
11.1E7 
11.0E7 
18.9E6 
17.6E6 
L6.3E6 
15.1E6 
13.8E6 
12.5E6 
11.3E6
900 1000
“i— |— r
1100 12
10.0E0 
00 m/z
PERKtN ELMER
113.96
%T
to
to
CD
OTBS CQ
TBSO"
'OTBS
oPMP
< I
Cl
( I 
( I
23.30
4000 3500 3000 2500 2000 1500 1000
02 /07 /0 8  12 15 
X: 64 scans, 16.0cm -i, apod none, f l a t
II-MF-117
HMQC
CDC13
PhSO
i . i  i l  I
OTBS
TBSO'
'OTBS
PMP
>_ UKu U J L ppm
20
40
60
80
-100
-120
-140
-160
-180
- 2 0 0
T
0 ppm
II-MF-117
DEPT
CDC13
i., . i i
PhSO
OTBS
TBSO'
'OTBS
PMP
r mTTTT T™ Tm
190 180 170 160 150 140 130 120 110 100 90
pr-frr
80 70 60 50 40 30 20 10
II-MF-117
COSY
CDC13
PhS02\ ^ N ;* 0
TBSO"" x^O T B S
° Y °  - "'OTBS
PMP
j u u L i
J
1
3 
__?
jp &■
d" 9
°
a  a
*
il
a %
a
IS
I....... I
5 4
Su_ u
o
a  «Gb 
m*
ppm
t O
- 1
-3
-4
-5
- 6
0 ppm
II-MF-117
CARBON
CDC13
.OTBSTBSO'
'"OTBS
PMP
JJl iu a. .4 iL.weJuLLmJLL M
100 80 60 40 20 0 ppm
II-MF-117
PROTON
CDC13
PhS02v ^ C ^ O
TBSO""
^ O T B S
O y 0  " "'OTBS
PMP
jh d .
/
r
i
PERKIN ELMER
73.97
XT
CD
PhSO o
19.74
4000 3500 3000 2500 2000 1500 1000
01/09 /19  16:50
Yi 1 scan, 4 .Oca-1, f la t
al : FABLMiEP-Ident * fal 67 Win 1 0UUPPM Acq:
Magnet BpM:133 Bpl:13436636 TIC:145824480 Flags:HALL
File; 01SE3345 •61
ZAB-SE4F FAB+ 1— ^--
File Text: III-MF-118 FABMS MATRIX MNOBA + NA
1 0 0 k
95i
7 . 0E6 
L6.6E6
349
6.3E6
5.9E6
5.6E6
L5.2E6 
L4 . 9E6 
L4.5E6
PhS0275.
151
65. 4 . 2E6
3 . 8E6
55. 3.5E6
50. 3.1E6
45. 2 . 8E6
40. 2.4E6
35. 2.1E6
30. 1.7E6
25. 1.4E6
2 0 . 1.0E6
15.
7.0E5363
10. 371207 L3.5E5
LO.OEO
286
215.226 243 2^3 269 I 296 393335317
160
III-MF-118
CDC13
19/09/01
III-MF-118
CDC13
19/09/01
PhSO'
III-MF-118
CDC13
19/09/01
PhSO
J U _ l ppm
h i
h 2
r 3
<
r 4
h 5
h 6
T~ I TT i ■ n rT T I I T
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
III-MF-118
CDC13
19/09/01
PhS02
~r~r
8
“ |  i" “i  i— i— i— i— r —i— i —|  11— i i i i i  i i i | '
4 3 2 ppm
Ill-MF-121
CDCI3
14/08/01
PhSO' OTBS
'OTBS
1III-MF-121 COSY PhS02^  PM BQ ,,^\ .O T B S
CDC13 v. J
14/08/01 ^'''OTBS
ij 0
J  i i  J L J L jUl A _ J ppm
3 - i
0 - 2
-3
0 3
==:
-7■
- 8
i i r T"T
8
Ill-MF-121
CDC13
14/08/01
PhSO PMBQ,
Ill-MF-121
CDCI3
14/08/01
PhS02N PMBQ,, OTBS
''OTBS
— I--------- 1--------- 1--------- * | » i 1 i * | l [ i i i
200 180 160 140 120 100 80 60 40 20 0 ppm
III-MF-121 HMQC
CDC13
14/08/01
PhSO OTBS
J ii 1_ jUl u u ppm
20
40
60
80
-100
-120
-140
-160
-180
- 2 0 0
rTt — r — r m r TT—i—ri—i—i—i j n  i' i | i ri i ■»• ■ n — ri—i ■»—r rr
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
PGVCtN ELMSr?
79.57
XT
to
CM COto
CO
OTBSPhS02^  PMBQ,
cu "OTBS
i >
49.95
100015002500 20004000 3500 3000
01/08/14 10:21
X: 64 scans, 16.0cm-1, apod none, f la t
[File : Oi'SE334yA Ident:U Acq: -5-SEp-^U01^1b : : 2b +0.44 C 1 . t’ABLMU.320901
ZAB-SE4F FAB+ Magnet BpI:9488360 TIC:94920304 Flags:HAL 
File Text:III-MF-121 FABMS MATRIX MNOBA + NA 
1 0 0 %, 303
_ 8 . 3E5
1 7 .9 E 5
L 7 . 5 E 5
1 7 . 1 E 5
E_6 . 6E5PhS02\  PMBO
L 6 . 2 E 5
''OTBS
L 5 . 8 E 5
- 5 . 4 E 5
1 5 . 0 E 5
L 4 . 6 E 5
L 4 . 1 E 5
L 3 . 7 E 5
L 3 . 3 E 5
L 2 . 9 E 5
L 2 . 5 E 5
1 2 . 1 E 5
L 1 . 7 E 5
1 1 . 2 E 5
1 8 .3 E 4
L 4 . 1 E 4
0 . 0 E 0
m/z
IFile• 018fcillb0A Ident:2_b Win 1000PPM Acq: J-SKP-2UU1 lb:lb:b8 + U:lb cai: » ^ ^ * - L '  
ZAB-SE4F FAB+ Magnet BpM:115 BpX:18009294 TIC:343877472 Flags:HAL
File Text :III-MF-124 FABMS MATRIX MNOBA + NA
4651001
95 j
90J
85_
80_
75_
7 0_
65_
60_
55_
50_
45_
40_
35_
30_
25_
2 0_
15_2:.
10_
5_
Oi
24Jo
303
757
241 PhS02^  PMBCX, s \ ^ O T B S
""ul J
^ #,,OTBS
0
409
225 257
279
11
597
481
, 6P 6?7 675 699 I I 1. 71!
,k„ .n- . , | » I T ■ '» I ^  oAn
ioO 65 0 7 00  7 5 0  8(30
PERKIN ELMER
79.16
%T
cu
to
o
m
OTBSPhS02
''OTBS i iCU
IO
cu
35004000 3000 20002500 1500 1000
01/08/16 14:00 
Y: 64 scans, 16 .0cm-i, apod none, f la t
77
4.
9
III-MF-124
CDC13
15/08/01
PhS02v< PMBQ,
JUl * —
100 80 60 40 20 0 ppm
III-MF-124
CDC13
15/08/01
PhSO. PMBO/, OTBS
••a
'''OTBS
I ■ | - | 1 | ' | 1 I
220 200 180 160 140 120 100 80
~T~
60
I
40
~ r~
20 p p m
III-MF-124 COSY
CDC13
15/08/01
PhSO' OTBS
'"OTBS
jUl jK ^ , _A______________________________— ju ppm
J - o
r  1
-  2
-3
-4
am
-5
r 6
-7
m
m
- 8
i i i TTT TTr t r1—i—rTi i t tTT
0 p p m
III-MF-124
CDC13
15/08/01
PhSO. OTBSPMBO/,,
"h
'"OTBS
I  I '  I ...................... I .......................I ......................... I ' 1      V ...................... i ....................... i .......................I .......................
9 8 7 6 5 4 3 2 1 0  ppm
ZAB-
File
100%
»msF3347 Ident-5 Acq- 3-SKP-20U1 15:12:4b +U:iy cal :FABLMl 
SE4F FAB+ Magnet BpI:11525136 TIC:167546144 Flags:HALL 
Text • III-MF-125 FABMS MATRIX MNOBA + NA
303 *■
465
-x5.0 0-
PhS02>.
0 p U ^ O T B S
^  "OTBS
637
539
483 | 4 9 5 524
 r  i ■■■""
500
6 7 2 6 9 0 E
iJHykh if
700
« 3  . 7E6 
L3.5E6 
L3.3E6 
L3 .1E6 
L2.9E6 
L2 .8E6 
L2 .6E6 
L2 .4E6 
L2.2E6 
L2.0E6 
L1.8E6 
L1.7E6 
L1.5E6 
1.3E6 
1.1E6 
9.2E5 
7 . 4E5 
5 ♦ 5E5 
3 . 7E5 
L1.8E5
.0. OEO 
m/z
PERKIN B jMEER
8 1 .4 3
XT
11.77
4000 3500
01/00/21 18:53 
X: 64 scans, 4 .0 c « -l
17
0B
.0
cu
cu
CB
I
---- 1
1500
— I 
1000
III-MF-125 HMQC 
C6D6 
22/08/01
.l___________    A,
OH
>OTBS
OTBS
_AAa . A  A LA/ ppm
20
40
60
80
-100
-120
-140
TTTTT Tt
0 p p m
OH ,OTBS
'OTBS
III-MF-125
C6D6
22/08/01
PhSO
OH
,OTBS
'OTBS
I 1 I 1 I 
220 200 180 160
~T~
140 100
I
80 60 40
~~T~
20 p p m
III-MF-125 COSY
C6D6
22/08/01
-I   —A.
OH
OTBS
OTBS
A X a . ppm
- 0
- 1
-2
-3m
r 6
0 -7
*
- 8
T nr i » r ~ r-r—r
0 p p m
III-MF-125
C6D6
22/08/01
OH
OTBS
""OTBS
i= J l AJU
m  | i i  t “ i— r~ i  —i— i— r~
ppm
iFile-01E£!334fe Ident:49 Acq: 3-SBP-2001 lb:UU;sa +2:37 cal:FABbMUJ^ui*Ul_l 
ZAB-SE4F FAB+ Ma^et Bpl:7688270 TIC:99062696 Flags:HALL
File Text: III-MF-126 FABMS MATRIX MNOBA + NA  xlO.OO-
303100£
349367
PhS02
465
400
07 1449
5C
539 581
480 505523 
500
_2.0E6 
L1.9E6 
L1.8E6 
L1.7E6 
L1.6E6 
L1.5E6 
L1.4E6 
L1.3E6 
L1.2E6 
L1.1E6 
L9.9E5 
L8.9E5 
L7.9E5 
L6.9E5 
L5.9E5 
L4.9E5 
L3.9E5 
L3.0E5 
L2.0E5 
L9.9E4
O.OEO
0 m/z
PERKIN ELMER
48.69
8 S
PhSO,
I
01/06/22 16: 12
X: 64 scans, 16.Oca-1, apod nons. flat
III-MF-126 HMQC
C6D6
22/08/01
PhSO
OTBS
'OTB S
A <u* JUL A , ppm
20
40
60
80
-100
-120
7
- 1 4 0
f - 160
T T 1
0 p p m
III-MF-12 6
C6D6
22/08/01
I
200
OTBS
'OTBS
i » ] ■ | « i ■ i ■ n
180 160 140 120 100 80
III-MF-126
C6D6
22/08/01
PhS0 2
.OTBS
'OTBS
III-MF-126 COSY
C6D6
22/08/01
.OTBS
"OTBS
J l L A O L 1 1 ppm
JS -o
- 1
m
- 2
-3
-4
-5
r  6
- 7
m
- 8
Tr T « I T TT ■'T
0 p p m
I l l - M F - 1 2  6 
C 6 D 6  
22/08/01
P hS 02
>OTBS
'OTBS
I 1 1 1 ■ ■ ■ 1 1................... i ............ I ....................... i ■ 1
9 8 7 6 5 4 3
PERKIN ELMER
72.22
PhS02
OMe H
i
8
8
§
34.00
01/09/06 19:48
X: 64 scans, 4.Oca-1, flat
B9
1.
3
III-MF-145
C6D6
13/09/01
OMe H
OTBS
HO'" 'OTBS
III-MF-145
C6D6
13/09/01
PhSO.
OMe H
OTBS
HO'' 'OTBS
p m m
III-MF-145 COSY
C6D6
13/09/01
1
OMe H
OTBS
OTBS
11 A JuL PPIT
- 0
- 1ID
- 2
-3
-4
i — i— rT I I TiT TT T"r
0 p p m
III-MF-145
C6D6
13/09/01
OMe H
OTBS
""OTBSHO''
lFile-UlSKjJ4ti IdenfJ 4 Win 10UWPM Acq: J-SEF-lUOl 16:18:1' +1>;1« uai: f Am^l^l>01_l 
ZAB-SE4F FAB+ Magnet BpM:115 Bpl:3684096 TIC:74654976 Flags:HALL 
File Text:III-MF-104 FABMS MATRIX MNOBA + NA
100* 
95 
90 
85 
80^ 
75. 
7 0J 
65_  
6 0 j  
55- 
50_ 
45J  
40J  
35_ 
3 0_ 
25_ 
2 0J 
15i 
iO  i  
5i
303 w-
-x5.00-
PhS02^
| OMe h
^ O T B S
M  J
^""O TBS
554
347 371 0.0E0
-w_2 . 5E6 
L2.4E6 
L2.3E6 
L2.1E6 
L2 . 0E6 
L1.9E6 
L1.8E6 
L1.6E6 
L1.5E6 
11.4E6 
L1.3E6 
L1.1E6 
L1.0E6 
18.8E5 
L7.6E5 
L6.3E5 
L5.0E5 
L3.8E5 
L2.5E5 
L1.3E5
PERKIN ELMER
76.16
K
S
PhSO
I
OMe M
I f
19,19
01/08/28 18:28
X: 64 scans, 16.0c®-i, apod none, flat
III-MF-104 HMQC
CDC13
24/08/01
J U
PhSO
OMe h
.OTBS
'"OTBS
JuLA Ji. __ 1—^ J L ppm
20
40
60
80
-100
-120
-140
-160
-180
- 2 0 0
TT
0 p p m
III-MF-104
CDC13
24/08/01
PhSO-
OMe h
OTBS
'OTBS
III-MF-104
CDC13
24/08/01
OMe h
,OTBS
'OTBS
III-MF-104 COSY
CDC13
24/08/01
PhSO
OMe h
.OTBS
'"OTBS
LA __k A J L  w.__ j L _ ppir
- 0
- 1
a c - 2
-3
9
-4
r 5
r  6
r 7
r  8
-r
0 p p m
I I I - M F - 1 0 4
C D C 1 3
2 4 / 0 8 / 0 1
OMe h
,OTBS
'OTBS
J U
■ 1 i-r T
0 ppm
IPile-OlriBiJbl Idenf J_1J W m  lOUOP^M Acq: i-SEP-iUUl lb:i9 = ^ 0 +0:^ (Jal :FaBLM0^0?TC 
ZAB-SE4F FAB+ Magnet BpM:147 Bpl:19000972 TIC:382955616 Flags:HALL 
File Text:III-MF-131 FABMS MATRIX MNOBA + NA 
100%, 303
407 447
OMe h
OTBS
^  'OTBS 
OTBDPS
503
635 865
891
666 / D ^ 00<ik i 1 I
8.3E6 
L7.9E6 
L7.5E6 
L7.1E6 
L6.6E6 
L6.2E6 
L5.8E6 
L5.4E6 
L5.0E6 
14.6E6 
4.1E6 
3 . 7E6 
3.3E6 
2.9E6 
2.5E6 
2.1E6 
1.7E6 
1.2E6 
8.3E5 
4.1E5
T-T-T-]
1000
0.0EO 
m /z
PhSO-
OMe h
,OTBS
^  "OTBS 
OTBDPS
70.634  -
4000
— r __ 
3500
---- f—
3000
I—  
2500
— I—  
2000
0 2 /0 4 /2 3  1 6 :4 7
Y: 64 scans, 4 .0 c m -l,  f l a t
1 0 0 0
III-MF-131 HMQC
C6D6
30/08/01
PhSO-
OMe h
OTBS
^  "OTBS 
OTBDPS
20
40
60
80
-100
-120
-140
-160
-180
- 2 0 0
TT1 T T TT
0 p p m
III-MF-131
C6D6
30/08/01
OMe h
OTBS
^  "'OTBS 
OTBDPS
«Wmm* mr
III-MF-131
C6D6
30/08/01
PhSO
OMe h
OTBS
^  "'OTBS 
OTBDPS
(W Ummmum• Wmmmm m m #
III-MF-131 COSY
C6D6
30/08/01
OMe h
OTBS
^  'OTBS 
OTBDPS
 lL J PPIT
- 1
i -2
-3
- 8
8 p p m
III-MF-131
C6D6
30 / 08/01
OMe H
OTBS
^  "OTBS 
OTBDPS
ppm
PERKIN ELMER
PhSO
^  OTBS 
OTBDPS
01/06/31 15:49
X: 64 scans, 4 .0 c s -l. f la t
III-MF-132
C6D6
31/08/01
OMe H
OTBS
HO''' ^  "'OTBS 
OTBDPS
— |--------- T , , , T , , 1 T 1 , 1 , 1 I | '  I ’ I ’ i T r
220 2 0 0  1 8 0  1 6 0  1 4 0  1 2 0  1 0 0  80 60  40 2 0  0 ppm
C6D6
31/08/01
PhSO'
OMe H
OTBS
HO'' ^  'OTBS 
OTBDPS
1 0 0 80 60
T "
40 2 0 p p m
III-MF-132 COSY
C6D6
31/08/01
P hS 0 2
OMe H
OTBS
HO''' ^  "OTBS 
OTBDPS
ppm
J - 0
- 1
-2
-3
r  4
5
r  5
r  6
- 7
- 8
i —ii r i ■->T
0 p p m
III-MF-132
C6D6
31/08/01
PhSO
OMe H
OTBS
H O '' ^  "OTBS 
OTBDPS
| i > r > i » i » i | r-i i » » i i » i |
7 6 5
/
JL AuhL I
- i— i— I— i— I— i— r - "T"1"
i ppm
02/03/12 
10:01
X: 
64 
scans, 
16.0cm
-l, 
apod 
none, 
fla
t
oo
CO
CJ1oo
8oo
3031
2836 .3----
o
ro
8
Oo
1729.6
1 4 2 7 .3 -
1304.7
1254.9
1149.2
»■»ooo
1006.1
830.8
7 7 6 .1 -----
740.2
7 0 4 .1 -o3
JL
115.42
III-MF-135 
PhMe at RT 
11/09/01
naO i
9 8 7
t  i ~~rI > 1 1  .......... i .................... ' ' l ......................... I i
4 3 2 1 0 ppm
III-MF-135
PhMe at 95oC
11/09/01
PhSOj, ons
I ....................................1"‘T~r "ir"r ~|—1 ■ ■■ ■ | ......................................  ■ ' |  | .........................1 1 ' 1 ...................■ ■ ■ ■ , ................................... , ...............................■ ■ i   . ■
9 8 7 6 5 4 3 2 1 0  ppm
III-MF-135 COSY
PhMe at 95oC
11/09/01
J
3
x l
P hS O ^ OTB6
T E S O ^ S ^
O TM
Jl lJ L  w^Aii— iLii—. JL » .  .
|
»«
f - l  T I I I I I 1 — V - T-  I I— I— I T  I— I I f I I I I
o ft£
" " T
A J L
n a
ppm 
- 0
- 1
-2
3
-8
0 ppm
OTBSIII-MF-135 NOESY 
PhMe at 95oC 
11/09/01 TESOx
.OTBOP8
. L J L
J
3
TTT T " T T
7 6 5 4 3 2 1 0
'Pile-OlSKJiby Iden t-2b VS Win IOOOfpM Acq: 4-LKF-2001 11:39:44 +1:3* ial:FABL«u4Ul>Ul_T 
ZAB-SE4F FAB+ ^gnet 8 ^ 1 3 5  BpX:19327204 TIC:376460032 Flags:HALL 
File Text: III-MF-135 FABMS MATRIX MNOBA + NA 1
1002
95J
90 J
85_
80_
75.
70_
65_
60_
55_
50_
45_
40_
35_
30_
25_
4
20_
15.
10.
1
oJi
4(30
PhS02^
1 OMe h OTBS
TESO"'' || OTBS
-OTBDPS
783
1138
1005
. 1039 
949 I j 11061
^  , 
1000 1100
1260
1200
1.6E6
L1.5E6
L1.4E6
L1.3E6
L1.3E6
11.2E6
L1.1E6
L1.0E6
L9.5E5
18.7E5
17.9E5
L7.1E5
16.3E5
15.6E5
14.8E5
14.0E5
13.2E5
L2.4E5
L1.6E5
17.9E4
0.0EO 
1300 m/z
III-MF-135
C6D6 at 70oC
11/09/01
PhSO
OTBDPS
III-MF-13 5 
C 6 D 6  a t  R T  
11/09/01
PhSO.
OTBSOMe h
OTBSTESO'
OTBDPS
- p  r ' I ..............................—r  | 1 1 ' i - r -r . - .........................  , ........................... J ■ , ................................ I ................................ I .................................. I ..............................
9 8 7 6 5 4 3 2 1  0 ppm
File: 0TSE4061 Ident:ll_34 Win 1000PPM Acq: l-NOV-2001 10:03:33 +1:11 Cal: FABI.M0111U l_r 
ZAB-SE4F FAB+ Magnet BpM:119 BpI:18995542 TIC:1675206144 Flags:HALL 
File Text:III-MF-144 FABMS MATRIX MNOBA + NA
1 0 0 % 2 4 1  3 Q 4
PhS0 2 OTBSOMe h
OTBS
AcO'
OTBDPS
679
910
a 709 819 876 989935 haJbMI I I  I I I  i  1^  f  -  *~l
7 00 800 900 lO'OO
1030
•*-r
1.5E7 
L1.5E7 
L1.4E7 
Ll.3E7 
Ll.2E7 
L1.1E7 
L1.1E7 
L1.0E7 
L9.2E6 
L8.4E6 
L7.7E6 
L6.9E6 
L6.1E6 
L5.4E6 
L4.6E6 
L3.8E6 
13.1E6 
L2.3E6 
L1.5E6 
L7.7E5
10.0E0 
1 1 0 0 m/z
o
Id
O
o
o
cn
o
o
2856.6
CL
o
1747N>
1470.0 --------
1427.7 
1372.3 —
o
1315.0
960.6
032.6 -  
777.0
7 0 4 . 9 -
613.9
501.9o
PERKIN 
ELM
ER
III-MF-144
C6D6
HMQC
RT
PhSO
OTBSOMe h
OTBSAcO'
OTBDPS
^  A i I ppm
20
40
60
80
-100
-120
-140
-160
Tt—i—rt-i—i— ri—i—r■p
0 ppm
ppm
- J - 0
- 1
- 2
-3
-4
PhSO-
OTBSOMe h
OTBSAc O'
OTBDPS
■<
- 7
- 8
V t—r TTt—ri—r! I I' Vi—rt—rt—i—rt—rI ■■■■■■■■■ I I ■ 1 ■ 1 ■ 1 ■ i "' 1 ■ ■ ■ ■ ■ ■ ■ | .................. | .........   I .................... i i
8 7 6 5 4 3 2 1 0  ppm
Ill-MF-144 
C6D6 
DEPT 
RT
PhSO.
OTBSOMe h
OTBS
AcO'
OTBDPS
220 200 180 160 140
C6D6
CARBON
RT
PhSO.
OTBSOMe h
OTBSAcO'
OTBDPS
-i--------------------1--------------------1--------------------1--------------------r-
100 80 60 40 20 0 ppm
C 6 D 6
P R O T O N
R T
PhSO-
OTBSOMe h
OTBSAcO'
OTBDPS
3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
File:01SE4543 ldent:3_8 Win 1000PPM Acq: 3-DEC-2001 12:18:15 +0:21 Cal:FABLM0312 01_1 
ZAB-SE4F FAB+ Magnet BpM:509 BpI:553472 TIC:32406504 Flags:HALL 
File Text:IV-MF-11 FABMS MATRIX MNOBA + NA
509100%
PhS0 2^
1 OH H
AcO'' ]| -^""OH
[1 .OH
291
317
451
391
305 [B27 351 373 409 433 4
300 350 400 450
523 5 4 4  5 6 4 5 8 2
5.5E5
L5.3E5
L5.0E5
L4.7E5
14.4E5
L4.2E5
L3.9E5
13.6E5
L3.3E5
L3.0E5
L2.8E5
12.5E5
12.2E5
11.9E5
11.7E5
ll.4E5
11.1E5
18.3E4
15.5E4
12.8E4
J L o . 0E0 
6(J0 m/z
IV-MF-17 
PROTON RT 
C6D6
PhSO
OH H
OH
AcO'' OH
OH
IV-MF-17 
PROTON +50oC 
C6D6
PhSO
OH H
OH
AcO ''' OH
OH
T"‘ I ........................ I  I ........................ I ........................ I ............. “-"I'.  | ........................ | ........................ | ........................ | ...........................|
9 8 7 6 5 4 3 2 1 0  ppm
IV-MF-11
d4-MeOH
COSY
PhSO.
OH H
OH
AcO'' 'OH
OH
% #
-t— i— i— i— i—r*
ppm
- 1.0 
-1.5 
- 2  . 0 
-2.5 
-3.0 
r3.5 
-4.0 
-4.5 
-5.0 
-5.5 
- 6 . 0  
-6.5 
-7.0 
-7.5 
- 8 . 0
ppm
“i—i—i—i—i—r-
IV-MF-17
D E P T
d4-MeOH
OH H
,OH
AcO' 'OH
OH
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
IV-MF-17
CARBON
d4-MeOH
PhS02N
, 1 ° H HI ^ ^ O H
1
AcO' yf ' " ' O H
[1 ^ /O H
I ' I ' I * I
200 180 160 140
IV-MF-17
PROTON
d4-MeOH
PhSO
OH HI
I
•a, ,OH
'"OHAcO'
OH
j u k j l l J
File : 01SE452 0 Ident: 64_6T Win 100DPPM Acq:30-NOV-2U01 08:b'/:53 +3:30 Cal : FABLM3 011U'l_i 
ZAB-SE4F FAB+ Magnet BpM:199 BpI:18973696 TIC:2367700736 Flags:HALL 
File Text:III-MF-180 FABMS MATRIX TGT
100%. w--------------xlO.OO-
BzO’
.02SPh
OTBS
.OTBS
421
399
437
457
493
)0 450 5(1)0 550
1.9E7
1.8E7
1.7E7
1.6E7
1.5E7
1.4E7
1.3E7
1.2E7
1.1E7
1. 0E7
9.5E6
8.5E6
7.6E6
6 .6E6
5.7E6
4.7E6
3 . 8E6
2 . 8E6
1.9E6
9.5E5
0.0E0 
0 m/z
File: 01SE4519 ldent:l(02 Win ID 00PPM Acq: 3 0-NOV-2 0 01 08:48:37 +0:38 Cal: FABLM3 01101_1 
ZAB-SE4F FAB+ Magnet BpM:147 Bpl:6099968 TIC:76917584 Flags:HALL 
File Text:III-MF-183 FABMS MATRIX TGT 
100% 303
95-i
90J 
85J 
80J 
75J  
7 Oi 
65i 
60i 
55i 
50_i 
4 5 i  
40i 
3 5 i  
30J  
25i 
2 0i 
15i 
lOi 
5i
9
if
■v^OTBS
[1 1
^""OTBS
551
535
512 574
550
, I I 5 9 8 626 686
6io 650 7
9.2E5 
18.8E5 
18.3E5 
L7.8E5 
L7.4E5 
16.9E5 
16.4E5 
L6.0E5 
15.5E5 
15.1E5 
14.6E5 
14.1E5 
L3.7E5 
L3.2E5 
L2.8E5 
L2.3E5 
11.8E5 
L1.4E5 
19.2E4 
14.6E4
10.0E0
0 m/ z
IV-MF-0 6
HMQC
C6D6
Jj ta_ _A______
OTBS
'"OTBS
T*
ppm 
-  0
-  20
-  4 0
-  6 0  
-  8 0  
-100 
-120 
- 1 4 0  
- 1 6 0
0 ppm
IV-MF-06
DEPT
C6D6
OTBS
OTBS
"i rr
20 10
“ ■ I ....................... i ................. i —   i .......... i ..........  ■ i ....................i ..................... i ....................i .................... i "
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 ppm
IV-MF-06
CARBON
C6D6
OTBS
'OTBS
1 ’
0 ppm100 80 60 40 20
IV-MF-0 6
COSY
C6D6
_J____ CLAA. l l JH
83OTBS
OTBS
M.
t—I—rt—ri—r
ppm 
r 0 . 0
-0.5
- 1.0
7  1 .5
7 2 . 0
-2.5
r3 .0
r3 . 5
7 4 . 0
-4.5
7 5 . 0
-5.5
r 6 . 0
-6.5
-7.0
-7.5
0 ppm
IV-MF-06
PROTON
C6D6
t—i—r1 1 1 1 1 1 r
4
t—i—r t—i—i—i—i—r i
ppm02 13
6500000 
6000000 
5500000 
5000000 
4500000 
4000000 
3500000 
3000000 
2500000 | 
2 0 0 0 0 0 0  -  
1500000 
1000000 
500000
01031002: Scan Avg 215-216 (49.97 - 50.20 min) - Back
Base: 121.00 Int: 6.27e+006 Sample: VG70-SE Positive Ion FAB
121
0
87
5.8
4.0
199
illl.Jlii.
Sample: IV-MF-112
r v
Y ^ O T E S
TBDPSO L .0
I
'"OPMB
267
403S; 121
659
50 100 150 200 250 300 350
m/z
400 450 500 550 600 650 700 750
PERKIN ELMER
110.08
%T
CD
lOcuinO)Oi CU
14.39
cm"*1 5001 0 0 015004000 30003500 2500 2 0 0 0
0 2 /0 9 /1 6  09: 40
X: 64 scans, 1 6 .0 c m -l, apod none, f l a t
IV-MF-112
CDC13
HMQC
OTES
TBDPSO
OPMB
U jul M A .Ll JlA - U*____
t—i—ri—i—i—i—rTt—rr
ppm
-  20
- 40
- 60 
- 80 
-100
120
140
-160
ppm
I V - M F - 1 1 2
C D C 1 3
C O S Y
U jU
OTES
TBDPSO
OPMB
l ..................... I '
8  7
Jill A___
0
o
□ me>
n «
0  ta o
o a
r , .r.rnr_m , . !  !
6  5  4
ppm 
7  0  . 5
- 1.0
- 1 . 5
7 2 . 0
7  2  . 5
- 3 . 0
t 3  . 5
7  4  . 0
- 4 . 5
7 5 . 0
- 5 . 5
- 6 . 0
- 6 . 5
- 7 . 0
- 7 . 5
- 8 . 0
ppm
IV-MF-112
CDC13
DEPT
OPMB
IV-MF-112
CDC13
CARBON
OTES
TBDPSO
OPMB
raj lra« I w L
i 1 i • i * 1-------1-------1-------1-------r~
220 200 180 160 140 120
JL/L
100 80 60 40 20 0 ppm
IV-MF-112
CDC13
PROTON
OTES
TBDPSO
OPMB
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
01031002: Scan 238 (55.33 min) - Back t t
Base: 87.00 Int: 3.75712e+006 Sample: VG70-SE Positive Ion FAB
4000000
3500000
3000000
2500000
2 0 0 0 0 0 0
1500000
X 1 0
87
58
135
1 15
199
OTES
TBDPSO
OH
Sample: IV-MF-114
1 0 0 0 0 0 0  -
500000
267
369
. 425
539 663
300 350
m/z
400 450 500 550 600 650 700 750
PERKIN ELMER
107.93-
XT
CM
o
CM
CM
OTES
TBDPSO
o
OH
O)CM
100015003500 3000 2500 2000
02 /09 /30  09:40
X: 64 scans, 16 .0cm-1, apod none, f l a t
ppm
ft
10
20
40
50
60
70
80
90
OTES
TBDPSO ^ 1 0 0
■-110OH
H 120
^ 1 3 0
t—i—i—i—r '’Tt—i—i—|—i—rt—i—i—i—r t—i—r T
8 7 6 5 4 3 2 1  ppm
IV-MF
CDC13
COSY
-114
JLi J L _ _ U U ^ .
J
1
Ob
OTES
TBDPSO
OH
-c
t—i—r i—i—r t—It—r T"-i—rt—i—r
ppm 
7 0 . 5
- 1.0
-1.5
7 2 . 0
r2 .5
-3.0
r3 .5
7 4 . 0
7 4 . 5
-5.0
7 5 .5
- 6 . 0
-6.5
-7.0
r7.5
- 8 . 0
ppm
IV-MF-114
CDC13
DEPT
TBDPSO
I T I ' I '----1----T--- 1----'--- 1----'----1----•--- 1----' i ’ I T I T I ’
220 200 180 160 140 120 100 80 60 40 20 0 ppm
IV-MF-114
CDC13
CARBON
OTES
TBDPSO
OH
i ' i 1 i ' 1---------1---------1---------1---------1---------1---------r ~
220 200 180 160 140 120 100
JJl
80 60 40 20 0 ppm
IV-MF-114
CDC13
PROTON
OTES
TBDPSO
OH
    I I T “|— | 1 ' ' 1 -r-' 1 ' I 1 r ' ' ! 1 ' 1 ' I ' 1 . ' i ' | | | ■
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
File
ZAB-
File
100%
:02SE1993 Ident:70 Acq:29-MAY-2002 13:10:42 +3:59 Cal:FABLM290 502_1 
SE4F FAB+ Magnet Bpl:23371080 TIC:2486428416 Flags:HALL 
Text:IV-MF-117 FABMS MATRIX MNOBA + NA
783 w-------------------------------------------x2 0.00- . 7E6
TBDPSO
OMe H
OTBS
1274OTBDPS
. 8E6
1018
1086
14421145
1112
1185
1473
355 
I 11381 . 5E6
. 7E5
1000 1100 1200 1300 1400 1500
PERKIN ELMER
1 1 0 .1 7 -
XT
in
cuOH to
TBDPSO
in
OTBSOMe Hcu
OTBS
TESO"' (O
OTBDPScu
7 2 .7 2
35004000 3000 2 0 0 02500 1500 1 0 0 0
0 2 /0 5 /2 8  10: 14
Y: 64 scans, 4 .0 c m - l ,  f l a t
IV-MF-117
C6D6
DEPT
TBDPSO
OTBDPS
* * * * *
IV-MF-117
C6D6
CARBON
OH
TBDPSO
OTBSOMe H
OTBS
TESO
OTBDPS
  mwmm* tmw+mmwt*mWn*r m m tLrnm m m m Jm iiK m  m ltm  * * * * * * *
220 200 180 160 140 120 100 80 60 40 20 0 ppm
IV-MF-117
C6D6
COSY
TBDPSO k / O
| OMe H OTBS
TESO""Nf OTBS
[1 -OTBDPS
8  a
i....... I ................ I ' " '
8 7 6
ppm
bO
- 2
-4
- 6
-7
, r ....................| - ■
1 0 ppm
IV-MF-117
C6D6
NOESY
JlLL ppm
- 1
- 2
L 3
OH
-4TBDPSO
OTBSOMe H
-5
OTBSTESO' <
OTBDPS - 6
=
-7
ppm
IV-MF-117
C6D6
PROTON
OH
TBDPSO
OTBSOMe H
OTBSTESO'
OTBDPS
7 -5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3 • 5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
:02SE20 94 Ident:4_17 Win 1000PPM"Acq:10-JUN-2002 08:13:34 +0:36 Cal:FABLM10 0 602_1 
SE4F FAB+ Magnet BpM:149 BpI:15684170 TIC:647753088 Flags:HALL 
Text:IV-MF-121 FABMS MATRIX MNOBA + NA
782 k x8 . 00-----------------------
File
ZAB-
File
100%,
OBz
TBDPSO
OTBSOMe H
OTBS
TESO'
OTBDPS
1432
1377
1088
1024 1477
1327
650 
624 I 677
0 . 0E0
1400 15001300120011001000
PERKIN ELMER
92.36
%T
o
cu
55.36
30004000 3500 2500
- i —
2000
0 2 /0 6 /0 7  09: 13 
Y: 64 scans, 4 .0 c m - l
-OTBDPS
IV-MF-121
C6D6
HMQC
OBz
TBDPSO
OTBSOMe H
OTBS
TESO'"
OTBDPS
j u  J j u  L
H
ppm
-  0
-  20
- 40
- 60 
- 80 
-100 
-120 
-140 
-160
i i I i i-'i-i r- T
7
I —i—r—i—i—i—r- i i i I i— i i ->—m  i~ i ~~i— |— i i i i « i" 'i— r- i i I i i —i —i— i i i —i —r —I— r
0 ppm
IV-MF-121
C6D6
COSY
( ^ Y ^ T ^ 0 B z
TBDPSO L , 0
| OMe H OTBS
TESO'' ||
6 t b s
XDTBDPS
*)L. JJ_________A__
•
a j 0 f *
8 ©
3
9
fe
O <5>
2 f  °
a  a
°  a
l3g»
©
0
^  -
0
ee
a
*  00
a &
•
a
a
81 a
•  ’  &
O Q 
©
1 I "  "  "" ‘ ',-rT 
8 7
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i r y r - r r
3
ppm 
h  0
- 1
- 2
-3
-4
-5
- 6
-7
' i ' ' 1 
2 0 ppm
IV-MF-121
C6D6
CARBON
TBDPSO
«*p *+mm m pin
IV-MF-121
C6D6
PROTON
OBz
TBDPSO
OTBSOMe H
OTBS
TESO"
OTBDPS
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
File:02SE2335 Ident:37_42-14 Win 1000PPM Acq:21-JUN-20 02 09:19:07 +2:16 Cal:FABLM210602_1 
ZAB-SE4F FAB+ Magnet BpM:91 Bpl:19023872 TIC:436456320 Flags:HALL 
File Text:IV-MF-122 FABMS MATRIX MNOBA + NA
581100% 
95i 
90J  
85J  
80J  
75i 
7 0_i 
65i 
60i 
55J 
50J 
4 5J 
4 0i 
35i 
3 Oi 
2 5_i 
2 Oi 
15J 
10J 
5i
OH H
351 . 387 -419 4 4 3 4 8 1 549 i
0,379 ,i 4 3 2 | 462 523 - ° /
liilf Li^ .^LiiiiiiliL^  JyiJ IkLiJtlliil, jIi
400
f
597
450 500 550
6 0 6
60 0
652 
662
■ v -  
691
jiUMjL
7 j 3 7 3 0  
Wi.J iUIJ 1i1il1l.i1IiLiJ
9 . 0E6 
L8.5E6 
L8.1E6 
L7.6E6 
L7.2E6 
L6.7E6 
L6.3E6 
5.8E6 
z_ 5 .4E6 
L4.9E6 
L4.5E6 
L4.0E6 
L3.6E6 
L3.1E6 
L2.7E6 
L2.2E6 
Ll.8E6 
L1.3E6 
L9.0E5 
L4.5E5
650 7 0 0
E_0 . 0E0
750 m/z
IV-MF-122
d4-MeOH
CARBON
OBz
HO
OH
OH
HO'
OH
w m
i • i 1 r* ’ i ’ i-  —1 i 1 i ' i ' i * i “ i-  i
220 200 180 160 140 120 100 80 60 40 20 0 ppm
IV-MF-122
d4-MeOH
COSY
JLaJ l U
o
OBz
HO
OHOH H
OH
HO'
OH
i—r t—r '1~T t—r
ppm
1.0 
-1.5 
7 2 . 0 
-2 . 5 
7 3 . 0 
-3.5 
4.0 
h 4 . 5 
-5.0 
5.5 
- 6 . 0  
r6.5 
-7 . 0 
7 7 . 5 
r 8 . 0
ppm
IV-MF-122
d4-MeOH
PROTON
OBz
HO
OHOH H
OH
HO'
OH
' i ' ' ' ' I ' ’ ' ' i ' 1 ' 1 i 1 ' ' ' i ' 1 ’ ■ i ' ' ' ' i ' ' ' ' I 1 ' ' 1 I ' 1 ' ' I ' ' '■ I 1 1 1 1 I 1 1 1 1 I ' 1 1 1 I 1 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
File :’0'2'SEl024 ldent:32_34 Win 1000PPM Acq:'2 5-MAR-2 0 02 12:01:51 + 1:54 Cal:FABLM250302_1 
ZAB-SE4F FAB+ Magnet BpM:91 BpI:6485334 TIC:225626944 Flags:HALL 
File Text:IV-MF-67 FABMS MATRIX MNOBA + NA 
100%, 125
PhS02^
1 OMe H
0  II
'" " O H
n ,OH
307 327
l60 l20 140 160 180 200 220 240 260
495
l il.jlnlj III 1^E_ 0 . 0E0
0 480 500 520 m/z
PERKIN ELMER
83.60
XT
t
CD
CD
Ol CU
i~
TTCD
*0 D
COCO
CUr^
c n
c oPhS02
OMe H
OH
CU( I"OH
OH
57.04
4000 3500 3000 10002500 2000 1500
02 /03 /04  17:33
Y: 16 scans, 16 .0cm-1. apod none, f l a t
IV-MF-67
C6D6
PROTON
OMe H
,OH
'OH
OH
i J J W j M u .
File : 02SE102 5 Ident:17_24 Win 1000PPM Acq:25-MAR-2 002 12:10:51 +'1:14 Cal: FABLM2 50 3 U2_l 
ZAB-SE4F FAB+ Magnet BpM:225 BpI:1208704 TIC:46230404 Flags:HALL 
File Text:IV-MF-61 FABMS MATRIX MNOBA + NA 
100& 225
95J
90_i
85J
80
75_:
7 Oi
6 5 i
60_i
55i
50i
45i
40J
3 5 1  
3 0 _i
2 5i
2 0i
15J
10J
5J
PhS02N
1 OMe H
°  II
-^""OAc
|l ,OAc
491
343 361 
liiLl.lilJiIjiti ililiuli
507 5 2 5  
00 550
567 591 I 621
ILimI||J .uJlUtlJiluJiplllu
1.2E6
11.1E6
H.1E6
Ll.0E6
L9.7E5
19.1E5
18.5E5
17.9E5
17.3E5
16.6E5
16.0E5
15.4E5
14.8E5
14.2E5
13.6E5
13.0E5
12.4E5
11.8E5
11.2E5
16.0E4
10.0E0 
650 m/z
File:02SE280 Ident:6_10 win 1000PPM Acq:29-JAN-2002 16:10:45 +0:29 Cal:FABLM280102_1 
ZAB-SE4F FAB+ Magnet BpM:125 BpI:1208320 TIC:50721232 Flags:HALL 
File Text:IV-MF-33 FABMS MATRIX MNOBA + NA
_ 1 .2E6125
L1.1E6951
369
L1.1E69 01
11.0E6851
L9.7E580.
L9.1E5
18.5E57 01
L7.9E5651
17.2E5197 PhS02 391
16.6E5
136 ’OH 16.0E5
OH
15.4E545. 143
14.8E5401
14.2E515435^
13.6E53 01
295 13.0E5253251
12.4E52 01
165 186 207 225 11.8E5351151
277 323239 11.2E5101 175
307267 407333 16.0E4341 420
10.0E0
m/ z
5 99
PERKIN  ELMER
IVLMF'l?
81.41
%T
cu
in
o lo
0 10 1
CO
cu
'OH
ciOH
16.30
1500200025004000 3500 3000
02 /01 /23 09: 28 
Y: 64 scans, 4 .0cm -l
IV-MF-3 3
HMQC
C6D6
J j Jl aL aJ  . ppm
20
40
60
80
PhSO
-100'OH
OH
-120
-140
-
-160
t—i—rTT
1 ppm
I V - M F - 3  3
DEPT
C 6 D 6
PhSO
OH
OH
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
IV-MF-3 3
CARBON
C6D6
PhS0 2
'OH
OH
IV-MF-3 3
COSY
C6D6
Jl
OH
OH
Jl aLa_A_JLJL
' ' ' ~i~
pprn
7 1 . 0
-1.5
7 2 . 0 
-2.5 
7 3 . 0 
-3.5 
-4.0 
-4.5 
-5.0 
-5.5 
- 6 . 0  
r6.5 
-7.0 
-7.5 
- 8 . 0  
ppm
IV-MF-3 3
PROTON
C6D6
PhS0 2
'OH
OH
I 1  ....... | i 1 ■ |......... |..........|...........i
4 3 2 1 0 ppm
File:02SE281 Ident:6_ll win lOOOPPM A c q :  2 9'-JAN-20 02 16:14:47 +0:31 Cal:FABLM2 80102_1 
ZAB-SE4F FAB+ Magnet BpM:115 BpI:904619 TIC:28124124 Flags:HALL 
File Text:IV-MF-36 FABMS MATRIX MNOBA + NA
1 0 0 % 
95! 
9 0 l  
8 5 l  
8 0 l  
751  
701  
651 
601 
551 
501  
451 
401 
351 
301 
25 
2  0 1  
151 
1 0 1 
51 
01
115
125
PhS02^
o'' i f  t  z oU
351
136
197
153
43
165 
175
277
253
209 225
241
267
l6o 120 140 160 180 200 220 240 260 260 300 320 340 360 380
295
409
.9 . 0E5
.8. 6E5
. 8 .  1E5
.7 . 7E5
.7 . 2E5
.6. 8E5
.6. 3E5
.5 . 9E5
.5. 4E5
.5. 0E5
.4 . 5E5
.4 . 1E5
.3 . 6E5
.3 . 2E5
.2 . 7E5
.2 . 3E5
.1. 8E5
.1 .  4E5
.9 . 0E4
.4 . 5E4
.0 . 0E0
m/ z
36
P E K IN
\ \ i - m - l L
j
72.64-
in
(Oocn
-5 .6 4
4000 3500 3000
PhS02
— I—  
2500
02/01 /24 14:33 
Y: 64 scans. 4 .0cm -l
1
6
6
9
.0
/
ppm
20
40
60
80
PhSO
-100
-120
-140
-160
t—i—rt—i—i—rt—i—r t—i—rT
8 7 6 5 4 3 2 1  ppm
PhSO'
190 180 170 160 150 140 130 120 110 100
IV-MF-36
CARBON
C6D6
“ I '-----1-----1-----1-----'-----1-----1-----1
2 00 180 160 140 120
IV-MF-3 6
COSY
C6D6
JLA ppm
J
5
on
■m
t—i—i—i—i—i—r
1 ppm8
IV-MF-3 6
PROTON
C6D6
9 8 7 6 5 4 3 2 1 0  ppm
File": 02"SE"536 Ident:32 Acq: 13-FEB-2002 15:35:24 +1:48 Cal:FABLM130202_I 
ZAB-SE4F FAB+ Magnet BpI:11769408 TIC:146205344 Flags:HALL 
File Text:IV-MF-38 FABMS MATRIX MNOBA + NA
1 0 0 %, 423 r_3.5E6
L3.3E6
13.1E6
12.9E68 5 !
12.8E6801
12.6E675.
12.4E6
11.0E63 01
477 18.6E525.
16.9E52 01 439257
15.2E5•15j
13.5E5L76 3471 0
241 30783 209 :_1.7E5
4:93 511 530 : q npn
407 461320 336 379IL6 395
m/z
02/02/11 
09:40
Y: 
64 
scans, 
4.0cm
-l, 
fla
t
O
ooo
0 1
8o
3Oo
Io ro
ruooo
1722.3
»-*•
CJIoo jst1447.1 - 
1370.6
1307.2
1235.0
1 1  ' 1 0  «"4 — ~
1045.7 ——
996.4
640.5
724.4
690.0oai
N
IX
ta
d
IV-MF-3 8
C6D6
HMQC
OMe H
J Li J jL j JL ppm
20
40
60
80
-100
-120
-140
-160
-180
- 2 0 0
t—i—rr
ppm
IV-MF-3 8
C6D6
DEPT
PhSO
OMe h
IV-MF-3 8
C6D6
CARBON
PhSO
OMe h
JLA_
100 90 80 70 60 50 40 30 20 ppm
IV-MF-38
C6D6
COSY
3  
3
PhSO
OMe h
JjlJL
IV -M F-3  8
C6D6
PROTON
P hS 02
OMe h
' i ' ' ' ' i ' ' ' ' i ' ' ' ,_  l ' 1 ' ' I ' ' ' ' I ' ' ' ' I '' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I 1 ' 1 ' I ' ' ' ' I r ' 1 ' i ' ' ' '
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
File:02 SE2 9 0 Ident:26_27 Win 1000PPM Acq:3O-JAN-2O02 10:06:48 +1:30 Cal:FABLM3 0 0102_1 
ZAB-SE4F FAB+ Magnet BpM:135 Bpl:13371392 TIC:236499232 Flags:HALL 
File Text:Iv-MF-39 FABMS MATRIX MNOBA + NA
100%, 867 _3 . 4E6
L3 . 2E695i
L3.0E69 0 i
L2.9E685i
L2.7E680L
L2.5E67 5z
L2.4E67 Oi
L2.2E665i
L 2 .0E660J
PhSO L1.9E655i
Ll.7E650i
L1.5E645z
OTBDPS40J L1.3E6
3 5_i L1.2E6
3 0_i L1.0E6
2 5 i . 4E5
20i L6.7E5
15- 1.5.1E5570
689lOi L3.4E5
595 757
I 7 7 4 83 6
883
899 961
iiiytll.llljLlmlfLiu .^11 UI[LULLk^ lkUh|Lliii jU.^ UilLirlli.^ U)MlliU
448 Ll .7E5542
|iJ il|llL iiJ m |liiill
652 927481
L 0 .0E0
1000 m/ z
PE R K IN  ELMER ' 1 ' r T
105.46
%T
cu
cvi
cn
CU .  
T f CO
•** h*
CM
CD
O
CU
P hS 02 Me
o
o
OTBDPS
o (
3 7 .1 0
4000 3500 3000 2500 2000 1500 1000
02 /01 /29  11:28
Y: 64 scans, 4.0cm -i, f l a t
uidd
081-
091-
0 2 1 -
0 0 1 -
08
N 9»09
uidd
/Tiff
91AI
OSMd
9090 
O0NH 
6 8-dW-AI
IV-MF-39
DEPT
C6D6
mm*#
r  I " 1
190
mm
P hS 02 Me
OTBDPS
I | ■ • • |.........|......... ,.......... i ......... ,.......... i .......... !.......... r .
180 170 160 150 140 130 120 110 100 90
' ' I ............I"
80 70
 i .............i " "
60 50 40 30 20 10 0
""I................i
ppm
IV-MF-3 9
CARBON
C 6D6
PhSO
OTBDPS
l«JU» Sw wWiIIWwmmwM N W ^ ' l i lW W illl l l m ^ l  n J x w ifW w JwJwwww^www
IV-MF-3 9
COSY
C6D6
LuA ppm
-i
PhSO
Me
OTBDPS
ppm
IV-MF-3 9
PROTON
C6D6
P hS02 Me
OTBDPS
I ........................ I  I ........................ i ........................  |  |    . ,  | , ,  | ...........................|
9 8 7 6 5 4 3 2 1 0
IV-MF-41 
PhMe 
PROTON 
RT
PhSO
Me
TESO'''
OTBDPS
IV-MF 
C 6D 6 
NOESY 
+ 6O0C
P i r
PhSO
Me
TESO'''
OTBDPS
1 1 I 1 1 r ' ' ' ' I ' ' ................ I ...........
ppm
■1.0
1.5 
r 2 . 0  
-2.5 
L 3 . 0
3.5 
r4.0 
r4.5 
-5.0 
-5.5 
- 6 . 0
6.5 
7 . 0
7.5 
- 8 . 0
ppm
IV - M F - 4 1
C6D6 
PROTON 
+ 7 OoC
Me
• n ,
TESO'''
OTBDPS
JJV
' I 1 1 1 ■ I ' ' ' | ■ ■ ■ • | ' | ■ • ■ ■ | ■ ■ ’ ■ | • ■ ■ • | ■ ■ ■ ■ , ■ ■ ■ ' | ' 1 ■ | ' | - 1 ■ ■ ' | T-, | ' ' ' ' | '
8-0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
I V - M F - 4 1
C6D6
PROTON
RT
PhSO
Me
TESO'''
OTBDPS
n T 1 1 1 I 1 1 1 1 I 1 11 1 I 1 1 1 1 I 1 ' I ' ' ' ' I '
4 .0  3 .5  3 .0  2 . 5  2 . 0  1 .5  1 .0 ppm
RT
P hS 02 i
TESO'''
OTBDPS
T"r
ppm
-0.5
7 1 . 0
-1.5 
- 2 . 0  
-2.5 
-3.0 
-3.5 
7 4 . 0 
-4.5 
-5.0 
-5.5 
- 6 . 0  
-6.5 
-7.0 
7 7 . 5 
- 8 . 0  
ppm
IV-MF-41 
C6D6 
CARBON 
RT
P hS 02
TESO'''
OTBDPS
ppm
File:02SE537 Ident:33_36 Win 1000PPM Acq:13-FEB-2002 15:42:26 +1:56"Cal:FABLM130202_1 
ZAB-SE4F FAB+ Magnet BpM:115 Bpl:16993280 TIC:428534144 Flags:HALL 
File Text:IV-MF-41 FABMS MATRIX MNOBA + NA 
IOOIl 225 _3.0E6
-2.9E6
i2.7E6
i2.6E6
-2.4E6
i2.3E6
i2.1E6
-2.0E6
-1.8E6
il.7E6
-1.5E6
il.4E6
- 1.2E6
1 I.IE6
-9 . 1E5
i7.6E5
1 6 .1E5
i4 . 6E5
i3.0E5
il.5E5
8 8 8 926 10.0E0 
950 m/z
Appendix 2
T h is  in c lu d es  a n  u p d a te  o f th e  w o rk  c a rried  o u t in th e  bryostatin  fie ld .
Thomas’s synthesis of a C(1)-C(16) “Northern Hemisphere” fragment (2002)139
The development of a C(1)-C(16) Bryostatin A and B ring synthon 548 was undertaken by 
Thomas, in an alteration to his previous efforts using individual pyran rings (schemes 22 to 25). The 
formation of 548 constitutes a marked improvement over the synthesis of the bryostatin B-ring sections 
159 and 181, to subsequently feed into his total synthesis of bryostatin 11 via the coupling with a 
“southern hemisphere” bryostatin segment 160 (Scheme 22).
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Scheme 91 Thomas’s retrosynthetic plan for the bryostatin 11 A-B- ring intermediate 548.
The crux of this improved synthesis relied on the tandem acid-catalysed conjugate addition/b/s- 
cyclisation of the linear chain 550 to the bis-pyran 549 (Scheme 91), followed by exocyclic olefination to 
the requisite methyl ester 548. Disconnection of 550 releases the C(11)-C(1) synthon 552 and the C(16)- 
C(12) synthon 551. The latter would be formed via the copper-catalysed addition of the vinyl Grignard 
intermediate of 554 and protected glycidol 553. The propargyl ketone 552 would be formed via a number 
of successive chain elongation steps, initiated from the ring-opened intermediate 556 of (R)-pantalactone 
191.
The protection of 191 as its benzyl ether (Scheme 92) was carried out using its trichloro- 
acetimidate (BnOTCA), which then underwent lactone reduction to the lactols 557. The Wittig ring- 
opening was performed with the methylene phosphonium salt, and subsequent protection as its TBS 
ether gave 556 in good yields. Hydroboration of the terminal olefin and ensuing Swern oxidation to 
aldehyde 558 permitted the aldol condensation with the enolate of 559 to deliver the C(5) hydroxyl centre 
of 560 in excellent stereocontrol, albeit in diminished yields, which were attributed to the competing 
deprotonation of 559.
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Thomas’s formation of the C(1)-C(16) intermediate 548.
A Saksena-Evans reduction of 560 presented the C(3)-C(5) anti- hydroxyl array, which was 
protected as its acetonide, and desilylation with TBAF furnished 555 in reasonable yields. The formation 
of alkynone 552 began from the Swern oxidation of 555, treatment with the acetylenic Grignard reagent, 
and final oxidation with Dess-Martin periodinane in excellent overall conversion. A zinc-mediated 
reduction of 552 was completed with the (R)-allyl silane 551 (see Scheme 93) in a formal “ene” reaction, 
to form the requisite C(1)-C(16) carbon backbone in excellent stereocontrol. This allowed the critical 
deprotection/b/s-cyclisation to be carried out with aqueous HF, followed by an in-situ trapping of the C(9) 
acetal as its methyl glycoside, with trimethyl orthoformate. A bis-silylation of the resulting hydroxyls 
furnished 559, and all that remained was to complete the C(13) olefin to methyl enoate transmutation.
A two-step procedure was employed to first access the exocyclic ketone, with an initial 
hydroxylation of 559 followed by a periodate cleavage. Once the ketone 561 was in place, a selective 
olefination using Fuji’s chiral phosphanoacetate 59 was employed, delivering the enoate in a 2.6:1 
mixture of epimers in favour of the desired (E) form. In comparison, Evans’ found that his olefination on 
the exocyclic ketone of 58 using 59 (Scheme 15) was effected in a 5.5:1 ratio in favour of the desired 
isomer, and Nishiyama and Yamamura found that their olefination of 157 with 59 (Scheme 21) was 
completed in a 9:1 mixture in favour of the desired isomer.
The intermediate 551 began with the conversion of the allylic bromide 562 to the allylsilane 554 
(Scheme 93). This was followed by the copper-catalysed reaction of the Grignard component of 554 with 
the silyl protected (S)-glycidol 553 intermediate, and the synthesis of 551 was completed by the silyl 
etherification at C(16).
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Scheme 93 Thomas’s synthesis of the allylsilane intermediate 551.
Wender’s convergent synthesis of bryostatin analogue 379 140
During the course of his analogue programme, Wender found that the C(17)-C(27) bryostatin 
C-ring was of central importance for compounds possessing potent activity. In a second generation 
synthesis, Wender has shown that the analogue 379 (see Scheme 46) could be accessed via a more 
expedient route, using a more convergent synthesis (Scheme 94). This was carried out by the synthesis 
of the hydropyranone 563 that underwent elaboration to the known C(17)-C(27) C-ring 401. 
Disconnection of the pyran revealed the acid chloride 564, formed from the alkylation of methyl 
isobutyrate 566, and the ketone 567, formed via the addition of the enolate of acetone to the known 
aldehyde 385. The major significant enhancement of this route is the reduction in the number of steps 
required, and the selectivity achieved at C(23) of 81% ds, compared to its racemate. More elaborate 
schemes were also attempted utilising this more convergent strategy, however they resulted only in a 
greater number of transformations and reduced the selectivity achieved at C(23).
The redesigned synthesis began with the alkylation of methyl isobutyrate 565 (Scheme 95) 
using allyl bromide, and subsequent radical bromination to yield 568, which then underwent conversion to 
the PMB ether by displacement with the alkoxide ion, derived via the deprotonation with sodium hydride. 
It was fortuitously found that with an aqueous quench, the reaction delivered the acid in good overall 
yield, and this then underwent treatment with oxalyl chloride to form the acid chloride 564.
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Scheme 94 Wender’s updated synthesis of the analogue 379.
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Scheme 95 Wender’s convergent route to analogue 379.
The requisite C(27)-C(20) synthon 567 commenced with the first 5 steps of the previously 
reported synthesis (see Scheme 46) to produce the aldehyde 385 in 43% overall yield. This then 
underwent condensation with the enolate derived from acetone and LDA to deliver 567 in a much 
improved 81% ds for the C(23) hydroxyl, in comparison to a racemic mixture achieved in Scheme 46. 
Completion of the carbon backbone was generated from the bis-anion of 567 with the acid chloride 564, 
which then underwent ring closure and dehydration to the hydropyranone 569 under mildly acidic 
conditions.
The following transformations to 573 were a repetition of the work previously reported (steps ix 
to xviii in Scheme 46), although they are shown above for clarity, with the only difference being the in-situ 
base-mediated dehydration to yield the exocyclic olefin 572. Once 573 was in-hand, the PMB ether 
protecting groups were cleaved with DDQ, allowing the selective oxidation at C(15) with manganese 
dioxide to take place, thereby yielding the known a,p-unsaturated aldehyde 401. This could then in-turn 
be converted to the analogue 379 using the previously reported transformations in 5 steps.
The significance of this second generation synthesis has been to reduce the number of overall 
steps from 43 to 38, with the longest linear sequence reduced to 23 from 29 steps. It has also served to 
incorporate an increased selectivity at C(23), thus making possible future commercial exploitation.
Wender’s synthesis of novel bryostatin analogue 577
In continuation of his convergent strategy, Wender has developed analogue 577 to 
demonstrate the effectiveness of producing much simplified bryostatin scaffolds. In the case of 577 the 
spacer domain has been altered to incorporate a carbonate at C(20)-C(21), thereby dispensing with the 
exocyclic olefin and lipophilic side chain.
By treating diol 570 with triphosgene (Scheme 96) the hydroxyls were locked as their 
carbamate in, good yield. Removal of the PMB ether of 574 with DDQ and subsequent allylic oxidation 
yielded the a,p-unsaturated aldehyde 575, which then underwent hydrolysis of the methyl glycoside under 
the optimised conditions of aqueous HF at 45°C. This allowed the esterification under Yamaguchi 
conditions with the acid 421 (Schemes 47 and 48), and final ring closure of 576 under acidic conditions. 
The novel analogue 577 was completed by hydrogenation of the benzyl protecting group at C(26) in a 
significantly reduced 18 step synthesis.
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Scheme 96 Wender’s synthesis of the novel analogue 577.
The advancements which Wender has achieved are most notable, and in particular the activity 
of the new analogue are awaited in due course. This has shown the utility of a convergent strategy to 
reveal targets that are commercially viable, and sets a precedent in the field of bryostatin drug research. 
These results have been complemented by a number of patents describing the research, and are fore­
runners to developing meaningful drug candidates.
Advancements in the bryostatin biosynthesis and biological research field
Bryostatin 1 is currently undergoing a significant number of clinical trials in man, including 
treatments for recurrent epithelial ovarian carcinoma 141, renal cancer142, and human myeloid leukaemia 
cells 143. These have included the administration of bryostatin 1 as a singular candidate, but most often in 
co-administration with a second candidate. There have been some encouraging results, especially in the 
treatment of human breast cancer144, where it has been shown that bryostatin 1 causes up-regulation of 
the apoptotic p53 enzyme.
Further research into B-cell malignancies 145 has demonstrated that bryostatin 1, in conjunction 
with vincristine, activates PKC with a short-term exposure, but on prolonged exposure leads to a 
depletion of PKC. This has meant an increase in apoptotic frequency, leading to a clinical response or 
stable disease condition in a number of patients, although more investigation into the process is ongoing 
to understand the precise mechanism of action.
A greater understanding in the geographical differences if bryostatin natural production has 
also been established 146. This has investigated the fact that bryostatin may deter predators of its animal 
hosts, and that bryostatin biosynthesis is more likely to result not from a local adaptation of species, but 
as a response to bacterium produced as protection against predators. This has been carried out by 
studying mitochondrial cytochrome oxidase sequences, and their geographical distributions within Bugula 
neritina showing differences in individuals south of Cape Hatteras compared to its more northern 
counterparts.
There has also been significant investigation by the Haygood laboratory 147 into the role of the 
bacterium that live in the larvae of the host Bugula neritina, which play a part in the synthesis of 
bryostatin. The hope is to isolate or clone these microrganisms, to develop an economical process for 
bryostatin synthesis. Some initial work carried out has shown that laboratory cultured Bugula neritina, 
treated with antibiotics to decrease the levels of the bacteria within, has showed a decrease in bryostatin 
content. Continuation in this area has significance in the aquaculture of bryostatin in complementary 
efforts of meaningful amounts of bryostatin production.
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